Shire (SHPG) 10-K 22 Feb 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2016	Feb. 10, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Central Index Key	936,402
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Trading Symbol	SHP, SHPG
Entity Registrant Name	Shire plc
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	Yes
Entity Common Stock, Shares Outstanding		904,721,016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Entity Public Float			$ 55.5

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 528.8	$ 135.5
Restricted cash	25.6	86
Accounts receivable, net	2,616.5	1,201.2
Inventories	3,562.3	635.4
Prepaid expenses and other current assets	806.3	197.4
Total current assets	7,539.5	2,255.5
Investments	191.6	50.8
Property, plant and equipment (“PP&E”), net	6,469.6	828.1
Goodwill	17,888.2	4,147.8
Intangible assets, net	34,697.5	9,173.3
Deferred tax asset	96.7	121
Other non-current assets	152.3	33.3
Total assets	67,035.4	16,609.8
Current liabilities:
Accounts payable and accrued expenses	4,312.4	2,050.6
Short-term borrowings and capital lease obligations	3,068	1,512.7
Other current liabilities	362.9	142.8
Total current liabilities	7,743.3	3,706.1
Long-term Debt and Capital Lease Obligations	19,899.8	82.1
Deferred tax liability	8,322.7	2,205.9
Other non-current liabilities	2,121.6	786.6
Total liabilities	38,087.4	6,780.7
Commitments and contingencies
Equity:
Common stock of 5p par value; 1,500 shares authorized; and 912.2 shares issued and outstanding (2015: 1,000 shares authorized; and 601.1 shares issued and outstanding)	81.3	58.9
Additional paid-in capital	24,740.9	4,486.3
Treasury stock: 9.0 shares (2015: 9.7 shares)	(301.9)	(320.6)
Accumulated other comprehensive loss	(1,497.6)	(183.8)
Retained earnings	5,925.3	5,788.3
Total equity	28,948	9,829.1
Total liabilities and equity	67,035.4	16,609.8
Shire Income Access Share Trust
Current assets:
Cash and cash equivalents	0	0
Total assets	0	0
Current liabilities:
Total liabilities	0	0
Equity:
Total equity	0	0
Total liabilities and equity	$ 0	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - £ / shares shares in Millions	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Common Stock, Par Value (in GBP per share)	£ 0.05	£ 0.05
Common Stock, Shares Authorized	1,500	1,000
Common Stock, Shares, Issued	912.2	601.1
Common Stock, Shares, Outstanding	912.2	601.1
Treasury Stock, Shares	9	9.7

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenues:
Product sales	$ 10,885.8	$ 6,099.9	$ 5,830.4
Royalties and other revenues	510.8	316.8	191.7
Total revenues	11,396.6	6,416.7	6,022.1
Costs and expenses:
Cost of sales	3,816.5	969	979.3
Research and development	1,439.8	1,564	1,067.5
Selling, general and administrative	3,015.2	1,842.5	1,782
Amortization of acquired intangible assets	1,173.4	498.7	243.8
Integration and acquisition costs	883.9	39.8	158.8
Reorganization costs	121.4	97.9	180.9
Gain on sale of product rights	(16.5)	(14.7)	(88.2)
Total operating expenses, net	10,433.7	4,997.2	4,324.1
Operating income from continuing operations	962.9	1,419.5	1,698
Interest income	18.4	4.2	24.7
Interest expense	(469.6)	(41.6)	(30.8)
Other (expense)/income, net	(25.6)	3.7	8.9
Receipt of break fee	0	0	1,635.4
Total other (expense)/income, net	(476.8)	(33.7)	1,638.2
Income from continuing operations before income taxes and equity in (losses)/ earnings of equity method investees	486.1	1,385.8	3,336.2
Income taxes	126.1	(46.1)	(56.1)
Equity in (losses)/ earnings of equity method investees, net of taxes	(8.7)	(2.2)	2.7
Income from continuing operations, net of taxes	603.5	1,337.5	3,282.8
(Loss)/gain from discontinued operations, net of taxes	(276.1)	(34.1)	122.7
Net income / (loss)	$ 327.4	$ 1,303.4	$ 3,405.5
Earnings per ordinary share - basic
Earnings from continuing operations (in USD per share)	$ 0.780	$ 2.27	$ 5.596
(Loss)/gain from discontinued operations (in USD per share)	(0.350)	(0.058)	0.209
Earnings per ordinary share - basic (in USD per share)	0.43	2.21	5.81
Earnings per ordinary share - diluted
Earnings from continuing operations (in USD per share)	0.770	2.255	5.552
(Loss)/gain from discontinued operations (in USD per share)	(0.350)	(0.058)	0.208
Earnings per ordinary share - diluted (in USD per share)	0.42	2.20	5.76
Cash dividends declared per ordinary share (in USD per share)	0.27	0.23	0.21
Cash dividends paid per ordinary share (in USD per share)	$ 0.22	$ 0.23	$ 0.21
Weighted average number of shares (millions):
Basic (in shares)	770.1	590.4	586.7
Diluted (in shares)	776.2	593.1	591.3
Shire Income Access Share Trust
Costs and expenses:
Dividend income	$ 150.6	$ 127.7	$ 112.8
Net income / (loss)	$ 150.6	$ 127.7	$ 112.8

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Statement of Comprehensive Income [Abstract]
Net income	$ 457.3	$ 280.6	$ 327.4	$ 1,303.4	$ 3,405.5
Other comprehensive loss:
Foreign currency translation adjustments			(1,323.3)	(156.4)	(136.1)
Pension and other employee benefits (net of tax expense of $8.8 million)			(5.2)	0	0
Unrealized holding gain/(loss) on available-for-sale securities (net of tax benefit of $0.1 million, $nil, and $1.3 million)			8.3	4.1	(5.6)
Hedging activities (net of tax expense of $3.3 million)			6.4	0	0
Comprehensive income / (loss)			(986.4)	1,151.1	$ 3,263.8
Components of accumulated other comprehensive income
Foreign currency translation adjustments	(1,505.4)	(182.1)	(1,505.4)	(182.1)
Pension and other employee benefits, net of taxes	(5.2)	0	(5.2)	0
Unrealized holding gain/(loss) on available-for-sale securities, net of taxes	6.6	(1.7)	6.6	(1.7)
Hedging activities, net of taxes	6.4	0	6.4	0
Accumulated other comprehensive loss	$ (1,497.6)	$ (183.8)	$ (1,497.6)	$ (183.8)

Consolidated Statements of Com6

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Statement of Comprehensive Income [Abstract]
Pension and other employee benefits, tax	$ 8.8
Unrealized holding gain/(loss) on available-for-sale securities, tax	0.1	$ 0	$ 1.3
Hedging activities, tax	$ 3.3

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) shares in Millions, $ in Millions	Total	EBT	Common stock	Additional paid-in capital	Treasury stock	Treasury stockEBT	Accumulated other comprehensive (loss)/income	Retained earnings	Retained earningsEBT	Shire Income Access Share Trust	Shire Income Access Share TrustCapital account	Shire Income Access Share TrustRevenue account
As of January, 1 at Dec. 31, 2013	$ 5,366		$ 58.6	$ 4,186.3	$ (450.6)		$ 110.2	$ 1,461.5		$ 0	$ 0	$ 0
Beginning balance (in shares) at Dec. 31, 2013			597.5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	3,405.5							3,405.5		112.8	0	112.8
Other comprehensive (loss)/income, net of tax	(141.7)						(141.7)
Shares issued under employee benefit plans	15.2		$ 0.1	15.1
Option exercised (in shares)			1.6
Share-based compensation	97			97
Tax benefit associated with exercise of stock options	39.6			39.6
Shares released by employee benefit trust to satisfy exercise of stock options		$ 2.5				$ 104.7			$ (102.2)
Dividends	(121.2)							(121.2)		(112.8)	0	(112.8)
As of December 31, at Dec. 31, 2014	8,662.9		$ 58.7	4,338	(345.9)		(31.5)	4,643.6		0	0	0
Ending balance (in shares) at Dec. 31, 2014			599.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,303.4							1,303.4		127.7	0	127.7
Other comprehensive (loss)/income, net of tax	(152.3)						(152.3)
Shares issued under employee benefit plans	16.6		$ 0.2	16.4
Option exercised (in shares)			2
Share-based compensation	100.3			100.3
Tax benefit associated with exercise of stock options	31.6			31.6
Shares released by employee benefit trust to satisfy exercise of stock options		1				25.3			(24.3)
Dividends	(134.4)							(134.4)		(127.7)	0	(127.7)
As of December 31, at Dec. 31, 2015	$ 9,829.1		$ 58.9	4,486.3	(320.6)		(183.8)	5,788.3		0	0	0
Ending balance (in shares) at Dec. 31, 2015	601.1		601.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	$ 327.4							327.4		150.6	0	150.6
Other comprehensive (loss)/income, net of tax	(1,313.8)						(1,313.8)
Shares issued under employee benefit plans	138.8		$ 0.4	138.4
Shares issued for the acquisition of Baxalta (in shares)			305.2
Shares issued for the acquisition of Baxalta	19,810.9		$ 22	19,788.9
Option exercised (in shares)			5.9
Share-based compensation	318.5			318.5
Tax benefit associated with exercise of stock options	8.8			8.8
Shares released by employee benefit trust to satisfy exercise of stock options		$ (0.4)				$ 18.7			$ (19.1)
Dividends	(171.3)							(171.3)		(150.6)	0	(150.6)
As of December 31, at Dec. 31, 2016	$ 28,948		$ 81.3	$ 24,740.9	$ (301.9)		$ (1,497.6)	$ 5,925.3		$ 0	$ 0	$ 0
Ending balance (in shares) at Dec. 31, 2016	912.2		912.2

Consolidated Statements of Cha8

Consolidated Statements of Changes in Equity (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Dividends per share declared	$ 0.27	$ 0.23	$ 0.21
Dividends per share paid	$ 0.22	$ 0.23	$ 0.21
Dividends paid (in USD)	$ 171.3	$ 134.4	$ 121.2
Ordinary Shares
Dividends per share declared	$ 0.27	$ 0.23	$ 0.21
Dividends per share paid	0.27	0.23	0.21
ADS
Dividends per share declared	0.81	0.70	0.62
Dividends per share paid	$ 0.81	$ 0.70	$ 0.62

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 327.4	$ 1,303.4	$ 3,405.5
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,466.3	637.2	407.3
Share-based compensation	318.5	100.3	97
Amortization of deferred financing costs	125.5	0	0
Change in fair value of contingent consideration	11.1	(149.9)	14.7
Unwind of inventory fair value step-up	1,118	31.1	91.9
Impairment of intangible assets	8.9	643.7	190.3
Movement in deferred taxes	(594.6)	(198.2)	(14.3)
Write down of PP&E	92.4	0	0
Other, net	31.4	0	(27.9)
Changes in operating assets and liabilities:
Increase in accounts receivable	(701.7)	(211.4)	(66.1)
Increase in sales deduction accruals	288.3	97.6	107.6
Increase in inventory	(255.8)	(63.2)	(25.3)
Decrease/(increase) in prepayments and other assets	(198.4)	37.2	42.4
Increase in accounts and notes payable and other liabilities	621.6	109.2	5.3
Net cash provided by operating activities	2,658.9	2,337	4,228.4
CASH FLOWS FROM INVESTING ACTIVITIES:
Movements in restricted cash	62.8	(32)	(32.6)
Purchases of subsidiary undertakings and businesses, net of cash acquired	(17,476.2)	(5,553.4)	(4,104.4)
Purchases of non-current investments and PP&E	(648.7)	(124.2)	(100.1)
Proceeds from short-term investments	0	67	57.8
Proceeds received on sale of product rights	10.9	17.5	127
Other, net	0.9	18.7	21.5
Other, net	(41.9)	(13.5)	0.2
Net cash used in investing activities	(18,092.2)	(5,619.9)	(4,030.6)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long term and short term borrowings	32,443.4	3,760.8	2,310.8
Repayment of revolving line of credit, long term and short term borrowings	(16,404.3)	(3,110.9)	(1,461.8)
Repayment of debt acquired through business combinations	0	0	(551.5)
Proceeds from ViroPharma call options	0	0	346.7
Payment of dividend	(171.3)	(134.4)	(121.2)
Debt issuance costs	(172.3)	(24.1)	(10.2)
Contingent consideration payments	(8)	(101.2)	(15.2)
Proceeds from exercise of options	129	16.6	17.4
Other, net	9.3	32.2	39.5
Net cash provided by financing activities	15,825.8	439	554.5
Effect of foreign exchange rate changes on cash and cash equivalents	0.8	(3)	(9.3)
Net increase/(decrease) in cash and cash equivalents	393.3	(2,846.9)	743
Cash and cash equivalents at beginning of period	135.5	2,982.4	2,239.4
Cash and cash equivalents at end of period	528.8	135.5	2,982.4
Supplemental information associated with continuing operations:
Interest paid	(284)	(20)	(14.5)
Income taxes (paid)/received	(431)	(69)	194.4
Receipt of break fee	0	0	1,635.4
Shire Income Access Share Trust
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	150.6	127.7	112.8
Changes in operating assets and liabilities:
Net cash provided by operating activities	150.6	127.7	112.8
CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash used in investing activities	0	0	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Distributions made	150.6	127.7	112.8
Net cash provided by financing activities	(150.6)	(127.7)	(112.8)
Net increase/(decrease) in cash and cash equivalents	0	0	0
Cash and cash equivalents at beginning of period	0	0	0
Cash and cash equivalents at end of period	$ 0	$ 0	$ 0

Description of Operations

Description of Operations	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Operations	Description of Operations Shire plc and its subsidiaries (collectively referred to as either “Shire”, or the “Company”) is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions across core therapeutic areas including Hematology, Genetic Diseases, Neuroscience, Immunology, Internal Medicine, Ophthalmology, and Oncology. Some of the Company's marketed products include ADVATE/ADYNOVATE,VONVENDI and FEIBA for hematology, CINRYZE, ELAPRASE and REPLAGAL for genetic diseases, VYVANSE and ADDERALL XR for neuroscience, GAMMAGARD and HYQVIA for immunology, LIALDA/MEZAVANT and PENTASA for internal medicine, XIIDRA for ophthalmology and ONCASPAR and ONYVIDE for oncology. The Company has grown both organically and through acquisition, completing a series of major transactions that have brought therapeutic, geographic and pipeline growth and diversification. The Company will continue to conduct its own research and development (“R&D”) focused on rare diseases and other highly specialized conditions, as well as evaluate companies, products and pipeline opportunities that offer a strategic fit and have the potential to deliver value to all of the Company’s stakeholders: patients, physicians, policy makers, payers, partners, investors and employees.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of preparation The accompanying Consolidated Financial Statements include the accounts of Shire plc, all of its subsidiary undertakings and the Income Access Share trust, after elimination of inter-company accounts and transactions. They have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and U.S. Securities and Exchange Commission (“SEC”) regulations for annual reporting. On June 3, 2016, the Company completed its acquisition of Baxalta for $ 32.4 billion , representing the preliminary fair value of purchase consideration. The Company’s Consolidated Financial Statements include the results of Baxalta from the date of acquisition. For further details regarding the acquisition, refer to Note 3 , Business Combinations , to the Consolidated Financial Statements set forth in this Annual Report on Form 10-K. Due to the Baxalta acquisition, the Company concluded that it was appropriate to reclassify the Amortization of Acquired Intangibles from Selling, General and Administrative ("SG&A") on the Consolidated Statements of Operations. Accordingly, the Company reclassified the Amortization of Acquired Intangibles from SG&A in comparative periods to conform to the current classification. The Company reclassified capital lease obligations from Other current liabilities to the Short-term borrowings and from Other non-current liabilities to Long-term borrowings and capital lease obligations in comparative periods to conform the current classification. Use of estimates in Consolidated Financial Statements The preparation of the Consolidated Financial Statements, in conformity with U.S. GAAP and SEC regulations, requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities and equity at the date of the Consolidated Financial Statements and reported amounts of revenues and expenses during the reporting period. On an on-going basis, the Company evaluates its estimates, judgments and methodologies. Estimates are based on historical experience, current conditions and on various other assumptions that are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amounts of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions. Consolidation The Consolidated Financial Statements reflect the financial statements of the Company and those of the Company's wholly-owned subsidiaries. For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to non-controlling interests in its Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. Intercompany balances and transactions are eliminated in consolidation. The Company determines whether to consolidate subsidiaries based on either the variable interest entity (“VIE”) model or the voting interest model. The Company consolidates a VIE if it is determined that the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of an entity, management applies a qualitative approach that determines whether the Company has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. The Company consolidates entities that are not VIEs if it is determined that the Company holds a majority voting interest in the entity. Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Intercompany balances and transactions are eliminated in consolidation. Revenue recognition The Company recognizes revenue when all of the following criteria are met: • there is persuasive evidence an arrangement exists; • delivery has occurred or services have been rendered; • the price to the customer is fixed or determinable; and • collectibility is reasonably assured. Where applicable, all revenues are stated net of value added and similar taxes and trade discounts. The Company’s principal revenue streams and their respective accounting treatments are discussed below: Product sales Revenues from Product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery. Product sales are recorded net of applicable reserves for discounts and allowances. Reserves for Discounts and Allowances The Company establishes reserves for trade discounts, chargebacks, distribution service fees, Medicaid rebates, managed care rebates, incentive rebates, product returns and other governmental rebates or applicable allowances. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. Management's estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from estimates. If actual results vary, management adjusts these estimates, which have an effect on earnings in the period of adjustment. • Trade discounts are generally credits granted to wholesalers, specialty pharmacies and other customers for remitting payment on their purchases within established incentive periods and are classified as a reduction of accounts receivable, offset by revenue. • Chargebacks are credits or payments issued to wholesalers and distributors who provide products to qualified healthcare providers at prices lower than the list prices charged to the wholesaler or distributor. Reserves are estimated based on expected purchases by those qualified healthcare providers. Chargeback reserves are classified as a reduction of accounts receivable. • Distribution service fees are credits or payments issued to wholesalers, distributors and specialty pharmacies for compliance with various contractually-defined inventory management practices or services provided to support patient access to a product . These fees are generally based on a percentage of gross purchases but can also be based on additional services these entities provide. Most of these costs are reflected as a reduction of gross sales; however, to the extent benefit from services can be separately identified and the fair value determined, costs are classified in Selling, general and administrative expense. Reserves are classified within accrued expenses. • Medicaid rebates are payments to States under statutory and voluntary reimbursement arrangements. Reserves for these rebates are generally based on an estimate of expected product usage by Medicaid patients and expected rebate rates. Statutory rates are generally based on a percentage of selling price adjusted upwards for price increases in excess of published inflation indices. As a result, rebates generally increase as a percentage of the selling price over the life of the product (as prices increase). Medicaid rebate reserves are classified within accrued expenses. • Managed care rebates are payments to third parties, primarily pharmacy benefit managers and other health insurance providers. The reserve for these rebates is based on an estimate of customer buying patterns and applicable contractual rebate rates to be earned over each period. Reserves are classified within accrued expenses. • Incentive rebates are generally credits or payments issued to specialty pharmacies, distributors or Group Purchasing Organizations for qualified purchases of certain products. Reserves are estimated based on the terms of each individual contract and purchase volumes and are classified within accrued expenses. • Return credits are issued to customers for return of product damaged in shipment and, for certain products, return due to lot expiry. The majority of returns are due to expiry, and reserves are estimated based on historical returns experience. The returns reserve is classified within accrued expenses. • Other discounts and allowances include Medicare rebates, coupon and patient co-pay assistance. Medicare rebates are payments to health insurance providers of Medicare Part D coverage to qualified patients. Reserve estimates are based on customer buying patterns and applicable contractual rebate rates to be earned over each period. Coupon and co-pay assistance programs provide discounts to qualified patients. Reserve estimates are based on expected claim volumes under these programs and estimated cost per claim that the Company expects to pay. Reserves for Medicare and coupon and patient co-pay programs are classified within accrued expenses. Royalties and Other Revenue Royalty income relating to licensed technology is recognized when the licensee sells the underlying product, with the amount of royalty income recorded based on sales information received from the relevant licensee. The Company estimates sales amounts and related royalty income based on the historical product information for any period that the sales information is not available from the relevant licensee. Other revenue includes revenues derived from product out-licensing arrangements, which may consist of an initial up-front payment on inception of the license and subsequent milestone payments upon achievement of certain clinical and sales milestones. To the extent the license requires Shire to provide services to the licensee; up-front payments are deferred and recognized over the service period. Business combinations Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process research and development ("IPR&D") projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in the Consolidated Financial Statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree’s liability arising from a business combination it completed prior to the acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in earnings. Goodwill Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired in a business combination. Goodwill is not amortized, but instead is reviewed for impairment. Goodwill is reviewed annually, as of October 1, and whenever events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable. Events or changes in circumstances which could trigger an impairment review include but are not limited to: unexpected adverse business conditions, economic factors, unanticipated technological changes or competitive activities and acts by governments and courts. For the purpose of assessing the carrying value of goodwill for impairment, goodwill is allocated at the Company’s reporting unit level. As described in Note 22 , Segment Reporting , the Company operates in one operating segment which it considers to be its only reporting unit. The Company reviews goodwill for impairment by firstly assessing qualitative factors, including comparing the market capitalization of the Company to the carrying value of its assets, to determine whether events or circumstances exist which indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The Company assesses all events or circumstances and determines if it is more likely than not that the fair value of a reporting unit exceeds its carrying value. If, after assessing these qualitative factors, it is deemed more likely than not that the fair value of a reporting unit is less than its carrying value, a “two step” quantitative assessment is performed by comparing the carrying value of the reporting unit's net assets (including allocated goodwill) to the fair value of the reporting unit. The Company compares the fair value of its reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of its reporting unit, then it determines the implied fair value of its reporting unit’s goodwill. If the carrying value of the reporting unit’s goodwill exceeds its implied fair value, then an impairment loss equal to the difference is recorded. Intangible Assets Intangible assets primarily relate to commercially marketed products and IPR&D projects. Intangible assets are recorded at fair value at the time of their acquisition and are stated in the Consolidated Balance Sheets, net of accumulated amortization and impairments, if applicable. Intangible assets related to commercially marketed products are amortized over their estimated useful lives. Remaining useful lives range from 2 to 25 years (weighted average 20 years ) and the Company amortizes its intangibles on a straight-line basis. The Company reviews intangible assets for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. Milestone payments made to third parties on and subsequent to regulatory approval are capitalized as intangible assets, and amortized over the remaining useful life of the related product. The following factors, where applicable, are considered in estimating the useful lives of intangible assets: • expected use of the asset; • regulatory, legal or contractual provisions, including the regulatory approval and review process, patent issues and actions by government agencies; • the effects of obsolescence, changes in demand, competing products and other economic factors, including the stability of the market, known technological advances, development of competing drugs that are more effective clinically or economically; • actions of competitors, suppliers, regulatory agencies or others that may eliminate current competitive advantages; and • historical experience of renewing or extending similar arrangements. Acquired IPR&D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value. The revenue and costs projections used to value acquired IPR&D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology, and the nature and expected timing of new product introductions by the Company and its competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&D, the Company completes an assessment of whether the acquisition constitutes the purchase of a single asset or a group of assets. The Company considers multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and its rationale for entering into the transaction. If the Company acquires a business as defined under applicable accounting standards, then the acquired IPR&D is capitalized as an intangible asset. If the Company acquires an asset or group of assets that do not meet the definition of a business, then the acquired IPR&D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. IPR&D projects are considered to be indefinite-lived until completion of the associated R&D efforts. If and when development is complete, which generally occurs when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Intangible assets related to IPR&D projects are tested for impairment at least annually, as of October 1st, until commercialization, after which time the IPR&D is amortized over its estimated useful life. The Company evaluates the carrying value of long-lived assets, except for goodwill and indefinite lived intangible assets, whenever events or changes in circumstances indicate that the carrying amounts of the relevant assets may not be recoverable. When such a determination is made, management’s estimate of undiscounted cash flows to be generated by the use and ultimate disposition of these assets is compared to the carrying value of the assets to determine whether the carrying value is recoverable. If the carrying value is deemed not to be recoverable, the amount of the impairment recognized in the Consolidated Financial Statements is determined by estimating the fair value of the relevant assets and recording an impairment loss for the amount by which the carrying value exceeds the estimated fair value. This fair value is usually determined based on estimated discounted cash flows. When performing the impairment assessment, the Company calculates the fair value using the same methodology as described above. If the carrying value of the acquired IPR&D exceeds its fair value, then the intangible asset is written-down to its fair value. Fair Value Measurements The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements: • Level 1 - Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access; • Level 2 - Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates; and • Level 3 - Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. The majority of the Company's financial assets have been classified as Level 1 and 2. The Company's financial assets, which include cash equivalents, derivative contracts, marketable equity and debt securities, and plan assets for deferred compensation, have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other market observable data. The Company utilizes industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. Accounts receivable The Company's accounts receivable arise from Product sales and represent amounts due from its customers. The Company monitors the financial performance and credit worthiness of its large customers so that it can assess and respond to changes in their credit profile. The Company provides reserves against accounts receivable for estimated losses, if any, that may result from a customer's inability to pay. Amounts determined to be uncollectible are written-off against the reserve. Investments The Company has certain investments in pharmaceutical and biotechnology companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the cost method or the equity method of accounting, depending on its ownership percentage and other factors that suggest the Company has significant influence. Under the equity method of accounting, the Company records its investments in equity-method investees in the consolidated balance sheet under Investments and its share of the investees’ earnings or losses together with other-than- temporary impairments in value under equity in (losses)/ earnings of equity method investees, net of taxes in the Consolidated Statements of Operations. The Company monitors these investments to evaluate whether any decline in their value has occurred that would be other-than-temporary, based on the implied value of recent company financings, public market prices of comparable companies, and general market conditions. All other equity investments, which consist of investments for which the Company does not have the ability to exercise significant influence, are accounted for under the cost method or at fair value. Investments in private companies are carried at cost, less provisions for other-than-temporary impairment in value. For investments in equity investments that have readily determinable fair values, the Company classifies its equity investments as available-for-sale and, accordingly, records these investments at their fair values with unrealized holding gains and losses included in the consolidated statement of comprehensive income, net of any related tax effect. Realized gains and losses, and declines in value of available-for-sale securities judged to be other-than-temporary, are included in other income, net in the Consolidated Statements of Operations. The cost of securities sold is based on the specific identification method. Interest on securities classified as available-for-sale is included as interest income in the Consolidated Statements of Operations. Inventories Inventories are stated at the lower of cost or market. Cost incurred in bringing each product to its present location and condition is based on purchase costs calculated on a first-in, first-out basis, including transportation costs. The inventory costs are classified as long term when the Company expects to utilize the inventory beyond the normal operating cycle and includes these costs in Other assets in the Consolidated Balance Sheets. Capitalization of Inventory Costs The Company capitalizes inventory costs associated with its products prior to regulatory approval, when, based on management’s judgment, future commercialization is considered highly probable and the future economic benefit is expected to be realized. Obsolescence and Unmarketable Inventory Inventories are written down for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and estimated market value based upon assumptions about future demand and market conditions. Amounts written down due to unmarketable inventory are charged to Cost of product sales. Property, plant and equipment Property, plant and equipment are carried at cost, net of accumulated depreciation and impairment losses. Property, plant and equipment are subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits. Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the useful life of the underlying asset. The Company also capitalizes certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are amortized over the useful life of the related equipment. Depreciation of property, plant and equipment is calculated using the straight-line method over the estimated useful lives as follows: Asset category Estimated useful lives Land Not depreciated Buildings and leasehold improvements 15 to 50 years Office furniture, fittings and equipment 3 to 10 years Machinery, equipment and other 3 to 15 years At the time property, plant and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are eliminated from the asset and accumulated depreciation accounts. The profit or loss on such disposition is reflected in operating income. Discontinued operations Discontinued operations comprise those activities that were disposed of during the period or which were classified as held for sale at the end of the period, and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes. Contingent consideration payable Contingent consideration payable represents future milestones and royalties the Company may be required to pay in conjunction with various business combinations. The amounts ultimately payable by the Company are dependent upon the successful achievement of the underlying scientific or commercial event and future net sales of the relevant products over applicable term. The Company records an obligation for such contingent payments at fair value on the acquisition date. The Company assesses the probability, and estimated timing, of these milestones being achieved and the present value of forecast future net sales of the relevant products and re-measures the related contingent consideration to fair value each balance sheet date. The amount of contingent consideration which may ultimately be payable by Shire in relation to future royalties is dependent upon future net sales of the relevant products over the life of the royalty term. The fair value of the Company’s contingent consideration payable could significantly increase or decrease due to changes in certain assumptions which underpin the fair value measurements. Each set of assumptions and milestones is specific to the individual contingent consideration payable. The assumptions include, among other things, the probability of, and period in which, the relevant milestone event is expected to be achieved; the amount of royalties that will be payable based on forecast net sales of the relevant products; and the discount rates to be applied in calculating the present values of the relevant milestone or royalty. The Company regularly reviews these assumptions, and makes adjustments to the fair value measurements as required by facts and circumstances. Derivative financial instruments The Company uses derivative financial instruments to manage its exposure to foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities. For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the derivative is recorded in Accumulated Other Comprehensive Income (“AOCI”) and then recognized in earnings consistent with the underlying hedged item. Cash flow hedges are classified in revenues and cost of sales and primarily relate to forecasted third-party sales denominated in foreign currencies and forecasted intercompany sales denominated in foreign currencies, respectively. In its application of hedge accounting, the Company assesses, both at inception and on a prospective basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. The Company also assesses hedge effectiveness on a retrospective basis every quarter with any hedge ineffectiveness recorded to the Consolidated Statement of Operations. The Company uses forward contracts to mitigate the effects of changes in foreign exchange relating to certain of the Company’s intercompany and third-party receivables and payables. These derivative instruments generally are not formally designated as hedges and the terms of these instruments generally do not exceed three months. The fair values of these instruments are included on the balance sheet in current assets/liabilities, with changes in the fair value recognized in the Consolidated Statements of Operations. The cash flows relating to these instruments are presented within net cash provided by operating activities in the Consolidated Statements of Cash Flows, unless the derivative instruments are economically hedging specific investing or financing activities. Translation of foreign currency The functional currency for most of the foreign subsidiaries is their local currency. For the non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the foreign operations into U.S. dollars are excluded from the determination of Net income and are recorded in AOCI, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in Other income/(expense), net, in Net income. Foreign currency exchange transaction gains/(losses) included in Consolidated Statements of Operations in the years ended December 31, 2016 , 2015 and 2014 amounted to $17.7 million , $(26.5) million and $(15.6) million , respectively. Cost of product sales Cost of product sales includes the cost of purchasing finished product for sale, the cost of raw materials and costs of manufacturing those products including shipping and handling costs, depreciation and amortization of intangible assets in respect of favorable manufacturing contracts. Royalties payable to third party intellectual property owners related to the sold products are also included in Cost of product sales. Research and development ("R&D") expense Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations ("CROs"), clinical supply and manufacturing expenses. R&D expense also includes the impairment charges related to intangible assets. Research and development expenses are expensed as incurred. Payments that were made for research and development services prior to the services being rendered are recorded as Prepaid expenses and other current assets on the Consolidated Balance Sheets and are expensed as the services are provided. Management also accrues the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program. Selling, general and administrative expenses Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs. Adve

Business Combinations

Business Combinations	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Business Combinations	Business Combinations Acquisition of Baxalta On June 3, 2016, Shire acquired all of the outstanding common stock of Baxalta for $18.00 per share in cash and 0.1482 Shire American Depository Shares (“ADSs”) per Baxalta share, or if a former Baxalta shareholder properly elected, 0.4446 Shire ordinary shares per Baxalta share. Baxalta was a global biopharmaceutical company that focused on developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. The preliminary fair value of the purchase price consideration consisted of the following: (In millions) Estimated fair value Cash paid to shareholders $ 12,366.7 Fair value of stock issued to shareholders 19,353.2 Fair value of partially vested stock options and RSUs assumed 508.8 Contingent consideration payable 169.0 Total Purchase Consideration $ 32,397.7 The acquisition of Baxalta was accounted for as a business combination using the acquisition method of accounting. Shire issued 305.2 million shares to former Baxalta shareholders at the date of the acquisition. For a more detailed description of the fair value of the partially vested stock options and RSUs assumed, please see Note 27 , Share-based Compensation Plans , to the Consolidated Financial Statements set forth in this Annual Report on Form 10-K. The assets acquired and the liabilities assumed from Baxalta have been recorded at their preliminary fair value as of June 3, 2016, the date of acquisition. The Company’s Consolidated Financial Statements included the results of Baxalta from the date of acquisition. The amount of Baxalta’s post-acquisition revenues included in the Company’s Consolidated Statements of Operations for the year ended December 31, 2016 was $4,011.6 million . After the closing of the acquisition, the Company began integrating Baxalta and as such the combined business is now sharing various research and development and selling, general and administrative functions. As a result, computing a separate measure of Baxalta’s stand-alone profitability for periods after the acquisition date is not practical. The Company's preliminary allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date, including measurement period adjustments identified during the year ended December 31, 2016 , is outlined below. (In millions) Preliminary fair values as of June 3, 2016 Measurement period adjustments Preliminary fair values as of December 31, 2016 ASSETS Current assets: Cash and cash equivalents $ 583.2 $ — $ 583.2 Accounts receivable 1,071.7 (2.0 ) 1,069.7 Inventories 5,341.1 (1,447.7 ) 3,893.4 Other current assets 673.3 (97.3 ) 576.0 Total current assets 7,669.3 (1,547.0 ) 6,122.3 Property, plant and equipment 5,687.7 (235.0 ) 5,452.7 Investments 128.2 — 128.2 Goodwill 6,106.4 5,316.0 11,422.4 Intangible assets Currently marketed products 24,550.0 (2,555.0 ) 21,995.0 In-Process Research and Development ("IPR&D") 2,940.0 (2,210.0 ) 730.0 Contract based arrangements 72.2 (30.0 ) 42.2 Other non-current assets 103.3 51.7 155.0 Total assets $ 47,257.1 $ (1,209.3 ) $ 46,047.8 LIABILITIES Current liabilities: Accounts payable and accrued expenses $ 1,283.9 $ 38.0 $ 1,321.9 Other current liabilities 241.0 113.4 354.4 Long-term borrowings and capital lease obligations 5,424.9 — 5,424.9 Deferred tax liability 6,831.7 (1,386.4 ) 5,445.3 Other non-current liabilities 1,092.1 11.5 1,103.6 Total liabilities $ 14,873.6 $ (1,223.5 ) $ 13,650.1 Preliminary fair value of identifiable assets acquired and liabilities assumed $ 32,383.5 $ 14.2 $ 32,397.7 Consideration Preliminary fair value of purchase consideration $ 32,383.5 $ 14.2 $ 32,397.7 The purchase price allocation is preliminary pending final determination of the fair values of certain assets and liabilities. As of December 31, 2016 , certain items related to the fair values of inventories, intangible assets, PP&E, other current and non-current liabilities and current and deferred taxes have not been finalized and may be subject to change as additional information is received and certain tax returns are finalized. The finalization of these matters and any additional information received that was existed as of acquisition date may result in changes to the underlying assets, liabilities and goodwill. These changes may be material. The final determination of these fair values will be completed as soon as possible but no later than one year from the acquisition date. Intangible Assets The preliminary fair value of the identifiable intangible assets has been estimated using an income approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the incremental after tax cash flows an asset would generate over its remaining useful life.The preliminary useful lives for Currently marketed products were determined based upon the remaining useful economic lives of the assets that are expected to contribute to future cash flows. Currently marketed products totaling $21,995.0 million relate to intellectual property (“IP”) rights acquired for Baxalta’s currently marketed products. The estimated useful life of the intangible assets related to currently marketed products range from 8 to 23 years (weighted average 21 years ), with amortization being recorded on a straight line basis. IPR&D intangible assets totaling $730.0 million represent the value assigned to research and development ("R&D") projects acquired. The IPR&D intangible assets are capitalized and accounted for as indefinite-lived intangible assets and will be subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, the Company will make a separate determination of the estimated useful life of the IPR&D intangible asset and the related amortization will be recorded as an expense over the estimated useful life. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each asset or product (including net revenues, cost of sales, R&D costs, selling and marketing costs, working capital/asset contributory asset charges and other cash flow assumptions), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors. The discount rate used to arrive at the present value at the acquisition date of the IPR&D intangible assets was 9.5% to reflect the internal rate of return and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results. The measurement period adjustments for Intangible assets reflect changes in the estimated fair value of Currently marketed products and IPR&D. The changes in the estimated fair values for Intangible assets are primarily to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date. Goodwill Preliminary goodwill of $11,422.4 million , which is not deductible for tax purposes, includes the expected synergies that will result from combining the operations of Baxalta with Shire; intangible assets that do not qualify for separate recognition at the time of the acquisition; the value of the assembled workforce; and impacted by establishing a deferred tax liability for the acquired identifiable intangible assets which have no tax basis. For the year ended December 31, 2016 , the Company expensed $791.4 million relating to the acquisition and integration of Baxalta, which have been recorded within Integration and Acquisition costs in the Company’s Consolidated Statements of Operations. Contingent Consideration The Company acquired certain contingent obligations classified as contingent consideration related to Baxalta’s historical business combinations. Additional consideration is conditionally due upon the achievement of certain milestones related to the development, regulatory, first commercial sale and other sales milestones, which could total up to approximately $1.5 billion . The Company may also pay royalties based on certain Product sales. The Company estimated the preliminary fair value of the assumed contingent consideration to be $169.0 million using a probability weighting approach that considered the possible outcomes based on assumptions related to the timing and probability of the product launch date, discount rates matched to the timing of first payment, and probability of success rates and discount adjustments on the related cash flows. Inventory The preliminary estimated fair value of work-in-process and finished goods inventory was determined utilizing the Net realizable value, based on the expected selling price of the inventory, adjusted for incremental costs to complete the manufacturing process and for direct selling efforts, as well as for a reasonable profit allowance. The preliminary estimated fair value of raw material inventory was valued at replacement cost, which is equal to the value a market participant would pay to acquire the inventory. The changes in the estimated fair values for Inventory are primarily to better reflect the expected selling price of the inventory based on market participant assumptions existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date. Retirement plans The Company assumed pension plans as part of the acquisition of Baxalta, including defined benefit and post-retirement benefit plans in the United States and foreign jurisdictions which had a net liability balance of $610.4 million . As of June 3, 2016, the Baxalta defined benefit pension plans had assets with a preliminary fair value of $358.5 million . Supplemental disclosure of pro forma information The following unaudited pro forma financial information presents the combined results of the operations of Shire and Baxalta as if the acquisition of Baxalta had occurred as of January 1, 2015. The unaudited pro forma financial information is not necessarily indicative of what the consolidated results of operations actually would have been had the respective acquisitions been completed on January 1, 2015. In addition, the unaudited pro forma financial information does not purport to project the future results of operations of the combined Company. December 31, (In millions) 2016 2015 Revenues $ 13,999.6 $ 12,564.7 Net income/(loss) from continuing operations 2,235.9 (1,014.2 ) Per share amounts: Net income/(loss) from continuing operations per share - basic $ 2.90 $ (1.72 ) Net income/(loss) from continuing operations per share - diluted $ 2.88 $ (1.72 ) The unaudited pro forma financial information above reflects the following pro forma adjustments: (i) an adjustment to increase net income for the year ended December 31, 2016 by $678.9 million to eliminate integration and acquisition related costs incurred by Shire and Baxalta and a corresponding decrease in net income for the year ended December 31, 2015 by $678.9 million to give effect to the integration and acquisition of Baxalta as if it had occurred on January 1, 2015; (ii) an adjustment to increase net income for the year ended December 31, 2016 by $897.1 million and a corresponding decrease for the year ended December 31, 2015 by $1,428.2 million , respectively, to reflect amortization of the fair value adjustments for inventory as inventory is sold. As acquired inventory turns within 12 months of the acquisition, there has been no expense included in net income for the year ended December 31, 2016 ; (iii) an adjustment to increase amortization expense by $330.9 million and $815.0 million for the year ended December 31, 2016 and December 31, 2015 , respectively, related to the identifiable intangible assets acquired; and (iv) an adjustment to decrease net income for the year ended December 31, 2016 by $42.5 million and for the year ended December 31, 2015 by $357.6 million , respectively, primarily related to the additional interest expense and deferred debt issuance costs associated with the debt incurred to partially fund the acquisition of Baxalta and the bonds issued to replace the debt incurred for the acquisition. The adjustments above are stated net of their tax effects, where applicable. Acquisition of Dyax On January 22, 2016, Shire acquired all of the outstanding common stock of Dyax for $37.30 per share in cash. Under the terms of the merger agreement, former Dyax shareholders may receive additional value through a non-tradable contingent value right worth $4.00 per share, payable upon U.S. Food and Drug Administration (“FDA”) approval of SHP643 (formerly DX-2930) in Hereditary Angioedema (“HAE”). Dyax was a publicly-traded, Massachusetts-based rare disease biopharmaceutical company primarily focused on the development of plasma kallikrein (“pKal”) inhibitors for the treatment of HAE. Dyax’s most advanced clinical program was SHP643, a Phase 3 program with the potential for improved efficacy and convenience for HAE patients. SHP643 has received Fast Track, Breakthrough Therapy, and Orphan Drug Designations by the FDA and has also received Orphan Drug status in the EU. Dyax’s sole marketed product, KALBITOR, is a pKal inhibitor for the treatment of acute attacks of HAE in patients 12 years of age and older. The acquisition of Dyax was accounted for as a business combination using the acquisition method. The acquisition date fair value consideration was $6,330.0 million , comprising cash paid on closing of $5,934.0 million and the fair value of the contingent value right of $396.0 million (maximum payable $646.0 million ). The assets acquired and the liabilities assumed from Dyax have been recorded at their fair value as of January 22, 2016, the date of acquisition. The Company’s Consolidated Financial Statements include the results of Dyax as of January 22, 2016. The amount of Dyax’s post-acquisition revenues included in the Company’s Consolidated Statements of Operations for the year ended December 31, 2016 is $77.1 million . After the closing of the acquisition, the Company began integrating Dyax and as such the combined business is now sharing various research and development and selling, general and administrative functions. As a result, computing a separate measure of Dyax's stand-alone profitability for periods after the acquisition date is not practical. Since the acquisition date, the Company adjusted its valuation and allocation of purchase price consideration. The adjustment, which was not material, decreased goodwill and deferred tax liabilities. The revised allocation of the total purchase price is as follows: (In millions) Fair value ASSETS Current assets: Cash and cash equivalents $ 241.2 Accounts receivable 22.5 Inventories 20.2 Other current assets 8.1 Total current assets 292.0 Property, plant and equipment 5.8 Goodwill 2,702.1 Intangible assets Currently marketed projects 135.0 IPR&D 4,100.0 Contract based royalty arrangements 425.0 Other non-current assets 28.6 Total assets $ 7,688.5 LIABILITIES Current liabilities: Accounts payable and accrued expenses $ 30.0 Other current liabilities 1.7 Deferred tax liability 1,325.4 Other non-current liabilities 1.4 Total liabilities 1,358.5 Preliminary fair value of identifiable assets acquired and liabilities assumed $ 6,330.0 Consideration Preliminary fair value of purchase consideration $ 6,330.0 Currently marketed products Currently marketed products totaling $135.0 million relate to intellectual property rights acquired for KALBITOR. The fair value of the currently marketed product has been estimated using an income approach, based on the present value of incremental after tax cash flows attributable to KALBITOR. The estimated useful life of the KALBITOR intangible asset is 18 years , with amortization being recorded on a straight-line basis. IPR&D The IPR&D asset of $4,100.0 million relates to Dyax’s clinical program SHP643, a Phase 3 program with the potential for improved efficacy and convenience for HAE patients. The IPR&D intangible asset is capitalized and accounted for as indefinite-lived intangible assets and will be subject to impairment testing until completion or abandonment of the projects. The fair value of this IPR&D asset was estimated based on an income approach, using the present value of incremental after tax cash flows expected to be generated by this development project. The estimated cash flows have been probability adjusted to take into account the development stage of completion and the remaining risks and uncertainties surrounding the future development and commercialization. The estimated probability adjusted after tax cash flows used to estimate the fair value of Intangible assets have been discounted at 9% . Royalty rights Intangible assets totaling $425.0 million relate to royalty rights arising from licensing agreements of a portfolio of product candidates. This portfolio includes two approved products, marketed by Eli Lilly & Company, and various development-stage products. Multiple product candidates with other pharmaceutical companies are in various stages of clinical development for which the Company is eligible to receive future royalties and/or milestone payments. The fair value of these royalty rights has been estimated using an income approach, based on the present value of incremental after-tax cash flows attributable to each royalty right. The estimated useful lives of these royalty rights range from seven to nine years (weighted average eight years), with amortization being recorded on a straight-line basis. Goodwill Goodwill of $2,702.1 million , which is not deductible for tax purposes, includes the expected synergies that will result from combining the operations of Dyax with Shire; intangible assets that do not qualify for separate recognition at the time of the acquisition; the value of the assembled workforce; and impacted by establishing a deferred tax liability for the acquired identifiable intangible assets which have no tax basis. For the year ended December 31, 2016, the Company expensed $67.7 million relating to the acquisition and integration of Dyax, which has been recorded within Integration and Acquisition costs in the Company’s Consolidated Statements of Operations. Supplemental disclosure of pro forma information The following unaudited pro forma financial information presents the combined results of the operations of Shire and Dyax as if the acquisitions of Dyax had occurred as of January 1, 2015. The unaudited pro forma financial information is not necessarily indicative of what the consolidated results of operations actually would have been had the respective acquisitions been completed at the date indicated. In addition, the unaudited pro forma financial information does not purport to project the future results of operations of the combined Company. December 31, (In millions) 2016 2015 Revenues $ 11,402.5 $ 6,503.8 Net income from continuing operations 792.2 1,056.6 Per share amounts: Net income from continuing operations per share - basic $ 1.03 $ 1.79 Net income from continuing operations per share - diluted $ 1.02 $ 1.78 The unaudited pro forma financial information above reflects the following pro forma adjustments: (i) an adjustment to increase net income for the year ended December 31, 2016 by $111.1 million to eliminate acquisition related costs incurred by Shire and Dyax and a corresponding decrease in net income for the year ended December 31, 2015 by $111.1 million to give effect to the acquisition of Dyax as if it had occurred on January 1, 2015; (ii) an adjustment to decrease net income for the year ended December 31, 2015 by $5.4 million , to reflect amortization of the fair value adjustments for inventory as inventory is sold; (iii) an adjustment to increase amortization expense for the year ended December 31, 2016 by $1.3 million and a corresponding adjustment to decrease net income for the year ended December 31, 2015 by $21.6 million , related to the identifiable intangible assets acquired; and (iv) an adjustment to record interest expense for the year ended December 31, 2015 of $81.6 million associated with the debt incurred to partially fund the acquisition of Dyax and the amortization of related deferred debt issuance costs. The adjustments above are stated net of their tax effects, where applicable. Acquisition of NPS On February 21, 2015, Shire completed its acquisition of all of the outstanding common stock of NPS. As of the acquisition date, fair value of the cash consideration paid on closing was $5,219.6 million . The acquisition of NPS added GATTEX/REVESTIVE and NATPARA/NATPAR to Shire’s portfolio of currently marketed products. GATTEX/REVESTIVE is approved in the U.S. and EU for the treatment of adults with short bowel syndrome (“SBS”) who are dependent on parenteral support, a rare and potentially fatal gastrointestinal disorder. NATPARA/NATPAR is approved in the U.S. and indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism (“HPT”), a rare endocrine disease. The acquisition of NPS was accounted for as a business combination using the acquisition method. The assets acquired and the liabilities assumed from NPS have been recorded at their fair values at the date of acquisition, February 21, 2015. The Company’s Consolidated Financial Statements include the results of NPS from February 21, 2015. The purchase price allocation for the acquisition of NPS was finalized in the fourth quarter of 2015. The Company’s allocation of the purchase price to the fair value of assets acquired and liabilities assumed is outlined below: (In millions) Fair value ASSETS Current assets: Cash and cash equivalents $ 41.6 Short-term investments 67.0 Accounts receivable 33.4 Inventories 89.4 Other current assets 11.1 Total current assets 242.5 Property, plant and equipment 4.8 Goodwill 1,551.0 Intangible assets Currently marketed products 4,640.0 Royalty rights (categorized as "Other intangible assets") 353.0 Total assets $ 6,791.3 LIABILITIES Current liabilities: Accounts payable and other current liabilities $ 75.7 Short-term borrowings and capital lease obligations 27.4 Long-term borrowings and capital lease obligations 78.9 Deferred tax liabilities 1,385.2 Other non-current liabilities 4.5 Total liabilities 1,571.7 Fair value of identifiable assets acquired and liabilities assumed $ 5,219.6 Consideration Cash consideration paid $ 5,219.6 Currently marketed products Currently marketed products totaling $4,640.0 million relate to intellectual property rights of NATPARA/NATPAR and GATTEX/REVESTIVE. The fair value of the currently marketed products has been estimated using an income approach, based on the present value of incremental after tax cash flows attributable to each separately identifiable intangible asset. The estimated useful lives of the NATPARA/NATPAR and GATTEX/REVESTIVE intangible assets are 24 years, with amortization being recorded on a straight-line basis. Royalty rights Intangible assets totaling $353.0 million relate to the royalty rights arising from the collaboration agreements with Amgen Inc (“Amgen”), Depomed, Inc. (“Depomed”) and Kyowa Hakko Kirin Co. Ltd (“Kyowa Hakko Kirin”). Amgen markets cinacalcet HCl as Sensipar in the U.S. and as Mimpara in the EU; Depomed markets tapentadol as Nucynta in the U.S.; and Kyowa Hakko Kirin markets cinacalcet HCI as Regpara in Japan, Hong Kong, Malaysia, Macau, Singapore, and Taiwan. From the acquisition of NPS, the Company is entitled to royalties from the net sales of these products. The fair value of these royalty rights has been estimated using an income approach, based on the present value of incremental after tax cash flows attributable to each royalty right. The estimated useful lives of these royalty rights range from four to five years (weighted average four years) with amortization being recorded on a straight-line basis. Goodwill Goodwill of $1,551.0 million , which is not deductible for tax purposes, includes the expected synergies that will result from combining the operations of NPS with the operations of Shire; intangible assets that do not qualify for separate recognition at the time of the acquisition; the value of the assembled workforce; and impacted by establishing a deferred tax liability for the acquired identifiable intangible assets which have no tax basis. Supplemental disclosure of pro forma information The following unaudited pro forma financial information presents the combined results of the operations of Shire and NPS as if the acquisitions of NPS had occurred as of January 1, 2014. The unaudited pro forma financial information is not necessarily indicative of what the consolidated results of operations actually would have been had the respective acquisitions been completed on January 1, 2014. In addition, the unaudited pro forma financial information does not purport to project the future results of operations of the combined Company. December 31, (In millions) 2015 Revenues $ 6,446.6 Net income from continuing operations 1,293.6 Per share amounts: Net income from continuing operations per share - basic $ 2.19 Net income from continuing operations per share - diluted $ 2.18 The unaudited pro forma financial information above reflects the following pro forma adjustments: (i) an adjustment to increase net income for the year ended December 31, 2015 by $105.3 million , to eliminate acquisition related costs incurred by Shire and NPS; (ii) an adjustment to increase net income by $18.8 million for the year ended December 31, 2015, to reflect charges on the unwind of inventory fair value adjustments as acquisition date inventory is sold; and (iii) an adjustment to increase amortization expense for the year ended December 31, 2015 by $22.2 million , related to the identifiable intangible assets acquired. The adjustments above are stated net of their tax effects, where applicable.

Collaborative and Other Licensi

Collaborative and Other Licensing Arrangements	12 Months Ended
	Dec. 31, 2016
Collaborative and Other Licensing Arrangements Disclosure [Abstract]
Collaborative and Other Licensing Arrangements	Collaborative and Other Licensing Arrangements The Company is party to certain collaborative and licensing arrangements. In some of these arrangements, Shire and the licensee are both actively involved in the development and commercialization of the licensed product and have exposure to risks and rewards dependent on its commercial success. Out-licensing arrangements The Company has entered into various licensing arrangements where it has licensed certain product or intellectual property rights for consideration such as up-front payments, development milestones, sales milestones and/or royalty payments. Under the terms of these licensing arrangements, the Company may receive development milestone payments up to an aggregate amount of $10.3 million and sales milestones up to an aggregate amount of $15.7 million . The receipt of these substantive milestones is uncertain and contingent on the achievement of certain development milestones or the achievement of a specified level of annual net sales by the licensee. During the year ended 2016 and 2015 , the Company received cash related to up-front and milestone payments of $10.5 million and $19.6 million , respectively. During the year ended 2016 , 2015 and 2014 , the Company recognized milestone income of $17.4 million , $8.9 million and $16.7 million , respectively, in other revenues, and $63.0 million , $51.0 million and 46.5 million , respectively, in product sales for shipment of product to the relevant licensee. Collaboration and in-licensing arrangements The Company is party to various collaborative and in-licensing arrangements, many of which were acquired through the acquisition of Baxalta. These agreements generally provide for commercialization rights to a product or products being developed by the counterparty, and in exchange often resulted in an upfront payment upon execution of the agreement and an obligation that the Company make future development, regulatory approval or commercial milestone payments as well as royalty payments. The following is a description of the Company's significant collaboration agreements, including those that were acquired by the Company. The acquisition-date fair value of the collaboration agreements acquired from Baxalta was included in the IPR&D. Pfizer Inc. In July 2016, the Company licensed the global rights to all indications for SHP647 from Pfizer Inc. SHP647 is an investigational biologic being evaluated for the treatment of moderate-to-severe inflammatory bowel disease. Under the terms of the agreement, Pfizer received an upfront payment of $90.0 million , and is eligible to receive between $75.0 million to $460.0 million in milestone payments based on clinical, regulatory and commercialization milestones and low double-digit royalties on any potential sales if the product is approved. Sangamo BioSciences In September 2015, Shire and Sangamo BioSciences, Inc. (“Sangamo”) agreed to revise the collaboration and license agreement originally entered into in January 2012 to expedite the development of ZFP Therapeutics for hemophilia A and B and Huntington's disease. Under the revised terms, Shire has returned to Sangamo the exclusive world-wide rights to gene targets for the development, clinical testing and commercialization of ZFP Therapeutics for hemophilia A and B, and has retained rights and will continue to develop ZFP Therapeutic clinical leads for Huntington's disease and a ZFP Therapeutic for one additional gene target. Each company will be responsible for expenses associated with its own programs and will reimburse the other for any ongoing services provided. Sangamo has granted Shire a right of first negotiation to license the hemophilia A and B programs. No milestone payments will be made on any program and each company will pay certain royalties to the other on commercial sales up to a specified maximum cap. Precision BioSciences In June 2016, the Company acquired a strategic immuno-oncology collaboration with Precision BioSciences (“Precision”), a private biopharmaceutical company based in the United States, specializing in genome editing technology. The Company acquired the collaboration through the acquisition of Baxalta. Together, Shire and Precision will develop chimeric antigen receptor (“CAR”) T cell therapies for up to six unique targets, with the first program expected to enter clinical studies in late 2017. On a product-by-product basis, following successful completion of early-stage research activities up to Phase 2, Shire will have exclusive option rights to complete late-stage development and worldwide commercialization. Precision is responsible for development costs for each target prior to option exercise. Precision also has the right to participate in the development and commercialization of any licensed products resulting from the collaboration through a 50/50 co-development and co-promotion option in the United States. As of the balance sheet date, the Company had the potential to make future payments related to option fees and development, regulatory and commercial milestones totaling up to $1.5 billion , in addition to future royalty payments on worldwide sales. Symphogen In June 2016, the Company acquired a research, option and commercial agreement with Symphogen, a private biopharmaceutical company headquartered in Denmark that is developing recombinant antibodies and antibody mixtures. The Company acquired the agreement through the acquisition of Baxalta. Under the terms of the agreement, the Company has options to obtain exclusive licensing rights for four specified proteins in development for the treatment of immune-oncology diseases as well as two additional proteins that may be selected at a later date. Each option is exercisable for a period of 90 days when each protein is ready for Phase 2 clinical trials. Symphogen is responsible for development costs for each protein until option exercise, at which point Shire would become responsible for development costs. Each option exercise fee is variable depending on when it is exercised, with a maximum exercise price of up to €20.0 million for each protein. As of the balance sheet date, the Company had the potential to make additional future payments of up to approximately €1.2 billion related to development, regulatory and commercial milestones achieved after option exercise for all six proteins, in addition to future royalty payments. Merrimack Pharmaceuticals, Inc. In June 2016, the Company acquired an exclusive license agreement with Merrimack Pharmaceuticals, Inc. (“Merrimack”) relating to the development and commercialization of ONIVYDE (nanoliposomal irinotecan injection), also known as “nal-IRI” or MM-398. The Company acquired the agreement through the acquisition of Baxalta. The arrangement includes all potential indications for nal-IRI across all markets with the exception of the U.S. and Taiwan. The first indication being pursued is for the treatment of patients with metastatic pancreatic cancer who were previously treated with gemcitabine-based therapy. As of December 31, 2016, the company had potential payments related to development, regulatory and commercial milestones of $637.5 million . Coherus Biosciences, Inc. In June 2016, the Company acquired a license agreement with Coherus Biosciences, Inc. (“Coherus”) to develop and commercialize a biosimilar to ENBREL® (etanercept). The Company acquired the agreement through the acquisition of Baxalta. The Company also obtained the right of first refusal to certain other biosimilars in the collaboration. Under the terms of the agreement, Coherus was responsible for the development plan, preparation of regulatory filings, and manufacture of the product, subject to certain cost reimbursement by the Company. In September 2016, the Company terminated the licensing agreement with Coherus in accordance with its terms. Momenta Pharmaceuticals, Inc. In June 2016, the Company acquired an exclusive license agreement with Momenta Pharmaceuticals, Inc. (“Momenta”) to develop and commercialize biosimilars, including adalimumab (BAX 2923), a biosimilar product candidate for HUMIRA® (adalimumab). The agreement was acquired through the acquisition of Baxalta. The arrangement includes specified funding by the Company, as well as other responsibilities, relating to development and commercialization activities. In December 2016, the Company formally terminated its agreement with Momenta and agreed to pay $51.2 million , which was paid in January 2017, to satisfy its remaining obligations under the agreement, except with respect to certain clinical and regulatory services. The Company will be responsible for costs associated with those activities through April 2017. As part of this termination, on December 31, 2016, the Company and Momenta entered into an Asset Return and Termination Agreement that provided for the earlier termination of the license agreement and agreed to the terms associated with the termination. Other arrangements SFJ Pharmaceuticals Group In June 2015, Baxalta entered into a co-development agreement with SFJ Pharmaceuticals IX, L.P., a SFJ Pharmaceuticals Group company (“SFJ”) relating to BAX 2923, whereby SFJ would fund specified development costs related to the BAX 2923 program, in exchange for payments in the event the product obtains regulatory approval in the United States and Europe. There were certain termination provisions that could have triggered payment of the contingent success payments prior to regulatory approval. The preliminary fair value of the assumed contingency was recorded as a long-term liability at June 3, 2016 and as of the balance sheet date, as part of Company’s purchase accounting for the Baxalta acquisition. The fair value of the assumed contingency on the date of acquisition was $288.6 million . This co-development agreement was terminated by mutual agreement of the Company and SFJ in September 2016 and the Company made a one-time $288.0 million payment to SFJ in connection with the termination, in full satisfaction of the Company’s financial obligations under the agreement.

Integration and Acquisition Cos

Integration and Acquisition Costs	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Integration and Acquisition Costs	Integration and Acquisition Costs For the year ended December 31, 2016 , Shire recorded integration and acquisition costs of $883.9 million , primarily due to the acquisition and integration of Baxalta and Dyax and related contract termination costs. The Baxalta integration is estimated to be completed by mid to late 2019 and the integration of Dyax is substantially complete as of December 31, 2016 . As part of the Company’s activities to integrate Baxalta, it terminated certain employees and announced plans to close certain facilities. For the year ended December 31, 2016 , the Company incurred costs relating to employee termination benefits of $381.2 million including severance and acceleration of stock compensation. The Baxalta integration activities are ongoing and the Company is continuing to evaluate the total costs expected to be incurred and the time-frame. The following table summarizes the related reserve as of December 31, 2016 : (In millions) Severance and employee benefits As of January 1, 2016 $ — Amount charged to integration costs 267.3 Paid/utilized (193.3 ) As of December 31, 2016 $ 74.0 For the year ended December 31, 2015 , Shire recorded net integration and acquisition costs of $39.8 million . The net integration and acquisition costs principally comprises costs related to the acquisition and integration of NPS Pharma, Viropharma, Dyax and Baxalta of $189.7 million , offset by a net credit relating to the change in the fair value of contingent consideration liabilities of $149.9 million . This net credit principally relates to the acquisition of Lumena, reflecting the agreement in the third quarter of 2015 to settle all future contingent milestones payable to former Lumena shareholders for a one-time cash payment of $90.0 million and the acquisition of Lotus Tissue Repair, Inc. reflecting a lower probability of success for the SHP608 asset (for the treatment of Dystrophic Epidermolysis Bullosa (“DEB”)) as a result of certain preclinical toxicity findings. For the year ended December 31, 2014, Shire recorded integration and acquisition costs of $158.8 million , comprised of $144.1 million relating to the acquisition and integration of ViroPharma and a net charge of $14.7 million relating to the change in fair value of contingent consideration liabilities mainly related to the acquisition of SARcode Bioscience Inc. (“SARcode”) offset by credits in relation to the acquisition of FerroKin BioSciences, Inc., reflecting the decision to place the Phase 2 clinical trial for SHP602 on clinical hold.

Reorganization Costs

Reorganization Costs	12 Months Ended
	Dec. 31, 2016
Restructuring and Related Activities [Abstract]
Reorganization Costs	Reorganization Costs The Company incurred reorganization costs totaling $121.4 million during the year ended December 31, 2016 . The costs primarily relate to the planned closure of certain manufacturing facilities and associated asset impairments of $77.4 million and employee termination and other costs of $16.2 million . As of December 31, 2016 , cash payments associated with these costs were not significant. Other restructuring charges recorded, which were not significant for the year ended December 31, 2016 , relate to the closure of other offices and the related employee relocation. In October 2014, the Company announced its plans to relocate positions to Lexington, Massachusetts from its Chesterbrook, Pennsylvania site and establish Lexington as the Company’s U.S. operational headquarters in continuation of the One Shire efficiency program. During 2015 and 2014, the Company incurred reorganization costs totaling $97.9 million and $180.9 million , respectively, relating to employee involuntary termination benefits and other reorganization costs primarily related to the Company's One Shire business reorganization. The One Shire reorganization was substantially completed as of December 31, 2015.

Results of Discontinued Operati

Results of Discontinued Operations	12 Months Ended
	Dec. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
Results of Discontinued Operations	Results of Discontinued Operations Following the divestment of the Company’s DERMAGRAFT business in January 2014, the operating results associated with the DERMAGRAFT business have been classified as discontinued operations in the Consolidated Statements of Operations for all periods presented. During the year ended December 31, 2016 , the Company recorded a loss from discontinued operations of $276.1 million (net of tax of $98.8 million ), pr imarily due to legal contingencies related to the divested DERMAGRAFT business. During the year ended December 31, 2015 , the Company recorded a loss from discontinued operations of $34.1 million (net of tax of $18.9 million ), primarily relating to a change in estimate in relation to reserves for onerous leases retained by the Company. During the year ended December 31, 2014, the Company recorded a gain from discontinued operations of $122.7 million (net of tax of $211.3 million ). The gain from discontinued operations for the year ended December 31, 2014 includes a tax credit of $211.3 million primarily driven by a tax benefit arising following a reorganization of the former Regenerative Medicine business undertaken in the fourth quarter of 2014, associated with the divestment of the DERMAGRAFT business in the first quarter of 2014. This gain was partially offset by costs associated with the divestment of the DERMAGRAFT business, including a loss on re-measurement of contingent consideration receivable from Organogenesis to its fair value.

Accounts Receivable, Net

Accounts Receivable, Net	12 Months Ended
	Dec. 31, 2016
Receivables [Abstract]
Accounts Receivable, Net	Accounts Receivable, Net Accounts receivable as of December 31, 2016 of $2,616.5 million ( December 31, 2015 : $1,201.2 million ), are stated at the invoiced amount and net of provision for discounts and doubtful accounts of $169.6 million ( December 31, 2015 : $55.8 million , 2014 : $48.5 million ). Provision for discounts and doubtful accounts: (In millions) 2016 2015 2014 As of January 1, $ 55.8 $ 48.5 $ 47.9 Provision charged to operations 838.1 424.2 338.2 Provision utilization (724.3 ) (416.9 ) (337.6 ) As of December 31, $ 169.6 $ 55.8 $ 48.5 As of December 31, 2016 accounts receivable included $102.2 million ( December 31, 2015 : $79.0 million ) related to royalty receivable.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories are stated at the lower of cost or market. Inventories comprise: December 31, December 31, (In millions) 2016 2015 Finished goods $ 1,380.0 $ 184.9 Work-in-progress 1,491.0 302.0 Raw materials 691.3 148.5 $ 3,562.3 $ 635.4 As of December 31, 2016 and 2015 , there was $18.1 million and $nil amounts of inventory which have been capitalized in advance of regulatory approval, respectively. For a more detailed description of the inventories acquired with Baxalta and Dyax, refer to Note 3 , Business Combinations , to the Consolidated Financial Statements set forth in this Annual Report on Form 10-K.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2016
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Components of prepaid expenses and other current assets are summarized as follows: December 31, December 31, (In millions) 2016 2015 Income tax receivable $ 237.5 $ 73.6 Prepaid expenses 183.9 35.6 Value added taxes receivable 40.3 18.2 Other current assets 344.6 70.0 $ 806.3 $ 197.4

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net Property, plant and equipment are recorded at cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows: December 31, December 31, (In millions) 2016 2015 Land $ 337.9 $ 96.7 Buildings and leasehold improvements 1,915.4 606.4 Machinery, equipment and other 2,547.2 827.4 Assets under construction 2,632.5 93.7 Total property, plant and equipment at cost 7,433.0 1,624.2 Less: Accumulated depreciation (963.4 ) (796.1 ) Property, plant and equipment, net $ 6,469.6 $ 828.1 Depreciation expense for the years ended December 31, 2016 , 2015 and 2014 was $292.9 million , $138.5 million and $163.5 million , respectively.

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill The following table provides a roll-forward of the goodwill balance: (In millions) 2016 2015 As of January 1, $ 4,147.8 $ 2,474.9 Acquisitions 14,124.5 1,700.1 Foreign currency translation (384.1 ) (27.2 ) As of December 31, $ 17,888.2 $ 4,147.8 During 2016, the Company completed the acquisitions of Baxalta and Dyax which resulted in aggregate goodwill of $14,124.5 million . For a more detailed description of these transactions, refer to Note 3 , Business Combinations , to the Consolidated Financial Statements set forth in this Annual Report on Form 10-K.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2016
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Intangible Assets	Intangible Assets The following table summarizes the Company's intangible assets: (In millions) Currently marketed products IPR&D Other intangible assets Total December 31, 2016 Gross acquired intangible assets $ 31,217.5 $ 5,746.6 $ 842.2 $ 37,806.3 Accumulated amortization (2,908.6 ) — (200.2 ) (3,108.8 ) Intangible assets, net $ 28,308.9 $ 5,746.6 $ 642.0 $ 34,697.5 December 31, 2015 Gross acquired intangible assets $ 9,371.9 $ 1,362.0 $ 375.0 $ 11,108.9 Accumulated amortization (1,852.1 ) — (83.5 ) (1,935.6 ) Intangible assets, net $ 7,519.8 $ 1,362.0 $ 291.5 $ 9,173.3 Intangible assets are comprised primarily of royalty rights and other contract rights associated with Baxalta, Dyax and NPS. The change in the net book value of Intangible assets for the year ended December 31, 2016 and 2015 is shown in the table below: (In millions) 2016 2015 As of January 1, $ 9,173.3 $ 4,934.4 Additions 27,462.8 5,474.9 Amortization charged (1,173.4 ) (498.7 ) Impairment charges (8.9 ) (643.7 ) Foreign currency translation (756.3 ) (93.6 ) As of December 31, $ 34,697.5 $ 9,173.3 In connection with the acquisition of Baxalta, the Company acquired IP rights related to currently marketed products of $ 21,995.0 million , IPR&D assets of $ 730.0 million and other contract rights of $ 42.2 million . For a more detailed description of this acquisition, refer to Note 3 , Business Combinations , to the Consolidated Financial Statements set forth in this Annual Report on Form 10-K. In connection with the acquisition of Dyax, the Company acquired IP rights related to currently marketed products of $ 135.0 million , IPR&D assets of $ 4,100.0 million and royalty rights of $ 425.0 million . For a more detailed description of this acquisition, refer to Note 3 , Business Combinations , to the Consolidated Financial Statements set forth in this Annual Report on Form 10-K. In the year ended December 31, 2015 , the Company acquired intangible assets totaling $5,474.9 million , primarily relating to the fair value of intangible assets for currently marketed products and royalty rights acquired with NPS Pharma of $4,993.0 million and IPR&D assets of $475.0 million acquired with Meritage and Foresight. The Company reviews its intangible assets for impairment whenever events or circumstances suggest that their carrying value may not be recoverable. For the year ended December 31, 2015 , the Company recorded $643.7 million (within R&D expenses) in impairment charges related to its SHP625 and SHP608 IPR&D assets. The fair values of the related contingent consideration liabilities (recorded within integration and acquisition costs) were reduced by $203.2 million . Estimated amortization expense can be affected by various factors including future acquisitions, disposals of product rights, regulatory approval and subsequent amortization of acquired IPR&D projects, foreign exchange movements and the technological advancement and regulatory approval of competitor products. The estimated future amortization of acquired intangible assets for the next five years is expected to be as follows: (In millions) Anticipated future amortization 2017 $ 1,592.0 2018 1,585.2 2019 1,506.5 2020 1,502.8 2021 1,496.8

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement Assets and liabilities that are measured at fair value on a recurring basis As of December 31, 2016 and December 31, 2015 , the following financial assets and liabilities are measured at fair value on a recurring basis using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3). (In millions) Carrying value and fair value As of December 31, 2016 Total Level 1 Level 2 Level 3 Financial assets: Marketable equity securities $ 65.8 $ 65.8 $ — $ — Marketable debt securities 15.5 3.6 11.9 — Contingent consideration receivable 15.6 — — 15.6 Derivative contracts 18.0 — 18.0 — Total 114.9 69.4 29.9 15.6 Financial liabilities: Derivative contracts 8.3 — 8.3 — Contingent consideration payable 1,058.0 — — 1,058.0 Total $ 1,066.3 $ — $ 8.3 $ 1,058.0 (In millions) Carrying value and fair value As of December 31, 2015 Total Level 1 Level 2 Level 3 Financial assets: Marketable equity securities $ 17.2 $ 17.2 $ — $ — Contingent consideration receivable 13.8 — — 13.8 Derivative contracts 1.9 — 1.9 — Total 32.9 17.2 1.9 13.8 Financial liabilities: Derivative contracts 11.5 — 11.5 — Contingent consideration payable 475.9 — — 475.9 Total $ 487.4 $ — $ 11.5 $ 475.9 Marketable equity and debt securities are included within Investments in the Consolidated Balance Sheets. Shire's strategic investment portfolio includes investments in equity securities of certain biotechnology companies and in venture capital funds where the underlying investments are in equity securities of biotechnology companies. Contingent consideration receivable is included within Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets. Contingent consideration payable is included within Other current liabilities and Other non-current liabilities in the Consolidated Balance Sheets. For a more detailed description of the Company's derivative contracts, refer to Note 15 , Financial Instruments , to the Consolidated Financial Statements set forth in this Annual Report on Form 10-K. Certain estimates and judgments were required to develop the fair value amounts. The estimated fair value amounts shown above are not necessarily indicative of the amounts that the Company would realize upon disposition, nor do they indicate the Company’s intent or ability to dispose of the financial instrument. The following methods and assumptions were used to estimate the fair value of each material class of financial instrument: • Marketable equity securities: the fair values of marketable equity securities are estimated based on quoted market prices for those investments. • Marketable debt securities: the fair values of debt securities are obtained from pricing services or broker/dealers who either use quoted prices in an active market or proprietary pricing applications, which include observable market information for like or same securities. • Contingent consideration receivable: the fair value of the contingent consideration receivable has been estimated using the income approach (using a probability weighted discounted cash flow method). • Derivative contracts: the fair values of the swap and forward foreign exchange contracts have been determined using the month-end interest rate and foreign exchange rates, respectively. • Contingent consideration payable: the fair value of the contingent consideration payable has been estimated using the income approach (using a probability weighted discounted cash flow method). Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3) The following table provides a roll forward of the fair values of our contingent consideration receivable and payables which include Level 3 measurements: Contingent consideration receivable (In millions) 2016 2015 Balance at January 1, $ 13.8 $ 15.9 Change in fair value included in earnings 1.6 13.6 Other 0.2 (15.7 ) Balance at December 31, $ 15.6 $ 13.8 Contingent consideration payable (In millions) 2016 2015 Balance at January 1, $ 475.9 $ 629.9 Additions 565.4 92.8 Change in fair value included in earnings 11.1 (149.9 ) Other 5.6 (96.9 ) Balance at December 31, $ 1,058.0 $ 475.9 The increase in contingent consideration payable is primarily related to the Company’s acquisition of Dyax as well as contingent consideration payable assumed in the acquisition of Baxalta. Other primarily includes foreign currency adjustments. Of the $1,058.0 million of contingent consideration payable as of December 31, 2016 , $65.1 million is recorded within Other current liabilities and $992.9 million is recorded within Other non-current liabilities in the Company’s Consolidated Balance Sheets. Quantitative Information about Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3) Quantitative information about the Company’s recurring Level 3 fair value measurements is included below: Financial assets: Fair value at the measurement date As of December 31, 2016 (In millions, except %) Fair value Valuation technique Significant unobservable inputs Range Contingent consideration receivable ("CCR") $ 15.6 Income approach (probability weighted discounted cash flow) Probability weightings applied to different sales scenarios 10 to 90% Future forecast consideration receivable based on contractual terms with purchaser $0 to $21 million Assumed market participant discount rate 8% Financial liabilities: Fair value at the measurement Date As of December 31, 2016 (In millions, except %) Fair value Valuation technique Significant unobservable inputs Range Contingent consideration payable $ 1,058.0 Income approach (probability weighted discounted cash flow) Cumulative probability of milestones being achieved 6 to 90% Assumed market participant discount rate 1.2 to 10.5% Periods in which milestones are expected to be achieved 2017 to 2040 Forecast quarterly royalties payable on net sales of $0.1 to $7.5 million Contingent consideration payable represents future milestones and royalties the Company may be required to pay in conjunction with various business combinations and license agreements. The fair value of the Company’s contingent consideration receivable and payable could significantly increase or decrease due to changes in certain assumptions which underpin the fair value measurements. Each set of assumptions is specific to the individual contingent consideration receivable or payable. Financial assets and liabilities that are disclosed at fair value The carrying amounts and estimated fair values of the Company’s financial assets and liabilities are as follows: December 31, 2016 December 31, 2015 (In millions) Carrying amount Fair value Carrying amount Fair value Financial liabilities: Senior Notes $ 12,039.2 $ 11,633.8 $ — $ — Baxalta Notes 5,063.6 5,066.5 — — Capital lease obligation 353.6 353.6 13.4 13.4 The estimated fair values of Senior Notes and Baxalta Notes were based upon recent observable market prices and are considered level 2 in the fair value hierarchy. The estimated fair value of the capital lease obligations is based on Level 2 inputs. The carrying amounts of other financial assets and liabilities approximate their estimated fair value due to their short-term nature, such as liquidity and maturity of these amounts, or because there have been no significant changes since the asset or liability was last re-measured to fair value on a non-recurring basis.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2016
Derivative Instrument Detail [Abstract]
Financial Instruments	Financial Instruments Foreign Currency Contracts Due to the global nature of operations, portions of the Company’s revenues and operating expenses are recorded in currencies other than the U.S. dollar. The value of revenues and operating expenses measured in U.S. dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, the Company uses foreign currency forward contracts to lock in exchange rates associated with a portion of its forecasted international revenues and operating expenses. The main trading currencies of the Company are the U.S. dollar, Euro, Pounds sterling, Swiss franc, Canadian dollar and Japanese yen. Transactional exposure arises where transactions occur in currencies different to the functional currency of the relevant subsidiary. It is the Company’s policy that these exposures are minimized to the extent practicable by denominating transactions in the subsidiary’s functional currency. Where significant exposures remain, the Company uses foreign exchange contracts (spot, forward and swap contracts) to manage the exposure for balance sheet assets and liabilities that are denominated in currencies different to the functional currency of the relevant subsidiary. The Company has master netting agreements with a number of counterparties to these foreign exchange contracts and on the occurrence of specified events, the Company has the ability to terminate contracts and settle them with a net payment by one party to the other. The Company has elected to present derivative assets and derivative liabilities on a gross basis in the Consolidated Balance Sheets. The Company does not have credit risk related contingent features or collateral linked to the derivatives. Designated Derivative Instruments Certain foreign currency forward contracts have been designated as cash flow hedges and accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in AOCI. Realized gains and losses for the effective portion of such contracts are recognized in cost of sales when the sale of product in the currency being hedged is recognized. To the extent ineffective, hedge transaction gains and losses are reported in Other income/(expense), net. The amount of ineffectiveness for the years ended December 31, 2016 and December 31, 2015 was immaterial. As of December 31, 2016 , the foreign currency forward contracts had a total notional value of $78.7 million with a maximum duration of six months. The Company did not have any designated forward contracts as of December 31, 2015. As of December 31, 2016 , the fair value of these contracts was a net asset of $4.2 million (2015: $nil ). The portion of the fair value of these foreign currency forward contracts that was included in AOCI in total equity reflected net gain of $14.6 million as of December 31, 2016 . The Company expects all contracts to be settled over the next six months and any amounts in AOCI to be reported as an adjustment to revenue or cost of sales. The Company considers the impact of its and its counterparties’ credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of December 31, 2016 , credit risk did not change the fair value of the Company’s foreign currency forward contracts. Undesignated Derivative Instruments The Company uses forward contracts to mitigate the foreign currency risk related to certain balance sheet positions, including intercompany and third-party receivables and payables. The Company has not elected hedge accounting for these derivative instruments as the duration of these contracts is typically three months or less. The changes in fair value of these derivatives are reported in earnings. The notional amount of undesignated derivative instruments was $1,309.1 million and $645.2 million as of December 31, 2016 and 2015, respectively. As of December 31, 2016 the undesignated derivative instruments included option contracts assumed from Baxalta that were previously designated as cash flow hedges. The notional amount of these option contracts totaled $11.2 million as of December 31, 2016 . Upon acquisition, the Company did not elect to redesignate these option contracts as cash flow hedges. In addition, the company also assumed undesignated forward contracts from Baxalta, included in undesignated derivative instruments as of December 31, 2016 . The notional amount of these undesignated forward contracts totaled $776.4 million as of December 31, 2016 . As of December 31, 2016 , the fair value of these contracts was a net asset of $6.7 million (2015: $nil ). Interest Rate Contracts The Company is exposed to the risk that its earnings and cash flows could be adversely impacted by fluctuations in benchmark interest rates relating to its debt obligations on which interest is set at floating rates. The Company’s policy is to manage this risk to an acceptable level. The Company is principally exposed to interest rate risk on any borrowings under the Company’s various debt facilities and on part of the senior notes assumed in connection with the acquisition of Baxalta. Interest on each of these debt obligations is set at floating rates, to the extent utilized. Shire’s exposure under these facilities is to changes in U.S. dollar interest rates. For a more detailed description related to interest rates on the Company’s various debt facilities, refer to Note 17 , Borrowings and Capital Lease Obligations , to the Consolidated Financial Statements set forth in this Annual Report on Form 10-K. Designated Derivative Instruments As of December 31, 2016 , interest rate swap contracts with an aggregate notional amount of $1.0 billion and maturing in June 2020 and June 2025 were in place. These interest rate swap contracts were designated as fair value hedges. The effective portion of the changes in the fair value of interest rate swap contracts are recorded as a component of the underlying Baxalta Notes with the ineffective portion recorded as income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in the Consolidated Statements of Operations. As of December 31, 2016 , the fair value of these contracts was a net liability of $1.1 million (2015: $ nil ) presented within other non-current liabilities. For the year ended December 31, 2016 , the Company recognized a loss of $6.0 million as ineffectiveness (2015: $nil ) related to these contracts as a component of interest expense. Undesignated Derivative Instruments During the year ended December 31, 2016 , the Company entered into interest rate swap contracts with a total notional amount of $5.1 billion related to the November 2015 Facilities Agreement, which matured during 2016. The Company did not elect hedge accounting for these contracts. As of December 31, 2016 and December 31, 2015 , the Company did not have any outstanding undesignated derivative instruments. For the year ended December 31, 2016, the Company recognized $3.2 million (2015: $nil ) loss related to these contracts, which was recognized as a component of Interest expense. The following tables summarize the income statement locations and gains and losses on the Company’s designated and undesignated derivative instruments for the year ended December 31, 2016 . There were no designated derivatives for the year ended December 31, 2015. As of December 31, 2016 , the Company had in total 155 swaps and forward foreign exchange contracts. (In millions) Gain (loss) recognized in OCI Location in Statements of Operations Gain (loss) reclassified from AOCI into income Year ended December 31, 2016 2015 2016 2015 Designated Derivative Instruments Cash flow hedges Foreign exchange contracts $ 14.6 $ — Cost of sales $ 4.9 $ — (In millions) Location of gain (loss) in Statements of Operations Gain (loss) recognized in income Year ended December 31, 2016 2015 Fair value hedges Interest rate contracts Interest expense $ (6.0 ) $ — Undesignated Derivative Instruments Foreign exchange contracts Other (expense)/income, net (40.2 ) 9.5 Interest rate swap contracts Interest expense (3.2 ) — As of December 31, 2016 , $6.2 million of deferred gains, net of tax, on derivative instruments included in AOCI are expected to be recognized in earnings during the next 12 months, coinciding with when the hedged items are expected to impact earnings. The following table presents the classification and estimated fair value of the Company’s derivative instruments as of December 31, 2016 : Derivatives in asset positions Derivatives in liability positions (In millions) Balance Sheet location Fair value Balance Sheet location Fair value Designated Derivative Instruments Foreign exchange contracts Prepaid expenses and other current assets $ 4.3 Accounts payable and accrued expenses $ 0.1 Interest rate contracts Long term borrowings 0.1 Long term borrowings 1.3 4.4 1.4 Undesignated Derivative Instruments Foreign exchange forward contracts Prepaid expenses and other current assets 13.6 Accounts payable and accrued expenses 6.9 $ 18.0 $ 8.3 As of December 31, 2016 , the potential effect of rights to offset associated with the Interest rate swap and foreign exchange forward contracts would be an offset to both assets and liabilities of $1.7 million , resulting in net derivative assets and derivative liabilities of $16.3 million and $6.6 million , respectively.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2016
Accounts Payable and Accrued Liabilities, Current [Abstract]
Accounts Payable and Accrued Expenses	Accounts Payable and Accrued Expenses Components of Accounts payable and accrued expenses are summarized as follows: December 31, December 31, (In millions) 2016 2015 Accounts payable and accrued purchases $ 911.9 $ 441.4 Accrued employee compensation and benefits payable 574.8 254.5 Accrued rebates 1,431.3 982.4 Accrued sales returns 118.4 128.3 Other accrued expenses 1,276.0 244.0 $ 4,312.4 $ 2,050.6

Borrowings and Capital Lease Ob

Borrowings and Capital Lease Obligations	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Borrowings and Capital Lease Obligations	Borrowings and Capital Lease Obligations December 31, December 31, (In millions) 2016 2015 Short-term borrowings: Borrowings under the Revolving Credit Facilities Agreement (the “RCF”) $ 450.0 $ 750.0 Borrowings under the November 2015 Facilities Agreement 2,594.8 — Borrowings under the January 2015 Facilities Agreement — 750.0 Other borrowings and capital lease obligations (short term portion) 23.2 12.7 3,068.0 1,512.7 Long-term borrowings: Senior Notes 12,039.2 — Baxalta Notes 5,063.6 — Borrowings under the November 2015 Facilities Agreement 2,391.8 — Capital lease obligations (long term portion) 347.2 12.2 Other borrowings 58.0 69.9 $ 19,899.8 $ 82.1 $ 22,967.8 $ 1,594.8 The future payments related to short and long term borrowings and capital lease obligations, on maturities, as of December 31, 2016 are as follows: (In millions) 2017 $ 3,072.6 2018 3,217.2 2019 3,341.3 2020 1,035.3 2021 3,320.5 Thereafter 9,116.1 Total obligations 23,103.0 Less: Deferred financing costs (135.2 ) Total debt obligations $ 22,967.8 Senior Notes Issuance On September 23, 2016, Shire Acquisitions Investments Ireland Designated Activity Company ("SAIIDAC"), a wholly owned subsidiary of Shire Plc, issued senior notes with a total aggregate principal value of $12.1 billion (“SAIIDAC Notes”), guaranteed by Shire plc and, as of December 1, 2016, by Baxalta. SAIIDAC used the net proceeds to fully repay amounts outstanding under the January 2016 Facilities Agreement (discussed below), which was used to finance the cash consideration payable related to the Company’s acquisition of Baxalta. Below is a summary of the SAIIDAC Notes as of December 31, 2016 : (In millions, except %) Aggregate amount Coupon rate Effective interest rate Carrying amount Fixed-rate notes due 2019 $ 3,300.0 1.900 % 2.05 % $ 3,287.5 Fixed-rate notes due 2021 3,300.0 2.400 % 2.53 % 3,283.0 Fixed-rate notes due 2023 2,500.0 2.875 % 2.97 % 2,487.9 Fixed-rate notes due 2026 3,000.0 3.200 % 3.30 % 2,980.8 $ 12,100.0 $ 12,039.2 The SAIIDAC Notes are senior unsecured obligations and may be redeemed at SAIIDAC's option at the greater of (1) 100% of the principal amount plus accrued and unpaid interest or (2) the sum of the present values of the remaining scheduled payments of interest and principal discounted to the date of redemption on a semi-annual basis at the applicable treasury rate (as defined) plus an incremental margin, plus, in either case, accrued and unpaid interest. The SAIIDAC Notes also contain a change of control provision that may require that SAIIDAC to offer to purchase the SAIIDAC Notes at a price equal to 101% of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances. On December 1, 2016, Baxalta Inc., a wholly owned subsidiary of Shire Plc, fully and unconditionally guaranteed the SAIIDAC Notes. The costs and discount associated with this offering of $60.8 million have been recorded as a reduction to the carrying amount of the debt on the Consolidated Balance Sheets. These costs will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. Interest on the SAIIDAC Notes is payable March 23 and September 23 of each year, beginning on March 23, 2017. Baxalta Notes Shire plc guaranteed senior notes issued by Baxalta with a total aggregate principal amount of $5.0 billion in connection with the Baxalta acquisition (“Baxalta Notes”). Below is a summary of the Baxalta Notes as of December 31, 2016 : (In millions, except %) Aggregate principal Coupon rate Effective interest rate Carrying amount Variable-rate notes due 2018 $ 375.0 LIBOR plus 0.780% 2.20 % $ 371.6 Fixed-rate notes due 2018 375.0 2.000 % 2.00 % 374.8 Fixed-rate notes due 2020 1,000.0 2.875 % 2.80 % 1,004.3 Fixed-rate notes due 2022 500.0 3.600 % 3.30 % 508.4 Fixed-rate notes due 2025 1,750.0 4.000 % 3.90 % 1,772.8 Fixed-rate notes due 2045 1,000.0 5.250 % 5.10 % 1,031.7 Total Baxalta Notes $ 5,000.0 $ 5,063.6 The effective interest rates above exclude the effect of any related interest rate swaps. The book values above include any premiums and adjustments related to hedging instruments. For a more detailed description related to the interest rate derivative contracts, refer to Note 15 , Financial Instruments , to the Consolidated Financial Statements set forth in this Annual Report on Form 10-K. Revolving Credit Facilities Agreement On December 12, 2014 , Shire entered into a $2,100.0 million revolving credit facilities agreement (the “RCF”) with a number of financial institutions. Shire is an original borrower and original guarantor under the RCF. On January 15, 2016, SAIIDAC became an additional guarantor under the RCF and on December 1, 2016, Baxalta became an additional guarantor under the RCF. Shire has agreed to act as guarantor for any of its subsidiaries that become additional borrowers under the RCF. As of December 31, 2016 , the Company utilized $450.0 million of the RCF. The RCF, which terminates on December 12, 2021 , may be applied towards financing the general corporate purposes of Shire. The RCF incorporates a $250.0 million U.S. dollar and Euro swingline facility operating as a sub-limit thereof. Interest on any loans made under the RCF is payable on the last day of each interest period, which may be one week or one, two, three or six months at the election of Shire, or as otherwise agreed with the lenders. The interest rate for the RCF is: LIBOR (or, in relation to any revolving loan in Euro, EURIBOR); plus 0.30% per annum subject to change depending upon (i) the prevailing ratio of Net Debt to EBITDA (each as defined in the RCF) in respect of the most recently completed financial year or financial half year and (ii) the occurrence and continuation of an event of default in respect of the financial covenants or the failure to provide a compliance certificate. Shire shall also pay (i) a commitment fee equal to 35% of the applicable margin on available commitments under the RCF for the availability period applicable thereto and (ii) a utilization fee equal to (a) 0.10% per year of the aggregate of all outstanding loans up to an aggregate base currency amount equal to $700.0 million , (b) 0.15% per year of the amount by which the aggregate base currency amount of all outstanding loans exceeds $700.0 million but is equal to or less than $1,400.0 million and (c) 0.30% per year of the amount by which the aggregate base currency amount of all outstanding loans exceeds $1,400.0 million . The RCF includes customary representations and warranties, covenants and events of default, including requirements that Shire’s (i) ratio of Net Debt to EBITDA in respect of the most recently-ended 12 -month relevant period (each as defined in the RCF) must not, at any time, exceed 3.5 : 1 except that, following an acquisition fulfilling certain criteria, Shire may elect to increase this ratio to (a) 5.5 : 1 for the relevant period in which the acquisition was completed (b) 5.0 : 1 in respect of the first relevant period following the relevant period in which the acquisition was completed and (c) 4.5 : 1 in respect of the second relevant period following the relevant period in which the acquisition was completed and (ii) ratio of EBITDA to Net Interest for the most recently-ended 12 -month relevant period (each as defined in the RCF) must not be less than 4.0 : 1 . Shire elected to increase the Net Debt to EBITDA ratio in connection with the period ending June 30, 2016, following the completion of the acquisition of Baxalta during the period. Consequently, the applicable ratio for the period ending December 31, 2016 is 5.0 : 1 . The RCF restricts, subject to certain exceptions, Shire’s ability to incur additional financial indebtedness, grant security over its assets or provide loans/grant credit. Further, any lender may require mandatory prepayment of its participation if there is a change of control of Shire, subject to certain exceptions for schemes of arrangement and analogous schemes. Events of default under the RCF include, subject to customary grace periods and materiality thresholds: (i) non-payment of any amounts due under the finance documents (as defined in the RCF), (ii) failure to satisfy any financial covenants, (iii) material misrepresentation in any of the finance documents, (iv) failure to pay, or certain other defaults, under other financial indebtedness, (v) certain insolvency events or proceedings, (vi) material adverse changes in the business, operations, assets or financial condition of Shire as a whole, (vii) if it becomes unlawful for Shire (or any successor parent company) or any of their respective subsidiaries that are parties to the RCF to perform their obligations thereunder or (viii) if Shire (or any successor parent company) or any subsidiary thereof which is a party to the RCF repudiates such agreement or other finance document, among others. Term Loan Facilities Agreement January 2016 Facilities Agreement On January 11, 2016, Shire (as original guarantor and original borrower), entered into an $18.0 billion bridge facilities agreement with various financial institutions (the “January 2016 Facilities Agreement”). The January 2016 Facilities Agreement comprised two credit facilities: (i) a $13.0 billion term loan facility originally maturing on January 11, 2017 ("January 2016 Facility A") and (ii) a $5.0 billion revolving loan facility originally maturing on January 11, 2017 ("January 2016 Facility B"). On April 1, 2016, SAIIDAC became an additional borrower and additional guarantor under the January 2016 Facilities Agreement. The January 2016 Facility A was utilized to finance the cash consideration payable in respect of the acquisition of Baxalta on June 3, 2016 in the amount of $12,390.0 million . The net proceeds from the issuance of the SAIIDAC Notes were used to fully repay the amounts outstanding under the January 2016 Facility A in September 2016. The January 2016 Facility B was canceled effective July 11, 2016, in accordance with its terms. November 2015 Facilities Agreement On November 2, 2015 , Shire (as original guarantor and original borrower) entered into a $5.6 billion facilities agreement with various financial institutions (the “November 2015 Facilities Agreement”). The November 2015 Facilities Agreement comprises three credit facilities: (i) a $1.0 billion term loan facility of which, following the exercise of the one year extension option in the amount of $400.0 million , $600.0 million matured and was repaid on November 2, 2016 and $400.0 million matures on November 2, 2017 (“November 2015 Facility A”), (ii) a $2.2 billion amortizing term loan facility which matures on November 2, 2017 (“November 2015 Facility B”) and (iii) a $2.4 billion amortizing term loan facility which matures on November 2, 2018 (“November 2015 Facility C”). On January 15, 2016, SAIIDAC became an additional borrower and an additional guarantor under the November 2015 Facilities Agreement and on December 1, 2016, Baxalta became an additional guarantor under the November 2015 Facilities Agreement. As of December 31, 2016, the November 2015 Facilities Agreement was fully utilized by SAIIDAC as borrower in the amount of $5.0 billion to finance the cash consideration payable and certain costs related to the acquisition of Dyax. On January 30, 2017, SAIIDAC made its first repayment installment of $400.0 million of November 2015 Facility B in accordance with the terms of the agreement. Interest on any loans made under the November 2015 Facilities Agreement is payable on the last day of each interest period, which may be one week or one, two, three or six months, or as otherwise agreed with the lenders. The interest rate applicable is LIBOR plus, in the case of the November 2015 Facility A, 0.55% per annum, in the case of the November 2015 Facility B, 0.65% per annum and, in the case of the November 2015 Facility C, 0.75% per annum, in each case subject to change depending on (i) the prevailing ratio of Net Debt to EBITDA (each as defined in the November 2015 Facilities Agreement) in respect of the most recently completed financial year or financial half year and (ii) the occurrence and continuation of an event of default in respect of the financial covenants or failure to provide a compliance certificate. The November 2015 Facilities Agreement includes customary representations and warranties, covenants and events of default, including requirements that Shire’s (i) ratio of Net Debt to EBITDA in respect of the most recently ended 12 -month relevant period, (each as defined in the November 2015 Facilities Agreement), must not, at any time, exceed 3.5 : 1 , except that following an acquisition fulfilling certain criteria, Shire may elect to increase this ratio to (a) 5.5 : 1 for the relevant period in which the acquisition was completed, (b) 5.0 : 1 in respect of the first relevant period following the relevant period in which the acquisition was completed, and (c) 4.5 : 1 in respect of the second relevant period following the relevant period in which the acquisition was completed, Shire has elected to increase this ratio in connection with the period ending June 30, 2016, following the completion of the acquisition of Baxalta during the period and (ii) ratio of EBITDA to Net Interest in respect of the most recently ended 12 month relevant period, (each as defined in the November 2015 Facilities Agreement), must not be less than 4.0 : 1 . The November 2015 Facilities Agreement restricts, subject to certain exceptions, Shire's ability to incur additional financial indebtedness, grant security over its assets or provide loans/grant credit. Further, any lender may require mandatory prepayment of its participation if there is a change of control of Shire, subject to certain exceptions for schemes of arrangement and analogous schemes. Events of default under the November 2015 Facilities Agreement include, subject to customary grace periods and materiality thresholds: (i) non-payment of any amounts due under the finance documents (as defined in the November 2015 Facilities Agreement), (ii) failure to satisfy any financial covenants, (iii) material misrepresentation in any of the finance documents, (iv) failure to pay, or certain other defaults, under other financial indebtedness, (v) certain insolvency events or proceedings, (vi) material adverse changes in the business, operations, assets or financial condition of Shire as a whole, (vii) if it becomes unlawful for Shire (or any successor parent company) or any of their respective subsidiaries that are parties to the November 2015 Facilities Agreement to perform their obligations thereunder or (viii) if Shire (or any successor parent company) or any subsidiary thereof which is a party to the November 2015 Facilities Agreement repudiates the November 2015 Facilities Agreement or any other finance document, among others. January 2015 Facility Agreement On January 11, 2015 , Shire entered into an $850.0 million term facility agreement with various financial institutions (the “January 2015 Facility Agreement”) with an original maturity date of January 10, 2016 . The maturity date was subsequently extended to July 11, 2016 in line with the provisions within the January 2015 Facility Agreement allowing the maturity date to be extended twice, at Shire’s option, by six months on each occasion. The January 2015 Facility Agreement was used to finance Shire’s acquisition of NPS Pharma (including certain related costs). On September 28, 2015, the Company reduced the January 2015 Facility Agreement by $100.0 million . In January 2016 and at various points thereafter, the Company canceled parts of the January 2015 Facilities Agreement. On February 22, 2016, the Company repaid the remaining balance of $100.0 million of the January 2015 Facilities Agreement in full. Capital lease obligations As of December 31, 2016, capital lease obligations predominantly related to the obligations assumed as part of the Baxalta acquisition. These leases are primarily related to office and manufacturing facilities. As of December 31, 2016, the total capital lease obligations, including current portions, were $353.6 million . Short-term uncommitted lines of credit (“Credit lines”) Shire has access to various Credit lines from a number of banks which are available to be utilized from time to time to provide short-term cash management flexibility. These Credit lines can be withdrawn by the banks at any time. The Credit lines are not relied upon for core liquidity. As of December 31, 2016 , these Credit lines were not utilized.

Retirement and Other Benefit Pr

Retirement and Other Benefit Programs	12 Months Ended
	Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]
Retirement and Other Benefit Programs	Retirement and Other Benefit Programs The Company sponsored various pension and other post-employment benefit (“OPEB”) plans in the United States and other countries during 2016. The Company did not report any pension or OPEB obligations as of December 31, 2015. Reconciliation of Pension and OPEB Plan Obligations and Funded Status The benefit plan information is for the year ended December 31, 2016. (In millions) U.S. pensions International pensions OPEB Benefit obligations Beginning of period $ — $ — $ — Assumption of benefit obligations from Baxalta 441.6 503.8 23.5 Service cost 13.0 18.6 0.8 Interest cost 11.1 3.2 0.6 Participant contributions — 3.2 — Actuarial (gain) / loss (10.6 ) (29.8 ) 0.1 Benefit payments (1.6 ) (9.1 ) — Settlements — (3.2 ) — Curtailments (73.4 ) — — Foreign exchange — (18.3 ) — Other 4.0 113.0 — End of Period $ 384.1 $ 581.4 $ 25.0 Fair value of plan assets Beginning of period $ — $ — $ — Assumption of plan assets from Baxalta 218.0 140.5 — Actual return on plan assets 8.3 2.0 — Employer contributions 0.4 12.3 — Participant contributions — 3.2 — Benefit payments (1.6 ) (9.1 ) — Settlements — (3.2 ) — Foreign exchange — (3.8 ) — Other 3.3 56.0 — End of period 228.4 197.9 — Funded status at December 31, 2016 $ (155.7 ) $ (383.5 ) $ (25.0 ) Amounts recognized in the Consolidated Balance Sheets Other current liabilities $ (0.6 ) $ (8.8 ) $ (0.2 ) Other non-current liabilities (155.1 ) (374.7 ) (24.8 ) Net liability recognized at December 31, 2016 $ (155.7 ) $ (383.5 ) $ (25.0 ) Curtailments represent the adoption of an amendment to the company’s U.S. pension plans which eliminates the estimate of future compensation levels beyond the December 31, 2017 effective date. Other primarily represents the recognition of an additional defined benefit plan in Switzerland. Accumulated Benefit Obligation Information The pension obligation represents the projected benefit obligation (“PBO”) as of December 31, 2016. The PBO incorporates assumptions relating to future compensation levels. The accumulated benefit obligation (“ABO”) is the same as the PBO except that it does not include assumptions relating to future compensation levels. The ABO for all the U.S. pension plans was $373.2 million as of December 31, 2016 . The ABO for the International pension plans was $457.9 million as of December 31, 2016 . The funded status figures and ABO disclosed above reflect all of the Company's pension plans. The following ABO and plan asset information includes only those individual plans that have an ABO in excess of plan assets as of December 31, 2016 . (In millions) December 31, 2016 U.S. ABO $ 373.2 Fair value of plan assets 228.4 International ABO 437.5 Fair value of plan assets 176.2 Expected Net Pension and OPEB Plan Payments for the Next 10 Years (In millions) U.S. pensions International pensions OPEB 2017 $ 3.6 $ 21.1 $ 0.2 2018 5.7 18.6 0.3 2019 7.6 19.9 0.5 2020 9.7 20.1 0.6 2021 11.7 22.7 0.7 2022 through 2026 85.3 124.1 4.6 Total expected benefit payments for next 10 years $ 123.6 $ 226.5 $ 6.9 The expected net benefit payments reflect the Company’s share of the total net benefits expected to be paid from the plans’ assets (for funded plans) or from the Company’s assets (for unfunded plans) as of December 31, 2016 . The federal subsidies relating to the Medicare Prescription Drug, Improvement and Modernization Act are not expected to be significant. Amounts Recognized in AOCI The pension and OPEB plans' gains or losses not yet recognized in net periodic benefit cost are recognized on a net of tax basis in AOCI and will be amortized from AOCI to net periodic benefit cost in the future. The Company had net pre-tax gains included in AOCI as of December 31, 2016 of $ 14.0 million related to its U.S. pension plans and net pre-tax losses included in AOCI as of December 31, 2016 of $ 10.3 million and $ 0.1 million related to its International plans and OPEB plan, respectively. Refer to Note 19 , Accumulated Other Comprehensive Loss , for the net of tax balances included in AOCI as of December 31, 2016 . The Company does not expect to amortize a significant amount of AOCI to net periodic benefit cost in 2017. Following is a summary of the net of tax amounts recorded in OCI relating to the pension and OPEB plans during 2016: (In millions) U.S. pensions International pensions OPEB Gain (loss) arising during the year, net of tax expense of $30.9 million for U.S. plans and $3.8 million for international plans $ 52.5 $ (14.2 ) $ — Reclassification of gain to income statement, net of tax benefit of $25.9 million for U.S. plans (43.5 ) — — Pension and other employee benefits gain (loss), net of tax $ 9.0 $ (14.2 ) $ — Gain (loss) arising during the year includes a loss of $34.6 million , net of tax, related to the recognition of a defined benefit plan in Switzerland. The reclassification of gain to income statement represents the recognition of the curtailment gain associated with the U.S. pension plans as further described above. Net Periodic Benefit Cost The net periodic benefit cost is from June 3, 2016, the date the Company assumed the obligations from Baxalta, through December 31, 2016 : June 3, 2016 through December 31, 2016 (In millions) U.S. pensions International pensions OPEB Net periodic benefit cost Service cost $ 13.0 $ 18.6 $ 0.8 Interest cost 11.1 3.2 0.6 Expected return on plan assets (8.9 ) (3.9 ) — Curtailment and other (69.4 ) 20.0 — Net periodic benefit cost $ (54.2 ) $ 37.9 $ 1.4 Curtailment and other relates to the recognition of a curtailment gain of $69.4 million associated with the U.S. pension plans as described above and a loss of $20.0 million for the recognition of a defined benefit plan in Switzerland. Weighted-Average Assumptions Used in Determining Benefit Obligations at the Measurement Date The following weighted-average assumptions were used in calculating the December 31, 2016 measurement date benefit obligations. U.S. pensions International pensions OPEB Discount rate 4.2 % 1.0 % 4.3 % Rate of compensation increase 3.8 % 2.9 % n/a Annual rate of increase in the per-capita cost n/a n/a 6.3 % Rate decreased to n/a n/a 5.0 % by the year ended n/a n/a 2022 Weighted-Average Assumptions Used in Determining Net Periodic Benefit Cost The following weighted-average assumptions were used in determining net periodic benefit cost for 2016. U.S. pensions International pensions OPEB Discount rate 4.1 % 1.0 % 4.2 % Expected return on plan assets 7.0 % 4.5 % n/a Rate of compensation increase 3.8 % 3.2 % n/a Annual rate of increase in the per-capita cost n/a n/a 6.5 % Rate decreased to n/a n/a 5.0 % by the year ended n/a n/a 2022 The Company establishes the expected return on plan assets assumption based primarily on a review of historical compound average asset returns, both Company-specific and the broad market (and considering the Company’s asset allocations), an analysis of current market and economic information and future expectations. The effect of a one-percent change in the assumed healthcare cost trend rate would not have a significant impact on the OPEB plan benefit obligation as of December 31, 2016 or the plan’s service and interest cost during 2016. Pension Plan Assets A committee of members of senior management is responsible for supervising, monitoring and evaluating the invested assets of the Company’s funded pension plans. The committee abides by policies and procedures relating to investment goals, targeted asset allocations, risk management practices, allowable and prohibited investment holdings, diversification, use of derivatives, the relationship between plan assets and benefit obligations, and other relevant factors and considerations. In the United States, Goldman Sachs Asset Management acts as an outsourced chief investment officer (“oCIO”) to perform the day-to-day management of pension assets. The policies and procedures include the following: • Ability to pay all benefits when due; • Targeted long-term performance expectations relative to applicable market indices, such as Standard & Poor’s, Russell, MSCI EAFE, and other indices; • Targeted asset allocation percentage ranges (summarized below), and periodic reviews of these allocations; • Specified investment holding and transaction prohibitions (for example, private placements or other restricted securities, securities that are not traded in a sufficiently active market, short sales, certain derivatives, commodities and margin transactions); • Specified portfolio percentage limits on holdings in a single corporate or other entity (generally 5% , except for holdings in U.S. government or agency securities); • Specified average credit quality for the fixed-income securities portfolio (at least A- by Standard & Poor’s or A3 by Moody’s); • Specified portfolio percentage limits on foreign holdings; and • Periodic monitoring of oCIO performance and adherence to policies. Plan assets are invested using a total return investment approach whereby a mix of equity securities, debt securities and other investments are used to preserve asset values, diversify risk and exceed the planned benchmark investment return. Investment strategies and asset allocations are based on consideration of plan liabilities, the plans’ funded status and other factors, such as the plans’ demographics and liability durations. Investment performance is reviewed on a quarterly basis and asset allocations are reviewed at least annually. Plan assets are managed in a balanced equity and fixed income portfolio. The target allocations for plan assets are 75% in an equity portfolio and 25% in a fixed income portfolio. The policy includes an allocation range based on each individual investment type within the major portfolios that allows for a variance from the target allocations of approximately 5% . The equity portfolio may include common stock of U.S. and international companies, common/collective trust funds, mutual funds, hedge funds and real asset investments. The fixed income portfolio may include cash, money market funds with an original maturity of three months or less, U.S. and foreign government and governmental agency issues, common/collective trust funds, corporate bonds, municipal securities, derivative contracts and asset-backed securities. While the committee provides oversight over plan assets for U.S. and international plans, the summary above is specific to the plans in the U.S. The plan assets for international plans are managed and allocated by the entities in each country, with input and oversight provided by the committee. The following pension assets are recorded at fair value on a recurring basis using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3). Investments that are measured at fair value using the net asset value per share or its equivalent as a practical expedient are not classified in the fair value hierarchy. U.S. pension plan assets (In millions) Balance as of December 31, 2016 Level 1 Level 2 Level 3 Assets Fixed income Cash equivalents $ 5.7 $ — $ — $ — Collective trust funds 46.4 — — — Mutual fund 11.4 — — — Equity Collective trust funds 100.4 — — — Mutual fund 53.4 16.5 — — Hedge funds 11.1 — — — Fair value of pension plan assets $ 228.4 $ 16.5 $ — $ — International pension plan assets (In millions) Balance as of December 31, 2016 Level 1 Level 2 Level 3 Assets Fixed income Cash and cash equivalents $ 6.2 $ 6.2 $ — $ — Government agency issues 0.6 0.6 — — Corporate bonds 21.1 21.1 — — Mutual funds 24.4 24.4 — — Equity Common stock: Large cap 19.9 19.9 — — Mid cap 1.6 1.6 — — Total common stock 21.5 21.5 — — Mutual funds 40.6 40.6 — — Real estate funds 12.1 8.4 — — Other holdings 71.4 — 71.4 — Fair value of pension plan assets $ 197.9 $ 122.8 $ 71.4 $ — The assets and liabilities of the Company’s pension plans are valued using the following valuation methods: Investment category Valuation methodology Cash and cash equivalents These largely consist of a short-term investment fund, U.S. dollars and foreign currency. The fair value of the short-term investment fund is based on the net asset value Government agency issues Values are based on quoted prices in an active market Corporate bonds Values are based on the valuation date in an active market Common stock Values are based on the closing prices on the valuation date in an active market Mutual funds Values are based on the net asset value of the units held in the respective fund which are obtained from active markets or as reported by the fund managers Collective trust funds and hedge funds Values are based on the net asset value of the units held at year end Real estate funds The value of these assets are either determined by the net asset value of the units held in the respective fund which are obtained from active markets or based on the net asset value of the underlying assets of the fund provided by the fund manager Other holdings These primarily consist of insurance contracts whose value is based on the underlying assets and other holdings valued primarily based on reputable pricing vendors that typically use pricing matrices or models Expected Pension and OPEB Plan Funding The Company’s funding policy for its pension plans is to contribute amounts sufficient to meet legal funding requirements, plus any additional amounts that the Company may determine to be appropriate considering the funded status of the plans, tax deductibility, the cash flows generated by the Company, and other factors. Volatility in the global financial markets could have an unfavorable impact on future funding requirements. The Company has no obligation to fund its principal plans in the U.S. in 2017. The Company did not make any significant voluntary contributions to its U.S. Qualified plan from the June 3, 2016 acquisition date through December 31, 2016. During 2017, the Company expects to make cash contributions to its pension plans of at least $11.0 million , primarily related to its international plans, and expects to have net cash outflows relating to its OPEB plan of less than $1.0 million . The Company continually reassesses the amount and timing of any discretionary contributions, which could be significant in any period. The table below details the funded status percentage of the Company’s pension plans as of December 31, 2016 including certain plans that are unfunded in accordance with the guidelines of the Company’s funding policy outlined above. United States International (in millions, except %) Qualified plan Nonqualified plan Funded plans Unfunded plans Total Fair value of plan assets $ 228.4 n/a $ 197.9 n/a $ 426.3 PBO 352.8 31.3 413.7 167.7 965.5 Funded status percentage 65 % n/a 48 % n/a 44 % U.S. Defined Contribution Plans In addition to benefits provided under the pension and OPEB plans described above, the Company provides benefits under defined contribution plans. The Company's most significant defined contribution plans are in the United States. The Company recognized expenses related to U.S. defined contribution plans of $ 68.1 million , $ 38.9 million and $ 34.3 million during 2016, 2015 and 2014, respectively.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	12 Months Ended
	Dec. 31, 2016
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss The changes in Accumulated other comprehensive loss ("AOCL"), net of their related tax effects, in the years ended December 31, 2016 are shown below: (In millions) Foreign currency translation adjustment Pension and other employee benefits Unrealized holding gain/(loss) on available-for-sale securities Hedging activities Accumulated other comprehensive loss As of January 1, 2016 $ (182.1 ) $ — $ (1.7 ) $ — $ (183.8 ) Current period change: Other comprehensive (loss)/income before reclassification (1,323.3 ) 38.3 8.3 9.9 (1,266.8 ) Amounts reclassified from AOCL — (43.5 ) — (3.5 ) (47.0 ) Net current period other comprehensive (loss)/income (1,323.3 ) (5.2 ) 8.3 6.4 (1,313.8 ) As of December 31, 2016 $ (1,505.4 ) $ (5.2 ) $ 6.6 $ 6.4 $ (1,497.6 ) The following is a summary of the amounts reclassified from AOCL to net income during the fiscal year ended December 31, 2016 : Amounts reclassified from AOCL (In millions) 2016 Location of impact in Statements of Operations Pension and employee benefits Curtailment gain $ 69.4 Integration and acquisition costs 69.4 Total before tax (25.9 ) Tax expense 43.5 Net of tax Losses on hedging activities Foreign exchange contracts 4.9 Cost of sales 4.9 Total before tax (1.4 ) Tax expense 3.5 Net of tax Total reclassifications for the period $ 47.0 Total net of tax The changes in Accumulated other comprehensive loss, net of their related tax effects, in the year ended December 31, 2015 are shown below: (In millions) Foreign currency translation adjustment Unrealized holding gain/(loss) on available-for-sale securities Accumulated other comprehensive loss As of January 1, 2015 $ (25.7 ) $ (5.8 ) $ (31.5 ) Current period change: Net current period other comprehensive (loss)/income (156.4 ) 4.1 (152.3 ) As of December 31, 2015 $ (182.1 ) $ (1.7 ) $ (183.8 ) The amounts reclassified out of Accumulated other comprehensive loss and into the Statements of Operations for the fiscal year ended December 31, 2015 were immaterial.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share The following table reconciles net income and the weighted average ordinary shares outstanding for basic and diluted earnings per share for the periods presented: Years ended December 31, (In millions) 2016 2015 2014 Income from continuing operations, net of taxes $ 603.5 $ 1,337.5 $ 3,282.8 (Loss)/ gain from discontinued operations 1 (276.1 ) (34.1 ) 122.7 Numerator for basic and diluted earnings per share 327.4 1,303.4 3,405.5 Weighted average number of shares: Basic 770.1 590.4 586.7 Effect of dilutive shares: Share-based awards to employees 6.1 2.7 4.6 Diluted 776.2 593.1 591.3 Earnings per ordinary share - basic Earnings from continuing operations 0.78 2.27 5.60 (Loss)/gain from discontinued operations (0.35 ) (0.06 ) 0.21 Earnings per ordinary share - basic 0.43 2.21 5.81 Earnings per ordinary share - diluted Earnings from continuing operations 0.77 2.26 5.55 (Loss)/gain from discontinued operations (0.35 ) (0.06 ) 0.21 Earnings per ordinary share - diluted 0.42 2.20 5.76 Weighted average number of basic shares excludes shares purchased by the Employee Benefit Trust and those under the shares buy-back program, which are both presented by Shire as treasury stock. Share-based awards to employees are calculated using the treasury method. The share equivalents not included in the calculation of the diluted weighted average number of shares are shown below: 2016 2015 2014 (In millions) Number of shares Number of shares Number of shares Share-based awards to employees 4.1 3.4 0.3 Certain stock options have been excluded from the calculation of diluted EPS because (a) their exercise prices exceeded Shire’s average share price during the calculation period or (b) the required performance conditions were not satisfied as of the balance sheet date.

Taxation

Taxation	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Taxation	Taxation The components of pre-tax income from continuing operations are as follows: Years ended December 31, (In millions) 2016 2015 2014 Ireland $ 214.3 $ (11.4 ) $ 1,472.0 United States (75.3 ) 975.8 1,025.9 Rest of the world 347.1 421.4 838.3 $ 486.1 $ 1,385.8 $ 3,336.2 The provision for income taxes on continuing operations by location of the taxing jurisdiction for the years ended December 31, 2016 , 2015 and 2014 consisted of the following: Years ended December 31, (In millions) 2016 2015 2014 Current income taxes: Ireland $ 5.2 $ 0.8 $ — U.S. federal tax 318.6 191.7 291.8 U.S. state and local taxes 30.2 17.3 25.3 Rest of the world 68.9 17.8 (290.9 ) Total current taxes 422.9 227.6 26.2 Deferred taxes: Ireland 18.2 (38.8 ) — U.S. federal tax (433.8 ) (151.2 ) 39.7 U.S. state and local taxes (74.1 ) (1.7 ) (2.9 ) Rest of the world (59.3 ) 10.2 (6.9 ) Total deferred taxes (549.0 ) (181.5 ) 29.9 Total income taxes $ (126.1 ) $ 46.1 $ 56.1 The Company determines the amount of income tax expense or benefit allocable to continuing operations using the incremental approach. The amount of income tax attributed to discontinued operations is disclosed in Note 7 , Results of Discontinued Operations , to the Consolidated Financial Statements set forth in this Annual Report on Form 10-K. The operating results associated with the DERMAGRAFT business have been classified as discontinued operations for all periods presented. The reconciliation of income from continuing operations before income taxes and equity in earnings/(losses) of equity method investees at the statutory tax rate to the provision for income taxes is shown in the table below: Years ended December 31, 2016 2015 2014 Income from continuing operations before income taxes and equity in (losses)/ earnings of equity method investees (in millions) $ 486.1 $ 1,385.8 $ 3,336.2 Statutory tax rate (1) 25.0 % 25.0 % 25.0 % U.S. R&D credit (25.9 )% (7.7 )% (2.5 )% Intra-group items (2) (44.4 )% (18.6 )% (6.3 )% Other permanent items 4.5 % 1.1 % (0.2 )% U.S. Domestic Manufacturing Deduction (4.0 )% (1.6 )% (0.5 )% Acquisition Related Costs 8.5 % 1.1 % 0.7 % Irish Treasury Operations (8.6 )% 0.6 % 0.7 % Change in valuation allowance 7.9 % 1.0 % 0.8 % Difference in taxation rates (3) 13.0 % 7.3 % 3.4 % Change in provisions for uncertain tax positions (1.5 )% (0.4 )% 0.2 % Prior year adjustment 1.0 % (1.6 )% 0.1 % Change in fair value of contingent consideration 3.7 % (3.8 )% 0.3 % Change in tax rates (5.1 )% 0.9 % 0.5 % Receipt of break fee — % — % (12.3 )% Settlement with Canadian revenue authorities — % — % (7.0 )% Other — % — % (1.2 )% Provision for income taxes on continuing operations (25.9 )% 3.3 % 1.7 % (1) In addition to being subject to the Irish corporation tax rate of 25% in 2016 , the Company is also subject to income tax in other territories in which the Company operates, including: Canada ( 15% ); France ( 33.3% ); Germany ( 15% ); Italy ( 27.5% ); Japan ( 23.9% ); Luxembourg ( 21.0% ); the Netherlands ( 25% ); Belgium ( 33.99% ); Singapore ( 17% ); Spain ( 28% ); Sweden ( 22% ); Switzerland ( 8.5% ); United Kingdom ( 20% ) and the U.S. ( 35% ). The rates quoted represent the statutory federal income tax rates in each territory, and do not include any state taxes or equivalents or surtaxes or other taxes charged in individual territories, and do not purport to represent the effective tax rate for the Company in each territory. (2) Intra-group items principally relate to the effect of intra-territory eliminations, the pre-tax effect of which has been eliminated in arriving at the Company’s consolidated income from continuing operations before income taxes, noncontrolling interests and equity in earnings/(losses) of equity method investees. The Company's intra-group items primarily arise from its acquisition of third parties that result in income and expense being received and taxed in different jurisdictions at various tax rates. (3) The expense from the difference in taxation rates reflects the impact of the higher income tax rates in the United States offset by the impact of lower foreign jurisdiction income tax rates. As detailed in the income tax rate reconciliation above, the Company's effective tax rate differs from the Irish statutory rate each year due to foreign taxes that are different than the Irish statutory rate and certain operations that are subject to tax incentives. In addition, the effective tax rate can be impacted each period by certain discrete factors and events, which, in 2016, included items related to the Baxalta acquisition, primarily the reversal of deferred tax liabilities (including in higher tax territories) for inventory and intangible asset amortization, as well as acquisition and integration costs. These same items are also causing the significant reduction in the U.S. pre-tax book income that is evident in the components of pre-tax income table above. Provisions for uncertain tax positions The Company files income tax returns in the Republic of Ireland, the U.S. (both federal and state) and various other jurisdictions (see footnote 1 to the table above for major jurisdictions). With few exceptions, the Company is no longer subject to income tax examinations by tax authorities for years before 2012, although the Company is contesting certain matters pertaining to 2011 and 2012. Tax authorities in various jurisdictions are in the process of auditing the Company’s tax returns for fiscal periods primarily after 2011, with the earliest being 2007; these tax audits cover primarily transfer pricing, but may include other areas. In respect of the receipt of the break fee from AbbVie in 2014, the Company has obtained advice that the break fee should not be taxable in Ireland. The Company has therefore concluded that no tax liability should arise and did not recognize a tax charge in the income statement in 2014. The relevant tax return was submitted on September 23, 2015. While tax audits remain open, the Company also considers it reasonably possible that issues may be raised by tax authorities resulting in increases to the balance of unrecognized tax benefits, however, an estimate of such an increase cannot be made. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: (In millions) 2016 2015 2014 Balance as of January 1 $ 216.3 $ 207.8 $ 355.2 Increases based on tax positions related to the current year 34.3 27.0 20.3 Decreases based on tax positions taken in the current year — — — Increases for tax positions taken in prior years 0.5 3.9 64.2 Decreases for tax positions taken in prior years (17.8 ) (30.6 ) (211.0 ) Acquisition related items 29.5 17.9 — Decreases resulting from settlements with the taxing authorities (24.4 ) (1.2 ) (9.4 ) Decreases as a result of expiration of the statute of limitations (2.4 ) (4.4 ) (0.6 ) Foreign currency translation adjustments (1) 0.3 (4.1 ) (10.9 ) Balance as of December 31 (2) $ 236.3 $ 216.3 $ 207.8 (1) Foreign currency translation adjustments are recognized within Other Comprehensive Income. (2) As of December 31, 2016 , approximately $227 million ( 2015 : $207 million , 2014 : $181 million ) of which would affect the effective rate if recognized. The Company considers it reasonably possible that certain audits currently being conducted could be concluded in the next 12 months, and as a result the total amount of unrecognized tax benefits recorded as of December 31, 2016 could decrease by up to approximately $50.0 million . As of the balance sheet date, the Company believes that its reserves for uncertain tax positions are adequate to cover the resolution of these audits. However, the resolution of these audits could have a significant impact on the financial statements if the settlement differs from the amount reserved. The Company recognizes interest and penalties accrued related to unrecognized tax positions within income taxes. During the years ended December 31, 2016 , 2015 and 2014 , the Company recognized a charge / (credit) to income taxes of $4.2 million , $0.8 million and $(103.1) million in interest and penalties and the Company had a liability of $30.8 million , $26.5 million and $25.8 million for the payment of interest and penalties accrued as of December 31, 2016 , 2015 and 2014 , respectively. As part of Baxalta's separation from Baxter, a tax sharing agreement was entered into, effective on the date of separation, which employs a tracing approach to determine which company is liable for certain pre-separation income tax items. If a liability arises and is attributable to the former Baxalta business, the liability would be allocated to Baxalta. If the liability arises and is attributable to Baxter's Medical Device, Renal or Biosurgery businesses, it would be allocated to Baxter. The table above only reflects pre-acquisition liabilities for Baxalta for which it was the primary obligor. Deferred taxes The significant components of deferred tax assets and liabilities and their balance sheet classifications, as of December 31, are as follows: December 31, December 31, (In millions) 2016 2015 Deferred tax assets: Deferred revenue $ 16.8 $ 2.4 Inventory & warranty provisions 88.7 36.1 Losses carried forward (including tax credits) (1) 1,907.3 980.3 Provisions for sales deductions and doubtful accounts 191.6 178.0 Intangible assets 79.7 5.9 Share-based compensation 137.5 40.6 Excess of tax value over book value of assets 14.2 0.6 Accruals and provisions 448.6 130.4 Other 78.5 19.3 Gross deferred tax assets 2,962.9 1,393.6 Less: valuation allowance (569.4 ) (416.1 ) 2,393.5 977.5 Deferred tax liabilities: Intangible assets (9,073.4 ) (2,850.6 ) Excess of book value over tax value in inventory (150.3 ) (10.3 ) Excess of book value over tax value of assets and investments (1,304.2 ) (153.9 ) Other (91.6 ) (47.6 ) Net deferred tax liabilities (8,226.0 ) (2,084.9 ) Balance sheet classifications: Deferred tax assets - non-current 96.7 121.0 Deferred tax liabilities - non-current (8,322.7 ) (2,205.9 ) $ (8,226.0 ) $ (2,084.9 ) (1) Losses carried forward excludes $38.9 million of deferred tax assets as of December 31, 2016 ( 2015 : $30.4 million ), related to net operating losses that result from excess stock based compensation and for which any benefit realized will be recorded to stockholders' equity. As of December 31, 2016 , the Company had a valuation allowance of $569.4 million ( 2015 : $416.1 million ) to reduce its deferred tax assets to estimated realizable value. These valuation allowances related primarily to operating losses, capital losses and tax-credit carry-forwards in Switzerland ( 2016 : $176.8 million ; 2015 : $131.5 million ); U.S. ( 2016 : $155.1 million ; 2015 : $125.9 million ); Ireland ( 2016 : $22.4 million ; 2015 : $22.2 million ); and other foreign tax jurisdictions ( 2016 : $215.1 million ; 2015 : $136.5 million ). Management is required to exercise judgment in determining whether deferred tax assets will more likely than not be realized. A valuation allowance is established where there is an expectation that on the balance of probabilities management considers it is more likely than not that the relevant deferred tax assets will not be realized. In assessing the need for a valuation allowance, management weighs all available positive and negative evidence including cumulative losses in recent years, projections of future taxable income, carry forward and carry back potential under relevant tax law, expiration period of tax attributes, taxable temporary differences, and prudent and feasible tax-planning strategies. The net increase in valuation allowances of $153.3 million includes (i) increases of $166.4 million relating to operating losses in various jurisdictions for which management considers that there is insufficient positive evidence related to the factors described above to overcome negative evidence, such as cumulative losses and expiration periods and therefore it is more likely than not that the relevant deferred tax assets will not be realized in full, and (ii) decreases of $13.1 million primarily related to U.S. state tax losses, which based on the assessment of factors described above now provides sufficient positive evidence to support the losses are more likely than not to be realized. As of December 31, 2016 , based upon a consideration of the factors described above management believes it is more likely than not that the Company will realize the benefits of these deductible differences, net of the valuation allowances. However, the amount of the deferred tax asset considered realizable could be adjusted in the future if these factors are revised in future periods. The approximate tax effect of NOLs, capital losses and tax credit carry-forwards as of December 31, are as follows: (In millions) 2016 2015 U.S. federal tax $ 687.1 $ 149.3 U.S. state tax 170.7 77.2 Republic of Ireland 45.1 61.2 Foreign tax jurisdictions 614.9 434.9 R&D and other tax credits 389.5 257.7 $ 1,907.3 $ 980.3 The approximate gross value of net operating losses (“NOLs”) and capital losses at December 31, 2016 is $10,843.1 million ( 2015 : $5,562.3 million ). The tax effected NOLs, capital losses and tax credit carry-forwards shown above have the following expiration dates: December 31, (In millions) 2016 Within 1 year $ 0.3 Within 1 to 2 years 2.6 Within 2 to 3 years 45.5 Within 3 to 4 years 12.8 Within 4 to 5 years 52.6 Within 5 to 6 years 55.3 After 6 years 1,269.6 Indefinitely 468.6 The Company does not provide for deferred taxes on the excess of the financial reporting over the tax basis of investments in foreign subsidiaries that are essentially permanent in duration. As of December 31, 2016 , that excess totaled $16.6 billion ( 2015 : $11.3 billion ). As part of the acquisition of Baxalta, the Company determined that $1.5 billion of Baxalta's pre-acquisition earnings incurred outside of the U.S. are not permanently reinvested and has recorded an associated deferred tax liability of $503.0 million on these earnings as part of the business combination accounting for the acquisition. The determination of additional deferred taxes on the Company's permanently reinvested earnings that have not been provided is not practicable.

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Segment Reporting	Segment Reporting Shire comprises a single operating and reportable segment engaged in the research, development, licensing, manufacturing, marketing, distribution and sale of innovative specialist medicines to meet significant unmet patient needs. This is consistent with how the financial information is viewed for the purposes of evaluating performance, allocating resources, and planning and forecasting future periods and how the operations are managed by the Executive Committee (Shire’s chief operating decision maker). This segment is supported by several key functions: a Pipeline Committee, an In-Line Committee, a Technical Operations group and a Corporate group. The Pipeline Committee consists of R&D and Corporate Development and is responsible for prioritizing the activities towards progressing and acquiring development programs across a variety of therapeutic areas. The Technical Operations group is responsible for the Company’s global supply chain. The In-line Committee focuses on commercializing marketed products and support of the development of the Company's pipeline candidates. The business is also supported by a simplified, centralized corporate function group. None of these functional groups meets all of the criteria to be considered an individual operating segment. Geographic information Revenues (based on the geographic location from which the sale originated): Years ended December 31, (In millions) 2016 2015 2014 Ireland $ 41.6 $ 14.1 $ 18.5 United States 7,666.9 4,659.2 4,174.1 Rest of the world 3,688.1 1,743.4 1,829.5 Total revenues $ 11,396.6 $ 6,416.7 $ 6,022.1 Long-lived assets comprise all non-current assets, (excluding goodwill and intangible assets, deferred contingent consideration assets, deferred tax assets, investments and financial instruments) based on their relevant geographic location: Years ended December 31, (In millions) 2016 2015 Ireland $ 41.2 $ 1.7 United States 6,449.4 751.3 Rest of the world 84.0 82.2 Total $ 6,574.6 $ 835.2 Material customers In the periods set out below, certain customers accounted for greater than 10% of the Company’s Product sales: Years ended December 31, 2016 2016 2015 2015 2014 2014 (in millions, except %) % Product sales % Product sales % Product sales AmerisourceBergen Corp $ 1,695.3 16 $ 1,048.3 17 $ 759.2 13 McKesson Corp. 1,336.7 12 1,044.1 17 1,021.0 18 Cardinal Health Inc. 1,052.2 10 796.9 13 979.9 17 Amounts outstanding in respect of these material customers were as follows: December 31, (In millions) 2016 2015 AmerisourceBergen Corp $ 427.2 $ 171.5 McKesson Corp. 312.9 193.1 Cardinal Health Inc. 278.4 181.7 In the periods set out below, revenues by major product were as follows: December 31, December 31, December 31, (In millions) 2016 2015 2014 Product sales: HEMOPHILIA $ 1,789.0 $ — $ — INHIBITOR THERAPIES 451.8 — — Hematology total 2,240.8 — — CINRYZE 680.2 617.7 503.0 ELAPRASE 589.0 552.6 592.8 FIRAZYR 578.5 445.0 364.2 REPLAGAL 452.4 441.2 500.4 VPRIV 345.7 342.4 366.7 KALBITOR 52.2 — — Genetic Diseases total 2,698.0 2,398.9 2,327.1 VYVANSE 2,013.9 1,722.2 1,449.0 ADDERALL XR 363.8 362.8 383.2 Other Neuroscience 112.8 115.4 372.3 Neuroscience total 2,490.5 2,200.4 2,204.5 IMMUNOGLOBULIN THERAPIES 1,143.9 — — BIO THERAPEUTICS 372.2 — — Immunology total 1,516.1 — — LIALDA/MEZAVANT 792.1 684.4 633.8 PENTASA 309.4 305.8 289.7 GATTEX/REVESTIVE 219.4 141.7 — NATPARA 85.3 24.4 — Other Internal Medicine 349.3 344.3 375.3 Internal Medicine total 1,755.5 1,500.6 1,298.8 Oncology total 130.5 — — Ophthalmology Total 54.4 — — Total Product sales $ 10,885.8 $ 6,099.9 $ 5,830.4

Receipt of Break Fee

Receipt of Break Fee	12 Months Ended
	Dec. 31, 2016
Extraordinary and Unusual Items [Abstract]
Receipt of Break Fee	Receipt of Break Fee On July 18, 2014, the Boards of AbbVie and Shire announced that they had agreed the terms of a recommended combination of Shire with AbbVie, subject to a number of conditions including approval by shareholders and regulators. On the same date, Shire and AbbVie entered into a co-operation agreement in connection with the recommended combination. On October 16, 2014, the Board of AbbVie confirmed that it had withdrawn its recommendation of its offer for Shire as a result of the anticipated impact of a U.S. Treasury Notice on the benefits that AbbVie expected from its offer. As AbbVie’s offer was conditional on the approval of its stockholders, and given their Board’s decision to change its recommendation and to advise AbbVie’s stockholders to vote against the offer, there was no realistic prospect of satisfying this condition. Accordingly, Shire’s Board agreed with AbbVie to terminate the cooperation agreement on October 20, 2014. The Company entered into a termination agreement with AbbVie, pursuant to which AbbVie paid the break fee due under the cooperation agreement of approximately $1,635.4 million . The Company has obtained advice that the break fee should not be taxable in Ireland. The Company has therefore concluded that no tax liability should arise and has not recognized a tax charge in the income statement in 2014. The relevant tax return was submitted on September 23, 2015.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Leases Future minimum lease payments under operating leases as of December 31, 2016 are presented below: (In millions) Operating leases 2017 $ 155.5 2018 117.2 2019 98.7 2020 89.2 2021 82.7 Thereafter 441.9 $ 985.2 The Company leases land, facilities, motor vehicles and certain equipment under operating leases expiring through 2032. Lease and rental expense amounted to $100.8 million , $40.7 million and $32.9 million for the year ended December 31, 2016 , 2015 and 2014 , respectively, which is predominately included in SG&A expenses in the Company’s Consolidated Statement of Operations. Letters of credit and guarantees As of December 31, 2016 and 2015 , the Company had irrevocable standby letters of credit and guarantees with various banks and insurance companies totaling $139.7 million and $48.0 million (being the contractual amounts), respectively, providing security for the Company’s performance of various obligations. These obligations are primarily in respect of the recoverability of insurance claims, lease obligations and supply commitments. Commitments (i) Clinical testing As of December 31, 2016 , the Company had committed to pay approximately $1,037.4 million ( December 31, 2015 : $490.0 million ) to contract vendors for administering and executing clinical trials. The timing of these payments is dependent upon actual services performed by the organizations as determined by patient enrollment levels and related activities. (ii) Contract manufacturing As of December 31, 2016 , the Company had committed to pay approximately $528.9 million ( December 31, 2015 : $325.0 million ) in respect of contract manufacturing. The Company expects to pay $146.4 million of these commitments in 2017 . (iii) Other purchasing commitments As of December 31, 2016 , the Company had committed to pay approximately $1,745.4 million ( December 31, 2015 : $485.0 million ) for future purchases of goods and services, predominantly relating to active pharmaceutical ingredients sourcing. The Company expects to pay $436.6 million of these commitments in 2017 . (iv) Investment commitments As of December 31, 2016 , the Company had outstanding commitments to subscribe for interests in companies and partnerships for amounts totaling $76.4 million ( December 31, 2015 : $22.0 million ) which may all be payable in 2017 , depending on the timing of capital calls. The investment commitments include additional funding to certain VIEs of which Shire is not the primary beneficiary. (v) Capital commitments As of December 31, 2016 , the Company had committed to spend $100.5 million ( December 31, 2015 : $60.0 million ) on capital projects.

Legal and Other Proceedings

Legal and Other Proceedings	12 Months Ended
	Dec. 31, 2016
Legal Proceedings [Abstract]
Legal and Other Proceedings	Legal and Other Proceedings The Company expenses legal costs when incurred. The Company recognizes loss contingency provisions for probable losses when management is able to reasonably estimate the loss. When the estimated loss lies within a range, the Company records a loss contingency provision based on its best estimate of the probable loss. If no particular amount within that range is a better estimate than any other amount, the minimum amount is recorded. Estimates of losses may be developed before the ultimate loss is known, and are therefore refined each accounting period as additional information becomes known. An outcome that deviates from the Company’s estimate may result in an additional expense or release in a future accounting period. As of December 31, 2016 , provision for litigation losses, insurance claims and other disputes totaled $415.0 million ( December 31, 2015 : $9.9 million ). The Company’s principal pending legal and other proceedings are disclosed below. The outcomes of these proceedings are not always predictable and can be affected by various factors. For those legal and other proceedings for which it is considered at least reasonably possible that a loss has been incurred, the Company discloses the possible loss or range of possible loss in excess of the recorded loss contingency provision, if any, where such excess is both material and estimable. VYVANSE In May and June 2011, Shire was notified that six separate Abbreviated New Drug Applications ("ANDAs") were submitted under the Hatch-Waxman Act seeking permission to market generic versions of all approved strengths of VYVANSE. The notices were from Sandoz, Inc. ("Sandoz"); Amneal Pharmaceuticals LLC ("Amneal"); Watson Laboratories, Inc.; Roxane Laboratories, Inc. ("Roxane"); Mylan Pharmaceuticals, Inc. (“Mylan”); and Actavis Elizabeth LLC and Actavis Inc. (collectively, "Actavis"). Since filing suit against these ANDA filers, along with API suppliers Johnson Matthey Inc. and Johnson Matthey Pharmaceuticals Materials (collectively, “Johnson Matthey”), Shire has been engaged in a consolidated patent infringement litigation in the U.S. District Court for the District of New Jersey against the aforementioned parties (except Watson, who withdrew their ANDA). On June 23, 2014, the U.S. District Court for the District of New Jersey granted Shire’s summary judgment motion holding that 18 claims of the patents-in-suit were both infringed and valid. On September 24, 2015, the U.S. Court of Appeals of the Federal Circuit (“CAFC”) affirmed that ruling against all of the ANDA filers and remanded the case to the trial court for further proceedings. The CAFC ruling overturned the infringement ruling against Johnson Matthey and the case against Johnson Matthey has been dismissed. Following remand to the U.S. District Court for the District of New Jersey, the case has been fully resolved as a result of the Stipulation of Dismissal and Final Judgment entered by the court on August 30, 2016 in which the court imposed an injunction preventing all of the ANDA filers (Sandoz, Roxane, Amneal, Actavis and Mylan) from launching generic versions of VYVANSE until the expiration of these patents in 2023. In March, April and May 2016, Shire received Notices of Allegation (“NOA”) from Apotex Inc. (“Apotex”) informing Shire that Apotex filed an Abbreviated New Drug Submission (“ANDS”) with Health Canada seeking approval to market a generic version of VYVANSE in Canada. Within the requisite 45 days, Shire filed for orders of prohibition and, as a result, a 24-month stay of approval of the ANDS has been put into effect. Apotex has withdrawn the first two NOAs. On July 4, 2016, Apotex filed a Statement of Claim in Federal Court seeking a judicial declaration of invalidity and noninfringement of Shire’s Canadian patent relating to VYVANSE which Shire is actively defending. On April 14, 2016, Shire prevailed in upholding its European patent for ELVANSE. Shire initially prevailed in an opposition to its patent lodged by Johnson Matthey plc, Generics [UK] Limited (trading as Mylan) and Hexal AG and on April 14, 2016 Shire prevailed in the appeal. The decision by the appeals board of the European Patent Office is final and cannot be further appealed. LIALDA In May 2010, Shire was notified that Zydus Pharmaceuticals USA, Inc. (“Zydus”) had submitted an ANDA under the Hatch-Waxman Act seeking permission to market a generic version of LIALDA. Within the requisite 45-day period, Shire filed a lawsuit in the U.S. District Court for the District of Delaware against Zydus and Cadila Healthcare Limited, doing business as Zydus Cadila. A Markman hearing took place on January 29, 2015 and a Markman ruling was issued on July 28, 2015. A trial took place between March 28, 2016 and April 1, 2016. On September 16, 2016, the court issued its ruling finding that the proposed generic product would not infringe the asserted claims. Shire has appealed the ruling to the CAFC. In February 2012, Shire was notified that Osmotica Pharmaceutical Corporation (“Osmotica”) had submitted an ANDA under the Hatch-Waxman Act seeking permission to market a generic version of LIALDA. Within the requisite 45-day period, Shire filed a lawsuit in the U.S. District Court for the Northern District of Georgia against Osmotica. A Markman hearing took place on August 22, 2013 and a Markman ruling was issued on September 25, 2014. The court issued an Order on February 27, 2015 in which all dates in the scheduling order have been stayed. In March 2012, Shire was notified that Watson Laboratories Inc.-Florida had submitted an ANDA under the Hatch-Waxman Act seeking permission to market a generic version of LIALDA. Within the requisite 45-day period, Shire filed a lawsuit in the U.S. District Court for the Southern District of Florida against Watson Laboratories Inc.-Florida and Watson Pharmaceuticals, Inc., Watson Pharma, Inc. and Watson Laboratories, Inc. (collectively, “Watson”) were subsequently added as defendants. A trial took place in April 2013 and on May 9, 2013 the trial court issued a decision finding that the proposed generic product infringes the patent-in-suit and that the patent is not invalid. Watson appealed the trial court’s ruling to the CAFC and a hearing took place on December 2, 2013. The ruling of the CAFC was issued on March 28, 2014 overruling the trial court on the interpretation of two claim terms and remanding the case for further proceedings. Shire petitioned the Supreme Court for a writ of certiorari which was granted on January 26, 2015. The Supreme Court also vacated the CAFC decision and remanded the case to the CAFC for further consideration in light of the Supreme Court’s recent decision in Teva v. Sandoz. On June 3, 2015, the CAFC reaffirmed their previous decision to reverse the District Court’s claims construction and remanded the case to the U.S. District Court for the Southern District of Florida. A trial was held on January 25-27, 2016. A ruling was issued on March 28, 2016 upholding the validity of the patent and finding that Watson’s proposed ANDA product infringes the patent-in-suit. Watson appealed the ruling to the CAFC and oral argument took place on October 5, 2016. The CAFC issued a ruling on February 10, 2017 reversing the trial court’s ruling of infringement and remanding the case to the lower court for entry of a ruling of non-infringement. In April 2012, Shire was notified that Mylan had submitted an ANDA under the Hatch-Waxman Act seeking permission to market a generic version of LIALDA. Within the requisite 45-day period, Shire filed a lawsuit in the U.S. District Court for the Middle District of Florida against Mylan. A Markman hearing took place on December 22, 2014. A Markman ruling was issued on March 23, 2015. Following a four-day bench trial in September 2016 in the U.S. District Court for the Middle District of Florida, the court handed down a ruling that Mylan’s proposed generic version of LIALDA infringes claims 1 and 3 of the Orange Book listed patent for LIALDA. In connection with this finding of infringement, the court also entered an injunction prohibiting Mylan from making, using, selling, offering for sale and/or importing their proposed ANDA product before the expiration of the patent (June 8, 2020) and requiring that the approval date for their ANDA be on or after the expiration of the patent. In March 2015, Shire was notified that Amneal had submitted an ANDA under the Hatch-Waxman Act seeking permission to market a generic version of LIALDA. Within the requisite 45 day period, Shire filed a lawsuit in the U.S. District Court for the District of New Jersey against Amneal, Amneal Pharmaceuticals of New York, LLC and Amneal Pharmaceuticals Co. India Pvt. Ltd. A Markman hearing took place on July 25, 2016. A Markman ruling was issued on August 2, 2016. No trial date has been set. In September 2015, Shire was notified that Lupin Ltd. had submitted an ANDA under the Hatch-Waxman Act seeking permission to market a generic version of LIALDA. Within the requisite 45 day period, Shire filed a lawsuit in the U.S. District Court for the District of Maryland against Lupin Ltd., Lupin Pharmaceuticals Inc., Lupin Inc. and Lupin Atlantis Holdings SA. A Markman hearing originally scheduled to take place on November 10, 2016, was cancelled and has not yet been rescheduled. No trial date has been set. On October 7, 2015 the Patent Trial and Appeals Board (“PTAB”) of the United States Patent Office instituted an inter partes review (“IPR”) of U.S. Patent 6,773,720 which is the patent-in-suit in the litigations referred to above. The IPR process is designed to re-assess the patentability of the claims of the patent. A decision from the PTAB was issued on October 5, 2016 upholding the validity of the patent in view of the challenges put forward in the IPR. DERMAGRAFT The Department of Justice, including the U.S. Attorney’s Office for the Middle District of Florida, Tampa Division and the U.S. Attorney’s Office for Washington, DC, is conducting civil and criminal investigations into the sales and marketing practices of Advanced BioHealing Inc. (“ABH”) relating to DERMAGRAFT, which Shire acquired in June 2011. Following the disposal of the DERMAGRAFT business in January 2014, Shire retained certain legacy liabilities including any liability that may arise from this investigation. Over the several years, Shire has been cooperating fully with these investigations and engaged in discussions with the Department of Justice about a resolution. In August 2016, Shire announced that it reached an agreement with the Department of Justice on a proposal for a civil settlement in the amount of $350.0 million plus interest. Shire established a reserve for the expected settlement, $340.0 million in the second quarter of 2016 and an additional $10.0 million in the third quarter of 2016. Shire entered into a final settlement agreement with the Department of Justice, announced in January 2017, in the amount of $350.0 million , plus interest. Shire paid $345.5 million of the settlement amount in January 2017 and anticipates the remaining payment will be made in the second quarter of 2017. The agreement resolves the civil investigations conducted by the Department of Justice, including multiple U.S. Attorney’s Offices and relevant federal and state agencies. The agreement also resolves the federal government’s claims under the federal False Claims Act and the DERMAGRAFT Medicaid-related claims for states that opt into the settlement. Some states with DERMAGRAFT Medicaid-related claims might elect to opt out of the final settlement and those states’ claims would remain unresolved. Under the terms of Shire’s merger agreement with ABH, $37.5 million was held in escrow at the close of the transaction as an indemnity against potential breaches of representations and warranties on the part of ABH. After the civil settlement with the DOJ had been finalized, in January 2017, Shire made a formal demand upon ABH’s former equityholders to return the entire amount held in escrow to Shire. In February 2017, Shire and ABH’s equityholders entered into a settlement agreement, pursuant to which ABH’s equityholders agreed to release the full $37.5 million escrow to Shire and Shire will release the claims against ABH equityholders upon receipt of the entire amount held in escrow. VANCOCIN On April 6, 2012, ViroPharma Incorporated (“ViroPharma”) received a notification that the United States Federal Trade Commission (“FTC”) was conducting an investigation into whether ViroPharma had engaged in unfair methods of competition with respect to VANCOCIN which Shire acquired in January 2014. Following the divestiture of VANCOCIN in August 2014, Shire retained certain liabilities including any potential liabilities related to the VANCOCIN citizen petition. On August 3, 2012, and September 8, 2014, ViroPharma and Shire respectively received Civil Investigative Demands from the FTC requesting additional information related to this matter. Shire fully cooperated with the FTC’s investigation. On February 7, 2017, the FTC filed a Complaint against Shire alleging that ViroPharma engaged in conduct in violation of U.S. antitrust laws arising from a citizen petition ViroPharma filed in 2006 related to Food & Drug Administration’s policy for evaluating bioequivalence for generic versions of VANCOCIN. The complaint seeks equitable relief, including an injunction and disgorgement. At this time, Shire is unable to predict the outcome or duration of this case. ELAPRASE On September 24, 2014, Shire’s Brazilian affiliate, Shire Farmaceutica Brasil Ltda, was served with a lawsuit brought by the State of Sao Paulo and in which the Brazilian Public Attorney’s office has intervened alleging that Shire is obligated to provide certain medical care including ELAPRASE for an indefinite period at no cost to patients who participated in ELAPRASE clinical trials in Brazil, and seeking recoupment to the Brazilian government for amounts paid on behalf of these patients to date, and moral damages associated with these claims. On May 6, 2016, the trial court judge ruled on the case and dismissed all the claims under the class action, which was appealed. On February 20, 2017, the Court of Appeals in Sao Paulo issued the final decision on merit in favor of Shire and dismissed all the claims under the class action. The final decision can be appealed through the Superior Court of Justice or through the Supreme Court; however, the likelihood of one of those courts accepting the appeal is remote.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Shareholders' Equity Authorized common stock The authorized stock of Shire plc as of December 31, 2016 , was 1,500,000,000 ordinary shares and 2 subscriber ordinary shares. Dividends Under Jersey law, Shire plc is entitled to fund payments of dividends from any source (other than a capital redemption reserve or nominal capital account) subject to the Directors authorizing the distribution making a solvency statement in the prescribed statutory form. As of December 31, 2016 , Shire plc’s distributable reserves were approximately $4.4 billion . Treasury stock The Company records the purchase of its own shares by the EBT and under the share buy-back program as a reduction of shareholders’ equity based on the price paid for the shares. As of December 31, 2016 , the EBT held 0.5 million ordinary shares ( 2015 : 0.6 million ; 2014 : 0.7 million ) and 0.2 million ADSs ( 2015 : 0.2 million ; 2014 : 0.3 million ) and shares held under the share buy-back program were 8.0 million ordinary shares ( 2015 : 8.5 million ; 2014 : 9.0 million ). During the years ended December 31, 2016 and 2015 the Company did not purchase any shares either through the EBT or under any share buy-back program. Income Access Share Arrangements Shire has put into place income access share arrangements which enable ordinary shareholders, other than ADS holders, to choose whether they receive their dividends from Shire plc, a company tax resident in the Republic of Ireland, or from Shire Biopharmaceuticals Holdings (“Old Shire”), a Shire group company tax resident in the UK. Old Shire has issued one income access share to the Income Access Trust (the “IAS Trust”), which is held by the trustee of the IAS Trust (the “Trustee”). The mechanics of the arrangements are as follows: (i) If a dividend is announced or declared by Shire plc on its ordinary shares, an amount is paid by Old Shire by way of a dividend on the income access share to the Trustee, and such amount is paid by the Trustee to ordinary shareholders who have elected to receive dividends under these arrangements. The dividend which would otherwise be payable by Shire plc to its ordinary shareholders will be reduced by an amount equal to the amount paid to its ordinary shareholders by the Trustee. (ii) If the dividend paid on the income access share and on-paid by the Trustee to ordinary shareholders is less than the total amount of the dividend announced or declared by Shire plc on its ordinary shares, Shire plc will be obliged to pay a dividend on the relevant ordinary shares equivalent to the amount of the shortfall. In such a case, any dividend paid on the ordinary shares will generally be subject to Irish withholding tax at the rate of 20% or such lower rate as may be applicable under exemptions from withholding tax contained in Irish law. (iii) An ordinary shareholder is entitled to make an income access share election such that he/she will receive his/her dividends (which would otherwise be payable by Shire plc) under these arrangements from Old Shire. This can be done by submitting an IAS arrangement election form containing information on the participating shareholders pursuant to Shire plc’s Articles of Association. The ADS Depositary has made an election on behalf of all holders of ADSs such that they will receive dividends from Old Shire under the income access share arrangements. Dividends paid by Old Shire under the income access share arrangements will not, under current legislation, be subject to any UK or Irish withholding taxes. If a holder of ADSs does not wish to receive dividends from Old Shire under the income access share arrangements, he/she must withdraw his/her ordinary shares from the ADS program prior to the dividend record date set by the ADS Depositary and request delivery of the Shire plc ordinary shares. This will enable him/her to receive dividends from Shire plc. It is the expectation, although there can be no certainty, that Old Shire will distribute dividends on the income access share to the Trustee for the benefit of all ordinary shareholders who make an income access share election in an amount equal to what would have been such ordinary shareholders’ entitlement to dividends from Shire plc in the absence of the income access share election. If any dividend paid on the income access share and or paid to the ordinary shareholders is less than such ordinary shareholders’ entitlement to dividends from Shire plc in the absence of the income access share election, the dividend on the income access share will be allocated pro rata among the ordinary shareholders and Shire plc will pay the balance to these ordinary shareholders by way of dividend. In such circumstances, there will be no grossing up by Shire plc in respect of, and Old Shire and Shire plc will not compensate those ordinary shareholders for, any adverse consequences including any Irish withholding tax consequences. Shire will be able to suspend or terminate these arrangements at any time, in which case the full Shire plc dividend will be paid directly by Shire plc to those ordinary shareholders (including the Depositary) who have made an income access share election. In such circumstances, there will be no grossing up by Shire plc in respect of, and Old Shire and Shire plc will not compensate those ordinary shareholders for, any adverse consequences including any Irish withholding tax consequences. In the year ended December 31, 2016 , Old Shire paid dividends totaling $150.6 million ( 2015 : $127.7 million ; 2014 : $112.8 million ) on the income access share to the Trustee in an amount equal to the dividend ordinary shareholders would have received from Shire plc.

Share-based Compensation Plans

Share-based Compensation Plans	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation Plans	Share-based Compensation Plans The following table shows the total share-based compensation expense (see below for types of share-based awards) included in the Consolidated Statements of Operations : For the years ended December 31, (In millions) 2016 2015 2014 Cost of product sales $ 23.3 $ 7.6 $ 8.5 Research and development 46.9 28.6 22.2 Selling, general and administrative 67.1 37.4 35.9 Integration and acquisitions costs 181.2 — — Reorganization costs — 26.7 30.4 Total 318.5 100.3 97.0 Less tax (85.3 ) (28.4 ) (23.8 ) $ 233.2 $ 71.9 $ 73.2 As of December 31, 2016 , the Company incurred total expense of $ 223.1 million ( 2015 : $nil , 2014 : $nil ) related to replacement and other awards held by Baxalta employees as further described below. This includes integration related expenses of $ 171.0 million due to the acceleration of unrecognized expense associated with certain employees impacted by the integration. There were no capitalized share-based compensation costs as of December 31, 2016 , 2015 and 2014 . As of December 31, 2016 , $244.2 million ( 2015 : $115.3 million , 2014 : $83.1 million ) of total unrecognized compensation cost relating to non-vested awards is expected to be recognized over a period of three years . Share-based compensation plans Prior to February 28, 2015, the Company granted stock-settled share appreciation rights (“SARs”) and performance share awards (“PSAs”) over ordinary shares and ADSs to Executive Directors and employees under the Shire Portfolio Share Plan (“PSP”) (Parts A and B). The SARs and PSAs granted under the PSP (Parts A and B) to Executive Directors are exercisable subject to performance and service criteria. Substantially all SARs and PSAs granted to employees are exercisable subject only to service criteria. The principal terms and conditions of SARs and PSAs under the PSP (Parts A and B) are as follows: (i) the contractual life of SARs is seven years , (ii) the vesting period of SARs and PSAs granted to employees below the level of Executive Vice President allows for graded vesting over three years , and (iii) awards granted to the level of Executive Director and Executive Vice President cliff vest after three years , of which awards to the level of Executive Director contain performance conditions based on growth in Non-GAAP adjusted return on invested capital (“Adjusted ROIC”) and Non-GAAP earnings before interest, taxation, depreciation and amortization (“Non-GAAP EBITDA”). In 2014, the Company granted PSAs under the PSP to employees at Executive Vice President level and to a select group of senior employees, which are exercisable subject to performance and service criteria. These PSAs cliff vest after three years and contain performance conditions as explained above. Since February 28, 2015, the Company has granted awards under the Shire Long Term Incentive Plan 2015 (“LTIP”). Under the LTIP, the Company grants stock-settled share appreciation rights (“SARs”), restricted stock units (“RSUs”) and performance share units (“PSUs”) over ordinary shares and ADSs to Executive Directors and employees. The PSUs granted under the LTIP and SARs granted to Executive Directors are exercisable subject to performance and service criteria. RSUs granted under the LTIP and SARs granted to all other employees are exercisable subject only to service criteria. The principal terms and conditions of SARs, RSUs and PSUs granted under the LTIP are as follows: (i) the contractual life of SARs is seven years , (ii) the vesting period of SARs and RSUs granted to employees below the level of Executive Vice President allows for graded vesting, and (iii) all SARs granted to Executive Directors and employees at Executive Vice President level and all PSUs granted cliff vest after three years and, with the exception of SARs granted to employees at Executive Vice President level, contain performance conditions based on Product sales and Non-GAAP EBITDA targets; a Non-GAAP Adjusted ROIC underpin is also used at the end of the three year performance period to assess the underlying performance of the Company before determining the final vesting levels for awards with performance conditions. In addition, a further two year holding period will apply to all awards granted to Executive Directors post vesting. The Company also operates a Global Employee Stock Purchase Plan and UK/Irish Sharesave Plans. Replacement Awards Issued to Baxalta Employees In connection with the acquisition of Baxalta and pursuant to the merger agreement associated with the acquisition, outstanding Baxalta equity awards held by Baxalta employees or employees of Baxter were cancelled and exchanged for Shire equity awards. The outstanding Baxalta equity awards consisted primarily of stock options and RSUs and hence were replaced with Shire’s stock options and RSUs. The replacement Shire awards generally have the same terms and conditions (including vesting) as the former Baxalta awards for which they were exchanged. The value of the replacement share-based awards granted was designed to generally preserve both the intrinsic value and the fair value of the award immediately prior to the acquisition. Following the acquisition, the Company records share-based compensation expense associated with the acquisition-date fair value of acquired Baxalta employees’ replacement options and RSUs that is attributable to post-acquisition service requirements, as well as share-based compensation expense for post-acquisition service requirements associated with certain remaining unvested Baxter share-based awards held by the acquired Baxalta employees. The portions of the acquisition-date fair values of the awards that are attributable to post-combination service are recognized over the remaining service period of the awards. The following awards were outstanding as of December 31, 2016 : Compensation type Number of awards Expiration period from date of issue Vesting period Stock-settled SARs SARs 10,646,207 7 years 3 years graded vesting and/or 3 years cliff vesting subject to performance criteria for Executive Directors only UK/Irish Sharesave Plans Stock options 119,300 6 months after vesting 3 or 5 years Global Employee Stock Purchase Plan Stock options 411,900 On vesting date 1 to 5 years Baxalta Replacement Options Stock options 10,692,426 10 years 3 years graded vesting Stock-settled SARs and stock options 21,869,833 RSUs, PSUs and PSAs RSUs, PSUs and PSAs 2,346,511 3 years 3 years graded vesting, 3 years cliff vesting subject to performance criteria for Executive Directors and certain senior employees only Baxalta Replacement RSUs RSU 1,630,146 3 years 3 years graded vesting RSUs/PSUs and PSAs 3,976,657 Stock-settled SARs and stock options SARs under LTIP and PSP (Part A) Stock-settled share appreciation rights ("SARs"), granted to Executive Directors, are exercisable subject to service and performance criteria. In respect of any award made to Executive Directors under the LTIP, performance criteria are based on Product sales and Non-GAAP EBITDA targets, with a Non-GAAP Adjusted ROIC underpin. In respect of any award made to Executive Directors under the PSP (Part A), performance criteria are based on growth in Non-GAAP Adjusted ROIC and Non-GAAP EBITDA. These performance measures are an important measure of the Company’s ability to meet the strategic objective to grow value for all of its stakeholders. Awards granted to employees below Executive Director level are not subject to performance conditions and are only subject to service conditions. Once awards have vested, participants will have until the seventh anniversary of the date of grant to exercise their awards. UK/Irish Sharesave Plans ("Sharesave Plans") Options granted under the Sharesave Plans are granted with an exercise price equal to 80% and 75% of the mid-market price on the day before invitations are issued to UK and Ireland employees, respectively. Employees may enter into three or five year savings contracts. No performance conditions apply. Shire Global Employee Stock Purchase Plan ("Stock Purchase Plan") Under the Stock Purchase Plan, options are granted with an exercise price equal to 85% of the fair market value of a share on the enrollment date (the first day of the offering period) or the exercise date (the last day of the offering period), whichever is the lower. Employees agree to save for a period up to 12 months . No performance conditions apply. Baxalta Replacement Options The replacement stock options were issued consistent with the vesting conditions of the replaced award (as explained above). Replacement stock options had contractual terms of 10 years from the initial grant date. The majority of stock options outstanding vested in one-third increments over a three year period, although certain awards cliff vest or have longer or shorter service periods. The fair value on the acquisition date attributable to post-combination service, adjusted for estimated forfeitures, is recognized as expense on a straight-line basis over the remaining vesting period. A summary of the status of the Company’s SARs and stock options including replacement awards as of December 31, 2016 and of the related activity during the period then ended is presented below: Year ended December 31, 2016 Weighted average exercise price Number of shares Intrinsic value (In millions) £ £ Outstanding as of beginning of period 52.02 7,796,496 Granted 42.37 6,506,762 Exercised 39.83 (4,717,106 ) Baxalta Replacement Options 34.30 13,328,592 Forfeited 48.49 (1,044,911 ) Outstanding as of end of period 38.98 21,869,833 76.6 Exercisable as of end of period 34.55 11,035,437 66.0 Excluded from the table above are replacement stock options issued to Baxter employees as part of the acquisition of Baxalta. The Company issued 8.8 million stock options to Baxter employees on June 3, 2016, out of which 7.7 million and 6.9 million were outstanding and exercisable, respectively, as of December 31, 2016 . The weighted average grant date fair value of SARs and stock options granted in the year ended December 31, 2016 was £8.25 ( 2015 : £10.36 ; 2014 : £6.19 ). SARs and stock options including Baxalta Replacement Options, outstanding as of December 31, 2016 have the following characteristics: Number of awards outstanding Exercise prices Weighted Average remaining contractual term (Years) Weighted average exercise price of awards outstanding Number of awards exercisable Weighted average exercise price of awards exercisable £ £ £ 3,433,225 14.59-28.00 3.0 25.37 3,422,480 25.38 10,704,846 28.01-40.00 7.3 35.56 6,161,513 34.91 7,731,762 40.01-70.48 5.7 49.77 1,451,444 54.67 21,869,833 11,035,437 RSUs, PSUs and PSAs RSUs and PSUs under LTIP and PSAs under PSP (Part B) PSUs and PSAs granted to Executive Directors and PSUs granted to certain senior employees are exercisable subject to certain performance and service criteria. RSUs and PSAs granted to employees below Executive Director are not subject to performance criteria and are only subject to service conditions. The performance criteria for PSUs granted under the LTIP is based on Product sales and Non-GAAP EBITDA targets, typically with a Non-GAAP Adjusted ROIC underpin. The performance criteria for PSAs under the PSP (Part B) is based on growth in Non-GAAP Adjusted ROIC and Non-GAAP EBITDA. Baxalta Replacement RSUs The replacement RSUs were issued consistent with the vesting conditions of the replaced award (as explained above) and generally continue to vest in one-third increments over a three -year period. The fair value on the acquisition date attributable to post-combination service, adjusted for estimated forfeitures, is recognized as expense on a straight-line basis over the remaining vesting period. A summary of the status of the Company’s RSUs, PSUs and PSAs as of December 31, 2016 and of the related activity during the period then ended is presented below: RSUs, PSUs and PSAs Number of shares Weighted average grant date fair value Weighted average remaining life £ Outstanding as of beginning of period 1,791,930 40.06 Granted 1,663,070 42.28 Exercised (2,470,179 ) 37.52 Baxalta Replacement RSUs 3,294,150 39.28 Forfeited (302,314 ) 48.47 Outstanding as of end of period 3,976,657 41.31 3.8 Exercisable as of end of period — — N/A Excluded from the table above are replacement RSUs issued to Baxter employees as part of the acquisition of Baxalta. The Company issued 0.5 million RSUs to Baxter employees on June 3, 2016, out of which 0.3 million were outstanding as of December 31, 2016 . Exercises of share-based awards The total intrinsic values of share-based awards exercised, including those held by Baxter employees, for the years ended December 31, 2016 , 2015 and 2014 were $214.6 million , $198.8 million and $200.8 million , respectively. The total cash received as a result of share option exercises for the period ended December 31, 2016 , 2015 and 2014 was approximately $129.0 million , $16.6 million and $17.4 million , respectively. In connection with these exercises, the tax benefit credited to additional paid-in capital for the years ended December 31, 2016 , 2015 and 2014 was $8.8 million , $31.6 million and $39.6 million , respectively. The Company will settle future awards with either newly listed ordinary shares or with shares held in the EBT. The number of shares that the EBT will purchase in 2017 is dependent on the number of awards granted and exercised during the year and Shire plc’s share price. As of December 31, 2016 , the EBT held 0.5 million ordinary shares and 0.2 million ADSs. Valuation methodologies The Company estimates the fair value of its share-based awards using a Black-Scholes valuation model. Key input assumptions used to estimate the fair value of share-based awards include the grant price of the award, the expected stock-based award term, volatility of the Company’s share price, the risk-free rate and the Company’s dividend yield. The Company believes that the valuation technique and the approach utilized to develop the underlying assumptions are appropriate in estimating the fair values of Shire’s stock-based awards. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by employees who receive equity awards, and subsequent events are not indicative of the reasonableness of the original estimates of fair value made by the Company. The fair value of share awards granted was estimated using the following assumptions: Years ended December 31, 2016 2015 2014 Risk-free interest rate 0.29-1.6% 0.6-1.8% 0.3-1.8% Expected dividend yield 0.3-0.5% 0.2-0.4% 0.2-0.4% Expected life 1-4 years 1-4 years 1-4 years Volatility 26-29% 23-26% 23-27% Forfeiture rate 5-7% 5-7% 5-7% The following assumptions were used to value share-based awards: • risk-free interest rate - for awards granted over ADSs, the U.S. Federal Reserve treasury constant maturities rate with a term consistent with the expected life of the award is used. For awards granted over ordinary shares, the yield on UK government bonds with a term consistent with the expected life of the award is used; • expected dividend yield - measured as the average annualized dividend estimated to be paid by the Company over the expected life of the award as a percentage of the share price at the grant date; • expected life - estimated based on the contractual term of the awards and the effects of employees’ expected exercise and post-vesting employment termination behavior; • expected volatility - measured using historical daily price changes of the Company’s share price over the respective expected life of the share-based awards at the date of the award; and • forfeiture rate - estimated using historical trends of the number of awards forfeited prior to vesting.

Agreements and Transactions wit

Agreements and Transactions with Baxter	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Agreements and Transactions with Baxter	Agreements and Transactions with Baxter In connection with Baxalta’s separation from Baxter on July 1, 2015, Baxalta and Baxter entered into several separation-related agreements that provided a framework for Baxalta’s relationship with Baxter after the separation. As a result of the acquisition of Baxalta, the Company became party to the separation-related agreements with Baxter. These agreements, among others, included a manufacturing and supply agreement, a transition services agreement, an international commercial operations agreement and tax matters agreement. Under the terms of the manufacturing and supply agreement, the Company manufactures certain products and materials and sells them to Baxter at an agreed-upon price reflecting the Company’s cost plus a mark-up for certain products and materials. The Company reported revenues associated with the manufacturing and supply agreement with Baxter of approximately $81 million from the June 3, 2016 acquisition date through December 31, 2016 . Under the terms of the transition services agreement, the Company and Baxter provide various services to each other on an interim, transitional basis. The services provided by Baxter to the Company include certain finance, information technology, human resources, quality, supply chain and other administrative services and functions, and are generally provided on a cost-plus basis. The services generally extend for approximately two years following the July 1, 2015 separation except for certain information technology services that may extend for three years following the July 1, 2015 separation. The Company reported SG&A expenses associated with the transition services agreement with Baxter of approximately $54 million from the June 3, 2016 acquisition date through December 31, 2016 . For a certain portion of Baxalta’s non U.S. operations, the legal transfer of net assets from Baxter had not occurred by the June 3, 2016 acquisition date due to the time required to transfer marketing authorizations and other regulatory requirements in each of these countries. Under the terms of the international commercial operations agreement with Baxter, the Company is responsible for the business activities conducted by Baxter on its behalf, and is subject to the risks and entitled to the benefits generated by these operations and assets. As a result, the related assets and liabilities and results of operations are reported in the Company’s Consolidated Financial Statements following the acquisition of Baxalta. The Company reported net sales related to these operations of $101 million from the June 3, 2016 acquisition date through December 31, 2016 . As of December 31, 2016 , the assets and liabilities of these operations consisted of inventories of $11 million , which are reported in Inventories on the Consolidated Balance Sheet, other assets of $50 million , which are reported as Prepaid expenses and other current assets, and liabilities of $3 million , which are reported in Other current liabilities. The majority of these operations have been transferred to the Company as of December 31, 2016 and the remaining are expected to transfer in 2017 or 2018. The tax matters agreement governs Baxter and Baxalta’s and now the Company’s respective rights, responsibilities and obligations after the distribution with respect to taxes for any tax period ending on or before the distribution date, as well as tax periods beginning before and ending after the distribution date. In addition, the tax matters agreement addresses the allocation of liability for taxes that were incurred as a result of restructuring activities undertaken to effectuate the distribution and provides for Baxalta to indemnify Baxter against any tax liabilities resulting from Baxalta’s action or inaction that causes the merger-related transactions to be taxable. The net tax-related indemnification amount reported by the Company as of December 31, 2016 was $26 million . As of December 31, 2016 , the Company had total amounts due from or to Baxter of $189 million reported in Prepaid expenses and other current assets, $34 million reported in Other non-current assets, $72 million reported in Other current liabilities and $92 million reported in Other non-current liabilities. These balances include the net tax-related indemnification liabilities and assets and liabilities of certain operations that have not transferred to the Company.

Guarantor Financial Information

Guarantor Financial Information	12 Months Ended
	Dec. 31, 2016
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Guarantor Financial Information	Guarantor Financial Information On June 3, 2016, Shire plc provided full and unconditional, joint and several guarantees of the floating rate senior notes due 2018, 2.0% senior notes due 2018, 2.875% senior notes due 2020, 3.6% senior notes due 2022, 4.0% senior notes due 2025, and 5.25% senior notes due 2045 (collectively, “Baxalta Notes”), of Baxalta, a 100% owned subsidiary of the Company. Amounts related to Baxalta and its subsidiaries are included in the condensed consolidating financial information for periods subsequent to June 3, 2016, the date of the Baxalta acquisition. On September 23, 2016, Shire plc provided full and unconditional, joint and several guarantees of the 1.90% senior notes due 2019, 2.40% senior notes due 2021, 2.875% senior notes due 2023 and 3.20% senior notes due 2026, of SAIIDAC (collectively "SAIIDAC Notes"), a 100% owned subsidiary of the Company. On December 1, 2016, Baxalta, a wholly-owned subsidiary of Shire, became a guarantor to the SAIIDAC Notes. Accordingly, both Baxalta and Shire are now co-guarantors of the SAIIDAC Notes. In accordance with the requirements of SEC Regulation S-X Rule 3-10 “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered”, the following tables present condensed consolidating financial statements of the two separate guarantee structures of the Baxalta Notes and SAIIDAC Notes, for: • Shire plc - Parent Guarantor; • SAIIDAC Subsidiary Issuer - issuer subsidiary of the SAIIDAC Notes; (a) • Baxalta Inc. - issuer subsidiary of the Baxalta Notes and guarantor subsidiary of the SAIIDAC Notes; (b) • Non-Guarantor Non-Issuer Subsidiaries - presents all other subsidiaries of the Parent Guarantor on a combined basis, none of which guarantee the Baxalta Notes or SAIIDAC Notes; (c) • Non-Guarantor Subsidiaries of Baxalta Notes - presents combined Non-Guarantor Non-Issuer Subsidiaries, including SAIIDAC, under the guarantee structure where Baxalta is the subsidiary issuer (a+c); and • Eliminations - primarily relate to eliminations of investments in subsidiaries and intercompany balances and transactions. The Condensed Consolidating Financial Statements present investments in subsidiaries using the equity method of accounting. Condensed Consolidating Balance Sheet (As of December 31, 2016) (In millions) Shire plc (Parent Guarantor) SAIIDAC (SAIIDAC Notes Subsidiary Issuer) Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ — $ — $ 41.7 $ 487.1 $ 487.1 $ — $ 528.8 Restricted cash — — — 25.6 25.6 — 25.6 Accounts receivable, net — — — 2,616.5 2,616.5 — 2,616.5 Inventories — — — 3,562.3 3,562.3 — 3,562.3 Prepaid expenses and other current assets 1.8 — 97.1 707.4 707.4 — 806.3 Intercompany receivables — 120.5 — 5,154.4 5,274.9 (5,274.9 ) — Short-term intercompany loan receivable — 2,594.8 — — 2,594.8 (2,594.8 ) — Total current assets 1.8 2,715.3 138.8 12,553.3 15,268.6 (7,869.7 ) 7,539.5 Investments 35,656.1 — 34,644.2 12,571.8 12,571.8 (82,680.5 ) 191.6 Property, plant and equipment, net — — 27.4 6,442.2 6,442.2 — 6,469.6 Goodwill — — — 17,888.2 17,888.2 — 17,888.2 Intangible assets, net — — — 34,697.5 34,697.5 — 34,697.5 Deferred tax asset — — 273.0 96.7 96.7 (273.0 ) 96.7 Long-term intercompany loan receivable — 14,431.0 480.7 — 14,431.0 (14,911.7 ) — Other non-current assets 3.9 — 33.8 114.6 114.6 — 152.3 Total assets $ 35,661.8 $ 17,146.3 $ 35,597.9 $ 84,364.3 $ 101,510.6 $ (105,734.9 ) $ 67,035.4 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses $ 1.3 $ 85.7 $ 20.0 $ 4,205.4 $ 4,291.1 $ — $ 4,312.4 Short-term borrowings and capital lease obligations 450.0 2,594.8 — 23.2 2,618.0 — 3,068.0 Intercompany payables 5,247.1 — 27.8 — — (5,274.9 ) — Short-term intercompany loans payable — — — 2,594.8 2,594.8 (2,594.8 ) — Other current liabilities — — 64.6 298.3 298.3 — 362.9 Total current liabilities 5,698.4 2,680.5 112.4 7,121.7 9,802.2 (7,869.7 ) 7,743.3 Long-term borrowings and capital lease obligations — 14,431.0 5,063.7 405.1 14,836.1 — 19,899.8 Deferred tax liability — — — 8,595.7 8,595.7 (273.0 ) 8,322.7 Long-term intercompany loans payable 610.1 — — 14,301.6 14,301.6 (14,911.7 ) — Other non-current liabilities 405.3 — 61.7 1,654.6 1,654.6 — 2,121.6 Total liabilities 6,713.8 17,111.5 5,237.8 32,078.7 49,190.2 (23,054.4 ) 38,087.4 Total equity 28,948.0 34.8 30,360.1 52,285.6 52,320.4 (82,680.5 ) 28,948.0 Total liabilities and equity $ 35,661.8 $ 17,146.3 $ 35,597.9 $ 84,364.3 $ 101,510.6 $ (105,734.9 ) $ 67,035.4 Condensed Consolidating Balance Sheet (As of December 31, 2015) (In millions) Shire plc (Parent Guarantor) SAIIDAC (SAIIDAC Notes Subsidiary Issuer) Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ — $ — $ — $ 135.5 $ 135.5 $ — $ 135.5 Restricted cash — — — 86.0 86.0 — 86.0 Accounts receivable, net — — — 1,201.2 1,201.2 — 1,201.2 Inventories — — — 635.4 635.4 — 635.4 Prepaid expenses and other current assets 1.9 9.6 — 185.9 195.5 — 197.4 Intercompany receivables — — — 3,164.9 3,164.9 (3,164.9 ) — Total current assets 1.9 9.6 — 5,408.9 5,418.5 (3,164.9 ) 2,255.5 Investments 14,477.2 — — 50.8 50.8 (14,477.2 ) 50.8 Property, plant and equipment, net — — — 828.1 828.1 — 828.1 Goodwill — — — 4,147.8 4,147.8 — 4,147.8 Intangible assets, net — — — 9,173.3 9,173.3 — 9,173.3 Deferred tax asset — — — 121.0 121.0 — 121.0 Other non-current assets 5.3 8.3 — 19.7 28.0 — 33.3 Total assets $ 14,484.4 $ 17.9 $ — $ 19,749.6 $ 19,767.5 $ (17,642.1 ) $ 16,609.8 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses $ 10.0 $ — $ — $ 2,040.6 $ 2,040.6 $ — $ 2,050.6 Short-term borrowings and capital lease obligations 1,500.0 — — 12.7 12.7 — 1,512.7 Intercompany payables 3,145.3 19.6 — — 19.6 (3,164.9 ) — Other current liabilities — — — 142.8 142.8 — 142.8 Total current liabilities 4,655.3 19.6 — 2,196.1 2,215.7 (3,164.9 ) 3,706.1 Long-term borrowings and capital lease obligations — — — 82.1 82.1 — 82.1 Deferred tax liability — — — 2,205.9 2,205.9 — 2,205.9 Other non-current liabilities — — — 786.6 786.6 — 786.6 Total liabilities 4,655.3 19.6 — 5,270.7 5,290.3 (3,164.9 ) 6,780.7 Total equity 9,829.1 (1.7 ) — 14,478.9 14,477.2 (14,477.2 ) 9,829.1 Total liabilities and equity $ 14,484.4 $ 17.9 $ — $ 19,749.6 $ 19,767.5 $ (17,642.1 ) $ 16,609.8 Condensed Consolidating Statements of Operations For the year ended December 31, 2016 (In millions) Shire plc (Parent Guarantor) SAIIDAC (SAIIDAC Notes Subsidiary Issuer) Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated Revenues: Product sales $ — $ — $ — $ 10,885.8 $ 10,885.8 $ — $ 10,885.8 Royalties and other revenues — — — 510.8 510.8 — 510.8 Total revenues — — — 11,396.6 11,396.6 — 11,396.6 Costs and expenses: Cost of sales — — — 3,816.5 3,816.5 — 3,816.5 Research and development — — 0.4 1,439.4 1,439.4 — 1,439.8 Selling, general and administrative 59.8 — 29.4 2,926.0 2,926.0 — 3,015.2 Amortization of acquired intangible assets — — — 1,173.4 1,173.4 — 1,173.4 Integration and acquisition costs — — 302.0 581.9 581.9 — 883.9 Reorganization costs — — — 121.4 121.4 — 121.4 Gain on sale of product rights — — — (16.5 ) (16.5 ) — (16.5 ) Total operating expenses, net 59.8 — 331.8 10,042.1 10,042.1 — 10,433.7 Operating income / (loss) from continuing operations (59.8 ) — (331.8 ) 1,354.5 1,354.5 — 962.9 Interest income / (expense), net (100.6 ) 36.5 (45.1 ) (342.0 ) (305.5 ) — (451.2 ) Other expense, net 0.9 — 2.7 (29.2 ) (29.2 ) — (25.6 ) Total other income / (expense), net (99.7 ) 36.5 (42.4 ) (371.2 ) (334.7 ) — (476.8 ) Income / (loss) from continuing operations before income taxes and equity in (losses)/earnings of equity method investees (159.5 ) 36.5 (374.2 ) 983.3 1,019.8 — 486.1 Income taxes 4.3 (9.1 ) 88.9 42.0 32.9 — 126.1 Equity in income / (losses) of equity method investees, net of taxes 482.6 — (657.5 ) (8.7 ) (8.7 ) 174.9 (8.7 ) Income / (loss) from continuing operations, net of taxes 327.4 27.4 (942.8 ) 1,016.6 1,044.0 174.9 603.5 Loss from discontinued operations, net of taxes — — — (276.1 ) (276.1 ) — (276.1 ) Net income / (loss) 327.4 27.4 (942.8 ) 740.5 767.9 174.9 327.4 Comprehensive (loss) / income $ (986.4 ) $ 27.4 $ (2,148.9 ) $ (572.9 ) $ (545.5 ) $ 2,694.4 $ (986.4 ) Condensed Consolidating Statements of Operations For the year ended December 31, 2015 (In millions) Shire plc (Parent Guarantor) SAIIDAC (SAIIDAC Notes Subsidiary Issuer) Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated Revenues: Product sales $ — $ — $ — $ 6,099.9 $ 6,099.9 $ — $ 6,099.9 Royalties and other revenues — — — 316.8 $ 316.8 — 316.8 Total revenues — — — 6,416.7 6,416.7 — 6,416.7 Costs and expenses: Cost of sales — — — 969.0 $ 969.0 — 969.0 Research and development — — — 1,564.0 $ 1,564.0 — 1,564.0 Selling, general and administrative 24.9 — — 1,816.2 $ 1,816.2 1.4 1,842.5 Amortization of acquired intangible assets — — — 498.7 $ 498.7 — 498.7 Integration and acquisition costs — — — 39.8 $ 39.8 — 39.8 Reorganization costs — — — 97.9 $ 97.9 — 97.9 Gain on sale of product rights — — — (14.7 ) $ (14.7 ) — (14.7 ) Total operating expenses, net 24.9 — — 4,970.9 4,970.9 1.4 4,997.2 Operating (loss) / income from continuing operations (24.9 ) — — 1,445.8 1,445.8 (1.4 ) 1,419.5 Interest (expense) / income, net (63.6 ) (1.7 ) — 27.9 $ 26.2 — (37.4 ) Other income / (expense), net 0.9 — — 2.8 $ 2.8 — 3.7 Total other (expense) / income, net (62.7 ) (1.7 ) — 30.7 29.0 — (33.7 ) (Loss) / income from continuing operations before income taxes and equity in (losses)/earnings of equity method investees (87.6 ) (1.7 ) — 1,476.5 1,474.8 (1.4 ) 1,385.8 Income taxes 2.9 — — (49.0 ) (49.0 ) — (46.1 ) Equity in income / (losses) of equity method investees, net of taxes 1,388.1 — — (2.2 ) (2.2 ) (1,388.1 ) (2.2 ) Income / (loss) from continuing operations, net of taxes 1,303.4 (1.7 ) — 1,425.3 1,423.6 (1,389.5 ) 1,337.5 Loss from discontinued operations, net of taxes — — — (34.1 ) (34.1 ) — (34.1 ) Net income / (loss) 1,303.4 (1.7 ) — 1,391.2 1,389.5 (1,389.5 ) 1,303.4 Comprehensive income/(loss) $ 1,151.1 $ (1.7 ) $ — $ 1,238.9 $ 1,237.2 $ (1,237.2 ) $ 1,151.1 Condensed Consolidating Statements of Operations (For the year ended December 31, 2014) Shire plc (Parent Guarantor) SAIIDAC (SAIIDAC Notes Subsidiary Issuer) Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated Revenues: Product sales $ — $ — $ — $ 5,830.4 $ 5,830.4 $ — $ 5,830.4 Royalties and other revenues — — — 191.7 191.7 — 191.7 Total revenues — — — 6,022.1 6,022.1 — 6,022.1 Costs and expenses: Cost of sales — — — 979.3 979.3 — 979.3 Research and development — — — 1,067.5 1,067.5 — 1,067.5 Selling, general and administrative 109.4 — — 1,671.2 1,671.2 1.4 1,782.0 Amortization of acquired intangible assets — — — 243.8 243.8 — 243.8 Integration and acquisition costs — — — 158.8 158.8 — 158.8 Reorganization costs — — — 180.9 180.9 — 180.9 Gain on sale of product rights — — — (88.2 ) (88.2 ) — (88.2 ) Total operating expenses, net 109.4 — — 4,213.3 4,213.3 1.4 4,324.1 Operating (loss) / income from continuing operations (109.4 ) — — 1,808.8 1,808.8 (1.4 ) 1,698.0 Interest (expense) / income, net (42.8 ) — — 36.7 36.7 — (6.1 ) Other income, net 0.3 — — 8.6 8.6 — 8.9 Receipt of break fee 1,635.4 — — — — — 1,635.4 Total other income, net 1,592.9 — — 45.3 45.3 — 1,638.2 Income / (loss) from continuing operations before income taxes and equity in (losses)/earnings of equity method investees 1,483.5 — — 1,854.1 1,854.1 (1.4 ) 3,336.2 Income taxes 2.2 — — (58.3 ) (58.3 ) — (56.1 ) Equity in income / (losses) of equity method investees, net of taxes 1,919.8 — — 2.7 2.7 (1,919.8 ) 2.7 Income / (loss) from continuing operations, net of taxes 3,405.5 — — 1,798.5 1,798.5 (1,921.2 ) 3,282.8 Income from discontinued operations, net of taxes — — — 122.7 122.7 — 122.7 Net income / (loss) 3,405.5 — — 1,921.2 1,921.2 (1,921.2 ) 3,405.5 Comprehensive income / (loss) $ 3,263.8 $ — $ — $ 1,779.5 $ 1,779.5 $ (1,779.5 ) $ 3,263.8 Condensed Consolidating Statement of Cash Flows (For the year ended December 31, 2016) (In millions) Shire plc (Parent Guarantor) SAIIDAC (SAIIDAC Notes Subsidiary Issuer) Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated CASH FLOWS FROM OPERATING ACTIVITIES Net cash (used in) / provided by operating activities $ (136.9 ) $ 232.8 $ (51.0 ) $ 2,614.0 $ 2,846.8 $ — $ 2,658.9 CASH FLOWS FROM INVESTING ACTIVITIES: Transactions with subsidiaries (2,890.0 ) (18,228.8 ) (480.7 ) (4,707.3 ) (22,936.1 ) 26,306.8 — Movements in restricted cash — — — 62.8 62.8 — 62.8 Purchases of subsidiary undertakings and businesses, net of cash acquired — — — (17,476.2 ) (17,476.2 ) — (17,476.2 ) Purchases of non-current investments and PP&E — — (11.1 ) (637.6 ) (637.6 ) — (648.7 ) Proceeds received on sale of product rights — — — 10.9 10.9 — 10.9 Proceeds from disposal of non-current investments and PP&E — — — 0.9 0.9 — 0.9 Other, net — — — (41.9 ) (41.9 ) — (41.9 ) Net cash (used in) / provided by investing activities (2,890.0 ) (18,228.8 ) (491.8 ) (22,788.4 ) (41,017.2 ) 26,306.8 (18,092.2 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from revolving line of credit, long term and short term borrowings 2,355.0 30,079.9 — 8.5 30,088.4 — 32,443.4 Repayment of revolving line of credit, long term and short term borrowings (3,405.0 ) (13,009.2 ) — 9.9 (12,999.3 ) — (16,404.3 ) Proceeds from intercompany borrowings 4,077.8 1,097.6 521.9 20,609.5 21,707.1 (26,306.8 ) — Payment of dividend (20.7 ) — — (150.6 ) (150.6 ) — (171.3 ) Debt issuance costs — (172.3 ) — — (172.3 ) — (172.3 ) Contingent consideration payments — — — (8.0 ) (8.0 ) — (8.0 ) Proceeds from exercise of options 19.8 — 92.7 16.5 16.5 — 129.0 Other, net — — (30.1 ) 39.4 39.4 — 9.3 Net cash provided by / (used in) financing activities 3,026.9 17,996.0 584.5 20,525.2 38,521.2 (26,306.8 ) 15,825.8 Effect of foreign exchange rate changes on cash and cash equivalents — — — 0.8 0.8 — 0.8 Net increase in cash and cash equivalents — — 41.7 351.6 351.6 — 393.3 Cash and cash equivalents at beginning of period — — — 135.5 135.5 — 135.5 Cash and cash equivalents at end of period $ — $ — $ 41.7 $ 487.1 $ 487.1 $ — $ 528.8 Condensed Consolidating Statement of Cash Flows (For the year ended December 31, 2015) (In millions) Shire plc (Parent Guarantor) SAIIDAC (SAIIDAC Notes Subsidiary Issuer) Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated CASH FLOWS FROM OPERATING ACTIVITIES Net cash (used in) / provided by operating activities $ (133.5 ) $ — $ — $ 2,470.5 $ 2,470.5 $ — $ 2,337.0 CASH FLOWS FROM INVESTING ACTIVITIES: Transactions with subsidiaries (3,570.0 ) — — (3,048.2 ) (3,048.2 ) 6,618.2 — Movements in restricted cash — — — (32.0 ) (32.0 ) — (32.0 ) Purchases of subsidiary undertakings and businesses, net of cash acquired — — — (5,553.4 ) (5,553.4 ) — (5,553.4 ) Purchases of non-current investments and PP&E — — — (124.2 ) (124.2 ) — (124.2 ) Proceeds from short-term investments — — — 67.0 67.0 — 67.0 Proceeds received on sale of product rights — — — 17.5 17.5 — 17.5 Proceeds from disposal of non-current investments and PP&E — — — 18.7 18.7 — 18.7 Other, net — — — (13.5 ) (13.5 ) — (13.5 ) Net cash provided by / (used in) investing activities (3,570.0 ) — — (8,668.1 ) (8,668.1 ) 6,618.2 (5,619.9 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from revolving line of credit, long term and short term borrowings 3,760.0 — — 0.8 0.8 — 3,760.8 Repayment of revolving line of credit, long term and short term borrowings (3,110.0 ) — — (0.9 ) (0.9 ) — (3,110.9 ) Proceeds from intercompany borrowings 3,048.2 — — 3,570.0 3,570.0 (6,618.2 ) — Payment of dividend (6.8 ) — — (127.6 ) (127.6 ) — (134.4 ) Debt issuance costs (4.5 ) — — (19.6 ) (19.6 ) — (24.1 ) Contingent consideration payments — — — (101.2 ) (101.2 ) — (101.2 ) Proceeds from exercise of options 16.6 — — — — — 16.6 Other, net — — — 32.2 32.2 — 32.2 Net cash provided by / (used in) financing activities 3,703.5 — — 3,353.7 3,353.7 (6,618.2 ) 439.0 Effect of foreign exchange rate changes on cash and cash equivalents — — — (3.0 ) (3.0 ) — (3.0 ) Net decrease in cash and cash equivalents — — — (2,846.9 ) (2,846.9 ) — (2,846.9 ) Cash and cash equivalents at beginning of period — — — 2,982.4 2,982.4 — 2,982.4 Cash and cash equivalents at end of period $ — $ — $ — $ 135.5 $ 135.5 $ — $ 135.5 Condensed Consolidating Statement of Cash Flows (For the year ended December 31, 2014) (In millions) Shire plc (Parent Guarantor) SAIIDAC (SAIIDAC Notes Subsidiary Issuer) Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated CASH FLOWS FROM OPERATING ACTIVITIES Net cash provided by / (used in) operating activities $ 1,512.6 $ — $ — $ 2,715.8 $ 2,715.8 $ — $ 4,228.4 CASH FLOWS FROM INVESTING ACTIVITIES: Transactions with subsidiaries (1,900.0 ) — — 458.3 458.3 1,441.7 — Movements in restricted cash — — — (32.6 ) (32.6 ) — (32.6 ) Purchases of subsidiary undertakings and businesses, net of cash acquired — — — (4,104.4 ) (4,104.4 ) — (4,104.4 ) Purchases of non-current investments and PP&E — — — (100.1 ) (100.1 ) — (100.1 ) Proceeds from short-term investments — — — 57.8 57.8 — 57.8 Proceeds received on sale of product rights — — — 127.0 127.0 — 127.0 Proceeds from disposal of non-current investments and PP&E — — — 21.5 21.5 — 21.5 Other, net — — — 0.2 0.2 — 0.2 Net cash provided by (used in) investing activities (1,900.0 ) — — (3,572.3 ) (3,572.3 ) 1,441.7 (4,030.6 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from revolving line of credit, long term and short term borrowings 2,310.0 — — 0.8 0.8 — 2,310.8 Repayment of revolving line of credit, long term and short term borrowings (1,460.0 ) — — (1.8 ) (1.8 ) — (1,461.8 ) Repayment of debt acquired through business combinations — — — (551.5 ) (551.5 ) — (551.5 ) Proceeds from ViroPharma call options — — — 346.7 346.7 — 346.7 Proceeds from intercompany borrowings (458.3 ) — — 1,900.0 1,900.0 (1,441.7 ) — Payment of dividend (8.9 ) — — (112.3 ) (112.3 ) — (121.2 ) Debt issuance costs (10.6 ) — — 0.4 0.4 — (10.2 ) Contingent consideration payments — — — (15.2 ) (15.2 ) — (15.2 ) Proceeds from exercise of options 15.2 — — 2.2 2.2 — 17.4 Other, net — — — 39.5 39.5 — 39.5 Net cash provided by / (used in) financing activities 387.4 — — 1,608.8 1,608.8 (1,441.7 ) 554.5 Effect of foreign exchange rate changes on cash and cash equivalents — — — (9.3 ) (9.3 ) — (9.3 ) Net increase in cash and cash equivalents — — — 743.0 743.0 — 743.0 Cash and cash equivalents at beginning of period — — — 2,239.4 2,239.4 — 2,239.4 Cash and cash equivalents at end of period $ — $ — $ — $ 2,982.4 $ 2,982.4 $ — $ 2,982.4

Quarterly Results of Operations

Quarterly Results of Operations (Unaudited)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Quarterly Results of Operations (Unaudited)	Quarterly results of operations (Unaudited) The following table presents summarized unaudited quarterly results for the years to December 31, 2016 and 2015 : 2016 Q1 Q2 Q3 Q4 (In millions, except per share data) Total revenues $ 1,709.3 $ 2,429.1 $ 3,452.1 $ 3,806.1 Cost of product sales 248.6 778.1 1,736.2 1,053.6 Income from continuing operations, net of taxes 409.5 86.6 (368.5 ) 475.9 Loss from discontinued operations, net of taxes 9.5 (248.7 ) (18.3 ) (18.6 ) Net income 419.0 (162.1 ) (386.8 ) 457.3 Earnings per ordinary share - basic Earnings from continuing operations $ 0.69 $ 0.12 $ (0.41 ) $ 0.53 Loss from discontinued operations 0.02 (0.36 ) (0.02 ) (0.02 ) Earnings per share - basic $ 0.71 $ (0.24 ) $ (0.43 ) $ 0.51 Earnings per ordinary share - diluted Earnings from continuing operations $ 0.69 $ 0.12 $ (0.41 ) $ 0.52 Loss from discontinued operations 0.02 (0.36 ) (0.02 ) (0.02 ) Earnings per share - diluted $ 0.71 $ (0.24 ) $ (0.43 ) $ 0.50 2015 Q1 Q2 Q3 Q4 (In millions,except per share data) Total revenues $ 1,488.4 $ 1,557.6 $ 1,655.0 $ 1,715.7 Cost of product sales 227.8 228.0 262.7 250.5 Income from continuing operations, net of taxes 412.9 164.1 477.1 283.4 (Loss)/gain from discontinued operations, net of taxes (2.5 ) (4.5 ) (24.3 ) (2.8 ) Net income 410.4 159.6 452.8 280.6 Earnings per ordinary share - basic Earnings from continuing operations $ 0.70 $ 0.28 $ 0.81 $ 0.48 (Loss)/gain from discontinued operations — (0.01 ) (0.04 ) (0.01 ) Earnings per share - basic $ 0.70 $ 0.27 $ 0.77 $ 0.47 Earnings per ordinary share - diluted Earnings from continuing operations $ 0.70 $ 0.28 $ 0.80 $ 0.48 (Loss)/gain from discontinued operations — (0.01 ) (0.04 ) (0.01 ) Earnings per share - diluted $ 0.70 $ 0.27 $ 0.76 $ 0.47

Notes to the Shire Income Acces

Notes to the Shire Income Access Share Trust Financial Statements	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Notes to the Shire Income Access Share Trust Financial Statements	NOTES TO THE SHIRE INCOME ACCESS SHARE TRUST FINANCIAL STATEMENTS 1. Description of the Trust The Shire Income Access Share Trust (the “Trust”) was established on August 29, 2008 by Shire Biopharmaceuticals Holdings (formerly Shire plc). The Trust is governed by the applicable laws of England and Wales and is resident in Jersey. The Trustee of the Trust is Equiniti Trust (Jersey) Limited, 26 New Street, St Helier, Jersey, JE4 3RA. The Trust was established as part of the Income Access Share mechanism, as outlined in Note 26 , Shareholders' Equity . 2. Basis of Preparation The financial statements of the Trust have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The financial statements have been prepared under the historical cost convention. The preparation of financial statements in conformity with U.S. GAAP requires the use of certain accounting estimates. It also requires management to exercise its judgment in the process of applying the Trust’s accounting policies. Actual results may differ from these estimates. The results of operations, the financial position and cash flows of the Trust are consolidated in the Company’s Financial Statements, as contained on pages F-1 to F-90. 3. Summary of Significant Accounting Policies Functional currency The functional currency of the Trust is U.S. dollars. Foreign currency translation Income and expense items denominated in currencies other than the functional currency are translated into the functional currency at the rate ruling on their transaction date. Monetary assets and liabilities recorded in currencies other than the functional currency have been expressed in the functional currency at the rates of exchange ruling at the respective balance sheet dates. Differences on translation are included in the Consolidated Statements of Operations. Dividend income Interim dividends declared on the Income Access Share are recognized on a paid basis unless the dividend has been confirmed by a general meeting of Shire, in which case income is recognized on the record date of the dividend by Shire on its ordinary shares. 4. Capital account The Capital account is represented by the Income Access Share of 5 pence settled in the Trust by Old Shire. 5. Distributions Distributions are made to those shareholders of Shire who have elected to receive dividends from the Trust in accordance with the Trust Deed. Unclaimed dividends are not included in distributions made. As of December 31, 2016 the unclaimed dividends are immaterial. Amounts are recorded as distributed once a wire transfer or check is issued. All checks are valid for one year from the date of issue. Any wire transfers that are not completed are replaced by checks. To the extent that checks expire or are returned unrepresented, the Trust records a liability for unclaimed dividends and a corresponding amount of cash. 6. Market and Similar Risks The Trust, in its normal course of business, is not subject to market risk, credit risk or liquidity risk. The Trustees do not consider that any foreign exchange exposure will materially affect the operations of the Trust.

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2016
Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	Schedule II - Valuation and Qualifying Accounts Provision for sales rebates, returns and coupons Beginning balance Provision charged to income Additions through acquisitions Costs incurred/ utilization Ending balance (In millions) 2016: Accrued rebates - Medicaid and HMOs $ 982.4 $ 2,702.4 $ 185.8 $ (2,439.3 ) $ 1,431.3 Sales returns reserve 128.3 19.5 — (29.4 ) 118.4 Accrued coupons 26.6 236.9 — (192.2 ) 71.3 $ 1,137.3 $ 2,958.8 $ 185.8 $ (2,660.9 ) $ 1,621.0 2015: Accrued rebates - Medicaid and HMOs $ 882.1 $ 2,128.0 $ — $ (2,027.7 ) $ 982.4 Sales returns reserve 131.7 19.4 — (22.8 ) 128.3 Accrued coupons 20.1 140.5 — (134.0 ) 26.6 $ 1,033.9 $ 2,287.9 $ — $ (2,184.5 ) $ 1,137.3 2014: Accrued rebates - Medicaid and HMOs $ 806.5 $ 1,877.7 $ — $ (1,802.1 ) $ 882.1 Sales returns reserve 97.9 60.1 — (26.3 ) 131.7 Accrued coupons 20.7 98.9 — (99.5 ) 20.1 $ 925.1 $ 2,036.7 $ — $ (1,927.9 ) $ 1,033.9 In the analysis above, due to systems limitations, it is not practical and has not been necessary to break out current versus prior year activity. When applicable, Shire has performed general ledger reviews of sales deduction provisions charged to income, and the utilization of these provisions in subsequent years. Shire has determined that adjustments made in each year as a result of changes to estimates that related to prior year sales, and adjustments made as a result of differences between prior period provisions and actual payments, did not have a material impact on the Company’s financial performance or position either in each individual year, or in the Company’s performance over the reported period.

Summary of Significant Accoun42

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Line Items]
Basis of presentation	Basis of preparation The accompanying Consolidated Financial Statements include the accounts of Shire plc, all of its subsidiary undertakings and the Income Access Share trust, after elimination of inter-company accounts and transactions. They have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and U.S. Securities and Exchange Commission (“SEC”) regulations for annual reporting.
Consolidation	Consolidation The Consolidated Financial Statements reflect the financial statements of the Company and those of the Company's wholly-owned subsidiaries. For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to non-controlling interests in its Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. Intercompany balances and transactions are eliminated in consolidation. The Company determines whether to consolidate subsidiaries based on either the variable interest entity (“VIE”) model or the voting interest model. The Company consolidates a VIE if it is determined that the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of an entity, management applies a qualitative approach that determines whether the Company has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. The Company consolidates entities that are not VIEs if it is determined that the Company holds a majority voting interest in the entity. Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Intercompany balances and transactions are eliminated in consolidation.
Use of estimates in consolidated financial statements	Use of estimates in Consolidated Financial Statements The preparation of the Consolidated Financial Statements, in conformity with U.S. GAAP and SEC regulations, requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities and equity at the date of the Consolidated Financial Statements and reported amounts of revenues and expenses during the reporting period. On an on-going basis, the Company evaluates its estimates, judgments and methodologies. Estimates are based on historical experience, current conditions and on various other assumptions that are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amounts of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.
Revenue recognition	Revenue recognition The Company recognizes revenue when all of the following criteria are met: • there is persuasive evidence an arrangement exists; • delivery has occurred or services have been rendered; • the price to the customer is fixed or determinable; and • collectibility is reasonably assured. Where applicable, all revenues are stated net of value added and similar taxes and trade discounts. The Company’s principal revenue streams and their respective accounting treatments are discussed below: Product sales Revenues from Product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery. Product sales are recorded net of applicable reserves for discounts and allowances. Reserves for Discounts and Allowances The Company establishes reserves for trade discounts, chargebacks, distribution service fees, Medicaid rebates, managed care rebates, incentive rebates, product returns and other governmental rebates or applicable allowances. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. Management's estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from estimates. If actual results vary, management adjusts these estimates, which have an effect on earnings in the period of adjustment. • Trade discounts are generally credits granted to wholesalers, specialty pharmacies and other customers for remitting payment on their purchases within established incentive periods and are classified as a reduction of accounts receivable, offset by revenue. • Chargebacks are credits or payments issued to wholesalers and distributors who provide products to qualified healthcare providers at prices lower than the list prices charged to the wholesaler or distributor. Reserves are estimated based on expected purchases by those qualified healthcare providers. Chargeback reserves are classified as a reduction of accounts receivable. • Distribution service fees are credits or payments issued to wholesalers, distributors and specialty pharmacies for compliance with various contractually-defined inventory management practices or services provided to support patient access to a product . These fees are generally based on a percentage of gross purchases but can also be based on additional services these entities provide. Most of these costs are reflected as a reduction of gross sales; however, to the extent benefit from services can be separately identified and the fair value determined, costs are classified in Selling, general and administrative expense. Reserves are classified within accrued expenses. • Medicaid rebates are payments to States under statutory and voluntary reimbursement arrangements. Reserves for these rebates are generally based on an estimate of expected product usage by Medicaid patients and expected rebate rates. Statutory rates are generally based on a percentage of selling price adjusted upwards for price increases in excess of published inflation indices. As a result, rebates generally increase as a percentage of the selling price over the life of the product (as prices increase). Medicaid rebate reserves are classified within accrued expenses. • Managed care rebates are payments to third parties, primarily pharmacy benefit managers and other health insurance providers. The reserve for these rebates is based on an estimate of customer buying patterns and applicable contractual rebate rates to be earned over each period. Reserves are classified within accrued expenses. • Incentive rebates are generally credits or payments issued to specialty pharmacies, distributors or Group Purchasing Organizations for qualified purchases of certain products. Reserves are estimated based on the terms of each individual contract and purchase volumes and are classified within accrued expenses. • Return credits are issued to customers for return of product damaged in shipment and, for certain products, return due to lot expiry. The majority of returns are due to expiry, and reserves are estimated based on historical returns experience. The returns reserve is classified within accrued expenses. • Other discounts and allowances include Medicare rebates, coupon and patient co-pay assistance. Medicare rebates are payments to health insurance providers of Medicare Part D coverage to qualified patients. Reserve estimates are based on customer buying patterns and applicable contractual rebate rates to be earned over each period. Coupon and co-pay assistance programs provide discounts to qualified patients. Reserve estimates are based on expected claim volumes under these programs and estimated cost per claim that the Company expects to pay. Reserves for Medicare and coupon and patient co-pay programs are classified within accrued expenses. Royalties and Other Revenue Royalty income relating to licensed technology is recognized when the licensee sells the underlying product, with the amount of royalty income recorded based on sales information received from the relevant licensee. The Company estimates sales amounts and related royalty income based on the historical product information for any period that the sales information is not available from the relevant licensee. Other revenue includes revenues derived from product out-licensing arrangements, which may consist of an initial up-front payment on inception of the license and subsequent milestone payments upon achievement of certain clinical and sales milestones. To the extent the license requires Shire to provide services to the licensee; up-front payments are deferred and recognized over the service period
Contingent consideration payable and Business combinations	Contingent consideration payable Contingent consideration payable represents future milestones and royalties the Company may be required to pay in conjunction with various business combinations. The amounts ultimately payable by the Company are dependent upon the successful achievement of the underlying scientific or commercial event and future net sales of the relevant products over applicable term. The Company records an obligation for such contingent payments at fair value on the acquisition date. The Company assesses the probability, and estimated timing, of these milestones being achieved and the present value of forecast future net sales of the relevant products and re-measures the related contingent consideration to fair value each balance sheet date. The amount of contingent consideration which may ultimately be payable by Shire in relation to future royalties is dependent upon future net sales of the relevant products over the life of the royalty term. The fair value of the Company’s contingent consideration payable could significantly increase or decrease due to changes in certain assumptions which underpin the fair value measurements. Each set of assumptions and milestones is specific to the individual contingent consideration payable. The assumptions include, among other things, the probability of, and period in which, the relevant milestone event is expected to be achieved; the amount of royalties that will be payable based on forecast net sales of the relevant products; and the discount rates to be applied in calculating the present values of the relevant milestone or royalty. The Company regularly reviews these assumptions, and makes adjustments to the fair value measurements as required by facts and circumstances. Business combinations Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process research and development ("IPR&D") projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in the Consolidated Financial Statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree’s liability arising from a business combination it completed prior to the acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in earnings.
Goodwill and intangible assets	Goodwill Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired in a business combination. Goodwill is not amortized, but instead is reviewed for impairment. Goodwill is reviewed annually, as of October 1, and whenever events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable. Events or changes in circumstances which could trigger an impairment review include but are not limited to: unexpected adverse business conditions, economic factors, unanticipated technological changes or competitive activities and acts by governments and courts. For the purpose of assessing the carrying value of goodwill for impairment, goodwill is allocated at the Company’s reporting unit level. As described in Note 22 , Segment Reporting , the Company operates in one operating segment which it considers to be its only reporting unit. The Company reviews goodwill for impairment by firstly assessing qualitative factors, including comparing the market capitalization of the Company to the carrying value of its assets, to determine whether events or circumstances exist which indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The Company assesses all events or circumstances and determines if it is more likely than not that the fair value of a reporting unit exceeds its carrying value. If, after assessing these qualitative factors, it is deemed more likely than not that the fair value of a reporting unit is less than its carrying value, a “two step” quantitative assessment is performed by comparing the carrying value of the reporting unit's net assets (including allocated goodwill) to the fair value of the reporting unit. The Company compares the fair value of its reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of its reporting unit, then it determines the implied fair value of its reporting unit’s goodwill. If the carrying value of the reporting unit’s goodwill exceeds its implied fair value, then an impairment loss equal to the difference is recorded. Intangible Assets Intangible assets primarily relate to commercially marketed products and IPR&D projects. Intangible assets are recorded at fair value at the time of their acquisition and are stated in the Consolidated Balance Sheets, net of accumulated amortization and impairments, if applicable. Intangible assets related to commercially marketed products are amortized over their estimated useful lives. Remaining useful lives range from 2 to 25 years (weighted average 20 years ) and the Company amortizes its intangibles on a straight-line basis. The Company reviews intangible assets for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. Milestone payments made to third parties on and subsequent to regulatory approval are capitalized as intangible assets, and amortized over the remaining useful life of the related product. The following factors, where applicable, are considered in estimating the useful lives of intangible assets: • expected use of the asset; • regulatory, legal or contractual provisions, including the regulatory approval and review process, patent issues and actions by government agencies; • the effects of obsolescence, changes in demand, competing products and other economic factors, including the stability of the market, known technological advances, development of competing drugs that are more effective clinically or economically; • actions of competitors, suppliers, regulatory agencies or others that may eliminate current competitive advantages; and • historical experience of renewing or extending similar arrangements. Acquired IPR&D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value. The revenue and costs projections used to value acquired IPR&D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology, and the nature and expected timing of new product introductions by the Company and its competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&D, the Company completes an assessment of whether the acquisition constitutes the purchase of a single asset or a group of assets. The Company considers multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and its rationale for entering into the transaction. If the Company acquires a business as defined under applicable accounting standards, then the acquired IPR&D is capitalized as an intangible asset. If the Company acquires an asset or group of assets that do not meet the definition of a business, then the acquired IPR&D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. IPR&D projects are considered to be indefinite-lived until completion of the associated R&D efforts. If and when development is complete, which generally occurs when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Intangible assets related to IPR&D projects are tested for impairment at least annually, as of October 1st, until commercialization, after which time the IPR&D is amortized over its estimated useful life. The Company evaluates the carrying value of long-lived assets, except for goodwill and indefinite lived intangible assets, whenever events or changes in circumstances indicate that the carrying amounts of the relevant assets may not be recoverable. When such a determination is made, management’s estimate of undiscounted cash flows to be generated by the use and ultimate disposition of these assets is compared to the carrying value of the assets to determine whether the carrying value is recoverable. If the carrying value is deemed not to be recoverable, the amount of the impairment recognized in the Consolidated Financial Statements is determined by estimating the fair value of the relevant assets and recording an impairment loss for the amount by which the carrying value exceeds the estimated fair value. This fair value is usually determined based on estimated discounted cash flows. When performing the impairment assessment, the Company calculates the fair value using the same methodology as described above. If the carrying value of the acquired IPR&D exceeds its fair value, then the intangible asset is written-down to its fair value.
Fair value measurements	Fair Value Measurements The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements: • Level 1 - Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access; • Level 2 - Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates; and • Level 3 - Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. The majority of the Company's financial assets have been classified as Level 1 and 2. The Company's financial assets, which include cash equivalents, derivative contracts, marketable equity and debt securities, and plan assets for deferred compensation, have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other market observable data. The Company utilizes industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.
Accounts receivable	Accounts receivable The Company's accounts receivable arise from Product sales and represent amounts due from its customers. The Company monitors the financial performance and credit worthiness of its large customers so that it can assess and respond to changes in their credit profile. The Company provides reserves against accounts receivable for estimated losses, if any, that may result from a customer's inability to pay. Amounts determined to be uncollectible are written-off against the reserve.
Investments	Investments The Company has certain investments in pharmaceutical and biotechnology companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the cost method or the equity method of accounting, depending on its ownership percentage and other factors that suggest the Company has significant influence. Under the equity method of accounting, the Company records its investments in equity-method investees in the consolidated balance sheet under Investments and its share of the investees’ earnings or losses together with other-than- temporary impairments in value under equity in (losses)/ earnings of equity method investees, net of taxes in the Consolidated Statements of Operations. The Company monitors these investments to evaluate whether any decline in their value has occurred that would be other-than-temporary, based on the implied value of recent company financings, public market prices of comparable companies, and general market conditions. All other equity investments, which consist of investments for which the Company does not have the ability to exercise significant influence, are accounted for under the cost method or at fair value. Investments in private companies are carried at cost, less provisions for other-than-temporary impairment in value. For investments in equity investments that have readily determinable fair values, the Company classifies its equity investments as available-for-sale and, accordingly, records these investments at their fair values with unrealized holding gains and losses included in the consolidated statement of comprehensive income, net of any related tax effect. Realized gains and losses, and declines in value of available-for-sale securities judged to be other-than-temporary, are included in other income, net in the Consolidated Statements of Operations. The cost of securities sold is based on the specific identification method. Interest on securities classified as available-for-sale is included as interest income in the Consolidated Statements of Operations.
Inventories	Inventories Inventories are stated at the lower of cost or market. Cost incurred in bringing each product to its present location and condition is based on purchase costs calculated on a first-in, first-out basis, including transportation costs. The inventory costs are classified as long term when the Company expects to utilize the inventory beyond the normal operating cycle and includes these costs in Other assets in the Consolidated Balance Sheets. Capitalization of Inventory Costs The Company capitalizes inventory costs associated with its products prior to regulatory approval, when, based on management’s judgment, future commercialization is considered highly probable and the future economic benefit is expected to be realized. Obsolescence and Unmarketable Inventory Inventories are written down for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and estimated market value based upon assumptions about future demand and market conditions. Amounts written down due to unmarketable inventory are charged to Cost of product sales.
Property, plant and equipment	Property, plant and equipment Property, plant and equipment are carried at cost, net of accumulated depreciation and impairment losses. Property, plant and equipment are subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits. Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the useful life of the underlying asset. The Company also capitalizes certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are amortized over the useful life of the related equipment. Depreciation of property, plant and equipment is calculated using the straight-line method over the estimated useful lives as follows: Asset category Estimated useful lives Land Not depreciated Buildings and leasehold improvements 15 to 50 years Office furniture, fittings and equipment 3 to 10 years Machinery, equipment and other 3 to 15 years At the time property, plant and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are eliminated from the asset and accumulated depreciation accounts. The profit or loss on such disposition is reflected in operating income.
Discontinued operations	Discontinued operations Discontinued operations comprise those activities that were disposed of during the period or which were classified as held for sale at the end of the period, and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes.
Derivative financial instruments	Derivative financial instruments The Company uses derivative financial instruments to manage its exposure to foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities. For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the derivative is recorded in Accumulated Other Comprehensive Income (“AOCI”) and then recognized in earnings consistent with the underlying hedged item. Cash flow hedges are classified in revenues and cost of sales and primarily relate to forecasted third-party sales denominated in foreign currencies and forecasted intercompany sales denominated in foreign currencies, respectively. In its application of hedge accounting, the Company assesses, both at inception and on a prospective basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. The Company also assesses hedge effectiveness on a retrospective basis every quarter with any hedge ineffectiveness recorded to the Consolidated Statement of Operations. The Company uses forward contracts to mitigate the effects of changes in foreign exchange relating to certain of the Company’s intercompany and third-party receivables and payables. These derivative instruments generally are not formally designated as hedges and the terms of these instruments generally do not exceed three months. The fair values of these instruments are included on the balance sheet in current assets/liabilities, with changes in the fair value recognized in the Consolidated Statements of Operations. The cash flows relating to these instruments are presented within net cash provided by operating activities in the Consolidated Statements of Cash Flows, unless the derivative instruments are economically hedging specific investing or financing activities.
Translation of foreign currency	Translation of foreign currency The functional currency for most of the foreign subsidiaries is their local currency. For the non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the foreign operations into U.S. dollars are excluded from the determination of Net income and are recorded in AOCI, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in Other income/(expense), net, in Net income.
Cost of product sales	Cost of product sales Cost of product sales includes the cost of purchasing finished product for sale, the cost of raw materials and costs of manufacturing those products including shipping and handling costs, depreciation and amortization of intangible assets in respect of favorable manufacturing contracts. Royalties payable to third party intellectual property owners related to the sold products are also included in Cost of product sales.
Research and development ("R&D") expense	Research and development ("R&D") expense Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations ("CROs"), clinical supply and manufacturing expenses. R&D expense also includes the impairment charges related to intangible assets. Research and development expenses are expensed as incurred. Payments that were made for research and development services prior to the services being rendered are recorded as Prepaid expenses and other current assets on the Consolidated Balance Sheets and are expensed as the services are provided. Management also accrues the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.
Selling, general and administrative expenses	Selling, general and administrative expenses Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.
Advertising expense	Advertising costs are expensed as incurred.
Collaborative arrangements	Collaborative arrangements The Company enters into collaborative arrangements to develop and commercialize drug candidates. These collaborative arrangements often require up-front, milestone, royalty or profit share payments, or a combination of these, with payments often contingent upon the success of the related development and commercialization efforts. Collaboration agreements entered into by the Company may also include expense reimbursements or other such payments to the collaborating partner. The Company records payments received from the collaborative partners for their share of the development costs as a reduction of research and development expense . For collaborations with commercialized products, if the Company is the principal, we record revenue and the corresponding operating costs in their respective line items in the Consolidated Statements of Operations. If we are not the principal, we record operating costs as a reduction of revenue.
Leased assets	Leased assets The costs of operating leases are charged to operations on a straight-line basis over the lease term, even if rental payments are not made on such a basis. Assets acquired under capital leases are included in the Consolidated Balance Sheets as property, plant and equipment and are depreciated over the shorter of the period of the lease or their useful lives. The capital element of future lease payments is recorded as a liability, while the interest element is charged to operations over the period of the lease to produce a level yield on the balance of the capital lease obligation.
Finance costs of debt	Finance costs of debt Financing costs relating to debt issued are recorded against the corresponding debt and amortized to the Consolidated Statements of Operations over the period to the earliest redemption date of the debt, using the effective interest rate method. On extinguishment of the related debt, any unamortized deferred financing costs are written off and charged to interest expense in the Consolidated Statements of Operations.
Income taxes	Income taxes The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method Uncertain tax positions are recognized in the Consolidated Financial Statements for positions which are considered more likely than not of being sustained, based on the technical merits of the position on audit by the tax authorities. The measurement of the tax benefit recognized in the Consolidated Financial Statements is based upon the largest amount of tax benefit that, in management’s judgment, is greater than 50% likely of being realized based on a cumulative probability assessment of the possible outcomes. The Company recognizes interest and penalties relating to income taxes within income taxes. Interest income on cash required to be deposited with the tax authorities is recognized within interest income. Deferred tax assets and liabilities are recognized for differences between the carrying amounts of assets and liabilities in the Consolidated Financial Statements and the tax bases of assets and liabilities that will result in future taxable or deductible amounts. The deferred tax assets and liabilities are measured using the enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.
Earnings per share	Earnings per share Basic earnings per share is based upon net income attributable to the Company divided by the weighted average number of ordinary shares outstanding during the period. Diluted earnings per share is based upon net income attributable to the Company divided by the weighted average number of ordinary share equivalents outstanding during the period, adjusted for the dilutive effect of all potential ordinary shares equivalents that were outstanding during the year. Such potentially dilutive shares are excluded when the effect would be to increase diluted earnings per share or reduce the diluted loss per share.
Share-based compensation	Share-based compensation The share-based compensation programs grant awards that include stock-settled share appreciation rights (“SARs”), stock options, performance share awards (“PSAs”), restricted stock units (“RSUs”) and performance share units (“PSUs”). The Company also operates a Global Employee Stock Purchase Plan, and Sharesave Plans in the UK and Ireland. Share-based compensation represents the cost of share-based awards granted to employees. The Company measures share-based compensation cost for awards classified as equity at the grant date, based on the estimated fair value of the award. Predominantly all of the Company’s awards have service and/or performance conditions and the fair values of these awards are estimated using a Black-Scholes valuation model. For share-based compensation awards which cliff vest, the Company recognizes the cost of the relevant share-based payment award as an expense on a straight-line basis (net of estimated forfeitures) over the employee’s requisite service period. For those share-based compensation awards with a graded vesting schedule, the Company recognizes the cost of the relevant share-based payment award as an expense on a straight-line basis (net of estimated forfeitures) over the requisite service period for the entire award (that is, over the requisite service period for the last separately vesting portion of the award). The share-based compensation expense is recorded in Cost of product sales, R&D, SG&A, Reorganization costs and Integration and Acquisition costs in the Consolidated Statements of Operations based on the employees’ respective functions. The Company records deferred tax assets for awards that result in deductions on the Company’s income tax returns, based on the amount of compensation cost recognized and the Company’s statutory tax rate in the jurisdiction in which it will receive a deduction. Differences between the deferred tax assets recognized for financial reporting purposes and the actual tax deduction reported on the Company’s income tax return are recorded in additional paid-in capital (if the tax deduction exceeds the deferred tax asset) or in the Consolidated Statements of Operations (if the deferred tax asset exceeds the tax deduction and no additional paid-in capital exists from previous awards). The Company’s share-based compensation plans are described more fully in Note 27 , Share-based Compensation Plans .
New accounting pronouncements	New accounting pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on the Company’s financial position or results of operations upon adoption. Adopted during the period Reporting requirements for development stage entities In June 2014, the FASB issued Accounting Standards Update ("ASU") No. 2014-10 Development Stage Entities (Topic 915) Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. ASU 2014-10 simplified the existing guidance for development stage entities by removing all incremental financial reporting requirements and the exception available for development stage entities when determining whether the development stage entity is a variable interest entity. The elimination of the exception may change the consolidation analysis, consolidation decision, and disclosure requirements for a reporting entity that has an interest in an entity in the development stage. Shire adopted this guidance as of January 1, 2016, with prospective application. The adoption of this guidance did not impact the Company’s consolidated financial position, results of operations or cash flows. Debt Issuance Costs In April 2015, the FASB issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The new standard requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued additional guidance which clarified that debt issuance costs related to line-of-credit arrangements can be presented in the balance sheet as an asset and amortized over the term of the line-of-credit arrangement. The recognition and measurement guidance for debt issuance costs were not affected by these amendments. Shire adopted this guidance as of January 1, 2016, with retroactive application. The Short-term borrowings and Long-term borrowings line items in the Consolidated Balance Sheets and related footnote disclosures for all periods presented have been adjusted accordingly. The adoption of this guidance did not impact the Company’s results of operations or cash flows. Cloud Computing Arrangement In April 2015, the FASB issued ASU No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. Under the standard, if a cloud computing arrangement includes a software license, then the software license element of the arrangement should be accounted for consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the arrangement should be accounted for as a service contract. Shire adopted this guidance as of January 1, 2016, with prospective application. The adoption of this guidance did not impact the Company’s consolidated financial position, results of operations or cash flows. Measurement-Period Adjustments In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments to simplify the accounting for adjustments related to business combinations arising within one year of the acquisition. The standard simplifies the accounting for adjustments related to business combinations arising within one year of the acquisition. The new standard requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined and record the effect on earnings of those changes as if the accounting had been completed at the acquisition date, and sets forth new disclosure requirements related to the adjustments. Shire adopted this guidance as of January 1, 2016, with prospective application. The adoption of this guidance impacted the recognition and disclosure of measurement period adjustments identified during the twelve months ended December 31, 2016 related to the Baxalta and Dyax acquisitions. Refer to Note 3 , Business Combinations for further information. Financial Instrument Accounting In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments. The new guidance clarifies the requirements for assessing whether contingent call and put options that can accelerate the payment of principal of debt instruments are clearly and closely related to their debt host. This guidance will be effective beginning on January 1, 2017, and modified retrospective application is required. Early adoption is permitted. Shire adopted this guidance as of 2016, and it had no impact on the Company's financial position or results of operations. Pension Plans In May 2015, the FASB issued ASU No. 2015-07, Fair Value Measurement (Topic 820): Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent). The new guidance removes the disclosure requirement to categorize within the fair value hierarchy all investments that measure fair value using the net asset value per share as a practical expedient and certain disclosures associated with these types of investments. This guidance became effective beginning on January 1, 2016, and retrospective application is required. This guidance was adopted during the current period and impacted the disclosure of certain acquired pension plan assets in the fair value hierarchy in Note 18 , Retirement and Other Benefit Programs , but did not impact the Company's financial position or results of operations. To be adopted in future periods Simplifying the Test for Goodwill Impairment In January 2017, the FASB issued ASU 2017-04-Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The new guidance eliminates Step 2 from the goodwill impairment test. Under Step 2, an entity had to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities (including unrecognized assets and liabilities) following the procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Instead, under the amendments in this Update, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. The Board also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. Therefore, the same impairment assessment applies to all reporting units. An entity is required to disclose the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendment is effective for the Company beginning on January 1, 2020, with early adoption permitted for annual goodwill impairment tests performed after January 1, 2017. The Company is currently evaluating the potential impact on its financial position and results of operations of the amendment. Definition of a Business In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This new standard will be effective for the Company beginning on January 1, 2018. Revenue from Contracts with Customers In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The new standard also requires additional qualitative and quantitative disclosures. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. In May 2016, the FASB rescinded several SEC Staff Announcements that are codified in ASC 605, including, among other items, guidance relating to accounting for shipping and handling fees and freight services. These standards have the same effective date and transition date of January 1, 2018. The Company is currently evaluating the method of adoption and the potential impact on its financial position and results of operations of adopting this guidance. Inventory In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The new guidance requires an entity to measure inventory at the lower of cost and net realizable value. Net realizable value is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This standard is effective for the Company as of January 1, 2017. Early adoption is permitted. The Company does not believe the adoption of this guidance will have a material impact on its financial position or results of operations. Financial Instrument Accounting In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in the results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in Other Comprehensive Income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The new standard will be effective for the Company as of January 1, 2018. The Company is currently evaluating the method of adoption and the potential impact on its financial position and results of operations of adopting this guidance. Leases In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new accounting guidance will require the recognition of all lease assets and lease liabilities by lessees and sets forth new disclosure requirements for those lease assets and liabilities. The standard requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements. This standard is effective for the Company as of January 1, 2019. Early adoption is permitted. The Company is currently evaluating the potential impact on its financial position and results of operations of adopting this guidance. For detail on the Company's commitments under operating leases see Note 24 Commitments and Contingencies . Share-Based Payment Accounting In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard requires recognition of the income tax effects of vested or settled awards in the income statement and involves several other aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows and allows a one-time accounting policy election to account for forfeitures as they occur. The new standard will be effective on January 1, 2017. The Company will adopt ASU 2016-09 in the first quarter of 2017. Currently, excess tax benefits or deficiencies from the Company's equity awards are recorded as Additional paid-in capital in its Consolidated Balance Sheets. Upon adoption, the Company will record any excess tax benefits or deficiencies from its equity awards in its Consolidated Statements of Operations in the reporting periods in which vesting or settlement occurs. Subsequent to adoption, the Company's income tax expense and associated effective tax rate will be impacted by fluctuations in stock price between the grant dates and vesting or settlement dates of equity awards and timing of employee exercise activity. Upon adoption of ASU 2016-09, the Company will elect to change its accounting policy to account for forfeitures as they occur. These changes will be applied on a modified retrospective basis with an immaterial cumulative effect adjustment to retained earnings as of January 1, 2017. Statement of Cash Flows In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new standard clarifies certain aspects of the statement of cash flows, and aims to reduce diversity in practice regarding how certain transactions are classified in the statement of cash flows. This amendment is effective for the Company as of January 1, 2018. Early adoption is permitted. The adoption of this guidance is not expected to have a significant impact on the Company's Consolidated Statement of Cash Flows. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The new guidance is intended to reduce diversity in the presentation of restricted cash and restricted cash equivalents in the statement. The guidance requires that restricted cash and restricted cash equivalents be included as components of total cash and cash equivalents as presented on the statement of cash flows. This pronouncement goes into effect for the Company as of January 1, 2018. The adoption of this guidance is not expected to have a significant impact on the Company's Consolidated Statement of Cash Flows.
Statutory accounts	Statutory accounts The Consolidated Financial Statements are prepared in accordance with U.S. GAAP, in fulfillment of the Company’s United Kingdom Listing Authority (“UKLA”) annual reporting requirements and will be filed with the UKLA in due course. Statutory accounts of Shire, consisting of the solus accounts of Shire plc for the year to December 31, 2016 are prepared in accordance with UK GAAP and the Companies (Jersey) Law 1991 and are included in the Annual Report.
Shire Income Access Share Trust
Accounting Policies [Line Items]
Consolidation	Basis of Preparation The financial statements of the Trust have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The financial statements have been prepared under the historical cost convention. The preparation of financial statements in conformity with U.S. GAAP requires the use of certain accounting estimates. It also requires management to exercise its judgment in the process of applying the Trust’s accounting policies. Actual results may differ from these estimates. The results of operations, the financial position and cash flows of the Trust are consolidated in the Company’s Financial Statements, as contained on pages F-1 to F-90.
Derivative financial instruments	The Trust, in its normal course of business, is not subject to market risk, credit risk or liquidity risk. The Trustees do not consider that any foreign exchange exposure will materially affect the operations of the Trust.
Translation of foreign currency	Functional currency The functional currency of the Trust is U.S. dollars. Foreign currency translation Income and expense items denominated in currencies other than the functional currency are translated into the functional currency at the rate ruling on their transaction date. Monetary assets and liabilities recorded in currencies other than the functional currency have been expressed in the functional currency at the rates of exchange ruling at the respective balance sheet dates. Differences on translation are included in the Consolidated Statements of Operations.
Dividend income, capital account, and distributions made	Distributions Distributions are made to those shareholders of Shire who have elected to receive dividends from the Trust in accordance with the Trust Deed. Unclaimed dividends are not included in distributions made. As of December 31, 2016 the unclaimed dividends are immaterial. Amounts are recorded as distributed once a wire transfer or check is issued. All checks are valid for one year from the date of issue. Any wire transfers that are not completed are replaced by checks. To the extent that checks expire or are returned unrepresented, the Trust records a liability for unclaimed dividends and a corresponding amount of cash. Dividend income Interim dividends declared on the Income Access Share are recognized on a paid basis unless the dividend has been confirmed by a general meeting of Shire, in which case income is recognized on the record date of the dividend by Shire on its ordinary shares. Capital account The Capital account is represented by the Income Access Share of 5 pence settled in the Trust by Old Shire.

Summary of Significant Accoun43

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Property, Plant and Equipment	Depreciation of property, plant and equipment is calculated using the straight-line method over the estimated useful lives as follows: Asset category Estimated useful lives Land Not depreciated Buildings and leasehold improvements 15 to 50 years Office furniture, fittings and equipment 3 to 10 years Machinery, equipment and other 3 to 15 years Property, plant and equipment are recorded at cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows: December 31, December 31, (In millions) 2016 2015 Land $ 337.9 $ 96.7 Buildings and leasehold improvements 1,915.4 606.4 Machinery, equipment and other 2,547.2 827.4 Assets under construction 2,632.5 93.7 Total property, plant and equipment at cost 7,433.0 1,624.2 Less: Accumulated depreciation (963.4 ) (796.1 ) Property, plant and equipment, net $ 6,469.6 $ 828.1

Business Combinations (Tables)

Business Combinations (Tables)	12 Months Ended
	Dec. 31, 2016
Business Acquisition [Line Items]
Schedule of Purchase Price Allocation	The preliminary fair value of the purchase price consideration consisted of the following: (In millions) Estimated fair value Cash paid to shareholders $ 12,366.7 Fair value of stock issued to shareholders 19,353.2 Fair value of partially vested stock options and RSUs assumed 508.8 Contingent consideration payable 169.0 Total Purchase Consideration $ 32,397.7
Baxalta
Business Acquisition [Line Items]
Schedule of Purchase Price Allocation	The Company's preliminary allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date, including measurement period adjustments identified during the year ended December 31, 2016 , is outlined below. (In millions) Preliminary fair values as of June 3, 2016 Measurement period adjustments Preliminary fair values as of December 31, 2016 ASSETS Current assets: Cash and cash equivalents $ 583.2 $ — $ 583.2 Accounts receivable 1,071.7 (2.0 ) 1,069.7 Inventories 5,341.1 (1,447.7 ) 3,893.4 Other current assets 673.3 (97.3 ) 576.0 Total current assets 7,669.3 (1,547.0 ) 6,122.3 Property, plant and equipment 5,687.7 (235.0 ) 5,452.7 Investments 128.2 — 128.2 Goodwill 6,106.4 5,316.0 11,422.4 Intangible assets Currently marketed products 24,550.0 (2,555.0 ) 21,995.0 In-Process Research and Development ("IPR&D") 2,940.0 (2,210.0 ) 730.0 Contract based arrangements 72.2 (30.0 ) 42.2 Other non-current assets 103.3 51.7 155.0 Total assets $ 47,257.1 $ (1,209.3 ) $ 46,047.8 LIABILITIES Current liabilities: Accounts payable and accrued expenses $ 1,283.9 $ 38.0 $ 1,321.9 Other current liabilities 241.0 113.4 354.4 Long-term borrowings and capital lease obligations 5,424.9 — 5,424.9 Deferred tax liability 6,831.7 (1,386.4 ) 5,445.3 Other non-current liabilities 1,092.1 11.5 1,103.6 Total liabilities $ 14,873.6 $ (1,223.5 ) $ 13,650.1 Preliminary fair value of identifiable assets acquired and liabilities assumed $ 32,383.5 $ 14.2 $ 32,397.7 Consideration Preliminary fair value of purchase consideration $ 32,383.5 $ 14.2 $ 32,397.7
Business Acquisition, Pro Forma Information	The following unaudited pro forma financial information presents the combined results of the operations of Shire and Baxalta as if the acquisition of Baxalta had occurred as of January 1, 2015. The unaudited pro forma financial information is not necessarily indicative of what the consolidated results of operations actually would have been had the respective acquisitions been completed on January 1, 2015. In addition, the unaudited pro forma financial information does not purport to project the future results of operations of the combined Company. December 31, (In millions) 2016 2015 Revenues $ 13,999.6 $ 12,564.7 Net income/(loss) from continuing operations 2,235.9 (1,014.2 ) Per share amounts: Net income/(loss) from continuing operations per share - basic $ 2.90 $ (1.72 ) Net income/(loss) from continuing operations per share - diluted $ 2.88 $ (1.72 )
Dyax
Business Acquisition [Line Items]
Schedule of Purchase Price Allocation	The revised allocation of the total purchase price is as follows: (In millions) Fair value ASSETS Current assets: Cash and cash equivalents $ 241.2 Accounts receivable 22.5 Inventories 20.2 Other current assets 8.1 Total current assets 292.0 Property, plant and equipment 5.8 Goodwill 2,702.1 Intangible assets Currently marketed projects 135.0 IPR&D 4,100.0 Contract based royalty arrangements 425.0 Other non-current assets 28.6 Total assets $ 7,688.5 LIABILITIES Current liabilities: Accounts payable and accrued expenses $ 30.0 Other current liabilities 1.7 Deferred tax liability 1,325.4 Other non-current liabilities 1.4 Total liabilities 1,358.5 Preliminary fair value of identifiable assets acquired and liabilities assumed $ 6,330.0 Consideration Preliminary fair value of purchase consideration $ 6,330.0
Business Acquisition, Pro Forma Information	The following unaudited pro forma financial information presents the combined results of the operations of Shire and Dyax as if the acquisitions of Dyax had occurred as of January 1, 2015. The unaudited pro forma financial information is not necessarily indicative of what the consolidated results of operations actually would have been had the respective acquisitions been completed at the date indicated. In addition, the unaudited pro forma financial information does not purport to project the future results of operations of the combined Company. December 31, (In millions) 2016 2015 Revenues $ 11,402.5 $ 6,503.8 Net income from continuing operations 792.2 1,056.6 Per share amounts: Net income from continuing operations per share - basic $ 1.03 $ 1.79 Net income from continuing operations per share - diluted $ 1.02 $ 1.78
NPS Pharma
Business Acquisition [Line Items]
Schedule of Purchase Price Allocation	The purchase price allocation for the acquisition of NPS was finalized in the fourth quarter of 2015. The Company’s allocation of the purchase price to the fair value of assets acquired and liabilities assumed is outlined below: (In millions) Fair value ASSETS Current assets: Cash and cash equivalents $ 41.6 Short-term investments 67.0 Accounts receivable 33.4 Inventories 89.4 Other current assets 11.1 Total current assets 242.5 Property, plant and equipment 4.8 Goodwill 1,551.0 Intangible assets Currently marketed products 4,640.0 Royalty rights (categorized as "Other intangible assets") 353.0 Total assets $ 6,791.3 LIABILITIES Current liabilities: Accounts payable and other current liabilities $ 75.7 Short-term borrowings and capital lease obligations 27.4 Long-term borrowings and capital lease obligations 78.9 Deferred tax liabilities 1,385.2 Other non-current liabilities 4.5 Total liabilities 1,571.7 Fair value of identifiable assets acquired and liabilities assumed $ 5,219.6 Consideration Cash consideration paid $ 5,219.6
Business Acquisition, Pro Forma Information	The following unaudited pro forma financial information presents the combined results of the operations of Shire and NPS as if the acquisitions of NPS had occurred as of January 1, 2014. The unaudited pro forma financial information is not necessarily indicative of what the consolidated results of operations actually would have been had the respective acquisitions been completed on January 1, 2014. In addition, the unaudited pro forma financial information does not purport to project the future results of operations of the combined Company. December 31, (In millions) 2015 Revenues $ 6,446.6 Net income from continuing operations 1,293.6 Per share amounts: Net income from continuing operations per share - basic $ 2.19 Net income from continuing operations per share - diluted $ 2.18

Integration and Acquisition C45

Integration and Acquisition Costs (Tables)	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Summary of Employee Termination Related Reserve	The following table summarizes the related reserve as of December 31, 2016 : (In millions) Severance and employee benefits As of January 1, 2016 $ — Amount charged to integration costs 267.3 Paid/utilized (193.3 ) As of December 31, 2016 $ 74.0

Accounts Receivable, Net (Table

Accounts Receivable, Net (Tables)	12 Months Ended
	Dec. 31, 2016
Receivables [Abstract]
Provision for discounts and doubtful accounts	Provision for discounts and doubtful accounts: (In millions) 2016 2015 2014 As of January 1, $ 55.8 $ 48.5 $ 47.9 Provision charged to operations 838.1 424.2 338.2 Provision utilization (724.3 ) (416.9 ) (337.6 ) As of December 31, $ 169.6 $ 55.8 $ 48.5

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories comprise: December 31, December 31, (In millions) 2016 2015 Finished goods $ 1,380.0 $ 184.9 Work-in-progress 1,491.0 302.0 Raw materials 691.3 148.5 $ 3,562.3 $ 635.4

Prepaid Expenses and Other Cu48

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2016
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expense and Other Assets, Current	Components of prepaid expenses and other current assets are summarized as follows: December 31, December 31, (In millions) 2016 2015 Income tax receivable $ 237.5 $ 73.6 Prepaid expenses 183.9 35.6 Value added taxes receivable 40.3 18.2 Other current assets 344.6 70.0 $ 806.3 $ 197.4

Property, Plant and Equipment49

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Depreciation of property, plant and equipment is calculated using the straight-line method over the estimated useful lives as follows: Asset category Estimated useful lives Land Not depreciated Buildings and leasehold improvements 15 to 50 years Office furniture, fittings and equipment 3 to 10 years Machinery, equipment and other 3 to 15 years Property, plant and equipment are recorded at cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows: December 31, December 31, (In millions) 2016 2015 Land $ 337.9 $ 96.7 Buildings and leasehold improvements 1,915.4 606.4 Machinery, equipment and other 2,547.2 827.4 Assets under construction 2,632.5 93.7 Total property, plant and equipment at cost 7,433.0 1,624.2 Less: Accumulated depreciation (963.4 ) (796.1 ) Property, plant and equipment, net $ 6,469.6 $ 828.1

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table provides a roll-forward of the goodwill balance: (In millions) 2016 2015 As of January 1, $ 4,147.8 $ 2,474.9 Acquisitions 14,124.5 1,700.1 Foreign currency translation (384.1 ) (27.2 ) As of December 31, $ 17,888.2 $ 4,147.8

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2016
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Schedule of Other Intangible Assets	The following table summarizes the Company's intangible assets: (In millions) Currently marketed products IPR&D Other intangible assets Total December 31, 2016 Gross acquired intangible assets $ 31,217.5 $ 5,746.6 $ 842.2 $ 37,806.3 Accumulated amortization (2,908.6 ) — (200.2 ) (3,108.8 ) Intangible assets, net $ 28,308.9 $ 5,746.6 $ 642.0 $ 34,697.5 December 31, 2015 Gross acquired intangible assets $ 9,371.9 $ 1,362.0 $ 375.0 $ 11,108.9 Accumulated amortization (1,852.1 ) — (83.5 ) (1,935.6 ) Intangible assets, net $ 7,519.8 $ 1,362.0 $ 291.5 $ 9,173.3
Intangible Assets (Excluding Goodwill) Roll Forward	The change in the net book value of Intangible assets for the year ended December 31, 2016 and 2015 is shown in the table below: (In millions) 2016 2015 As of January 1, $ 9,173.3 $ 4,934.4 Additions 27,462.8 5,474.9 Amortization charged (1,173.4 ) (498.7 ) Impairment charges (8.9 ) (643.7 ) Foreign currency translation (756.3 ) (93.6 ) As of December 31, $ 34,697.5 $ 9,173.3
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The estimated future amortization of acquired intangible assets for the next five years is expected to be as follows: (In millions) Anticipated future amortization 2017 $ 1,592.0 2018 1,585.2 2019 1,506.5 2020 1,502.8 2021 1,496.8

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	As of December 31, 2016 and December 31, 2015 , the following financial assets and liabilities are measured at fair value on a recurring basis using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3). (In millions) Carrying value and fair value As of December 31, 2016 Total Level 1 Level 2 Level 3 Financial assets: Marketable equity securities $ 65.8 $ 65.8 $ — $ — Marketable debt securities 15.5 3.6 11.9 — Contingent consideration receivable 15.6 — — 15.6 Derivative contracts 18.0 — 18.0 — Total 114.9 69.4 29.9 15.6 Financial liabilities: Derivative contracts 8.3 — 8.3 — Contingent consideration payable 1,058.0 — — 1,058.0 Total $ 1,066.3 $ — $ 8.3 $ 1,058.0 (In millions) Carrying value and fair value As of December 31, 2015 Total Level 1 Level 2 Level 3 Financial assets: Marketable equity securities $ 17.2 $ 17.2 $ — $ — Contingent consideration receivable 13.8 — — 13.8 Derivative contracts 1.9 — 1.9 — Total 32.9 17.2 1.9 13.8 Financial liabilities: Derivative contracts 11.5 — 11.5 — Contingent consideration payable 475.9 — — 475.9 Total $ 487.4 $ — $ 11.5 $ 475.9
Assets Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3)	The following table provides a roll forward of the fair values of our contingent consideration receivable and payables which include Level 3 measurements: Contingent consideration receivable (In millions) 2016 2015 Balance at January 1, $ 13.8 $ 15.9 Change in fair value included in earnings 1.6 13.6 Other 0.2 (15.7 ) Balance at December 31, $ 15.6 $ 13.8
Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3)	Contingent consideration payable (In millions) 2016 2015 Balance at January 1, $ 475.9 $ 629.9 Additions 565.4 92.8 Change in fair value included in earnings 11.1 (149.9 ) Other 5.6 (96.9 ) Balance at December 31, $ 1,058.0 $ 475.9
Fair Value Inputs, Assets Quantitative Information Table	Quantitative information about the Company’s recurring Level 3 fair value measurements is included below: Financial assets: Fair value at the measurement date As of December 31, 2016 (In millions, except %) Fair value Valuation technique Significant unobservable inputs Range Contingent consideration receivable ("CCR") $ 15.6 Income approach (probability weighted discounted cash flow) Probability weightings applied to different sales scenarios 10 to 90% Future forecast consideration receivable based on contractual terms with purchaser $0 to $21 million Assumed market participant discount rate 8%
Fair Value Measurements, Nonrecurring	The carrying amounts and estimated fair values of the Company’s financial assets and liabilities are as follows: December 31, 2016 December 31, 2015 (In millions) Carrying amount Fair value Carrying amount Fair value Financial liabilities: Senior Notes $ 12,039.2 $ 11,633.8 $ — $ — Baxalta Notes 5,063.6 5,066.5 — — Capital lease obligation 353.6 353.6 13.4 13.4
Fair Value Inputs, Liabilities Quantitative Information Table	Financial liabilities: Fair value at the measurement Date As of December 31, 2016 (In millions, except %) Fair value Valuation technique Significant unobservable inputs Range Contingent consideration payable $ 1,058.0 Income approach (probability weighted discounted cash flow) Cumulative probability of milestones being achieved 6 to 90% Assumed market participant discount rate 1.2 to 10.5% Periods in which milestones are expected to be achieved 2017 to 2040 Forecast quarterly royalties payable on net sales of $0.1 to $7.5 million

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2016
Derivative Instrument Detail [Abstract]
Schedule of Foreign Exchange Contracts, Statement of Financial Position	The following table presents the classification and estimated fair value of the Company’s derivative instruments as of December 31, 2016 : Derivatives in asset positions Derivatives in liability positions (In millions) Balance Sheet location Fair value Balance Sheet location Fair value Designated Derivative Instruments Foreign exchange contracts Prepaid expenses and other current assets $ 4.3 Accounts payable and accrued expenses $ 0.1 Interest rate contracts Long term borrowings 0.1 Long term borrowings 1.3 4.4 1.4 Undesignated Derivative Instruments Foreign exchange forward contracts Prepaid expenses and other current assets 13.6 Accounts payable and accrued expenses 6.9 $ 18.0 $ 8.3
Schedule of Foreign Exchange Contracts, Gain (Loss) in Other Income (Expense)	The following tables summarize the income statement locations and gains and losses on the Company’s designated and undesignated derivative instruments for the year ended December 31, 2016 . There were no designated derivatives for the year ended December 31, 2015. As of December 31, 2016 , the Company had in total 155 swaps and forward foreign exchange contracts. (In millions) Gain (loss) recognized in OCI Location in Statements of Operations Gain (loss) reclassified from AOCI into income Year ended December 31, 2016 2015 2016 2015 Designated Derivative Instruments Cash flow hedges Foreign exchange contracts $ 14.6 $ — Cost of sales $ 4.9 $ — (In millions) Location of gain (loss) in Statements of Operations Gain (loss) recognized in income Year ended December 31, 2016 2015 Fair value hedges Interest rate contracts Interest expense $ (6.0 ) $ — Undesignated Derivative Instruments Foreign exchange contracts Other (expense)/income, net (40.2 ) 9.5 Interest rate swap contracts Interest expense (3.2 ) —

Accounts Payable and Accrued 54

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2016
Accounts Payable and Accrued Liabilities, Current [Abstract]
Schedule of Accounts Payable and Accrued Expenses	Components of Accounts payable and accrued expenses are summarized as follows: December 31, December 31, (In millions) 2016 2015 Accounts payable and accrued purchases $ 911.9 $ 441.4 Accrued employee compensation and benefits payable 574.8 254.5 Accrued rebates 1,431.3 982.4 Accrued sales returns 118.4 128.3 Other accrued expenses 1,276.0 244.0 $ 4,312.4 $ 2,050.6

Borrowings and Capital Lease 55

Borrowings and Capital Lease Obligations (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Schedule of Borrowings	December 31, December 31, (In millions) 2016 2015 Short-term borrowings: Borrowings under the Revolving Credit Facilities Agreement (the “RCF”) $ 450.0 $ 750.0 Borrowings under the November 2015 Facilities Agreement 2,594.8 — Borrowings under the January 2015 Facilities Agreement — 750.0 Other borrowings and capital lease obligations (short term portion) 23.2 12.7 3,068.0 1,512.7 Long-term borrowings: Senior Notes 12,039.2 — Baxalta Notes 5,063.6 — Borrowings under the November 2015 Facilities Agreement 2,391.8 — Capital lease obligations (long term portion) 347.2 12.2 Other borrowings 58.0 69.9 $ 19,899.8 $ 82.1 $ 22,967.8 $ 1,594.8 Below is a summary of the Baxalta Notes as of December 31, 2016 : (In millions, except %) Aggregate principal Coupon rate Effective interest rate Carrying amount Variable-rate notes due 2018 $ 375.0 LIBOR plus 0.780% 2.20 % $ 371.6 Fixed-rate notes due 2018 375.0 2.000 % 2.00 % 374.8 Fixed-rate notes due 2020 1,000.0 2.875 % 2.80 % 1,004.3 Fixed-rate notes due 2022 500.0 3.600 % 3.30 % 508.4 Fixed-rate notes due 2025 1,750.0 4.000 % 3.90 % 1,772.8 Fixed-rate notes due 2045 1,000.0 5.250 % 5.10 % 1,031.7 Total Baxalta Notes $ 5,000.0 $ 5,063.6 Below is a summary of the SAIIDAC Notes as of December 31, 2016 : (In millions, except %) Aggregate amount Coupon rate Effective interest rate Carrying amount Fixed-rate notes due 2019 $ 3,300.0 1.900 % 2.05 % $ 3,287.5 Fixed-rate notes due 2021 3,300.0 2.400 % 2.53 % 3,283.0 Fixed-rate notes due 2023 2,500.0 2.875 % 2.97 % 2,487.9 Fixed-rate notes due 2026 3,000.0 3.200 % 3.30 % 2,980.8 $ 12,100.0 $ 12,039.2
Summary of debt maturities	The future payments related to short and long term borrowings and capital lease obligations, on maturities, as of December 31, 2016 are as follows: (In millions) 2017 $ 3,072.6 2018 3,217.2 2019 3,341.3 2020 1,035.3 2021 3,320.5 Thereafter 9,116.1 Total obligations 23,103.0 Less: Deferred financing costs (135.2 ) Total debt obligations $ 22,967.8

Retirement and Other Benefit 56

Retirement and Other Benefit Programs (Tables)	12 Months Ended
	Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]
Schedule of Defined Benefit Plans Disclosures	The benefit plan information is for the year ended December 31, 2016. (In millions) U.S. pensions International pensions OPEB Benefit obligations Beginning of period $ — $ — $ — Assumption of benefit obligations from Baxalta 441.6 503.8 23.5 Service cost 13.0 18.6 0.8 Interest cost 11.1 3.2 0.6 Participant contributions — 3.2 — Actuarial (gain) / loss (10.6 ) (29.8 ) 0.1 Benefit payments (1.6 ) (9.1 ) — Settlements — (3.2 ) — Curtailments (73.4 ) — — Foreign exchange — (18.3 ) — Other 4.0 113.0 — End of Period $ 384.1 $ 581.4 $ 25.0 Fair value of plan assets Beginning of period $ — $ — $ — Assumption of plan assets from Baxalta 218.0 140.5 — Actual return on plan assets 8.3 2.0 — Employer contributions 0.4 12.3 — Participant contributions — 3.2 — Benefit payments (1.6 ) (9.1 ) — Settlements — (3.2 ) — Foreign exchange — (3.8 ) — Other 3.3 56.0 — End of period 228.4 197.9 — Funded status at December 31, 2016 $ (155.7 ) $ (383.5 ) $ (25.0 ) Amounts recognized in the Consolidated Balance Sheets Other current liabilities $ (0.6 ) $ (8.8 ) $ (0.2 ) Other non-current liabilities (155.1 ) (374.7 ) (24.8 ) Net liability recognized at December 31, 2016 $ (155.7 ) $ (383.5 ) $ (25.0 )
Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets	individual plans that have an ABO in excess of plan assets as of December 31, 2016 . (In millions) December 31, 2016 U.S. ABO $ 373.2 Fair value of plan assets 228.4 International ABO 437.5 Fair value of plan assets 176.2
Schedule of Expected Benefit Payments	Expected Net Pension and OPEB Plan Payments for the Next 10 Years (In millions) U.S. pensions International pensions OPEB 2017 $ 3.6 $ 21.1 $ 0.2 2018 5.7 18.6 0.3 2019 7.6 19.9 0.5 2020 9.7 20.1 0.6 2021 11.7 22.7 0.7 2022 through 2026 85.3 124.1 4.6 Total expected benefit payments for next 10 years $ 123.6 $ 226.5 $ 6.9
Schedule of Amounts Recognized in Other Comprehensive Income (Loss)	ollowing is a summary of the net of tax amounts recorded in OCI relating to the pension and OPEB plans during 2016: (In millions) U.S. pensions International pensions OPEB Gain (loss) arising during the year, net of tax expense of $30.9 million for U.S. plans and $3.8 million for international plans $ 52.5 $ (14.2 ) $ — Reclassification of gain to income statement, net of tax benefit of $25.9 million for U.S. plans (43.5 ) — — Pension and other employee benefits gain (loss), net of tax $ 9.0 $ (14.2 ) $ —
Schedule of Net Benefit Costs	The net periodic benefit cost is from June 3, 2016, the date the Company assumed the obligations from Baxalta, through December 31, 2016 : June 3, 2016 through December 31, 2016 (In millions) U.S. pensions International pensions OPEB Net periodic benefit cost Service cost $ 13.0 $ 18.6 $ 0.8 Interest cost 11.1 3.2 0.6 Expected return on plan assets (8.9 ) (3.9 ) — Curtailment and other (69.4 ) 20.0 — Net periodic benefit cost $ (54.2 ) $ 37.9 $ 1.4
Schedule of Assumptions Used	The assets and liabilities of the Company’s pension plans are valued using the following valuation methods: Investment category Valuation methodology Cash and cash equivalents These largely consist of a short-term investment fund, U.S. dollars and foreign currency. The fair value of the short-term investment fund is based on the net asset value Government agency issues Values are based on quoted prices in an active market Corporate bonds Values are based on the valuation date in an active market Common stock Values are based on the closing prices on the valuation date in an active market Mutual funds Values are based on the net asset value of the units held in the respective fund which are obtained from active markets or as reported by the fund managers Collective trust funds and hedge funds Values are based on the net asset value of the units held at year end Real estate funds The value of these assets are either determined by the net asset value of the units held in the respective fund which are obtained from active markets or based on the net asset value of the underlying assets of the fund provided by the fund manager Other holdings These primarily consist of insurance contracts whose value is based on the underlying assets and other holdings valued primarily based on reputable pricing vendors that typically use pricing matrices or models Weighted-Average Assumptions Used in Determining Benefit Obligations at the Measurement Date The following weighted-average assumptions were used in calculating the December 31, 2016 measurement date benefit obligations. U.S. pensions International pensions OPEB Discount rate 4.2 % 1.0 % 4.3 % Rate of compensation increase 3.8 % 2.9 % n/a Annual rate of increase in the per-capita cost n/a n/a 6.3 % Rate decreased to n/a n/a 5.0 % by the year ended n/a n/a 2022 Weighted-Average Assumptions Used in Determining Net Periodic Benefit Cost The following weighted-average assumptions were used in determining net periodic benefit cost for 2016. U.S. pensions International pensions OPEB Discount rate 4.1 % 1.0 % 4.2 % Expected return on plan assets 7.0 % 4.5 % n/a Rate of compensation increase 3.8 % 3.2 % n/a Annual rate of increase in the per-capita cost n/a n/a 6.5 % Rate decreased to n/a n/a 5.0 % by the year ended n/a n/a 2022
Schedule of Allocation of Plan Assets	The following pension assets are recorded at fair value on a recurring basis using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3). Investments that are measured at fair value using the net asset value per share or its equivalent as a practical expedient are not classified in the fair value hierarchy. U.S. pension plan assets (In millions) Balance as of December 31, 2016 Level 1 Level 2 Level 3 Assets Fixed income Cash equivalents $ 5.7 $ — $ — $ — Collective trust funds 46.4 — — — Mutual fund 11.4 — — — Equity Collective trust funds 100.4 — — — Mutual fund 53.4 16.5 — — Hedge funds 11.1 — — — Fair value of pension plan assets $ 228.4 $ 16.5 $ — $ — International pension plan assets (In millions) Balance as of December 31, 2016 Level 1 Level 2 Level 3 Assets Fixed income Cash and cash equivalents $ 6.2 $ 6.2 $ — $ — Government agency issues 0.6 0.6 — — Corporate bonds 21.1 21.1 — — Mutual funds 24.4 24.4 — — Equity Common stock: Large cap 19.9 19.9 — — Mid cap 1.6 1.6 — — Total common stock 21.5 21.5 — — Mutual funds 40.6 40.6 — — Real estate funds 12.1 8.4 — — Other holdings 71.4 — 71.4 — Fair value of pension plan assets $ 197.9 $ 122.8 $ 71.4 $ —
Schedule of Net Funded Status	The table below details the funded status percentage of the Company’s pension plans as of December 31, 2016 including certain plans that are unfunded in accordance with the guidelines of the Company’s funding policy outlined above. United States International (in millions, except %) Qualified plan Nonqualified plan Funded plans Unfunded plans Total Fair value of plan assets $ 228.4 n/a $ 197.9 n/a $ 426.3 PBO 352.8 31.3 413.7 167.7 965.5 Funded status percentage 65 % n/a 48 % n/a 44 % U.S. Defined Contribution Plans In addition to benefits provided under the pension and OPEB plans described above, the Company provides benefits under defined contribution plans. The Company's most significant defined contribution plans are in the United States. The Company recognized expenses related to U.S. defined contribution plans of $ 68.1 million , $ 38.9 million and $ 34.3 million during 2016, 2015 and 2014, respectively.

Accumulated Other Comprehensi57

Accumulated Other Comprehensive Loss (Tables)	12 Months Ended
	Dec. 31, 2016
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Changes in Accumulated Other Comprehensive Loss, Net of Tax	The changes in Accumulated other comprehensive loss ("AOCL"), net of their related tax effects, in the years ended December 31, 2016 are shown below: (In millions) Foreign currency translation adjustment Pension and other employee benefits Unrealized holding gain/(loss) on available-for-sale securities Hedging activities Accumulated other comprehensive loss As of January 1, 2016 $ (182.1 ) $ — $ (1.7 ) $ — $ (183.8 ) Current period change: Other comprehensive (loss)/income before reclassification (1,323.3 ) 38.3 8.3 9.9 (1,266.8 ) Amounts reclassified from AOCL — (43.5 ) — (3.5 ) (47.0 ) Net current period other comprehensive (loss)/income (1,323.3 ) (5.2 ) 8.3 6.4 (1,313.8 ) As of December 31, 2016 $ (1,505.4 ) $ (5.2 ) $ 6.6 $ 6.4 $ (1,497.6 ) The following is a summary of the amounts reclassified from AOCL to net income during the fiscal year ended December 31, 2016 : Amounts reclassified from AOCL (In millions) 2016 Location of impact in Statements of Operations Pension and employee benefits Curtailment gain $ 69.4 Integration and acquisition costs 69.4 Total before tax (25.9 ) Tax expense 43.5 Net of tax Losses on hedging activities Foreign exchange contracts 4.9 Cost of sales 4.9 Total before tax (1.4 ) Tax expense 3.5 Net of tax Total reclassifications for the period $ 47.0 Total net of tax The changes in Accumulated other comprehensive loss, net of their related tax effects, in the year ended December 31, 2015 are shown below: (In millions) Foreign currency translation adjustment Unrealized holding gain/(loss) on available-for-sale securities Accumulated other comprehensive loss As of January 1, 2015 $ (25.7 ) $ (5.8 ) $ (31.5 ) Current period change: Net current period other comprehensive (loss)/income (156.4 ) 4.1 (152.3 ) As of December 31, 2015 $ (182.1 ) $ (1.7 ) $ (183.8 )
Reclassification out of Accumulated Other Comprehensive Income	The following is a summary of the amounts reclassified from AOCL to net income during the fiscal year ended December 31, 2016 : Amounts reclassified from AOCL (In millions) 2016 Location of impact in Statements of Operations Pension and employee benefits Curtailment gain $ 69.4 Integration and acquisition costs 69.4 Total before tax (25.9 ) Tax expense 43.5 Net of tax Losses on hedging activities Foreign exchange contracts 4.9 Cost of sales 4.9 Total before tax (1.4 ) Tax expense 3.5 Net of tax Total reclassifications for the period $ 47.0 Total net of tax

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Schedule of Calculation of Numerator and Denominator in Earnings Per Share	The following table reconciles net income and the weighted average ordinary shares outstanding for basic and diluted earnings per share for the periods presented: Years ended December 31, (In millions) 2016 2015 2014 Income from continuing operations, net of taxes $ 603.5 $ 1,337.5 $ 3,282.8 (Loss)/ gain from discontinued operations 1 (276.1 ) (34.1 ) 122.7 Numerator for basic and diluted earnings per share 327.4 1,303.4 3,405.5 Weighted average number of shares: Basic 770.1 590.4 586.7 Effect of dilutive shares: Share-based awards to employees 6.1 2.7 4.6 Diluted 776.2 593.1 591.3 Earnings per ordinary share - basic Earnings from continuing operations 0.78 2.27 5.60 (Loss)/gain from discontinued operations (0.35 ) (0.06 ) 0.21 Earnings per ordinary share - basic 0.43 2.21 5.81 Earnings per ordinary share - diluted Earnings from continuing operations 0.77 2.26 5.55 (Loss)/gain from discontinued operations (0.35 ) (0.06 ) 0.21 Earnings per ordinary share - diluted 0.42 2.20 5.76
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The share equivalents not included in the calculation of the diluted weighted average number of shares are shown below: 2016 2015 2014 (In millions) Number of shares Number of shares Number of shares Share-based awards to employees 4.1 3.4 0.3

Taxation (Tables)

Taxation (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	The components of pre-tax income from continuing operations are as follows: Years ended December 31, (In millions) 2016 2015 2014 Ireland $ 214.3 $ (11.4 ) $ 1,472.0 United States (75.3 ) 975.8 1,025.9 Rest of the world 347.1 421.4 838.3 $ 486.1 $ 1,385.8 $ 3,336.2
Schedule of Components of Income Tax Expense (Benefit)	The provision for income taxes on continuing operations by location of the taxing jurisdiction for the years ended December 31, 2016 , 2015 and 2014 consisted of the following: Years ended December 31, (In millions) 2016 2015 2014 Current income taxes: Ireland $ 5.2 $ 0.8 $ — U.S. federal tax 318.6 191.7 291.8 U.S. state and local taxes 30.2 17.3 25.3 Rest of the world 68.9 17.8 (290.9 ) Total current taxes 422.9 227.6 26.2 Deferred taxes: Ireland 18.2 (38.8 ) — U.S. federal tax (433.8 ) (151.2 ) 39.7 U.S. state and local taxes (74.1 ) (1.7 ) (2.9 ) Rest of the world (59.3 ) 10.2 (6.9 ) Total deferred taxes (549.0 ) (181.5 ) 29.9 Total income taxes $ (126.1 ) $ 46.1 $ 56.1
Schedule of Effective Income Tax Rate Reconciliation	The reconciliation of income from continuing operations before income taxes and equity in earnings/(losses) of equity method investees at the statutory tax rate to the provision for income taxes is shown in the table below: Years ended December 31, 2016 2015 2014 Income from continuing operations before income taxes and equity in (losses)/ earnings of equity method investees (in millions) $ 486.1 $ 1,385.8 $ 3,336.2 Statutory tax rate (1) 25.0 % 25.0 % 25.0 % U.S. R&D credit (25.9 )% (7.7 )% (2.5 )% Intra-group items (2) (44.4 )% (18.6 )% (6.3 )% Other permanent items 4.5 % 1.1 % (0.2 )% U.S. Domestic Manufacturing Deduction (4.0 )% (1.6 )% (0.5 )% Acquisition Related Costs 8.5 % 1.1 % 0.7 % Irish Treasury Operations (8.6 )% 0.6 % 0.7 % Change in valuation allowance 7.9 % 1.0 % 0.8 % Difference in taxation rates (3) 13.0 % 7.3 % 3.4 % Change in provisions for uncertain tax positions (1.5 )% (0.4 )% 0.2 % Prior year adjustment 1.0 % (1.6 )% 0.1 % Change in fair value of contingent consideration 3.7 % (3.8 )% 0.3 % Change in tax rates (5.1 )% 0.9 % 0.5 % Receipt of break fee — % — % (12.3 )% Settlement with Canadian revenue authorities — % — % (7.0 )% Other — % — % (1.2 )% Provision for income taxes on continuing operations (25.9 )% 3.3 % 1.7 %
Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: (In millions) 2016 2015 2014 Balance as of January 1 $ 216.3 $ 207.8 $ 355.2 Increases based on tax positions related to the current year 34.3 27.0 20.3 Decreases based on tax positions taken in the current year — — — Increases for tax positions taken in prior years 0.5 3.9 64.2 Decreases for tax positions taken in prior years (17.8 ) (30.6 ) (211.0 ) Acquisition related items 29.5 17.9 — Decreases resulting from settlements with the taxing authorities (24.4 ) (1.2 ) (9.4 ) Decreases as a result of expiration of the statute of limitations (2.4 ) (4.4 ) (0.6 ) Foreign currency translation adjustments (1) 0.3 (4.1 ) (10.9 ) Balance as of December 31 (2) $ 236.3 $ 216.3 $ 207.8
Schedule of Deferred Tax Assets and Liabilities	The significant components of deferred tax assets and liabilities and their balance sheet classifications, as of December 31, are as follows: December 31, December 31, (In millions) 2016 2015 Deferred tax assets: Deferred revenue $ 16.8 $ 2.4 Inventory & warranty provisions 88.7 36.1 Losses carried forward (including tax credits) (1) 1,907.3 980.3 Provisions for sales deductions and doubtful accounts 191.6 178.0 Intangible assets 79.7 5.9 Share-based compensation 137.5 40.6 Excess of tax value over book value of assets 14.2 0.6 Accruals and provisions 448.6 130.4 Other 78.5 19.3 Gross deferred tax assets 2,962.9 1,393.6 Less: valuation allowance (569.4 ) (416.1 ) 2,393.5 977.5 Deferred tax liabilities: Intangible assets (9,073.4 ) (2,850.6 ) Excess of book value over tax value in inventory (150.3 ) (10.3 ) Excess of book value over tax value of assets and investments (1,304.2 ) (153.9 ) Other (91.6 ) (47.6 ) Net deferred tax liabilities (8,226.0 ) (2,084.9 ) Balance sheet classifications: Deferred tax assets - non-current 96.7 121.0 Deferred tax liabilities - non-current (8,322.7 ) (2,205.9 ) $ (8,226.0 ) $ (2,084.9 ) (1) Losses carried forward excludes $38.9 million of deferred tax assets as of December 31, 2016 ( 2015 : $30.4 million ), related to net operating losses that result from excess stock based compensation and for which any benefit realized will be recorded to stockholders' equity.
Summary of Operating Loss and Tax Credit Carryforwards	The approximate tax effect of NOLs, capital losses and tax credit carry-forwards as of December 31, are as follows: (In millions) 2016 2015 U.S. federal tax $ 687.1 $ 149.3 U.S. state tax 170.7 77.2 Republic of Ireland 45.1 61.2 Foreign tax jurisdictions 614.9 434.9 R&D and other tax credits 389.5 257.7 $ 1,907.3 $ 980.3
Schedule of Carryforwards Available to Reduce Future Taxes, Expiration Periods	The tax effected NOLs, capital losses and tax credit carry-forwards shown above have the following expiration dates: December 31, (In millions) 2016 Within 1 year $ 0.3 Within 1 to 2 years 2.6 Within 2 to 3 years 45.5 Within 3 to 4 years 12.8 Within 4 to 5 years 52.6 Within 5 to 6 years 55.3 After 6 years 1,269.6 Indefinitely 468.6

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	Revenues (based on the geographic location from which the sale originated): Years ended December 31, (In millions) 2016 2015 2014 Ireland $ 41.6 $ 14.1 $ 18.5 United States 7,666.9 4,659.2 4,174.1 Rest of the world 3,688.1 1,743.4 1,829.5 Total revenues $ 11,396.6 $ 6,416.7 $ 6,022.1 Long-lived assets comprise all non-current assets, (excluding goodwill and intangible assets, deferred contingent consideration assets, deferred tax assets, investments and financial instruments) based on their relevant geographic location: Years ended December 31, (In millions) 2016 2015 Ireland $ 41.2 $ 1.7 United States 6,449.4 751.3 Rest of the world 84.0 82.2 Total $ 6,574.6 $ 835.2
Schedule of Revenue by Major Customers by Reporting Segments	In the periods set out below, certain customers accounted for greater than 10% of the Company’s Product sales: Years ended December 31, 2016 2016 2015 2015 2014 2014 (in millions, except %) % Product sales % Product sales % Product sales AmerisourceBergen Corp $ 1,695.3 16 $ 1,048.3 17 $ 759.2 13 McKesson Corp. 1,336.7 12 1,044.1 17 1,021.0 18 Cardinal Health Inc. 1,052.2 10 796.9 13 979.9 17
Schedule of Trade Receivables by Major Customers by Reporting Segments	Amounts outstanding in respect of these material customers were as follows: December 31, (In millions) 2016 2015 AmerisourceBergen Corp $ 427.2 $ 171.5 McKesson Corp. 312.9 193.1 Cardinal Health Inc. 278.4 181.7
Schedule of Segment Revenue from Major Products	In the periods set out below, revenues by major product were as follows: December 31, December 31, December 31, (In millions) 2016 2015 2014 Product sales: HEMOPHILIA $ 1,789.0 $ — $ — INHIBITOR THERAPIES 451.8 — — Hematology total 2,240.8 — — CINRYZE 680.2 617.7 503.0 ELAPRASE 589.0 552.6 592.8 FIRAZYR 578.5 445.0 364.2 REPLAGAL 452.4 441.2 500.4 VPRIV 345.7 342.4 366.7 KALBITOR 52.2 — — Genetic Diseases total 2,698.0 2,398.9 2,327.1 VYVANSE 2,013.9 1,722.2 1,449.0 ADDERALL XR 363.8 362.8 383.2 Other Neuroscience 112.8 115.4 372.3 Neuroscience total 2,490.5 2,200.4 2,204.5 IMMUNOGLOBULIN THERAPIES 1,143.9 — — BIO THERAPEUTICS 372.2 — — Immunology total 1,516.1 — — LIALDA/MEZAVANT 792.1 684.4 633.8 PENTASA 309.4 305.8 289.7 GATTEX/REVESTIVE 219.4 141.7 — NATPARA 85.3 24.4 — Other Internal Medicine 349.3 344.3 375.3 Internal Medicine total 1,755.5 1,500.6 1,298.8 Oncology total 130.5 — — Ophthalmology Total 54.4 — — Total Product sales $ 10,885.8 $ 6,099.9 $ 5,830.4

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Lease Payments under Operating Leases	Future minimum lease payments under operating leases as of December 31, 2016 are presented below: (In millions) Operating leases 2017 $ 155.5 2018 117.2 2019 98.7 2020 89.2 2021 82.7 Thereafter 441.9 $ 985.2

Share-based Compensation Plans

Share-based Compensation Plans (Tables)	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation Expense	The following table shows the total share-based compensation expense (see below for types of share-based awards) included in the Consolidated Statements of Operations : For the years ended December 31, (In millions) 2016 2015 2014 Cost of product sales $ 23.3 $ 7.6 $ 8.5 Research and development 46.9 28.6 22.2 Selling, general and administrative 67.1 37.4 35.9 Integration and acquisitions costs 181.2 — — Reorganization costs — 26.7 30.4 Total 318.5 100.3 97.0 Less tax (85.3 ) (28.4 ) (23.8 ) $ 233.2 $ 71.9 $ 73.2
Share-based Awards Outstanding	The following awards were outstanding as of December 31, 2016 : Compensation type Number of awards Expiration period from date of issue Vesting period Stock-settled SARs SARs 10,646,207 7 years 3 years graded vesting and/or 3 years cliff vesting subject to performance criteria for Executive Directors only UK/Irish Sharesave Plans Stock options 119,300 6 months after vesting 3 or 5 years Global Employee Stock Purchase Plan Stock options 411,900 On vesting date 1 to 5 years Baxalta Replacement Options Stock options 10,692,426 10 years 3 years graded vesting Stock-settled SARs and stock options 21,869,833 RSUs, PSUs and PSAs RSUs, PSUs and PSAs 2,346,511 3 years 3 years graded vesting, 3 years cliff vesting subject to performance criteria for Executive Directors and certain senior employees only Baxalta Replacement RSUs RSU 1,630,146 3 years 3 years graded vesting RSUs/PSUs and PSAs 3,976,657
Summary of Status of Stock Appreciation Rights and Stock Options	A summary of the status of the Company’s SARs and stock options including replacement awards as of December 31, 2016 and of the related activity during the period then ended is presented below: Year ended December 31, 2016 Weighted average exercise price Number of shares Intrinsic value (In millions) £ £ Outstanding as of beginning of period 52.02 7,796,496 Granted 42.37 6,506,762 Exercised 39.83 (4,717,106 ) Baxalta Replacement Options 34.30 13,328,592 Forfeited 48.49 (1,044,911 ) Outstanding as of end of period 38.98 21,869,833 76.6 Exercisable as of end of period 34.55 11,035,437 66.0
Schedule of Stock Appreciation Rights and Stock Options Outstanding, by Exercise Price Range	SARs and stock options including Baxalta Replacement Options, outstanding as of December 31, 2016 have the following characteristics: Number of awards outstanding Exercise prices Weighted Average remaining contractual term (Years) Weighted average exercise price of awards outstanding Number of awards exercisable Weighted average exercise price of awards exercisable £ £ £ 3,433,225 14.59-28.00 3.0 25.37 3,422,480 25.38 10,704,846 28.01-40.00 7.3 35.56 6,161,513 34.91 7,731,762 40.01-70.48 5.7 49.77 1,451,444 54.67 21,869,833 11,035,437
Schedule of Performance Share Awards	A summary of the status of the Company’s RSUs, PSUs and PSAs as of December 31, 2016 and of the related activity during the period then ended is presented below: RSUs, PSUs and PSAs Number of shares Weighted average grant date fair value Weighted average remaining life £ Outstanding as of beginning of period 1,791,930 40.06 Granted 1,663,070 42.28 Exercised (2,470,179 ) 37.52 Baxalta Replacement RSUs 3,294,150 39.28 Forfeited (302,314 ) 48.47 Outstanding as of end of period 3,976,657 41.31 3.8 Exercisable as of end of period — — N/A
Schedule of Share-based Payment Award, Valuation Assumptions	The fair value of share awards granted was estimated using the following assumptions: Years ended December 31, 2016 2015 2014 Risk-free interest rate 0.29-1.6% 0.6-1.8% 0.3-1.8% Expected dividend yield 0.3-0.5% 0.2-0.4% 0.2-0.4% Expected life 1-4 years 1-4 years 1-4 years Volatility 26-29% 23-26% 23-27% Forfeiture rate 5-7% 5-7% 5-7%

Guarantor Financial Informati63

Guarantor Financial Information (Tables)	12 Months Ended
	Dec. 31, 2016
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Condensed Balance Sheet	Condensed Consolidating Balance Sheet (As of December 31, 2016) (In millions) Shire plc (Parent Guarantor) SAIIDAC (SAIIDAC Notes Subsidiary Issuer) Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ — $ — $ 41.7 $ 487.1 $ 487.1 $ — $ 528.8 Restricted cash — — — 25.6 25.6 — 25.6 Accounts receivable, net — — — 2,616.5 2,616.5 — 2,616.5 Inventories — — — 3,562.3 3,562.3 — 3,562.3 Prepaid expenses and other current assets 1.8 — 97.1 707.4 707.4 — 806.3 Intercompany receivables — 120.5 — 5,154.4 5,274.9 (5,274.9 ) — Short-term intercompany loan receivable — 2,594.8 — — 2,594.8 (2,594.8 ) — Total current assets 1.8 2,715.3 138.8 12,553.3 15,268.6 (7,869.7 ) 7,539.5 Investments 35,656.1 — 34,644.2 12,571.8 12,571.8 (82,680.5 ) 191.6 Property, plant and equipment, net — — 27.4 6,442.2 6,442.2 — 6,469.6 Goodwill — — — 17,888.2 17,888.2 — 17,888.2 Intangible assets, net — — — 34,697.5 34,697.5 — 34,697.5 Deferred tax asset — — 273.0 96.7 96.7 (273.0 ) 96.7 Long-term intercompany loan receivable — 14,431.0 480.7 — 14,431.0 (14,911.7 ) — Other non-current assets 3.9 — 33.8 114.6 114.6 — 152.3 Total assets $ 35,661.8 $ 17,146.3 $ 35,597.9 $ 84,364.3 $ 101,510.6 $ (105,734.9 ) $ 67,035.4 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses $ 1.3 $ 85.7 $ 20.0 $ 4,205.4 $ 4,291.1 $ — $ 4,312.4 Short-term borrowings and capital lease obligations 450.0 2,594.8 — 23.2 2,618.0 — 3,068.0 Intercompany payables 5,247.1 — 27.8 — — (5,274.9 ) — Short-term intercompany loans payable — — — 2,594.8 2,594.8 (2,594.8 ) — Other current liabilities — — 64.6 298.3 298.3 — 362.9 Total current liabilities 5,698.4 2,680.5 112.4 7,121.7 9,802.2 (7,869.7 ) 7,743.3 Long-term borrowings and capital lease obligations — 14,431.0 5,063.7 405.1 14,836.1 — 19,899.8 Deferred tax liability — — — 8,595.7 8,595.7 (273.0 ) 8,322.7 Long-term intercompany loans payable 610.1 — — 14,301.6 14,301.6 (14,911.7 ) — Other non-current liabilities 405.3 — 61.7 1,654.6 1,654.6 — 2,121.6 Total liabilities 6,713.8 17,111.5 5,237.8 32,078.7 49,190.2 (23,054.4 ) 38,087.4 Total equity 28,948.0 34.8 30,360.1 52,285.6 52,320.4 (82,680.5 ) 28,948.0 Total liabilities and equity $ 35,661.8 $ 17,146.3 $ 35,597.9 $ 84,364.3 $ 101,510.6 $ (105,734.9 ) $ 67,035.4 Condensed Consolidating Balance Sheet (As of December 31, 2015) (In millions) Shire plc (Parent Guarantor) SAIIDAC (SAIIDAC Notes Subsidiary Issuer) Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ — $ — $ — $ 135.5 $ 135.5 $ — $ 135.5 Restricted cash — — — 86.0 86.0 — 86.0 Accounts receivable, net — — — 1,201.2 1,201.2 — 1,201.2 Inventories — — — 635.4 635.4 — 635.4 Prepaid expenses and other current assets 1.9 9.6 — 185.9 195.5 — 197.4 Intercompany receivables — — — 3,164.9 3,164.9 (3,164.9 ) — Total current assets 1.9 9.6 — 5,408.9 5,418.5 (3,164.9 ) 2,255.5 Investments 14,477.2 — — 50.8 50.8 (14,477.2 ) 50.8 Property, plant and equipment, net — — — 828.1 828.1 — 828.1 Goodwill — — — 4,147.8 4,147.8 — 4,147.8 Intangible assets, net — — — 9,173.3 9,173.3 — 9,173.3 Deferred tax asset — — — 121.0 121.0 — 121.0 Other non-current assets 5.3 8.3 — 19.7 28.0 — 33.3 Total assets $ 14,484.4 $ 17.9 $ — $ 19,749.6 $ 19,767.5 $ (17,642.1 ) $ 16,609.8 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses $ 10.0 $ — $ — $ 2,040.6 $ 2,040.6 $ — $ 2,050.6 Short-term borrowings and capital lease obligations 1,500.0 — — 12.7 12.7 — 1,512.7 Intercompany payables 3,145.3 19.6 — — 19.6 (3,164.9 ) — Other current liabilities — — — 142.8 142.8 — 142.8 Total current liabilities 4,655.3 19.6 — 2,196.1 2,215.7 (3,164.9 ) 3,706.1 Long-term borrowings and capital lease obligations — — — 82.1 82.1 — 82.1 Deferred tax liability — — — 2,205.9 2,205.9 — 2,205.9 Other non-current liabilities — — — 786.6 786.6 — 786.6 Total liabilities 4,655.3 19.6 — 5,270.7 5,290.3 (3,164.9 ) 6,780.7 Total equity 9,829.1 (1.7 ) — 14,478.9 14,477.2 (14,477.2 ) 9,829.1 Total liabilities and equity $ 14,484.4 $ 17.9 $ — $ 19,749.6 $ 19,767.5 $ (17,642.1 ) $ 16,609.8
Condensed Income Statement	Condensed Consolidating Statements of Operations For the year ended December 31, 2016 (In millions) Shire plc (Parent Guarantor) SAIIDAC (SAIIDAC Notes Subsidiary Issuer) Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated Revenues: Product sales $ — $ — $ — $ 10,885.8 $ 10,885.8 $ — $ 10,885.8 Royalties and other revenues — — — 510.8 510.8 — 510.8 Total revenues — — — 11,396.6 11,396.6 — 11,396.6 Costs and expenses: Cost of sales — — — 3,816.5 3,816.5 — 3,816.5 Research and development — — 0.4 1,439.4 1,439.4 — 1,439.8 Selling, general and administrative 59.8 — 29.4 2,926.0 2,926.0 — 3,015.2 Amortization of acquired intangible assets — — — 1,173.4 1,173.4 — 1,173.4 Integration and acquisition costs — — 302.0 581.9 581.9 — 883.9 Reorganization costs — — — 121.4 121.4 — 121.4 Gain on sale of product rights — — — (16.5 ) (16.5 ) — (16.5 ) Total operating expenses, net 59.8 — 331.8 10,042.1 10,042.1 — 10,433.7 Operating income / (loss) from continuing operations (59.8 ) — (331.8 ) 1,354.5 1,354.5 — 962.9 Interest income / (expense), net (100.6 ) 36.5 (45.1 ) (342.0 ) (305.5 ) — (451.2 ) Other expense, net 0.9 — 2.7 (29.2 ) (29.2 ) — (25.6 ) Total other income / (expense), net (99.7 ) 36.5 (42.4 ) (371.2 ) (334.7 ) — (476.8 ) Income / (loss) from continuing operations before income taxes and equity in (losses)/earnings of equity method investees (159.5 ) 36.5 (374.2 ) 983.3 1,019.8 — 486.1 Income taxes 4.3 (9.1 ) 88.9 42.0 32.9 — 126.1 Equity in income / (losses) of equity method investees, net of taxes 482.6 — (657.5 ) (8.7 ) (8.7 ) 174.9 (8.7 ) Income / (loss) from continuing operations, net of taxes 327.4 27.4 (942.8 ) 1,016.6 1,044.0 174.9 603.5 Loss from discontinued operations, net of taxes — — — (276.1 ) (276.1 ) — (276.1 ) Net income / (loss) 327.4 27.4 (942.8 ) 740.5 767.9 174.9 327.4 Comprehensive (loss) / income $ (986.4 ) $ 27.4 $ (2,148.9 ) $ (572.9 ) $ (545.5 ) $ 2,694.4 $ (986.4 ) Condensed Consolidating Statements of Operations For the year ended December 31, 2015 (In millions) Shire plc (Parent Guarantor) SAIIDAC (SAIIDAC Notes Subsidiary Issuer) Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated Revenues: Product sales $ — $ — $ — $ 6,099.9 $ 6,099.9 $ — $ 6,099.9 Royalties and other revenues — — — 316.8 $ 316.8 — 316.8 Total revenues — — — 6,416.7 6,416.7 — 6,416.7 Costs and expenses: Cost of sales — — — 969.0 $ 969.0 — 969.0 Research and development — — — 1,564.0 $ 1,564.0 — 1,564.0 Selling, general and administrative 24.9 — — 1,816.2 $ 1,816.2 1.4 1,842.5 Amortization of acquired intangible assets — — — 498.7 $ 498.7 — 498.7 Integration and acquisition costs — — — 39.8 $ 39.8 — 39.8 Reorganization costs — — — 97.9 $ 97.9 — 97.9 Gain on sale of product rights — — — (14.7 ) $ (14.7 ) — (14.7 ) Total operating expenses, net 24.9 — — 4,970.9 4,970.9 1.4 4,997.2 Operating (loss) / income from continuing operations (24.9 ) — — 1,445.8 1,445.8 (1.4 ) 1,419.5 Interest (expense) / income, net (63.6 ) (1.7 ) — 27.9 $ 26.2 — (37.4 ) Other income / (expense), net 0.9 — — 2.8 $ 2.8 — 3.7 Total other (expense) / income, net (62.7 ) (1.7 ) — 30.7 29.0 — (33.7 ) (Loss) / income from continuing operations before income taxes and equity in (losses)/earnings of equity method investees (87.6 ) (1.7 ) — 1,476.5 1,474.8 (1.4 ) 1,385.8 Income taxes 2.9 — — (49.0 ) (49.0 ) — (46.1 ) Equity in income / (losses) of equity method investees, net of taxes 1,388.1 — — (2.2 ) (2.2 ) (1,388.1 ) (2.2 ) Income / (loss) from continuing operations, net of taxes 1,303.4 (1.7 ) — 1,425.3 1,423.6 (1,389.5 ) 1,337.5 Loss from discontinued operations, net of taxes — — — (34.1 ) (34.1 ) — (34.1 ) Net income / (loss) 1,303.4 (1.7 ) — 1,391.2 1,389.5 (1,389.5 ) 1,303.4 Comprehensive income/(loss) $ 1,151.1 $ (1.7 ) $ — $ 1,238.9 $ 1,237.2 $ (1,237.2 ) $ 1,151.1 Condensed Consolidating Statements of Operations (For the year ended December 31, 2014) Shire plc (Parent Guarantor) SAIIDAC (SAIIDAC Notes Subsidiary Issuer) Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated Revenues: Product sales $ — $ — $ — $ 5,830.4 $ 5,830.4 $ — $ 5,830.4 Royalties and other revenues — — — 191.7 191.7 — 191.7 Total revenues — — — 6,022.1 6,022.1 — 6,022.1 Costs and expenses: Cost of sales — — — 979.3 979.3 — 979.3 Research and development — — — 1,067.5 1,067.5 — 1,067.5 Selling, general and administrative 109.4 — — 1,671.2 1,671.2 1.4 1,782.0 Amortization of acquired intangible assets — — — 243.8 243.8 — 243.8 Integration and acquisition costs — — — 158.8 158.8 — 158.8 Reorganization costs — — — 180.9 180.9 — 180.9 Gain on sale of product rights — — — (88.2 ) (88.2 ) — (88.2 ) Total operating expenses, net 109.4 — — 4,213.3 4,213.3 1.4 4,324.1 Operating (loss) / income from continuing operations (109.4 ) — — 1,808.8 1,808.8 (1.4 ) 1,698.0 Interest (expense) / income, net (42.8 ) — — 36.7 36.7 — (6.1 ) Other income, net 0.3 — — 8.6 8.6 — 8.9 Receipt of break fee 1,635.4 — — — — — 1,635.4 Total other income, net 1,592.9 — — 45.3 45.3 — 1,638.2 Income / (loss) from continuing operations before income taxes and equity in (losses)/earnings of equity method investees 1,483.5 — — 1,854.1 1,854.1 (1.4 ) 3,336.2 Income taxes 2.2 — — (58.3 ) (58.3 ) — (56.1 ) Equity in income / (losses) of equity method investees, net of taxes 1,919.8 — — 2.7 2.7 (1,919.8 ) 2.7 Income / (loss) from continuing operations, net of taxes 3,405.5 — — 1,798.5 1,798.5 (1,921.2 ) 3,282.8 Income from discontinued operations, net of taxes — — — 122.7 122.7 — 122.7 Net income / (loss) 3,405.5 — — 1,921.2 1,921.2 (1,921.2 ) 3,405.5 Comprehensive income / (loss) $ 3,263.8 $ — $ — $ 1,779.5 $ 1,779.5 $ (1,779.5 ) $ 3,263.8
Condensed Cash Flow Statement	Condensed Consolidating Statement of Cash Flows (For the year ended December 31, 2016) (In millions) Shire plc (Parent Guarantor) SAIIDAC (SAIIDAC Notes Subsidiary Issuer) Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated CASH FLOWS FROM OPERATING ACTIVITIES Net cash (used in) / provided by operating activities $ (136.9 ) $ 232.8 $ (51.0 ) $ 2,614.0 $ 2,846.8 $ — $ 2,658.9 CASH FLOWS FROM INVESTING ACTIVITIES: Transactions with subsidiaries (2,890.0 ) (18,228.8 ) (480.7 ) (4,707.3 ) (22,936.1 ) 26,306.8 — Movements in restricted cash — — — 62.8 62.8 — 62.8 Purchases of subsidiary undertakings and businesses, net of cash acquired — — — (17,476.2 ) (17,476.2 ) — (17,476.2 ) Purchases of non-current investments and PP&E — — (11.1 ) (637.6 ) (637.6 ) — (648.7 ) Proceeds received on sale of product rights — — — 10.9 10.9 — 10.9 Proceeds from disposal of non-current investments and PP&E — — — 0.9 0.9 — 0.9 Other, net — — — (41.9 ) (41.9 ) — (41.9 ) Net cash (used in) / provided by investing activities (2,890.0 ) (18,228.8 ) (491.8 ) (22,788.4 ) (41,017.2 ) 26,306.8 (18,092.2 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from revolving line of credit, long term and short term borrowings 2,355.0 30,079.9 — 8.5 30,088.4 — 32,443.4 Repayment of revolving line of credit, long term and short term borrowings (3,405.0 ) (13,009.2 ) — 9.9 (12,999.3 ) — (16,404.3 ) Proceeds from intercompany borrowings 4,077.8 1,097.6 521.9 20,609.5 21,707.1 (26,306.8 ) — Payment of dividend (20.7 ) — — (150.6 ) (150.6 ) — (171.3 ) Debt issuance costs — (172.3 ) — — (172.3 ) — (172.3 ) Contingent consideration payments — — — (8.0 ) (8.0 ) — (8.0 ) Proceeds from exercise of options 19.8 — 92.7 16.5 16.5 — 129.0 Other, net — — (30.1 ) 39.4 39.4 — 9.3 Net cash provided by / (used in) financing activities 3,026.9 17,996.0 584.5 20,525.2 38,521.2 (26,306.8 ) 15,825.8 Effect of foreign exchange rate changes on cash and cash equivalents — — — 0.8 0.8 — 0.8 Net increase in cash and cash equivalents — — 41.7 351.6 351.6 — 393.3 Cash and cash equivalents at beginning of period — — — 135.5 135.5 — 135.5 Cash and cash equivalents at end of period $ — $ — $ 41.7 $ 487.1 $ 487.1 $ — $ 528.8 Condensed Consolidating Statement of Cash Flows (For the year ended December 31, 2015) (In millions) Shire plc (Parent Guarantor) SAIIDAC (SAIIDAC Notes Subsidiary Issuer) Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated CASH FLOWS FROM OPERATING ACTIVITIES Net cash (used in) / provided by operating activities $ (133.5 ) $ — $ — $ 2,470.5 $ 2,470.5 $ — $ 2,337.0 CASH FLOWS FROM INVESTING ACTIVITIES: Transactions with subsidiaries (3,570.0 ) — — (3,048.2 ) (3,048.2 ) 6,618.2 — Movements in restricted cash — — — (32.0 ) (32.0 ) — (32.0 ) Purchases of subsidiary undertakings and businesses, net of cash acquired — — — (5,553.4 ) (5,553.4 ) — (5,553.4 ) Purchases of non-current investments and PP&E — — — (124.2 ) (124.2 ) — (124.2 ) Proceeds from short-term investments — — — 67.0 67.0 — 67.0 Proceeds received on sale of product rights — — — 17.5 17.5 — 17.5 Proceeds from disposal of non-current investments and PP&E — — — 18.7 18.7 — 18.7 Other, net — — — (13.5 ) (13.5 ) — (13.5 ) Net cash provided by / (used in) investing activities (3,570.0 ) — — (8,668.1 ) (8,668.1 ) 6,618.2 (5,619.9 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from revolving line of credit, long term and short term borrowings 3,760.0 — — 0.8 0.8 — 3,760.8 Repayment of revolving line of credit, long term and short term borrowings (3,110.0 ) — — (0.9 ) (0.9 ) — (3,110.9 ) Proceeds from intercompany borrowings 3,048.2 — — 3,570.0 3,570.0 (6,618.2 ) — Payment of dividend (6.8 ) — — (127.6 ) (127.6 ) — (134.4 ) Debt issuance costs (4.5 ) — — (19.6 ) (19.6 ) — (24.1 ) Contingent consideration payments — — — (101.2 ) (101.2 ) — (101.2 ) Proceeds from exercise of options 16.6 — — — — — 16.6 Other, net — — — 32.2 32.2 — 32.2 Net cash provided by / (used in) financing activities 3,703.5 — — 3,353.7 3,353.7 (6,618.2 ) 439.0 Effect of foreign exchange rate changes on cash and cash equivalents — — — (3.0 ) (3.0 ) — (3.0 ) Net decrease in cash and cash equivalents — — — (2,846.9 ) (2,846.9 ) — (2,846.9 ) Cash and cash equivalents at beginning of period — — — 2,982.4 2,982.4 — 2,982.4 Cash and cash equivalents at end of period $ — $ — $ — $ 135.5 $ 135.5 $ — $ 135.5 Condensed Consolidating Statement of Cash Flows (For the year ended December 31, 2014) (In millions) Shire plc (Parent Guarantor) SAIIDAC (SAIIDAC Notes Subsidiary Issuer) Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated CASH FLOWS FROM OPERATING ACTIVITIES Net cash provided by / (used in) operating activities $ 1,512.6 $ — $ — $ 2,715.8 $ 2,715.8 $ — $ 4,228.4 CASH FLOWS FROM INVESTING ACTIVITIES: Transactions with subsidiaries (1,900.0 ) — — 458.3 458.3 1,441.7 — Movements in restricted cash — — — (32.6 ) (32.6 ) — (32.6 ) Purchases of subsidiary undertakings and businesses, net of cash acquired — — — (4,104.4 ) (4,104.4 ) — (4,104.4 ) Purchases of non-current investments and PP&E — — — (100.1 ) (100.1 ) — (100.1 ) Proceeds from short-term investments — — — 57.8 57.8 — 57.8 Proceeds received on sale of product rights — — — 127.0 127.0 — 127.0 Proceeds from disposal of non-current investments and PP&E — — — 21.5 21.5 — 21.5 Other, net — — — 0.2 0.2 — 0.2 Net cash provided by (used in) investing activities (1,900.0 ) — — (3,572.3 ) (3,572.3 ) 1,441.7 (4,030.6 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from revolving line of credit, long term and short term borrowings 2,310.0 — — 0.8 0.8 — 2,310.8 Repayment of revolving line of credit, long term and short term borrowings (1,460.0 ) — — (1.8 ) (1.8 ) — (1,461.8 ) Repayment of debt acquired through business combinations — — — (551.5 ) (551.5 ) — (551.5 ) Proceeds from ViroPharma call options — — — 346.7 346.7 — 346.7 Proceeds from intercompany borrowings (458.3 ) — — 1,900.0 1,900.0 (1,441.7 ) — Payment of dividend (8.9 ) — — (112.3 ) (112.3 ) — (121.2 ) Debt issuance costs (10.6 ) — — 0.4 0.4 — (10.2 ) Contingent consideration payments — — — (15.2 ) (15.2 ) — (15.2 ) Proceeds from exercise of options 15.2 — — 2.2 2.2 — 17.4 Other, net — — — 39.5 39.5 — 39.5 Net cash provided by / (used in) financing activities 387.4 — — 1,608.8 1,608.8 (1,441.7 ) 554.5 Effect of foreign exchange rate changes on cash and cash equivalents — — — (9.3 ) (9.3 ) — (9.3 ) Net increase in cash and cash equivalents — — — 743.0 743.0 — 743.0 Cash and cash equivalents at beginning of period — — — 2,239.4 2,239.4 — 2,239.4 Cash and cash equivalents at end of period $ — $ — $ — $ 2,982.4 $ 2,982.4 $ — $ 2,982.4

Quarterly Results of Operatio64

Quarterly Results of Operations (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Quarterly Results of Operations	The following table presents summarized unaudited quarterly results for the years to December 31, 2016 and 2015 : 2016 Q1 Q2 Q3 Q4 (In millions, except per share data) Total revenues $ 1,709.3 $ 2,429.1 $ 3,452.1 $ 3,806.1 Cost of product sales 248.6 778.1 1,736.2 1,053.6 Income from continuing operations, net of taxes 409.5 86.6 (368.5 ) 475.9 Loss from discontinued operations, net of taxes 9.5 (248.7 ) (18.3 ) (18.6 ) Net income 419.0 (162.1 ) (386.8 ) 457.3 Earnings per ordinary share - basic Earnings from continuing operations $ 0.69 $ 0.12 $ (0.41 ) $ 0.53 Loss from discontinued operations 0.02 (0.36 ) (0.02 ) (0.02 ) Earnings per share - basic $ 0.71 $ (0.24 ) $ (0.43 ) $ 0.51 Earnings per ordinary share - diluted Earnings from continuing operations $ 0.69 $ 0.12 $ (0.41 ) $ 0.52 Loss from discontinued operations 0.02 (0.36 ) (0.02 ) (0.02 ) Earnings per share - diluted $ 0.71 $ (0.24 ) $ (0.43 ) $ 0.50 2015 Q1 Q2 Q3 Q4 (In millions,except per share data) Total revenues $ 1,488.4 $ 1,557.6 $ 1,655.0 $ 1,715.7 Cost of product sales 227.8 228.0 262.7 250.5 Income from continuing operations, net of taxes 412.9 164.1 477.1 283.4 (Loss)/gain from discontinued operations, net of taxes (2.5 ) (4.5 ) (24.3 ) (2.8 ) Net income 410.4 159.6 452.8 280.6 Earnings per ordinary share - basic Earnings from continuing operations $ 0.70 $ 0.28 $ 0.81 $ 0.48 (Loss)/gain from discontinued operations — (0.01 ) (0.04 ) (0.01 ) Earnings per share - basic $ 0.70 $ 0.27 $ 0.77 $ 0.47 Earnings per ordinary share - diluted Earnings from continuing operations $ 0.70 $ 0.28 $ 0.80 $ 0.48 (Loss)/gain from discontinued operations — (0.01 ) (0.04 ) (0.01 ) Earnings per share - diluted $ 0.70 $ 0.27 $ 0.76 $ 0.47

Summary of Significant Accoun65

Summary of Significant Accounting Policies (Useful Lives of Property, Plant and Equipment) (Details)	12 Months Ended
	Dec. 31, 2016
Buildings and leasehold improvements | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life of PP&E	15 years
Buildings and leasehold improvements | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life of PP&E	50 years
Office furniture, fittings and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life of PP&E	3 years
Office furniture, fittings and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life of PP&E	10 years
Machinery, equipment and other | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life of PP&E	3 years
Machinery, equipment and other | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life of PP&E	15 years

Summary of Significant Accoun66

Summary of Significant Accounting Policies (Narrative) (Details) - USD ($) $ in Millions	Jun. 03, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Foreign currency exchange transaction gain (loss)		$ 17.7	$ (26.5)	$ (15.6)
Advertising costs		$ 216	$ 56.1	$ 56.4
Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets		2 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets		25 years
Weighted Average
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets		20 years
Baxalta
Finite-Lived Intangible Assets [Line Items]
Preliminary fair value of purchase consideration	$ 32,397.7

Business Combinations (Acquisit

Business Combinations (Acquisition of Baxalta) (Narrative) (Details) $ / shares in Units, shares in Millions, $ in Millions	Jun. 03, 2016USD ($)$ / sharesshares	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Business Acquisition [Line Items]
Goodwill		$ 17,888.2	$ 4,147.8	$ 2,474.9
Integration and acquisition costs		883.9	$ 39.8	$ 158.8
Baxalta
Business Acquisition [Line Items]
Purchase price payment per share in cash | $ / shares	$ 18
Stock Issued During Period, Shares, Acquisitions | shares	305.2
Revenue since acquisition		4,011.6
Goodwill	$ 11,422.4
Integration and acquisition costs		$ 791.4
Contingent consideration, high outcome	1,500
Liabilities incurred	169
Pension and Other Postretirement Defined Benefit Plans, Liabilities	610.4
Fair value of plan assets	$ 358.5
Baxalta | ADS
Business Acquisition [Line Items]
Business Combination, Shares Offered Per Existing Share Ratio	0.1482
Baxalta | Common stock
Business Acquisition [Line Items]
Business Combination, Shares Offered Per Existing Share Ratio	0.4446
Currently marketed products | Baxalta
Business Acquisition [Line Items]
Intangible assets	$ 21,995
Weighted-average useful life	21 years
IPR&D | Baxalta
Business Acquisition [Line Items]
Intangible assets	$ 730
Discount Rate Used in Determining Fair Value of Acquired in Process Research and Development, Low Rate	9.50%
Minimum
Business Acquisition [Line Items]
Estimated useful life of intangible assets		2 years
Minimum | Currently marketed products | Baxalta
Business Acquisition [Line Items]
Estimated useful life of intangible assets	8 years
Maximum
Business Acquisition [Line Items]
Estimated useful life of intangible assets		25 years
Maximum | Currently marketed products | Baxalta
Business Acquisition [Line Items]
Estimated useful life of intangible assets	23 years

Business Combinations (Baxalta

Business Combinations (Baxalta Purchase Price Consideration) (Details) - Baxalta $ in Millions	Jun. 03, 2016USD ($)
Business Acquisition [Line Items]
Cash paid to shareholders	$ 12,366.7
Fair value of stock issued to shareholders	19,353.2
Fair value of partially vested stock options and RSUs assumed	508.8
Contingent consideration payable	169
Total Purchase Consideration	$ 32,397.7

Business Combinations (Baxalt69

Business Combinations (Baxalta Assets Acquired and Liabilities Assumed) (Details) - USD ($) $ in Millions	Jun. 03, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Goodwill		$ 17,888.2	$ 4,147.8	$ 2,474.9
Baxalta
Current assets:
Cash and cash equivalents	$ 583.2
Accounts receivable	1,069.7
Inventories	3,893.4
Other current assets	576
Total current assets	6,122.3
Property, plant and equipment	5,452.7
Investments	128.2
Goodwill	11,422.4
Other non-current assets	155
Total assets	46,047.8
Current liabilities:
Accounts payable and accrued expenses	1,321.9
Other current liabilities	354.4
Long-term borrowings and capital lease obligations	5,424.9
Deferred tax liability	5,445.3
Other non-current liabilities	1,103.6
Total liabilities	13,650.1
Preliminary fair value of identifiable assets acquired and liabilities assumed	32,397.7
Preliminary fair value of purchase consideration	32,397.7
Restatement Adjustment | Baxalta
Current assets:
Cash and cash equivalents	0
Accounts receivable	(2)
Inventories	(1,447.7)
Other current assets	(97.3)
Total current assets	(1,547)
Property, plant and equipment	(235)
Investments	0
Goodwill	5,316
Other non-current assets	51.7
Total assets	(1,209.3)
Current liabilities:
Accounts payable and accrued expenses	38
Other current liabilities	113.4
Long-term borrowings and capital lease obligations	0
Deferred tax liability	(1,386.4)
Other non-current liabilities	11.5
Total liabilities	(1,223.5)
Preliminary fair value of identifiable assets acquired and liabilities assumed	14.2
Preliminary fair value of purchase consideration	14.2
Scenario, Previously Reported | Baxalta
Current assets:
Cash and cash equivalents	583.2
Accounts receivable	1,071.7
Inventories	5,341.1
Other current assets	673.3
Total current assets	7,669.3
Property, plant and equipment	5,687.7
Investments	128.2
Goodwill	6,106.4
Other non-current assets	103.3
Total assets	47,257.1
Current liabilities:
Accounts payable and accrued expenses	1,283.9
Other current liabilities	241
Long-term borrowings and capital lease obligations	5,424.9
Deferred tax liability	6,831.7
Other non-current liabilities	1,092.1
Total liabilities	14,873.6
Preliminary fair value of identifiable assets acquired and liabilities assumed	32,383.5
Preliminary fair value of purchase consideration	32,383.5
IPR&D | Baxalta
Current assets:
Intangible assets	730
IPR&D | Restatement Adjustment | Baxalta
Current assets:
Intangible assets	(2,210)
IPR&D | Scenario, Previously Reported | Baxalta
Current assets:
Intangible assets	2,940
Favorable Manufacturing Contract | Baxalta
Current assets:
Intangible assets	42.2
Favorable Manufacturing Contract | Restatement Adjustment | Baxalta
Current assets:
Intangible assets	(30)
Favorable Manufacturing Contract | Scenario, Previously Reported | Baxalta
Current assets:
Intangible assets	72.2
Currently marketed products | Baxalta
Current assets:
Intangible assets	21,995
Currently marketed products | Restatement Adjustment | Baxalta
Current assets:
Intangible assets	(2,555)
Currently marketed products | Scenario, Previously Reported | Baxalta
Current assets:
Intangible assets	$ 24,550

Business Combinations (Baxalt70

Business Combinations (Baxalta Pro Forma Information) (Details) - Baxalta - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Revenues	$ 13,999.6	$ 12,564.7
Net income/(loss) from continuing operations	$ 2,235.9	$ (1,014.2)
Net income/(loss) from continuing operations per share - basic	$ 2.90	$ (1.72)
Net income/(loss) from continuing operations per share - diluted	$ 2.88	$ (1.72)
Increase/(decrease) to net income to reflect acquisition related costs	$ 678.9	$ (678.9)
Increase/(decrease) to net income to reflect the fair value adjustment to acquisition date inventory.	897.1	(1,428.2)
An adjustment to increase amortization of intangible assets	330.9	815
Decrease to net income to reflect the additional interest expense	$ 42.5	$ 357.6

Business Combinations (Acquis71

Business Combinations (Acquisition of Dyax) (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	Jan. 22, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill		$ 17,888.2	$ 4,147.8	$ 2,474.9
Integration and acquisition costs		883.9	$ 39.8	$ 158.8
Dyax
Business Acquisition [Line Items]
Purchase price payment per share in cash	$ 37.30
Additional consideration per share	$ 4
Preliminary fair value of identifiable assets acquired and liabilities assumed	$ 6,330
Cash payments to acquire business	5,934
Liabilities incurred	396
Contingent consideration, high outcome	646
Revenue since acquisition		77.1
Goodwill	2,702.1
Integration and acquisition costs		$ 67.7
Currently marketed products | Dyax
Business Acquisition [Line Items]
Intangible assets	135
IPR&D | Dyax
Business Acquisition [Line Items]
Intangible assets	4,100
Other intangible assets | Dyax
Business Acquisition [Line Items]
Intangible assets	$ 425
Weighted-average useful life	8 years
KALBITOR | Dyax
Business Acquisition [Line Items]
Estimated useful life of intangible assets	18 years
shp643 | Dyax
Business Acquisition [Line Items]
Discount rate used in determining fair value of acquired in process research and development, high rate	9.00%
Minimum
Business Acquisition [Line Items]
Estimated useful life of intangible assets		2 years
Minimum | Other intangible assets | Dyax
Business Acquisition [Line Items]
Estimated useful life of intangible assets	7 years
Maximum
Business Acquisition [Line Items]
Estimated useful life of intangible assets		25 years
Maximum | Other intangible assets | Dyax
Business Acquisition [Line Items]
Estimated useful life of intangible assets	9 years

Business Combinations (Dyax Ass

Business Combinations (Dyax Assets Acquired and Liabilities Assumed) (Details) - USD ($) $ in Millions	Jan. 22, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Goodwill		$ 17,888.2	$ 4,147.8	$ 2,474.9
Dyax
Current assets:
Cash and cash equivalents	$ 241.2
Accounts receivable	22.5
Inventories	20.2
Other current assets	8.1
Total current assets	292
Property, plant and equipment	5.8
Goodwill	2,702.1
Other non-current assets	28.6
Total assets	7,688.5
Current liabilities:
Accounts payable and accrued expenses	30
Other current liabilities	1.7
Deferred tax liability	1,325.4
Other non-current liabilities	1.4
Total liabilities	1,358.5
Preliminary fair value of identifiable assets acquired and liabilities assumed	6,330
Preliminary fair value of purchase consideration	6,330
Currently marketed products | Dyax
Current assets:
Intangible assets	135
IPR&D | Dyax
Current assets:
Intangible assets	4,100
Contract based royalty arrangements | Dyax
Current assets:
Intangible assets	$ 425

Business Combinations (Dyax Pro

Business Combinations (Dyax Pro Forma Information) (Details) - Dyax - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Revenues	$ 11,402.5	$ 6,503.8
Net income from continuing operations	$ 792.2	$ 1,056.6
Net income from continuing operations per share - basic	$ 1.03	$ 1.79
Net income from continuing operations per share - diluted	$ 1.02	$ 1.78
Increase/(decrease) to net income to reflect acquisition related costs	$ 111.1	$ (111.1)
Increase/(decrease) to net income to reflect the fair value adjustment to acquisition date inventory.		(5.4)
An adjustment to increase amortization of intangible assets	$ 1.3	21.6
Decrease to net income to reflect the additional interest expense		$ (81.6)

Business Combinations (Acquis74

Business Combinations (Acquisition of NPS) (Narrative) (Details) - USD ($) $ in Millions	Feb. 21, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill		$ 17,888.2	$ 4,147.8	$ 2,474.9
NPS Pharma
Business Acquisition [Line Items]
Cash payments to acquire business	$ 5,219.6
Intangible assets			$ 5,474.9
Goodwill	1,551
Currently marketed products | NPS Pharma
Business Acquisition [Line Items]
Intangible assets	4,640
Other intangible assets | NPS Pharma
Business Acquisition [Line Items]
Intangible assets	$ 353
Weighted-average useful life	4 years
NATPARA | Currently marketed products | NPS Pharma
Business Acquisition [Line Items]
Estimated useful life of intangible assets	24 years
Minimum
Business Acquisition [Line Items]
Estimated useful life of intangible assets		2 years
Minimum | Other intangible assets | NPS Pharma
Business Acquisition [Line Items]
Estimated useful life of intangible assets	4 years
Maximum
Business Acquisition [Line Items]
Estimated useful life of intangible assets		25 years
Maximum | Other intangible assets | NPS Pharma
Business Acquisition [Line Items]
Estimated useful life of intangible assets	5 years

Business Combinations (NPS Asse

Business Combinations (NPS Assets Acquired and Liabilities Assumed) (Details) - USD ($) $ in Millions	Feb. 21, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Goodwill		$ 17,888.2	$ 4,147.8	$ 2,474.9
NPS Pharma
Current assets:
Cash and cash equivalents	$ 41.6
Short-term investments	67
Accounts receivable	33.4
Inventories	89.4
Other current assets	11.1
Total current assets	242.5
Property, plant and equipment	4.8
Goodwill	1,551
Intangible assets			$ 5,474.9
Total assets	6,791.3
Current liabilities:
Accounts payable and accrued expenses	75.7
Short-term borrowings and capital lease obligations	27.4
Long-term borrowings and capital lease obligations	78.9
Deferred tax liability	1,385.2
Other non-current liabilities	4.5
Total liabilities	1,571.7
Preliminary fair value of identifiable assets acquired and liabilities assumed	5,219.6
Cash payments to acquire business	5,219.6
Currently marketed products | NPS Pharma
Current assets:
Intangible assets	4,640
Royalty rights (categorized as Other intangible assets) | NPS Pharma
Current assets:
Intangible assets	$ 353

Business Combinations (NPS Pro

Business Combinations (NPS Pro Forma Information) (Details) - NPS Pharma - USD ($) $ / shares in Units, $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2015
Business Acquisition [Line Items]
Revenues		$ 6,446.6
Net income from continuing operations		$ 1,293.6
Net income from continuing operations per share - basic		$ 2.19
Net income from continuing operations per share - diluted		$ 2.18
Increase/(decrease) to net income to reflect acquisition related costs	$ 105.3
Increase/(decrease) to net income to reflect the fair value adjustment to acquisition date inventory.	$ 18.8
An adjustment to increase amortization of intangible assets		$ 22.2

Collaborative and Other Licen77

Collaborative and Other Licensing Arrangements (Narrative) (Details) € in Millions	Jun. 03, 2016USD ($)	Jun. 03, 2016EUR (€)	Jan. 31, 2017USD ($)	Sep. 30, 2016USD ($)	Jul. 31, 2016USD ($)	Jun. 30, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Jun. 03, 2016EUR (€)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Option exercise fee, for each protein | €										€ 20
Out-licensing Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments received							$ 10,500,000	$ 19,600,000
Out-licensing Arrangement | Development Milestone
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum milestone payment receivable							10,300,000
Out-licensing Arrangement | Sales Milestone
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum milestone payment receivable							15,700,000
Other Revenues | Out-licensing Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenues recognized							17,400,000	8,900,000	$ 16,700,000
Product Sales | Out-licensing Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenues recognized							$ 63,000,000	$ 51,000,000	$ 46,500,000
Collaboration with Precision BioSciences | In-licensing Arrangement | Certain Success Criteria, and Development and Sales Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum conditional obligation						$ 1,500,000,000
Research Collaboration with Symphogen | In-licensing Arrangement | Certain Success Criteria, and Development and Sales Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones payment | €		€ 1,200
License Agreement with Merrimack Pharmaceuticals | Out-licensing Arrangement | Certain Success Criteria, and Development and Sales Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones payment	$ 638,000,000
Agreement with SFJ Pharmaceuticals IX, L.P.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Fair value of assumed contingency	$ 288,600,000
Pfizer Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment					$ 90,000,000
SFJ Pharmaceuticals Group
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payments to terminate agreement				$ 288,000,000
Minimum | Pfizer Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones payment					75,000,000
Maximum | Pfizer Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones payment					$ 460,000,000
Baxalta | Option to Obtain Exclusive Licensing Rights
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Exercise period after protein is ready for Phase 2 clinical trials						90 days
Subsequent Event | Momenta Pharmaceuticals | Out-licensing Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones payment			$ 51,200,000

Integration and Acquisition C78

Integration and Acquisition Costs (Summary of Related Reserve) (Details) - Severance and employee benefits $ in Millions	12 Months Ended
	Dec. 31, 2016USD ($)
Restructuring Reserve [Roll Forward]
As of January 1,	$ 0
Amount charged to integration costs	267.3
Paid/utilized	(193.3)
As of December 31,	$ 74

Integration and Acquisition C79

Integration and Acquisition Costs (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Integration and acquisition costs	$ 883.9	$ 39.8	$ 158.8
Baxalta
Business Acquisition [Line Items]
Integration and acquisition costs	791.4
NPS Pharma, Viropharma and Baxalta
Business Acquisition [Line Items]
Integration and acquisition costs		189.7
Lumena and Lotus Tissue Repair
Business Acquisition [Line Items]
Change in fair value of contingent consideration		149.9	14.7
Payments for restructuring		$ 90
Viropharma
Business Acquisition [Line Items]
Integration and acquisition costs			$ 144.1
Involuntary termination benefits | Baxalta
Business Acquisition [Line Items]
Integration related costs	$ 381.2

Reorganization Costs (Narrative

Reorganization Costs (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Restructuring Cost and Reserve [Line Items]
Reorganization costs	$ 121.4	$ 97.9	$ 180.9
Offices
Restructuring Cost and Reserve [Line Items]
Reorganization costs	77.4
Severance and employee benefits
Restructuring Cost and Reserve [Line Items]
Reorganization costs	$ 16.2

Results of Discontinued Opera81

Results of Discontinued Operations (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss)/ gain from discontinued operations	$ (18.6)	$ (18.3)	$ (248.7)	$ 9.5	$ (2.8)	$ (24.3)	$ (4.5)	$ (2.5)	$ (276.1)	$ (34.1)	$ 122.7
DERMAGRAFT | Discontinued operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss)/ gain from discontinued operations									276.1	(34.1)	122.7
Income tax expense (benefit)									$ 98.8	$ (18.9)	$ 211.3

Accounts Receivable, Net (Narra

Accounts Receivable, Net (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Receivables [Abstract]
Accounts receivable, net	$ 2,616.5	$ 1,201.2
Allowance for doubtful accounts	169.6	55.8	$ 48.5	$ 47.9
Accounts receivable related to royalty income	$ 102.2	$ 79

Accounts Receivable, Net (Provi

Accounts Receivable, Net (Provision for Discounts and Doubtful Accounts) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Provision for discounts and doubtful accounts
As of January 1,	$ 55.8	$ 48.5	$ 47.9
Provision charged to operations	838.1	424.2	338.2
Provision utilization	(724.3)	(416.9)	(337.6)
As at December 31,	$ 169.6	$ 55.8	$ 48.5

Inventories (Summary of Invento

Inventories (Summary of Inventories) (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Schedule of Inventory
Finished goods	$ 1,380	$ 184.9
Work-in-progress	1,491	302
Raw materials	691.3	148.5
Inventories	$ 3,562.3	$ 635.4

Inventories (Narrative) (Detail

Inventories (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Capitalized inventory	$ 18.1	$ 0

Prepaid Expenses and Other Cu86

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Prepaid Expense and Other Assets, Current [Abstract]
Income tax receivable	$ 237.5	$ 73.6
Prepaid expenses	183.9	35.6
Value added taxes receivable	40.3	18.2
Other current assets	344.6	70
Prepaid expenses and other current assets, total	$ 806.3	$ 197.4

Property, Plant and Equipment87

Property, Plant and Equipment, Net (Summary of Property, Plant and Equipment, Net) (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment, Net
Land	$ 337.9	$ 96.7
Buildings and leasehold improvements	1,915.4	606.4
Machinery, equipment and other	2,547.2	827.4
Assets under construction	2,632.5	93.7
Total property, plant and equipment at cost	7,433	1,624.2
Less: Accumulated depreciation	(963.4)	(796.1)
Property, plant and equipment, net	$ 6,469.6	$ 828.1

Property, Plant and Equipment88

Property, Plant and Equipment, Net (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation	$ 292.9	$ 138.5	$ 163.5

Goodwill (Goodwill Rollforward)

Goodwill (Goodwill Rollforward) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Goodwill [Roll Forward]
As of January 1,	$ 4,147.8	$ 2,474.9
Acquisitions	14,124.5	1,700.1
Foreign currency translation	(384.1)	(27.2)
As of December 31,	$ 17,888.2	$ 4,147.8

Goodwill (Narrative) (Details)

Goodwill (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Acquisitions	$ 14,124.5	$ 1,700.1

Intangible Assets (Summary of I

Intangible Assets (Summary of Intangible Assets) (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Gross acquired intangible assets	$ 37,806.3	$ 11,108.9
Accumulated amortization	(3,108.8)	(1,935.6)
Intangible assets, net	34,697.5	9,173.3	$ 4,934.4
Currently marketed products
Finite-Lived Intangible Assets [Line Items]
Gross acquired intangible assets	31,217.5	9,371.9
Accumulated amortization	(2,908.6)	(1,852.1)
Intangible assets, net	28,308.9	7,519.8
IPR&D
Finite-Lived Intangible Assets [Line Items]
Gross acquired intangible assets	5,746.6	1,362
Accumulated amortization	0	0
Intangible assets, net	5,746.6	1,362
Other intangible assets
Finite-Lived Intangible Assets [Line Items]
Gross acquired intangible assets	842.2	375
Accumulated amortization	(200.2)	(83.5)
Intangible assets, net	$ 642	$ 291.5

Intangible Assets (Roll Forward

Intangible Assets (Roll Forward) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Other Intangible Assets Roll Forward
As at January 1,	$ 9,173.3	$ 4,934.4
Acquisitions	27,462.8	5,474.9
Amortization charged	(1,173.4)	(498.7)	$ (243.8)
Impairment charges	(8.9)	(643.7)	(190.3)
Foreign currency translation	(756.3)	(93.6)
As at December 31,	$ 34,697.5	$ 9,173.3	$ 4,934.4

Intangible Assets (Narrative) (

Intangible Assets (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Jun. 03, 2016	Jan. 22, 2016	Feb. 21, 2015
Finite-Lived Intangible Assets [Line Items]
Impairment charges	$ 8.9	$ 643.7	$ 190.3
Change in fair value of contingent consideration	$ (11.1)	149.9	$ (14.7)
NPS Pharma
Finite-Lived Intangible Assets [Line Items]
Intangible assets		5,474.9
Currently marketed products | Baxalta
Finite-Lived Intangible Assets [Line Items]
Intangible assets				$ 21,995
Currently marketed products | Dyax
Finite-Lived Intangible Assets [Line Items]
Intangible assets					$ 135
Currently marketed products | NPS Pharma
Finite-Lived Intangible Assets [Line Items]
Intangible assets						$ 4,640
IPR&D | Baxalta
Finite-Lived Intangible Assets [Line Items]
Intangible assets				730
IPR&D | Dyax
Finite-Lived Intangible Assets [Line Items]
Intangible assets					4,100
IPR&D | Meritage and Foresight
Finite-Lived Intangible Assets [Line Items]
Intangible assets		475
Favorable Manufacturing Contract | Baxalta
Finite-Lived Intangible Assets [Line Items]
Intangible assets				$ 42.2
Other intangible assets | Dyax
Finite-Lived Intangible Assets [Line Items]
Intangible assets					$ 425
Other intangible assets | NPS Pharma
Finite-Lived Intangible Assets [Line Items]
Intangible assets						$ 353
Currently marketed products and royalty rights | NPS Pharma
Finite-Lived Intangible Assets [Line Items]
Intangible assets		4,993
SHP625 and SHP608 combined | Lumena and Lotus Tissue Repair
Finite-Lived Intangible Assets [Line Items]
Change in fair value of contingent consideration		$ (203.2)

Intangible Assets (Future Amort

Intangible Assets (Future Amortization Expense) (Details) $ in Millions	Dec. 31, 2016USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2,017	$ 1,592
2,018	1,585.2
2,019	1,506.5
2,020	1,502.8
2,021	$ 1,496.8

Fair Value Measurement (Assets

Fair Value Measurement (Assets and Liabilities That are Measured and Not Measured at Fair Value on a Recurring Basis) (Details) - Recurring Basis - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Estimated fair value
Financial assets:
Contingent consideration receivable	$ 15.6	$ 13.8
Derivative contracts	18	1.9
Total	114.9	32.9
Financial liabilities:
Derivative contracts	8.3	11.5
Contingent consideration payable	1,058	475.9
Total	1,066.3	487.4
Level 1
Financial assets:
Contingent consideration receivable	0	0
Derivative contracts	0	0
Total	69.4	17.2
Financial liabilities:
Derivative contracts	0	0
Contingent consideration payable	0	0
Total	0	0
Level 2
Financial assets:
Contingent consideration receivable	0	0
Derivative contracts	18	1.9
Total	29.9	1.9
Financial liabilities:
Derivative contracts	8.3	11.5
Contingent consideration payable	0	0
Total	8.3	11.5
Level 3
Financial assets:
Contingent consideration receivable	15.6	13.8
Derivative contracts	0	0
Total	15.6	13.8
Financial liabilities:
Derivative contracts	0	0
Contingent consideration payable	1,058	475.9
Total	1,058	475.9
Marketable equity securities | Estimated fair value
Financial assets:
Marketable securities	65.8	17.2
Marketable equity securities | Level 1
Financial assets:
Marketable securities	65.8	17.2
Marketable equity securities | Level 2
Financial assets:
Marketable securities	0	0
Marketable equity securities | Level 3
Financial assets:
Marketable securities	0	$ 0
Marketable debt securities | Estimated fair value
Financial assets:
Marketable securities	15.5
Marketable debt securities | Level 1
Financial assets:
Marketable securities	3.6
Marketable debt securities | Level 2
Financial assets:
Marketable securities	11.9
Marketable debt securities | Level 3
Financial assets:
Marketable securities	$ 0

Fair Value Measurement (Asset96

Fair Value Measurement (Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Change in the Fair Value of Contigent Consideration Receivable
Balance at January 1,	$ 13.8	$ 15.9
Change in fair value included in earnings	1.6	13.6
Other	0.2	(15.7)
Balance at December 31,	15.6	13.8	$ 15.9
Change in the Fair Value of Contigent Consideration Payable
Balance at January 1,	475.9	629.9
Additions	565.4	92.8
Change in fair value included in earnings	11.1	(149.9)	14.7
Other	5.6	(96.9)
Balance at December 31,	$ 1,058	$ 475.9	$ 629.9

Fair Value Measurement (Narrati

Fair Value Measurement (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Contingent consideration payable	$ 1,058	$ 475.9	$ 629.9
Contingent consideration payable, current (within other current liabilities)	65.1
Contingent consideration payable, non-current (within other non-current liabilities)	$ 992.9

Fair Value Measurement (Quantit

Fair Value Measurement (Quantitative Information About Recurring and Non-recurring Level 3 Fair Value Measurements) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair Value Inputs
Impairment of intangible assets	$ 8.9	$ 643.7	$ 190.3
Recurring Basis | Contingent Consideration Payable | Minimum
Fair Value Inputs
Assumed market participant discount rate	1.20%
Cumulative probability of milestones being achieved (in percent)	6.00%
Periods in which milestones are expected to be achieved	2,017
Forecast quarterly royalties payable on net sales of relevant products	$ 0.1
Recurring Basis | Contingent Consideration Payable | Maximum
Fair Value Inputs
Assumed market participant discount rate	10.50%
Cumulative probability of milestones being achieved (in percent)	90.00%
Periods in which milestones are expected to be achieved	2,040
Forecast quarterly royalties payable on net sales of relevant products	$ 7.5
Recurring Basis | Contingent Consideration Payable | Income approach (probability weighted discounted cash flow)
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Liabilities	1,058
Recurring Basis | Contingent Consideration Receivable | Income approach (probability weighted discounted cash flow)
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Assets	$ 15.6
Fair Value Inputs
Assumed market participant discount rate	8.00%
Recurring Basis | Contingent Consideration Receivable | Income approach (probability weighted discounted cash flow) | Minimum
Fair Value Inputs
Probability weightings applied to different sales scenarios (in percent)	10.00%
Future forecast consideration receivable based on contractual terms with purchaser	$ 0
Recurring Basis | Contingent Consideration Receivable | Income approach (probability weighted discounted cash flow) | Maximum
Fair Value Inputs
Probability weightings applied to different sales scenarios (in percent)	90.00%
Future forecast consideration receivable based on contractual terms with purchaser	$ 21

Fair Value Measurements (Financ

Fair Value Measurements (Financial Assets and Liabilities Not Measured on a Recurring Basis) (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Capital lease obligation	$ 354
Carrying amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Senior notes	12,039.2	$ 0
Capital lease obligation	353.6	13.4
Fair value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Senior notes	11,634	0
Capital lease obligation	353.6	13.4
Baxalta | Carrying amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Senior notes	5,064	0
Baxalta | Fair value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Senior notes	$ 5,067	$ 0

Financial Instruments (Narrativ

Financial Instruments (Narrative) (Details)	12 Months Ended
	Dec. 31, 2016USD ($)derivative	Dec. 31, 2015USD ($)
Derivative [Line Items]
Number of instruments | derivative	155
Deferred gains to be reclassified in next 12 months	$ 6,200,000
Potential effect of rights to offset associated with foreign exchange and interest rate swap	1,700,000
Derivative asset	16,300,000
Derivative liability	6,600,000
Designated as Hedging Instrument
Derivative [Line Items]
Derivative asset, fair value	4,400,000
Derivative liability, fair value	1,400,000
Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative asset, fair value	18,000,000
Derivative liability, fair value	8,300,000
Foreign exchange contracts | Designated as Hedging Instrument
Derivative [Line Items]
Derivative, notional amount	78,700,000
Derivative asset, fair value	4,200,000	$ 0
Amount of net gains/(losses) recognized in OCI	14,600,000	0
Foreign exchange contracts | Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative, notional amount	1,309,100,000	645,200,000
Interest Rate Swap | Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative, notional amount	5,100,000,000
Baxalta | Foreign exchange contracts | Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative, notional amount	776,400,000
Derivative asset, fair value	6,700,000	0
Baxalta | Cash Flow Hedging | Foreign exchange contracts | Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative, notional amount	11,200,000
Baxalta | Fair Value Hedging | Interest Rate Swap | Designated as Hedging Instrument
Derivative [Line Items]
Derivative, notional amount	1,000,000,000
Other Noncurrent Assets | Interest rate contracts | Designated as Hedging Instrument
Derivative [Line Items]
Derivative liability, fair value	1,100,000	0
Interest expense | Interest rate contracts
Derivative [Line Items]
Amount of losses recognized in income	3,200,000	0
Interest expense | Interest rate contracts | Designated as Hedging Instrument
Derivative [Line Items]
Amount of net gains/(losses) recognized in OCI	(6,000,000)	0
Interest expense | Interest rate contracts | Not Designated as Hedging Instrument
Derivative [Line Items]
Amount of losses recognized in income	$ 3,200,000	$ 0

Financial Instruments (Derivati

Financial Instruments (Derivative Income Statement Location, Gains & Losses) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Foreign exchange contracts | Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of net gains/(losses) recognized in OCI	$ 14.6	$ 0
Reclassification out of AOCI | Accumulated Net Gain (Loss) from Cash Flow Hedges | Foreign exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) reclassified from AOCI into income	4.9	0
Other income/(expense) | Foreign exchange contracts | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of net gains/(losses) recognized in income	(40.2)	9.5
Interest expense | Interest rate contracts
Derivative Instruments, Gain (Loss) [Line Items]
Amount of net gains/(losses) recognized in income	(3.2)	0
Interest expense | Interest rate contracts | Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of net gains/(losses) recognized in OCI	(6)	0
Interest expense | Interest rate contracts | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of net gains/(losses) recognized in income	$ (3.2)	$ 0

Financial Instruments (Foreign

Financial Instruments (Foreign Exchange Risk and Its Classification on Balance Sheet) (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Assets	$ 4,400,000
Liabilities	1,400,000
Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Assets	18,000,000
Liabilities	8,300,000
Foreign exchange contracts | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Assets	4,200,000	$ 0
Foreign exchange contracts | Designated as Hedging Instrument | Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Assets	4,300,000
Foreign exchange contracts | Designated as Hedging Instrument | Accounts payable and accrued expenses
Derivatives, Fair Value [Line Items]
Liabilities	100,000
Foreign exchange contracts | Not Designated as Hedging Instrument | Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Assets	13,600,000
Foreign exchange contracts | Not Designated as Hedging Instrument | Accounts payable and accrued expenses
Derivatives, Fair Value [Line Items]
Liabilities	6,900,000
Interest rate contracts | Designated as Hedging Instrument | Long term borrowings
Derivatives, Fair Value [Line Items]
Assets	100,000
Liabilities	$ 1,300,000

Accounts Payable and Accrued103

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Accounts Payable and Accrued Liabilities, Current [Abstract]
Accounts payable and accrued purchases	$ 911.9	$ 441.4
Accrued employee compensation and benefits payable	574.8	254.5
Accrued rebates	1,431.3	982.4
Accrued sales returns	118.4	128.3
Other accrued expenses	1,276	244
Accounts payable and accrued expenses, total	$ 4,312.4	$ 2,050.6

Borrowings and Capital Lease104

Borrowings and Capital Lease Obligations (Short-term Borrowings) (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Short-term Debt [Line Items]
Other borrowings and capital lease obligations (short term portion)	$ 23.2	$ 12.7
Short-term Debt, Total	3,068	1,512.7
Revolving Credit Facilities Agreement (RCF)
Short-term Debt [Line Items]
Borrowings under the Facilities Agreement	450	750
November 2015 Facilities Agreement
Short-term Debt [Line Items]
Borrowings under the Facilities Agreement	2,594.8	0
January 2016 Facilities Agreement
Short-term Debt [Line Items]
Borrowings under the Facilities Agreement	$ 0	$ 750

Borrowings and Capital Lease105

Borrowings and Capital Lease Obligations (Long-term Borrowings) (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Senior Notes	$ 12,039.2	$ 0
Capital lease obligations (long term portion)	347.2	12.2
Other borrowings	58	69.9
Long-term Debt and Capital Lease Obligations	19,899.8	82.1
Total obligations	22,967.8	1,594.8
November 2015 Facilities Agreement
Debt Instrument [Line Items]
Borrowings under the November 2015 Facilities Agreement	2,391.8	0
Baxalta
Debt Instrument [Line Items]
Senior Notes	$ 5,063.6	$ 0

Borrowings and Capital Lease106

Borrowings and Capital Lease Obligations (Narrative) (Details)

Jan. 30, 2017USD ($)

Nov. 02, 2016USD ($)

Jul. 11, 2016

Feb. 22, 2016USD ($)

Nov. 02, 2015USD ($)contract

Sep. 28, 2015USD ($)

Jan. 11, 2015USD ($)

Dec. 12, 2014USD ($)

Dec. 31, 2016USD ($)

Dec. 31, 2015USD ($)

Dec. 31, 2014USD ($)

Sep. 23, 2016USD ($)

Jun. 03, 2016USD ($)

Jan. 11, 2016USD ($)contract

Line of Credit Facility [Line Items]

Short-term borrowings and capital lease obligations

$ 3,068,000,000

$ 1,512,700,000

Repayment of lines of credit

16,404,300,000

$ 3,110,900,000

$ 1,461,800,000

Capital lease obligation

354,000,000

Baxalta

Line of Credit Facility [Line Items]

Face amount

5,000,000,000

January 2016 Facilities Agreement

Line of Credit Facility [Line Items]

Facility agreement total amount

$ 18,000,000,000

Number of term loan facilities | contract

2

January 2015 Facility Agreement

Line of Credit Facility [Line Items]

Facility agreement initiation date

Jan. 11, 2015

Facility agreement expiration date

Jul. 11, 2016

Jan. 10, 2016

Facility agreement total amount

$ 850,000,000

Maturity extension option

6 months

Repayment of lines of credit

$ 100,000,000

$ 100,000,000

November 2015 Facilities Agreement

Line of Credit Facility [Line Items]

Facility agreement initiation date

Nov. 2, 2015

Net Debt to EBITDA ratio

3.5

Facility agreement total amount

$ 5,600,000,000

Number of term loan facilities | contract

3

Repayment of lines of credit

$ 600,000,000

November 2015 Facilities Agreement | Increase of Net Debt to EBITDA ratio for the Relevant Period in which an acquisiton was completed

Line of Credit Facility [Line Items]

Net Debt to EBITDA ratio

5.5

November 2015 Facilities Agreement | Increase of Net Debt to EBITDA ratio for the first Relevant Period in which an acquisiton was completed

Line of Credit Facility [Line Items]

Net Debt to EBITDA ratio

5

November 2015 Facilities Agreement | Increase of Net Debt to EBITDA ratio for the second Relevant Period in which an acquisiton was completed

Line of Credit Facility [Line Items]

Net Debt to EBITDA ratio

4.5

Maximum | November 2015 Facilities Agreement

Line of Credit Facility [Line Items]

Net Debt to EBITDA ratio

4

November 2015 Facility A | November 2015 Facilities Agreement

Line of Credit Facility [Line Items]

Basis spread on variable rate

0.55%

November 2015 Facility B | November 2015 Facilities Agreement

Line of Credit Facility [Line Items]

Facility agreement expiration date

Nov. 2, 2017

Basis spread on variable rate

0.65%

Term loan facility

$ 2,200,000,000

November 2015 Facility B | November 2015 Facilities Agreement | Subsequent Event

Line of Credit Facility [Line Items]

Repayment of lines of credit

$ 400,000,000

November 2015 Facility C | November 2015 Facilities Agreement

Line of Credit Facility [Line Items]

Facility agreement expiration date

Nov. 2, 2018

Basis spread on variable rate

0.75%

Term loan facility

$ 2,400,000,000

January 2016 Facility B | January 2016 Facilities Agreement

Line of Credit Facility [Line Items]

Term loan facility

$ 5,000,000,000

January 2016 Facility A | January 2016 Facilities Agreement

Line of Credit Facility [Line Items]

Term loan facility

$ 13,000,000,000

Long-term borrowings

$ 12,390,000,000

Revolving Credit Facilities Agreement (RCF)

Line of Credit Facility [Line Items]

Face amount

$ 2,100,000,000

Facility agreement initiation date

Dec. 12, 2014

Short-term borrowings and capital lease obligations

450,000,000

Facility agreement expiration date

Dec. 12, 2021

Swingline Facility

$ 250,000,000

Basis spread on variable rate

0.30%

Rate of commitment fee, of the applicable interest rate margin

35.00%

Net Debt to EBITDA ratio

3.5

Revolving Credit Facilities Agreement (RCF) | Increase of Net Debt to EBITDA ratio for the Relevant Period in which an acquisiton was completed

Line of Credit Facility [Line Items]

Net Debt to EBITDA ratio

5.5

Revolving Credit Facilities Agreement (RCF) | Increase of Net Debt to EBITDA ratio for the first Relevant Period in which an acquisiton was completed

Line of Credit Facility [Line Items]

Net Debt to EBITDA ratio

5

Revolving Credit Facilities Agreement (RCF) | Increase of Net Debt to EBITDA ratio for the second Relevant Period in which an acquisiton was completed

Line of Credit Facility [Line Items]

Net Debt to EBITDA ratio

4.5

Revolving Credit Facilities Agreement (RCF) | Base Currency Amount Equal to $700million

Line of Credit Facility [Line Items]

Rate of utilization fee

0.10%

Revolving Credit Facilities Agreement (RCF) | Base Currency amount exceeds $700m but equal or less than $1400m

Line of Credit Facility [Line Items]

Rate of utilization fee

0.15%

Revolving Credit Facilities Agreement (RCF) | Base currency amount exceeds $1400m

Line of Credit Facility [Line Items]

Rate of utilization fee

0.30%

Revolving Credit Facilities Agreement (RCF) | Minimum

Line of Credit Facility [Line Items]

Utilization fee, base amount

$ 700,000,000

Revolving Credit Facilities Agreement (RCF) | Maximum

Line of Credit Facility [Line Items]

Utilization fee, base amount

$ 1,400,000,000

Net Debt to EBITDA ratio

4

Senior Notes | Baxalta

Line of Credit Facility [Line Items]

Face amount

$ 5,000,000,000

Senior Notes | SAIIDAC Notes

Line of Credit Facility [Line Items]

Face amount

$ 12,100,000,000

Redemption option one

100.00%

Redemption option two

101.00%

Term Loans | November 2015 Facilities Agreement - Exercise Option [Member]

Line of Credit Facility [Line Items]

Facility agreement total amount

400,000,000

Term Loans | November 2015 Facilities Agreement

Line of Credit Facility [Line Items]

Facility agreement total amount

1,000,000,000

Term Loans | November 2015 Facility A | November 2015 Facilities Agreement

Line of Credit Facility [Line Items]

Facility agreement total amount

$ 400,000,000

Shire Acquisitions Investment Ireland Designated Activity Company | Senior Notes

Line of Credit Facility [Line Items]

Face amount

$ 12,100,000,000

Deferred finance costs

$ 60,800,000

Borrowings and Capital Lease107

Borrowings and Capital Lease Obligations (Maturities of Debt) (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
2,017	$ 3,072.6
2,018	3,217.2
2,019	3,341.3
2,020	1,035.3
2,021	3,320.5
Thereafter	9,116.1
Total obligations	23,103
Less: Deferred financing costs	(135.2)
Total obligations	$ 22,967.8	$ 1,594.8

Borrowings and Capital Lease108

Borrowings and Capital Lease Obligations (Senior Notes Issued by SAIIDAC) (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Carrying amount	$ 22,967.8	$ 1,594.8
Shire Acquisitions Investment Ireland Designated Activity Company | Senior Notes
Debt Instrument [Line Items]
Aggregate Amount	12,100
Carrying amount	12,039.2
Shire Acquisitions Investment Ireland Designated Activity Company | Senior Notes | Fixed-rate notes due 2019
Debt Instrument [Line Items]
Aggregate Amount	$ 3,300
Coupon Rate	1.90%
Effective Interest Rate	2.05%
Carrying amount	$ 3,287.5
Shire Acquisitions Investment Ireland Designated Activity Company | Senior Notes | Fixed-rate notes due 2021
Debt Instrument [Line Items]
Aggregate Amount	$ 3,300
Coupon Rate	2.40%
Effective Interest Rate	2.53%
Carrying amount	$ 3,283
Shire Acquisitions Investment Ireland Designated Activity Company | Senior Notes | Fixed-rate notes due 2023
Debt Instrument [Line Items]
Aggregate Amount	$ 2,500
Coupon Rate	2.875%
Effective Interest Rate	2.97%
Carrying amount	$ 2,487.9
Shire Acquisitions Investment Ireland Designated Activity Company | Senior Notes | Fixed-rate notes due 2026
Debt Instrument [Line Items]
Aggregate Amount	$ 3,000
Coupon Rate	3.20%
Effective Interest Rate	3.30%
Carrying amount	$ 2,980.8

Borrowings and Capital Lease109

Borrowings and Capital Lease Obligations (Senior Notes Related to Baxalta Acquisition) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Carrying amount	$ 22,967,800,000	$ 1,594,800,000
Baxalta
Debt Instrument [Line Items]
Aggregate Amount	5,000,000,000
Baxalta | Senior Notes
Debt Instrument [Line Items]
Aggregate Amount	5,000,000,000
Carrying amount	5,063,600,000
Baxalta | Senior Notes | Variable-rate notes due 2018
Debt Instrument [Line Items]
Aggregate Amount	$ 375,000,000
Effective Interest Rate	2.20%
Carrying amount	$ 371,600,000
Baxalta | Senior Notes | Variable-rate notes due 2018 | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate	0.78%
Baxalta | Senior Notes | Fixed-rate notes due 2018
Debt Instrument [Line Items]
Aggregate Amount	$ 375,000,000
Coupon Rate	2.00%
Effective Interest Rate	2.00%
Carrying amount	$ 374,800,000
Baxalta | Senior Notes | Fixed-rate notes due 2020
Debt Instrument [Line Items]
Aggregate Amount	$ 1,000,000,000
Coupon Rate	2.875%
Effective Interest Rate	2.80%
Carrying amount	$ 1,004,300,000
Baxalta | Senior Notes | Fixed-rate notes due 2022
Debt Instrument [Line Items]
Aggregate Amount	$ 500,000,000
Coupon Rate	3.60%
Effective Interest Rate	3.30%
Carrying amount	$ 508,400,000
Baxalta | Senior Notes | Fixed-rate notes due 2025
Debt Instrument [Line Items]
Aggregate Amount	$ 1,750,000,000
Coupon Rate	4.00%
Effective Interest Rate	3.90%
Carrying amount	$ 1,772,800,000
Baxalta | Senior Notes | Fixed-rate notes due 2045
Debt Instrument [Line Items]
Aggregate Amount	$ 1,000,000,000
Coupon Rate	5.25%
Effective Interest Rate	5.10%
Carrying amount	$ 1,031,700,000

Retirement and Other Benefit110

Retirement and Other Benefit Programs (Change in Benefit Obligations and Fair Value of Plan Assets) (Details) - Baxalta - USD ($) $ in Millions	7 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2016	Jun. 03, 2016
Benefit obligations
End of Period	$ 965.5	$ 965.5
Fair value of plan assets
End of period	426.3	426.3
Amounts recognized in the Consolidated Balance Sheets
Net liability recognized			$ (610.4)
U.S. pensions
Benefit obligations
Beginning of period		0
Assumption of benefit obligations from Baxalta		441.6
Service cost	13	13
Interest cost	11.1	11.1
Participant contributions		0
Actuarial (gain) / loss		10.6
Benefit payments		(1.6)
Settlements		0
Curtailments		(73.4)
Foreign exchange		0
Other		4
End of Period	384.1	384.1
Fair value of plan assets
Beginning of period		0
Assumption of plan assets from Baxalta		218
Actual return on plan assets		8.3
Employer contributions		0.4
Settlements		0
Foreign exchange		0
Other		3.3
End of period	228.4	228.4
Funded status	(155.7)	(155.7)
Amounts recognized in the Consolidated Balance Sheets
Other current liabilities	(0.6)	(0.6)
Other non-current liabilities	(155.1)	(155.1)
Net liability recognized	(155.7)	(155.7)
International pensions
Benefit obligations
Beginning of period		0
Assumption of benefit obligations from Baxalta		503.8
Service cost	18.6	18.6
Interest cost	3.2	3.2
Participant contributions		3.2
Actuarial (gain) / loss		29.8
Benefit payments		(9.1)
Settlements		(3.2)
Curtailments		0
Foreign exchange		(18.3)
Other		113
End of Period	581.4	581.4
Fair value of plan assets
Beginning of period		0
Assumption of plan assets from Baxalta		140.5
Actual return on plan assets		2
Employer contributions		12.3
Settlements		(3.2)
Foreign exchange		(3.8)
Other		56
End of period	197.9	197.9
Funded status	(383.5)	(383.5)
Amounts recognized in the Consolidated Balance Sheets
Other current liabilities	(8.8)	(8.8)
Other non-current liabilities	(374.7)	(374.7)
Net liability recognized	(383.5)	(383.5)
OPEB
Benefit obligations
Beginning of period		0
Assumption of benefit obligations from Baxalta		23.5
Service cost	0.8	0.8
Interest cost	0.6	0.6
Participant contributions		0
Actuarial (gain) / loss		(0.1)
Benefit payments		0
Settlements		0
Curtailments		0
Foreign exchange		0
Other		0
End of Period	25	25
Fair value of plan assets
Beginning of period		0
Assumption of plan assets from Baxalta		0
Actual return on plan assets		0
Employer contributions		0
Settlements		0
Foreign exchange		0
Other		0
End of period	0	0
Funded status	(25)	(25)
Amounts recognized in the Consolidated Balance Sheets
Other current liabilities	(0.2)	(0.2)
Other non-current liabilities	(24.8)	(24.8)
Net liability recognized	$ (25)	$ (25)

Retirement and Other Benefit111

Retirement and Other Benefit Programs (Narrative) (Details) - USD ($)	7 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Baxalta
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Target plan asset allocations range variance		5.00%
U.S. pensions | Baxalta
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Accumulated benefit obligation	$ 373,200,000	$ 373,200,000
Accumulated other comprehensive income (loss), net gains (losses)	14,000,000	14,000,000
Loss arising during the year		$ (52,500,000)
Curtailment gains (losses)	$ 69,400,000
Discount rate	4.20%	4.20%
Employer contributions		$ 400,000
International pensions | Baxalta
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Accumulated benefit obligation	$ 457,900,000	457,900,000
Accumulated other comprehensive income (loss), net gains (losses)	10,300,000	10,300,000
Loss arising during the year		$ 14,200,000
Curtailment gains (losses)	$ (20,000,000)
Discount rate	1.00%	1.00%
Employer contributions		$ 12,300,000
Expected contributions in current year		1,000,000
OPEB | Baxalta
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Accumulated other comprehensive income (loss), net gains (losses)	$ 100,000	100,000
Loss arising during the year		$ 0
Curtailment gains (losses)	$ 0
Discount rate	4.30%	4.30%
Employer contributions		$ 0
Expected net cash outflow in current year		$ 11,000,000
Equity Securities | Baxalta
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Target allocation for plan assets		75.00%
Fixed Income Securities | Baxalta
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Target allocation for plan assets		25.00%
Switzerland | International pensions | Baxalta
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Loss arising during the year		$ 34,600,000
Curtailment gains (losses)	$ (20,000,000)
United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Expenses recognized for defined contribution plan		$ 68,100,000	$ 38,900,000	$ 34,300,000

Retirement and Other Benefit112

Retirement and Other Benefit Programs (Summary of Funded Status of Plan) (Details) - Baxalta - USD ($) $ in Millions	Dec. 31, 2016	Jun. 03, 2016
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets		$ 358.5
U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
ABO	$ 373.2
Fair value of plan assets	228.4
International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
ABO	437.5
Fair value of plan assets	$ 176.2

Retirement and Other Benefit113

Retirement and Other Benefit Programs (Expected Net Pension and OPEB Plan Payments for the Next 10 Years) (Details) - Baxalta $ in Millions	Dec. 31, 2016USD ($)
U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
2,017	$ 3.6
2,018	5.7
2,019	7.6
2,020	9.7
2,021	11.7
2022 through 2026	85.3
Total expected benefit payments for next 10 years	123.6
International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
2,017	21.1
2,018	18.6
2,019	19.9
2,020	20.1
2,021	22.7
2022 through 2026	124.1
Total expected benefit payments for next 10 years	226.5
OPEB
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
2,017	0.2
2,018	0.3
2,019	0.5
2,020	0.6
2,021	0.7
2022 through 2026	4.6
Total expected benefit payments for next 10 years	$ 6.9

Retirement and Other Benefit114

Retirement and Other Benefit Programs (Summary of Amounts Recorded in AOCI) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2016USD ($)
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Gain arising during the year, tax expense	$ 3.8
Baxalta | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Gain (loss) arising during the year, net of tax expense of $30.9 million for U.S. plans and $3.8 million for international plans	52.5
Reclassification of gain to income statement, net of tax benefit of $25.9 million for U.S. plans	(43.5)
Pension and other employee benefits gain (loss), net of tax	9
Gain arising during the year, tax expense	30.9
Reclassification of gain to income statement, tax benefit	25.9
Baxalta | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Gain (loss) arising during the year, net of tax expense of $30.9 million for U.S. plans and $3.8 million for international plans	(14.2)
Reclassification of gain to income statement, net of tax benefit of $25.9 million for U.S. plans	0
Pension and other employee benefits gain (loss), net of tax	(14.2)
Baxalta | OPEB
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Gain (loss) arising during the year, net of tax expense of $30.9 million for U.S. plans and $3.8 million for international plans	0
Reclassification of gain to income statement, net of tax benefit of $25.9 million for U.S. plans	0
Pension and other employee benefits gain (loss), net of tax	$ 0

Retirement and Other Benefit115

Retirement and Other Benefit Programs (Summary of Net Periodic Benefit Cost) (Details) - Baxalta - USD ($) $ in Millions	7 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2016
U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Service cost	$ 13	$ 13
Interest cost	11.1	11.1
Expected return on plan assets	(8.9)
Curtailment and other	(69.4)
Net periodic benefit cost	(54.2)
International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Service cost	18.6	18.6
Interest cost	3.2	3.2
Expected return on plan assets	(3.9)
Curtailment and other	20
Net periodic benefit cost	37.9
OPEB
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Service cost	0.8	0.8
Interest cost	0.6	$ 0.6
Expected return on plan assets	0
Curtailment and other	0
Net periodic benefit cost	$ 1.4

Retirement and Other Benefit116

Retirement and Other Benefit Programs (Weighted-Average Assumptions Used for Benefit Obligation and Net Periodic Benefit Cost) (Details)	12 Months Ended
	Dec. 31, 2016
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]
Expected return on plan assets	0.00%
Baxalta | U.S. pensions
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]
Discount rate	4.20%
Rate of compensation increase	3.80%
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]
Discount rate	0.00%
Rate of compensation increase	0.00%
Baxalta | International pensions
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]
Discount rate	1.00%
Rate of compensation increase	2.90%
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]
Discount rate	0.00%
Rate of compensation increase	0.00%
Baxalta | OPEB
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]
Discount rate	4.30%
Annual rate of increase in the per-capita cost	6.30%
Rate decreased to	5.00%
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]
Discount rate	0.00%
Annual rate of increase in the per-capita cost	0.00%
Rate decreased to	0.00%

Retirement and Other Benefit117

Retirement and Other Benefit Programs (Fair Value Measurements of Plan Assets and Liabilities) (Details) - Baxalta - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	$ 426.3
International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	197.9	$ 0
U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	228.4	$ 0
Other Holdings | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	71.4
Cash and cash equivalents | Fixed Income Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	6.2
Cash and cash equivalents | Fixed Income Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	5.7
Collective trust funds | Fixed Income Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	46.4
Collective trust funds | Equity Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	100.4
Mutual funds | Fixed Income Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	24.4
Mutual funds | Fixed Income Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	11.4
Mutual funds | Equity Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	40.6
Mutual funds | Equity Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	53.4
Hedge funds | Equity Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	11.1
Government agency issues | Fixed Income Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0.6
Corporate bonds | Fixed Income Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	21.1
Common stock | Equity Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	21.5
Large cap | Equity Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	19.9
Mid cap | Equity Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	1.6
Real estate funds | Equity Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	12.1
Level 1 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	122.8
Level 1 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	16.5
Level 1 | Other Holdings | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 1 | Cash and cash equivalents | Fixed Income Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	6.2
Level 1 | Cash and cash equivalents | Fixed Income Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 1 | Collective trust funds | Fixed Income Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 1 | Collective trust funds | Equity Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 1 | Mutual funds | Fixed Income Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	24.4
Level 1 | Mutual funds | Fixed Income Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 1 | Mutual funds | Equity Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	40.6
Level 1 | Mutual funds | Equity Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	16.5
Level 1 | Hedge funds | Equity Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 1 | Government agency issues | Fixed Income Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0.6
Level 1 | Corporate bonds | Fixed Income Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	21.1
Level 1 | Common stock | Equity Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	21.5
Level 1 | Large cap | Equity Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	19.9
Level 1 | Mid cap | Equity Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	1.6
Level 1 | Real estate funds | Equity Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	8.4
Level 2 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	71.4
Level 2 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 2 | Other Holdings | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	71.4
Level 2 | Cash and cash equivalents | Fixed Income Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 2 | Cash and cash equivalents | Fixed Income Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 2 | Collective trust funds | Fixed Income Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 2 | Collective trust funds | Equity Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 2 | Mutual funds | Fixed Income Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 2 | Mutual funds | Fixed Income Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 2 | Mutual funds | Equity Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 2 | Mutual funds | Equity Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 2 | Hedge funds | Equity Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 2 | Government agency issues | Fixed Income Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 2 | Corporate bonds | Fixed Income Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 2 | Common stock | Equity Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 2 | Large cap | Equity Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 2 | Mid cap | Equity Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 2 | Real estate funds | Equity Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 3 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 3 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 3 | Other Holdings | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 3 | Cash and cash equivalents | Fixed Income Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 3 | Cash and cash equivalents | Fixed Income Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 3 | Collective trust funds | Fixed Income Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 3 | Collective trust funds | Equity Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 3 | Mutual funds | Fixed Income Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 3 | Mutual funds | Fixed Income Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 3 | Mutual funds | Equity Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 3 | Mutual funds | Equity Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 3 | Hedge funds | Equity Securities | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 3 | Government agency issues | Fixed Income Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 3 | Corporate bonds | Fixed Income Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 3 | Common stock | Equity Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 3 | Large cap | Equity Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 3 | Mid cap | Equity Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 3 | Real estate funds | Equity Securities | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	$ 0

Retirement and Other Benefit118

Retirement and Other Benefit Programs (Plan Valuation Methods) (Details) - Baxalta	12 Months Ended
	Dec. 31, 2016
Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Valuation methodology	These largely consist of a short-term investment fund, U.S. dollars and foreign currency. The fair value of the short-term investment fund is based on the net asset value
Government agency issues
Defined Benefit Plan Disclosure [Line Items]
Valuation methodology	Values are based on quoted prices in an active market
Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Valuation methodology	Values are based on the valuation date in an active market
Common stock
Defined Benefit Plan Disclosure [Line Items]
Valuation methodology	Values are based on the closing prices on the valuation date in an active market
Mutual funds
Defined Benefit Plan Disclosure [Line Items]
Valuation methodology	Values are based on the net asset value of the units held in the respective fund which are obtained from active markets or as reported by the fund managers
Collective trust funds and hedge funds
Defined Benefit Plan Disclosure [Line Items]
Valuation methodology	Values are based on the net asset value of the units held at year end
Real estate funds
Defined Benefit Plan Disclosure [Line Items]
Valuation methodology	The value of these assets are either determined by the net asset value of the units held in the respective fund which are obtained from active markets or based on the net asset value of the underlying assets of the fund provided by the fund manager
Hedge funds | Other Holdings
Defined Benefit Plan Disclosure [Line Items]
Valuation methodology	These primarily consist of insurance contracts whose value is based on the underlying assets and other holdings valued primarily based on reputable pricing vendors that typically use pricing matrices or models

Retirement and Other Benefit119

Retirement and Other Benefit Programs (Funded and Unfunded Statuses of Plans) (Details) - Baxalta - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Plan assets	$ 426.3
Projected benefit obligation	$ 965.5
Funded status percentage	44.00%
U.S. pensions
Defined Benefit Plan Disclosure [Line Items]
Plan assets	$ 228.4	$ 0
Projected benefit obligation	384.1	0
U.S. pensions | Qualified plan
Defined Benefit Plan Disclosure [Line Items]
Plan assets	228.4
Projected benefit obligation	$ 352.8
Funded status percentage	65.00%
U.S. pensions | Nonqualified plan
Defined Benefit Plan Disclosure [Line Items]
Projected benefit obligation	$ 31.3
International pensions
Defined Benefit Plan Disclosure [Line Items]
Plan assets	197.9	0
Projected benefit obligation	581.4	$ 0
International pensions | Funded plans
Defined Benefit Plan Disclosure [Line Items]
Plan assets	197.9
Projected benefit obligation	$ 413.7
Funded status percentage	48.00%
International pensions | Unfunded plans
Defined Benefit Plan Disclosure [Line Items]
Projected benefit obligation	$ 167.7

Accumulated Other Comprehens120

Accumulated Other Comprehensive Loss (Rollforward of Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
AOCI Attributable to Parent, Net of Tax [Roll Forward]
As of January, 1	$ 9,829.1	$ 8,662.9	$ 5,366
Current period change:
Net current period other comprehensive (loss)/income	(1,313.8)	(152.3)	(141.7)
As of December 31,	28,948	9,829.1	8,662.9
Accumulated other comprehensive loss
AOCI Attributable to Parent, Net of Tax [Roll Forward]
As of January, 1	(183.8)	(31.5)	110.2
Current period change:
Other comprehensive (loss)/income before reclassification	(1,266.8)
Gain transferred to the income statement (within Other income, net) on disposal of available-for-sale securities	(47)
Net current period other comprehensive (loss)/income	(1,313.8)	(152.3)	(141.7)
As of December 31,	(1,497.6)	(183.8)	(31.5)
Foreign currency translation adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
As of January, 1	(182.1)	(25.7)
Current period change:
Other comprehensive (loss)/income before reclassification	(1,323.3)
Gain transferred to the income statement (within Other income, net) on disposal of available-for-sale securities	0
Net current period other comprehensive (loss)/income	(1,323.3)	(156.4)
As of December 31,	(1,505.4)	(182.1)	(25.7)
Hedging activities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
As of January, 1	0
Current period change:
Other comprehensive (loss)/income before reclassification	38.3
Gain transferred to the income statement (within Other income, net) on disposal of available-for-sale securities	(43.5)
Net current period other comprehensive (loss)/income	(5.2)
As of December 31,	(5.2)	0
Hedging activities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
As of January, 1	0
Current period change:
Other comprehensive (loss)/income before reclassification	9.9
Gain transferred to the income statement (within Other income, net) on disposal of available-for-sale securities	(3.5)
Net current period other comprehensive (loss)/income	6.4
As of December 31,	6.4	0
Unrealized holding gain/(loss) on available-for-sale securities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
As of January, 1	(1.7)	(5.8)
Current period change:
Other comprehensive (loss)/income before reclassification	8.3
Gain transferred to the income statement (within Other income, net) on disposal of available-for-sale securities	0
Net current period other comprehensive (loss)/income	8.3	4.1
As of December 31,	$ 6.6	$ (1.7)	$ (5.8)

Accumulated Other Comprehens121

Accumulated Other Comprehensive Loss (Reclassifications from Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Integration and acquisition costs									$ 883.9	$ 39.8	$ 158.8
Cost of sales	$ 1,053.6	$ 1,736.2	$ 778.1	$ 248.6	$ 250.5	$ 262.7	$ 228	$ 227.8	3,816.5	969	979.3
Income from continuing operations before income taxes and equity in (losses)/ earnings of equity method investees									486.1	1,385.8	3,336.2
Income taxes									126.1	(46.1)	(56.1)
Income from continuing operations, net of taxes	$ 475.9	$ (368.5)	$ 86.6	$ 409.5	$ 283.4	$ 477.1	$ 164.1	$ 412.9	603.5	$ 1,337.5	$ 3,282.8
Total reclassifications for the period									47
Hedging activities
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Integration and acquisition costs									69.4
Income from continuing operations before income taxes and equity in (losses)/ earnings of equity method investees									69.4
Income taxes									(25.9)
Income from continuing operations, net of taxes									43.5
Losses on hedging activities | Reclassification out of AOCI
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Income from continuing operations before income taxes and equity in (losses)/ earnings of equity method investees									4.9
Income taxes									(1.4)
Income from continuing operations, net of taxes									3.5
Losses on hedging activities | Foreign exchange contracts | Reclassification out of AOCI
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Cost of sales									$ 4.9

Earnings Per Share (Calculation

Earnings Per Share (Calculation of EPS) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Earnings Per Share [Abstract]
Income from continuing operations, net of taxes	$ 475.9	$ (368.5)	$ 86.6	$ 409.5	$ 283.4	$ 477.1	$ 164.1	$ 412.9	$ 603.5	$ 1,337.5	$ 3,282.8
(Loss)/ gain from discontinued operations	(18.6)	(18.3)	(248.7)	9.5	(2.8)	(24.3)	(4.5)	(2.5)	(276.1)	(34.1)	122.7
Net income / (loss)	$ 457.3	$ (386.8)	$ (162.1)	$ 419	$ 280.6	$ 452.8	$ 159.6	$ 410.4	$ 327.4	$ 1,303.4	$ 3,405.5
Schedule of Weighted Average Number of Shares
Basic (in shares)									770.1	590.4	586.7
Effect of dilutive shares:
Share based awards to employees (in shares)									6.1	2.7	4.6
Diluted (in shares)									776.2	593.1	591.3
Earning per ordinary share - basic
Earnings from continuing operations (in USD per share)	$ 0.53	$ (0.41)	$ 0.12	$ 0.69	$ 0.48	$ 0.81	$ 0.28	$ 0.70	$ 0.780	$ 2.27	$ 5.596
(Loss)/gain from discontinued operations (in USD per share)	(0.02)	(0.02)	(0.36)	0.02	(0.01)	(0.04)	(0.01)	0	(0.350)	(0.058)	0.209
Earnings per ordinary share - basic (in USD per share)	0.51	(0.43)	(0.24)	0.71	0.47	0.77	0.27	0.70	0.43	2.21	5.81
Earnings per ordinary share - diluted
Earnings from continuing operations (in USD per share)	0.52	(0.41)	0.12	0.69	0.48	0.80	0.28	0.70	0.770	2.255	5.552
(Loss)/gain from discontinued operations (in USD per share)	(0.02)	(0.02)	(0.36)	0.02	(0.01)	(0.04)	(0.01)	0	(0.350)	(0.058)	0.208
Earnings per ordinary share - diluted (in USD per share)	$ 0.50	$ (0.43)	$ (0.24)	$ 0.71	$ 0.47	$ 0.76	$ 0.27	$ 0.70	$ 0.42	$ 2.20	$ 5.76

Earnings Per Share (Antidilutiv

Earnings Per Share (Antidilutive Securities) (Details) - shares shares in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Stock Compensation Plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Share-based awards to employees	4.1	3.4	0.3

Taxation (Components of Pre-tax

Taxation (Components of Pre-tax Income) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Contingency [Line Items]
Income from continuing operations before income taxes and equity in (losses)/ earnings of equity method investees	$ 486.1	$ 1,385.8	$ 3,336.2
Ireland
Income Tax Contingency [Line Items]
Republic of Ireland	214.3	(11.4)	1,472
United States
Income Tax Contingency [Line Items]
Pre-tax income from continuing operations, foreign	(75.3)	975.8	1,025.9
Rest of the world
Income Tax Contingency [Line Items]
Pre-tax income from continuing operations, foreign	$ 347.1	$ 421.4	$ 838.3

Taxation (Pretax Income from Co

Taxation (Pretax Income from Continuing Operations and Provision for Income Taxes) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current income taxes:
Total current taxes	$ 422.9	$ 227.6	$ 26.2
Deferred taxes:
Total deferred taxes	(549)	(181.5)	29.9
Total income taxes	(126.1)	46.1	56.1
Republic of Ireland
Current income taxes:
Current domestic tax expense (benefit)	5.2	0.8	0
Deferred taxes:
Deferred domestic tax expense (benefit)	18.2	(38.8)	0
U.S. federal tax
Current income taxes:
Current foreign tax expense (benefit)	318.6	191.7	291.8
Deferred taxes:
Deferred foreign tax expense (benefit)	(433.8)	(151.2)	39.7
Other
Current income taxes:
Other, current	68.9	17.8	(290.9)
Deferred taxes:
Other, deferred	(59.3)	10.2	(6.9)
U.S. state and local taxes
Current income taxes:
Current foreign tax expense (benefit)	30.2	17.3	25.3
Deferred taxes:
Deferred foreign tax expense (benefit)	$ (74.1)	$ (1.7)	$ (2.9)

Taxation (Effective Income Tax

Taxation (Effective Income Tax Rate Reconciliation, and Statutory Tax Rates) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Effective Income Tax Rate Reconciliation
Income from continuing operations before income taxes and equity in (losses)/ earnings of equity method investees (in millions)	$ 486.1	$ 1,385.8	$ 3,336.2
Statutory tax rate	25.00%	25.00%	25.00%
U.S. R&D credit	(25.90%)	(7.70%)	(2.50%)
Intra-group items	(44.40%)	(18.60%)	(6.30%)
Other permanent items	4.50%	1.10%	(0.20%)
U.S. Domestic Manufacturing Deduction	(4.00%)	(1.60%)	(0.50%)
Acquisition Related Costs	8.50%	1.10%	0.70%
Irish Treasury Operations	(8.60%)	0.60%	0.70%
Change in valuation allowance	7.90%	1.00%	0.80%
Difference in taxation rates	13.00%	7.30%	3.40%
Change in provisions for uncertain tax positions	(1.50%)	(0.40%)	0.20%
Prior year adjustment	1.00%	(1.60%)	0.10%
Change in fair value of contingent consideration	3.70%	(3.80%)	0.30%
Change in tax rates	(5.10%)	0.90%	0.50%
Receipt of break fee	(0.00%)	(0.00%)	(12.30%)
Settlement with Canadian revenue authorities	(0.00%)	(0.00%)	(7.00%)
Other	0.00%	0.00%	(1.20%)
Provision for income taxes on continuing operations	(25.90%)	3.30%	1.70%

Taxation (Narrative) (Details)

Taxation (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Contingency [Line Items]
Undistributed earnings of foreign subsidiaries	$ 16,600	$ 11,300
Gross value of NOLs and capital losses	10,843.1	5,562.3
Net operating losses that result from excess stock based compensation	38.9	30.4
Unrecognized tax benefits that would impact effective tax rate if recognized	$ 227	207	$ 181
Statutory tax rate	25.00%
Future decrease in the unrecognized tax benefit	$ 50
Income tax penalties and interest expense	4.2	1	(103.1)
Income tax penalties and interest expense accrued	30.8	26.5	25.8
Valuation Allowances	569.4	416.1
Net increase (decrease) in valuation allowances	$ 153.3
Canada
Income Tax Contingency [Line Items]
Statutory tax rate	15.00%
Singapore
Income Tax Contingency [Line Items]
Statutory tax rate	17.00%
Ireland
Income Tax Contingency [Line Items]
Valuation Allowances	$ 22.4	22.2
United States
Income Tax Contingency [Line Items]
Statutory tax rate	35.00%
Valuation Allowances	$ 155.1	125.9
Pre-tax income from continuing operations, foreign	$ (75.3)	975.8	1,025.9
Switzerland
Income Tax Contingency [Line Items]
Statutory tax rate	8.50%
Valuation Allowances	$ 176.8	131.5
United Kingdom
Income Tax Contingency [Line Items]
Statutory tax rate	20.00%
France
Income Tax Contingency [Line Items]
Statutory tax rate	33.30%
Germany
Income Tax Contingency [Line Items]
Statutory tax rate	15.00%
Italy
Income Tax Contingency [Line Items]
Statutory tax rate	27.50%
Japan
Income Tax Contingency [Line Items]
Statutory tax rate	23.90%
Luxembourg
Income Tax Contingency [Line Items]
Statutory tax rate	21.00%
Netherlands
Income Tax Contingency [Line Items]
Statutory tax rate	25.00%
Belgium
Income Tax Contingency [Line Items]
Statutory tax rate	33.99%
Spain
Income Tax Contingency [Line Items]
Statutory tax rate	28.00%
Sweden
Income Tax Contingency [Line Items]
Statutory tax rate	22.00%
Rest of the world
Income Tax Contingency [Line Items]
Pre-tax income from continuing operations, foreign	$ 347.1	421.4	$ 838.3
Other foreign tax jurisdictions
Income Tax Contingency [Line Items]
Valuation Allowances	215.1	$ 136.5
Baxalta
Income Tax Contingency [Line Items]
Deferred tax liability	503
Baxalta | Rest of the world
Income Tax Contingency [Line Items]
Pre-tax income from continuing operations, foreign	1,500
Operating Loss Carryforwards
Income Tax Contingency [Line Items]
Net increase (decrease) in valuation allowances	166.4
US State Tax Losses
Income Tax Contingency [Line Items]
Net increase (decrease) in valuation allowances	$ (13)

Taxation (Rollforward of Unreco

Taxation (Rollforward of Unrecognized Tax Benefits) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Reconciliation of Unrecognized Tax Benefits
Balance as of January 1	$ 216.3	$ 207.8	$ 355.2
Increases based on tax positions related to the current year	34.3	27	20.3
Decreases based on tax positions taken in the current year	0	0	0
Increases for tax positions taken in prior years	0.5	3.9	64.2
Decreases for tax positions taken in prior years	(17.8)	(30.6)	(211)
Acquisition related items	29.5	17.9	0
Decreases resulting from settlements with the taxing authorities	(24.4)	(1.2)	(9.4)
Decreases as a result of expiration of the statute of limitations	(2.4)	(4.4)	(0.6)
Foreign currency translation adjustments	0.3	(4.1)	(10.9)
Balance as of December 31	$ 236.3	$ 216.3	$ 207.8

Taxation (Deferred Tax Assets a

Taxation (Deferred Tax Assets and Liabilities, and Valuation Allowances) (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Deferred revenue	$ 16.8	$ 2.4
Inventory & warranty provisions	88.7	36.1
Losses carried forward (including tax credits)	1,907.3	980.3
Provisions for sales deductions and doubtful accounts	191.6	178
Intangible assets	79.7	5.9
Share-based compensation	137.5	40.6
Excess of tax value over book value of assets	14.2	0.6
Accruals and provisions	448.6	130.4
Other	78.5	19.3
Gross deferred tax assets	2,962.9	1,393.6
Less: valuation allowance	(569.4)	(416.1)
Deferred tax assets, net	2,393.5	977.5
Deferred tax liabilities:
Intangible assets	(9,073.4)	(2,850.6)
Excess of book value over tax value in inventory	(150.3)	(10.3)
Excess of book value over tax value of assets and investments	(1,304.2)	(153.9)
Other	(91.6)	(47.6)
Net deferred tax liabilities	(8,226)	(2,084.9)
Balance sheet classifications:
Deferred tax assets - non-current	96.7	121
Deferred tax liabilities - non-current	$ (8,322.7)	$ (2,205.9)

Taxation (Operating Loss and Ta

Taxation (Operating Loss and Tax Credit Carryforwards, and Their Expiration Dates) (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Tax Credit Carryforward [Line Items]
Tax credit carryforwards	$ 1,907.3	$ 980.3
Expirations of Tax Benefit Carryforwards
Within 1 year	0.3
Within 1 to 2 years	2.6
Within 2 to 3 years	45.5
Within 3 to 4 years	12.8
Within 4 to 5 years	52.6
Within 5 to 6 years	55.3
After 6 years	1,269.6
Indefinitely	468.6
U.S. federal tax
Tax Credit Carryforward [Line Items]
Tax credit carryforwards	687.1	149.3
US state
Tax Credit Carryforward [Line Items]
Tax credit carryforwards	170.7	77.2
Republic of Ireland
Tax Credit Carryforward [Line Items]
Tax credit carryforwards	45.1	61.2
Foreign tax jurisdictions
Tax Credit Carryforward [Line Items]
Tax credit carryforwards	614.9	434.9
R&D and other tax credits
Tax Credit Carryforward [Line Items]
Tax credit carryforwards	$ 389.5	$ 257.7

Segment Reporting (Revenues and

Segment Reporting (Revenues and Long-lived Assets by Geographic Location) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 3,806.1	$ 3,452.1	$ 2,429.1	$ 1,709.3	$ 1,715.7	$ 1,655	$ 1,557.6	$ 1,488.4	$ 11,396.6	$ 6,416.7	$ 6,022.1
Long-Lived Assets	6,574.6				835.2				6,574.6	835.2
Ireland
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									41.6	14.1	18.5
Long-Lived Assets	41.2				1.7				41.2	1.7
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									7,666.9	4,659.2	4,174.1
Long-Lived Assets	6,449.4				751.3				6,449.4	751.3
Rest of the world
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									3,688.1	1,743.4	$ 1,829.5
Long-Lived Assets	$ 84				$ 82.2				$ 84	$ 82.2

Segment Reporting (Revenues 132

Segment Reporting (Revenues and Accounts Receivable by Major Customers) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenue, Major Customer [Line Items]
Product sales	$ 10,885.8	$ 6,099.9	$ 5,830.4
AmerisourceBergen Corp
Revenue, Major Customer [Line Items]
Product sales	$ 1,695.3	$ 1,048.3	$ 759.2
Revenue by major customer, percent	16.00%	17.00%	13.00%
Accounts Receivable, Net	$ 427.2	$ 171.5
McKesson Corp.
Revenue, Major Customer [Line Items]
Product sales	$ 1,336.7	$ 1,044.1	$ 1,021
Revenue by major customer, percent	12.00%	17.00%	18.00%
Accounts Receivable, Net	$ 312.9	$ 193.1
Cardinal Health Inc.
Revenue, Major Customer [Line Items]
Product sales	$ 1,052.2	$ 796.9	$ 979.9
Revenue by major customer, percent	10.00%	13.00%	17.00%
Accounts Receivable, Net	$ 278.4	$ 181.7

Segment Reporting (Revenue by P

Segment Reporting (Revenue by Product) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenue from External Customer [Line Items]
Product sales	$ 10,885.8	$ 6,099.9	$ 5,830.4
Hematology
Revenue from External Customer [Line Items]
Product sales	2,240.8	0	0
HEMOPHILIA
Revenue from External Customer [Line Items]
Product sales	1,789	0	0
INHIBITOR THERAPIES
Revenue from External Customer [Line Items]
Product sales	451.8	0	0
Genetic Diseases
Revenue from External Customer [Line Items]
Product sales	2,698	2,398.9	2,327.1
CINRYZE
Revenue from External Customer [Line Items]
Product sales	680.2	617.7	503
ELAPRASE
Revenue from External Customer [Line Items]
Product sales	589	552.6	592.8
FIRAZYR
Revenue from External Customer [Line Items]
Product sales	578.5	445	364.2
REPLAGAL
Revenue from External Customer [Line Items]
Product sales	452.4	441.2	500.4
VPRIV
Revenue from External Customer [Line Items]
Product sales	345.7	342.4	366.7
KALBITOR
Revenue from External Customer [Line Items]
Product sales	52.2	0	0
Neuroscience
Revenue from External Customer [Line Items]
Product sales	2,490.5	2,200.4	2,204.5
VYVANSE
Revenue from External Customer [Line Items]
Product sales	2,013.9	1,722.2	1,449
ADDERALL XR
Revenue from External Customer [Line Items]
Product sales	363.8	362.8	383.2
Other Neuroscience
Revenue from External Customer [Line Items]
Product sales	112.8	115.4	372.3
Immunology
Revenue from External Customer [Line Items]
Product sales	1,516.1	0	0
IMMUNOGLOBULIN THERAPIES
Revenue from External Customer [Line Items]
Product sales	1,143.9	0	0
BIO THERAPEUTICS
Revenue from External Customer [Line Items]
Product sales	372.2	0	0
Internal Medicine
Revenue from External Customer [Line Items]
Product sales	1,755.5	1,500.6	1,298.8
LIALDA/MEZAVANT
Revenue from External Customer [Line Items]
Product sales	792.1	684.4	633.8
PENTASA
Revenue from External Customer [Line Items]
Product sales	309.4	305.8	289.7
GATTEX/REVESTIVE
Revenue from External Customer [Line Items]
Product sales	219.4	141.7	0
NATPARA
Revenue from External Customer [Line Items]
Product sales	85.3	24.4	0
Other Internal Medicine
Revenue from External Customer [Line Items]
Product sales	349.3	344.3	375.3
Oncology
Revenue from External Customer [Line Items]
Product sales	130.5	0	0
Opthalmology
Revenue from External Customer [Line Items]
Product sales	$ 54.4	$ 0	$ 0

Receipt of Break Fee (Narrative

Receipt of Break Fee (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Extraordinary and Unusual Items [Abstract]
Receipt of break fee	$ 0	$ 0	$ 1,635.4

Commitments and Contingencie135

Commitments and Contingencies (Future Minimum Lease Payments ) (Details) $ in Millions	Dec. 31, 2016USD ($)
Future Minimum Lease Payments under Operating Leases
2,017	$ 155.5
2,018	117.2
2,019	98.7
2,020	89.2
2,021	82.7
Thereafter	441.9
Future minimum lease payments, total	$ 985.2

Commitments and Contingencie136

Commitments and Contingencies (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Loss Contingencies [Line Items]
Lease and rental expense	$ 100.8	$ 40.7	$ 32.9
Irrevocable standby letters of credit and guarantees	139.7	48
Clinical Testing
Loss Contingencies [Line Items]
Commitment amount	1,037.4	490
Contract Manufacturing
Loss Contingencies [Line Items]
Commitment amount	529	325
Commitments expected to be paid in next year	146.4
Other Purchasing Commitment
Loss Contingencies [Line Items]
Commitment amount	1,745	485
Commitments expected to be paid in next year	436.6
Investment Commitment
Loss Contingencies [Line Items]
Commitment amount	76	22
Capital Commitment
Loss Contingencies [Line Items]
Commitment amount	$ 101	$ 60

Legal and Other Proceedings (Na

Legal and Other Proceedings (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		12 Months Ended
	Jan. 31, 2017	Sep. 30, 2016	Jun. 30, 2016	Dec. 31, 2016	Feb. 28, 2017	Dec. 31, 2015
Subsequent Event [Line Items]
Provisions for litigation loss, insurance claims and other disputes				$ 415		$ 9.9
Settlement amount				$ 350
Accrual for expected settlement		$ 10	$ 340
Subsequent Event
Subsequent Event [Line Items]
Settlement amount	$ 345.5
ABH | Subsequent Event
Subsequent Event [Line Items]
Cash held in escrow					$ 37.5

Shareholders' Equity (Narrative

Shareholders' Equity (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Equity, Class of Treasury Stock [Line Items]
Ordinary shares authorized	1,500,000,000	1,000,000,000
Subscriber ordinary shares authorized	2
Distributable reserves (in USD)	$ 4,400
Irish withholding tax rate	20.00%
Ordinary Shares | Shares held by EBT
Equity, Class of Treasury Stock [Line Items]
Treasury stock held	500,000	600,000	700,000
Ordinary Shares | Shares held under share buy-back program
Equity, Class of Treasury Stock [Line Items]
Treasury stock held	8,000,000	8,500,000	9,000,000
ADS | Shares held by EBT
Equity, Class of Treasury Stock [Line Items]
Treasury stock held	200,000	200,000	300,000
Shire Income Access Share Trust
Equity, Class of Treasury Stock [Line Items]
Cash dividends paid to Income Access Share Trustee (in USD)	$ 150.6	$ 127.7	$ 112.8

Share-based Compensation Pla139

Share-based Compensation Plans (Share-based Compensation Expense) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 318.5	$ 100.3	$ 97
Less tax	(85.3)	(28.4)	(23.8)
Share-based compensation expense, net	233.2	71.9	73.2
Cost of product sales
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	23.3	7.6	8.5
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	46.9	28.6	22.2
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	67.1	37.4	35.9
Integration and acquisitions costs
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	181.2	0	0
Reorganization costs
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 0	$ 26.7	$ 30.4

Share-based Compensation Pla140

Share-based Compensation Plans (Narrative) (Details) $ in Millions	Jun. 03, 2016shares	Dec. 31, 2016USD ($)£ / sharesshares	Dec. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)£ / sharesshares	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)£ / shares	Dec. 31, 2014USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense | $			$ 318.5		$ 100.3		$ 97
Unrecognized compensation cost relating to non-vested awards | $		$ 244.2	$ 244.2	$ 115.3	115.3	$ 83.1	83.1
Unrecognized compensation cost relating to non-vested awards, expected period for recognition			3 years
Intrinsic values of share-based awards exercised | $		$ 214.6	$ 214.6	$ 198.8	198.8	$ 200.8	200.8
Proceeds from exercise of options | $			129		16.6		17.4
Tax benefit associated with exercise of stock options | $			$ 8.8		$ 31.6		39.6
SARs and Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)			6,506,762
Outstanding (in shares)		21,869,833	21,869,833	7,796,496	7,796,496
Exercisable (in shares)		11,035,437	11,035,437
Weighted average grant date fair value (GBP per share) | £ / shares		$ 8.25		$ 10.36		$ 6.19
SARs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period from date of issue			7 years
RSUs, PSUs and PSAs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted			1,663,070
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number		3,976,657	3,976,657	1,791,930	1,791,930
Expiration period from date of issue			3 years
Additional holding period after vesting			2 years
Outstanding (in shares)		3,976,657	3,976,657
SARs | SARs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period from date of issue			7 years
Vesting period			3 years
Outstanding (in shares)		10,646,207	10,646,207
RSUs, PSUs and PSAs | RSUs, PSUs and PSAs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period from date of issue			3 years
Vesting period			3 years
Outstanding (in shares)		2,346,511	2,346,511
UK/Irish Sharesave Scheme | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period from date of issue			6 months
Outstanding (in shares)		119,300	119,300
Global Employee Stock Purchase Plan | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of common stock, percent			85.00%
Savings period			12 months
Outstanding (in shares)		411,900	411,900
United Kingdom | UK/Irish Sharesave Scheme | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of common stock, percent			80.00%
Ireland | UK/Irish Sharesave Scheme | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of common stock, percent			75.00%
EBT | Ordinary Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Treasury stock held (in shares)		500,000	500,000
EBT | ADS
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Treasury stock held (in shares)		200,000	200,000
Baxalta | Baxalta Replacement Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense | $			$ 223.1		$ 0		$ 0
Integration related costs | $			$ 171
Baxalta | Replacement Awards Issued, Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period from date of issue			10 years
Vesting period			3 years
Outstanding (in shares)		10,692,426	10,692,426
Baxalta | Replacement Awards Issued, Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period from date of issue			3 years
Vesting period			3 years
Outstanding (in shares)		1,630,146	1,630,146
Employees below the level of Executive Vice President | RSUs, PSUs and PSAs | RSUs, PSUs and PSAs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period from date of issue			3 years
Executive Director and Executive Vice President | RSUs, PSUs and PSAs | RSUs, PSUs and PSAs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period from date of issue			3 years
Minimum | UK/Irish Sharesave Scheme | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Minimum | Global Employee Stock Purchase Plan | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			1 year
Maximum | UK/Irish Sharesave Scheme | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			5 years
Maximum | Global Employee Stock Purchase Plan | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			5 years
Tranche One | Baxalta | Replacement Awards Issued, Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage			33.33%
Tranche One | Baxalta | Replacement Awards Issued, Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage			33.33%
Tranche Two | Baxalta | Replacement Awards Issued, Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage			33.33%
Tranche Two | Baxalta | Replacement Awards Issued, Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage			33.33%
Tranche Three | Baxalta | Replacement Awards Issued, Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage			33.33%
Tranche Three | Baxalta | Replacement Awards Issued, Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage			33.33%
Baxter employees | SARs and Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	8,800,000
Outstanding (in shares)		7,700,000	7,700,000
Exercisable (in shares)		6,900,000	6,900,000
Baxter employees | RSUs, PSUs and PSAs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	500,000
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number		300,000	300,000

Share-based Compensation Pla141

Share-based Compensation Plans (Summary of Awards Outstanding and Vesting Schedules) (Details) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
SARs and Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards	21,869,833	7,796,496
Stock-settled SARs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period from date of issue	7 years
RSUs, PSUs and PSAs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards	3,976,657
Expiration period from date of issue	3 years
SARs | Stock-settled SARs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards	10,646,207
Expiration period from date of issue	7 years
Vesting period	3 years
UK/Irish Sharesave Scheme | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards	119,300
Expiration period from date of issue	6 months
UK/Irish Sharesave Scheme | Stock Options | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
UK/Irish Sharesave Scheme | Stock Options | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years
Global Employee Stock Purchase Plan | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards	411,900
Global Employee Stock Purchase Plan | Stock Options | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Global Employee Stock Purchase Plan | Stock Options | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years
RSUs, PSUs and PSAs | RSUs, PSUs and PSAs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards	2,346,511
Expiration period from date of issue	3 years
Vesting period	3 years
Baxalta | Replacement Awards Issued, Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards	10,692,426
Expiration period from date of issue	10 years
Vesting period	3 years
Baxalta | Replacement Awards Issued, Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards	1,630,146
Expiration period from date of issue	3 years
Vesting period	3 years

Share-based Compensation Pla142

Share-based Compensation Plans (Stock Options and SARs) (Details) - SARs and Stock Options £ / shares in Units, £ in Millions	12 Months Ended
	Dec. 31, 2016GBP (£)£ / sharesshares
Weighted average exercise price
Outstanding as at beginning of period (GBP per share)	£ 52.02
Granted (GBP per share)	42.37
Exercised (GBP per share)	39.83
Baxalta Replacement Options (GBP per share)	34.30
Forfeited (GBP per share)	48.49
Outstanding as at end of period (GBP per share)	38.98
Exercisable as at end of period (GBP per share)	£ 34.55
Number of shares
Outstanding as at beginning of period (in shares) | shares	7,796,496
Granted (in shares) | shares	6,506,762
Exercised (in shares) | shares	(4,717,106)
Baxalta Replacement Options (in shares) | shares	13,328,592
Forfeited (in shares) | shares	(1,044,911)
Outstanding as at end of period (in shares) | shares	21,869,833
Exercisable as at end of period (in shares) | shares	11,035,437
Outstanding as at end of period Intrinsic Value (in GBP) | £	£ 76.6
Exercisable as at end of period Intrinsic Value (in GBP) | £	£ 66
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Abstract]
Number of awards outstanding (in shares) | shares	21,869,833
Number of awards exercisable (in shares) | shares	11,035,437
14.59-28.00 GBP
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Abstract]
Number of awards outstanding (in shares) | shares	3,433,225
Weighted Average remaining contractual term (Years)	3 years
Weighted average exercise price of awards outstanding (GBP per share)	£ 25.37
Number of awards exercisable (in shares) | shares	3,422,480
Weighted average exercise price of awards exercisable (GBP per share)	£ 25.38
Exercise prices, minimum (GBP per share)	14.59
Exercise prices, maximum (GBP per share)	£ 28
28.01-40.00 GBP
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Abstract]
Number of awards outstanding (in shares) | shares	10,704,846
Weighted Average remaining contractual term (Years)	7 years 3 months 18 days
Weighted average exercise price of awards outstanding (GBP per share)	£ 35.56
Number of awards exercisable (in shares) | shares	6,161,513
Weighted average exercise price of awards exercisable (GBP per share)	£ 34.91
Exercise prices, minimum (GBP per share)	28.01
Exercise prices, maximum (GBP per share)	£ 40
40.01-70.48 GBP
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Abstract]
Number of awards outstanding (in shares) | shares	7,731,762
Weighted Average remaining contractual term (Years)	5 years 8 months 12 days
Weighted average exercise price of awards outstanding (GBP per share)	£ 49.77
Number of awards exercisable (in shares) | shares	1,451,444
Weighted average exercise price of awards exercisable (GBP per share)	£ 54.67
Exercise prices, minimum (GBP per share)	40.01
Exercise prices, maximum (GBP per share)	£ 70.48

Share-based Compensation Pla143

Share-based Compensation Plans (Performance Share Awards) (Details) - RSUs, PSUs and PSAs	12 Months Ended
	Dec. 31, 2016£ / sharesshares
Performance Share Awards Outstanding [Roll Forward]
Outstanding as of beginning of period | shares	1,791,930
Granted | shares	1,663,070
Exercised | shares	(2,470,179)
Baxalta Replacement RSUs | shares	3,294,150
Forfeited | shares	(302,314)
Outstanding as of end of period | shares	3,976,657
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Outstanding as of beginning of period (GBP per share) | £ / shares	£ 40.06
Granted (GBP per share) | £ / shares	42.28
Exercised (GBP per share) | £ / shares	37.52
Baxalta Replacement RSUs (GBP per share) | £ / shares	39.28
Forfeited (GBP per share) | £ / shares	48.47
Outstanding as of end of period (GBP per share) | £ / shares	£ 41.31
Weighted average remaining life	3 years 10 months
Exercisable as of end of period | shares	0
Exercisable as at end of period (GBP per share) | £ / shares	£ 0

Share-based Compensation Pla144

Share-based Compensation Plans (Fair Value Assumptions) (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Minimum
Fair Value Assumptions and Methodology
Risk-free interest rate	0.60%	0.30%
Expected dividend yield	0.20%	0.20%
Expected life	1 year	1 year
Expected volatility	23.00%	23.00%
Forfeiture rate	5.00%	5.00%
Maximum
Fair Value Assumptions and Methodology
Risk-free interest rate	1.80%	1.80%
Expected dividend yield	0.40%	0.40%
Expected life	4 years	4 years
Expected volatility	26.00%	27.00%
Forfeiture rate	7.00%	7.00%

Agreements and Transactions 145

Agreements and Transactions with Baxter (Narrative) (Details) - USD ($) $ in Millions	7 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Related Party Transaction [Line Items]
Selling, general and administrative		$ 3,015.2	$ 1,842.5	$ 1,782
Inventories	$ 3,562.3	3,562.3	635.4
Prepaid expenses and other current assets	806.3	806.3	197.4
Other current liabilities	362.9	362.9	$ 142.8
Tax indemnification	26	26
Prepaid expenses and other current assets related indemnification liabilities	189	189
Other non current assets	34	34
Current tax related indemnification liabilities	72	72
Long -term tax related indemnification liabilities	92	92
Manufacturing and Supply Agreement with Baxter
Related Party Transaction [Line Items]
Revenue	81
Transition Service Agreement with Baxter
Related Party Transaction [Line Items]
Selling, general and administrative	54
Operations Not Yet Transferred to Baxalta
Related Party Transaction [Line Items]
Revenue	101
Inventories	11	11
Prepaid expenses and other current assets	50	50
Other current liabilities	$ 3	$ 3

Guarantor Financial Informat146

Guarantor Financial Information (Narrative) (Details) - Senior Notes	Dec. 31, 2016
Shire Acquisitions Investment Ireland Designated Activity Company | Fixed-rate notes due 2019
Debt Instrument [Line Items]
Coupon Rate	1.90%
Shire Acquisitions Investment Ireland Designated Activity Company | Fixed-rate notes due 2021
Debt Instrument [Line Items]
Coupon Rate	2.40%
Shire Acquisitions Investment Ireland Designated Activity Company | Fixed-rate notes due 2023
Debt Instrument [Line Items]
Coupon Rate	2.875%
Shire Acquisitions Investment Ireland Designated Activity Company | Fixed-rate notes due 2026
Debt Instrument [Line Items]
Coupon Rate	3.20%
Baxalta | Fixed-rate notes due 2018
Debt Instrument [Line Items]
Coupon Rate	2.00%
Baxalta | Fixed-rate notes due 2020
Debt Instrument [Line Items]
Coupon Rate	2.875%
Baxalta | Fixed-rate notes due 2022
Debt Instrument [Line Items]
Coupon Rate	3.60%
Baxalta | Fixed-rate notes due 2025
Debt Instrument [Line Items]
Coupon Rate	4.00%
Baxalta | Fixed-rate notes due 2045
Debt Instrument [Line Items]
Coupon Rate	5.25%

Guarantor Financial Informat147

Guarantor Financial Information (Condensed Consolidated Balance Sheets) (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 528.8	$ 135.5	$ 2,982.4	$ 2,239.4
Restricted cash	25.6	86
Accounts receivable, net	2,616.5	1,201.2
Inventories	3,562.3	635.4
Prepaid expenses and other current assets	806.3	197.4
Intercompany receivables	0	0
Short-term intercompany loan receivable	0
Total current assets	7,539.5	2,255.5
Non-current assets:
Investments	191.6	50.8
Property, plant and equipment (“PP&E”), net	6,469.6	828.1
Goodwill	17,888.2	4,147.8	2,474.9
Intangible assets, net	34,697.5	9,173.3	4,934.4
Deferred tax asset	96.7	121
Long-term intercompany loan receivable	0
Other non-current assets	152.3	33.3
Total assets	67,035.4	16,609.8
Current liabilities:
Accounts payable and accrued expenses	4,312.4	2,050.6
Short-term borrowings and capital lease obligations	3,068	1,512.7
Intercompany payables	0	0
Short-term intercompany loans payable	0
Other current liabilities	362.9	142.8
Total current liabilities	7,743.3	3,706.1
Non-current liabilities:
Long-term borrowings	19,899.8	82.1
Deferred tax liability	8,322.7	2,205.9
Long-term intercompany loans payable	0
Other non-current liabilities	2,121.6	786.6
Total liabilities	38,087.4	6,780.7
Equity:
Total equity	28,948	9,829.1	8,662.9	5,366
Total liabilities and equity	67,035.4	16,609.8
Parent Company
Current assets:
Cash and cash equivalents	0	0	0	0
Restricted cash	0	0
Accounts receivable, net	0	0
Inventories	0	0
Prepaid expenses and other current assets	1.8	1.9
Intercompany receivables	0	0
Short-term intercompany loan receivable	0
Total current assets	1.8	1.9
Non-current assets:
Investments	35,656.1	14,477.2
Property, plant and equipment (“PP&E”), net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Deferred tax asset	0	0
Long-term intercompany loan receivable	0
Other non-current assets	3.9	5.3
Total assets	35,661.8	14,484.4
Current liabilities:
Accounts payable and accrued expenses	1.3	10
Short-term borrowings and capital lease obligations	450	1,500
Intercompany payables	5,247.1	3,145.3
Short-term intercompany loans payable	0
Other current liabilities	0	0
Total current liabilities	5,698.4	4,655.3
Non-current liabilities:
Long-term borrowings	0	0
Deferred tax liability	0	0
Long-term intercompany loans payable	610.1
Other non-current liabilities	405.3	0
Total liabilities	6,713.8	4,655.3
Equity:
Total equity	28,948	9,829.1
Total liabilities and equity	35,661.8	14,484.4
SAIIDAC (SAIIDAC Notes Subsidiary Issuer)
Current assets:
Cash and cash equivalents	0	0	0	0
Restricted cash	0	0
Accounts receivable, net	0	0
Inventories	0	0
Prepaid expenses and other current assets	0	9.6
Intercompany receivables	120.5	0
Short-term intercompany loan receivable	2,594.8
Total current assets	2,715.3	9.6
Non-current assets:
Investments	0	0
Property, plant and equipment (“PP&E”), net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Deferred tax asset	0	0
Long-term intercompany loan receivable	14,431
Other non-current assets	0	8.3
Total assets	17,146.3	17.9
Current liabilities:
Accounts payable and accrued expenses	85.7	0
Short-term borrowings and capital lease obligations	2,594.8	0
Intercompany payables	0	19.6
Short-term intercompany loans payable	0
Other current liabilities	0	0
Total current liabilities	2,680.5	19.6
Non-current liabilities:
Long-term borrowings	14,431	0
Deferred tax liability	0	0
Long-term intercompany loans payable	0
Other non-current liabilities	0	0
Total liabilities	17,111.5	19.6
Equity:
Total equity	34.8	(1.7)
Total liabilities and equity	17,146.3	17.9
Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor)
Current assets:
Cash and cash equivalents	41.7	0	0	0
Restricted cash	0	0
Accounts receivable, net	0	0
Inventories	0	0
Prepaid expenses and other current assets	97.1	0
Intercompany receivables	0	0
Short-term intercompany loan receivable	0
Total current assets	138.8	0
Non-current assets:
Investments	34,644.2	0
Property, plant and equipment (“PP&E”), net	27.4	0
Goodwill	0	0
Intangible assets, net	0	0
Deferred tax asset	273	0
Long-term intercompany loan receivable	480.7
Other non-current assets	33.8	0
Total assets	35,597.9	0
Current liabilities:
Accounts payable and accrued expenses	20	0
Short-term borrowings and capital lease obligations	0	0
Intercompany payables	27.8	0
Short-term intercompany loans payable	0
Other current liabilities	64.6	0
Total current liabilities	112.4	0
Non-current liabilities:
Long-term borrowings	5,063.7	0
Deferred tax liability	0	0
Long-term intercompany loans payable	0
Other non-current liabilities	61.7	0
Total liabilities	5,237.8	0
Equity:
Total equity	30,360.1	0
Total liabilities and equity	35,597.9	0
Non-Guarantor Non-Issuer Subsidiaries
Current assets:
Cash and cash equivalents	487.1	135.5	2,982.4	2,239.4
Restricted cash	25.6	86
Accounts receivable, net	2,616.5	1,201.2
Inventories	3,562.3	635.4
Prepaid expenses and other current assets	707.4	185.9
Intercompany receivables	5,154.4	3,164.9
Short-term intercompany loan receivable	0
Total current assets	12,553.3	5,408.9
Non-current assets:
Investments	12,571.8	50.8
Property, plant and equipment (“PP&E”), net	6,442.2	828.1
Goodwill	17,888.2	4,147.8
Intangible assets, net	34,697.5	9,173.3
Deferred tax asset	96.7	121
Long-term intercompany loan receivable	0
Other non-current assets	114.6	19.7
Total assets	84,364.3	19,749.6
Current liabilities:
Accounts payable and accrued expenses	4,205.4	2,040.6
Short-term borrowings and capital lease obligations	23.2	12.7
Intercompany payables	0	0
Short-term intercompany loans payable	2,594.8
Other current liabilities	298.3	142.8
Total current liabilities	7,121.7	2,196.1
Non-current liabilities:
Long-term borrowings	405.1	82.1
Deferred tax liability	8,595.7	2,205.9
Long-term intercompany loans payable	14,301.6
Other non-current liabilities	1,654.6	786.6
Total liabilities	32,078.7	5,270.7
Equity:
Total equity	52,285.6	14,478.9
Total liabilities and equity	84,364.3	19,749.6
Non-Guarantor Subsidiaries of Baxalta Notes
Current assets:
Cash and cash equivalents	487.1	135.5	2,982.4	2,239.4
Restricted cash	25.6	86
Accounts receivable, net	2,616.5	1,201.2
Inventories	3,562.3	635.4
Prepaid expenses and other current assets	707.4	195.5
Intercompany receivables	5,274.9	3,164.9
Short-term intercompany loan receivable	2,594.8
Total current assets	15,268.6	5,418.5
Non-current assets:
Investments	12,571.8	50.8
Property, plant and equipment (“PP&E”), net	6,442.2	828.1
Goodwill	17,888.2	4,147.8
Intangible assets, net	34,697.5	9,173.3
Deferred tax asset	96.7	121
Long-term intercompany loan receivable	14,431
Other non-current assets	114.6	28
Total assets	101,510.6	19,767.5
Current liabilities:
Accounts payable and accrued expenses	4,291.1	2,040.6
Short-term borrowings and capital lease obligations	2,618	12.7
Intercompany payables	0	19.6
Short-term intercompany loans payable	2,594.8
Other current liabilities	298.3	142.8
Total current liabilities	9,802.2	2,215.7
Non-current liabilities:
Long-term borrowings	14,836.1	82.1
Deferred tax liability	8,595.7	2,205.9
Long-term intercompany loans payable	14,301.6
Other non-current liabilities	1,654.6	786.6
Total liabilities	49,190.2	5,290.3
Equity:
Total equity	52,320.4	14,477.2
Total liabilities and equity	101,510.6	19,767.5
Eliminations
Current assets:
Cash and cash equivalents	0	0	$ 0	$ 0
Restricted cash	0	0
Accounts receivable, net	0	0
Inventories	0	0
Prepaid expenses and other current assets	0	0
Intercompany receivables	(5,274.9)	(3,164.9)
Short-term intercompany loan receivable	(2,594.8)
Total current assets	(7,869.7)	(3,164.9)
Non-current assets:
Investments	(82,680.5)	(14,477.2)
Property, plant and equipment (“PP&E”), net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Deferred tax asset	(273)	0
Long-term intercompany loan receivable	(14,911.7)
Other non-current assets	0	0
Total assets	(105,734.9)	(17,642.1)
Current liabilities:
Accounts payable and accrued expenses	0	0
Short-term borrowings and capital lease obligations	0	0
Intercompany payables	(5,274.9)	(3,164.9)
Short-term intercompany loans payable	(2,594.8)
Other current liabilities	0	0
Total current liabilities	(7,869.7)	(3,164.9)
Non-current liabilities:
Long-term borrowings	0	0
Deferred tax liability	(273)	0
Long-term intercompany loans payable	(14,911.7)
Other non-current liabilities	0	0
Total liabilities	(23,054.4)	(3,164.9)
Equity:
Total equity	(82,680.5)	(14,477.2)
Total liabilities and equity	$ (105,734.9)	$ (17,642.1)

Guarantor Financial Informat148

Guarantor Financial Information (Condensed Consolidated Statements of Operations) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Condensed Income Statements, Captions [Line Items]
Product sales									$ 10,885.8	$ 6,099.9	$ 5,830.4
Royalties and other revenues									510.8	316.8	191.7
Total revenues	$ 3,806.1	$ 3,452.1	$ 2,429.1	$ 1,709.3	$ 1,715.7	$ 1,655	$ 1,557.6	$ 1,488.4	11,396.6	6,416.7	6,022.1
Cost of sales	1,053.6	1,736.2	778.1	248.6	250.5	262.7	228	227.8	3,816.5	969	979.3
Research and development									1,439.8	1,564	1,067.5
Selling, general and administrative									3,015.2	1,842.5	1,782
Amortization of acquired intangible assets									1,173.4	498.7	243.8
Integration and acquisition costs									883.9	39.8	158.8
Reorganization costs									121.4	97.9	180.9
Gain on sale of product rights									(16.5)	(14.7)	(88.2)
Total operating expenses, net									10,433.7	4,997.2	4,324.1
Operating income from continuing operations									962.9	1,419.5	1,698
Interest (expense) / income, net									(451.2)	(37.4)	(6.1)
Other (expense)/income, net									(25.6)	3.7	8.9
Receipt of break fee									0	0	1,635.4
Total other (expense)/income, net									(476.8)	(33.7)	1,638.2
Income from continuing operations before income taxes and equity in (losses)/ earnings of equity method investees (in millions)									486.1	1,385.8	3,336.2
Income taxes									126.1	(46.1)	(56.1)
Equity in (losses)/ earnings of equity method investees, net of taxes									(8.7)	(2.2)	2.7
Income from continuing operations, net of taxes	475.9	(368.5)	86.6	409.5	283.4	477.1	164.1	412.9	603.5	1,337.5	3,282.8
(Loss)/gain from discontinued operations, net of taxes	(18.6)	(18.3)	(248.7)	9.5	(2.8)	(24.3)	(4.5)	(2.5)	(276.1)	(34.1)	122.7
Net income / (loss)	$ 457.3	$ (386.8)	$ (162.1)	$ 419	$ 280.6	$ 452.8	$ 159.6	$ 410.4	327.4	1,303.4	3,405.5
Comprehensive income / (loss)									(986.4)	1,151.1	3,263.8
Eliminations
Condensed Income Statements, Captions [Line Items]
Product sales									0	0	0
Royalties and other revenues									0	0	0
Total revenues									0	0	0
Cost of sales									0	0	0
Research and development									0	0	0
Selling, general and administrative									0	1.4	1.4
Amortization of acquired intangible assets									0	0	0
Integration and acquisition costs									0	0	0
Reorganization costs									0	0	0
Gain on sale of product rights									0	0	0
Total operating expenses, net									0	1.4	1.4
Operating income from continuing operations									0	(1.4)	(1.4)
Interest (expense) / income, net									0	0	0
Other (expense)/income, net									0	0	0
Receipt of break fee											0
Total other (expense)/income, net									0	0	0
Income from continuing operations before income taxes and equity in (losses)/ earnings of equity method investees (in millions)									0	(1.4)	(1.4)
Income taxes									0	0	0
Equity in (losses)/ earnings of equity method investees, net of taxes									174.9	(1,388.1)	(1,919.8)
Income from continuing operations, net of taxes									174.9	(1,389.5)	(1,921.2)
(Loss)/gain from discontinued operations, net of taxes									0	0	0
Net income / (loss)									174.9	(1,389.5)	(1,921.2)
Comprehensive income / (loss)									2,694.4	(1,237.2)	(1,779.5)
Parent Company
Condensed Income Statements, Captions [Line Items]
Product sales									0	0	0
Royalties and other revenues									0	0	0
Total revenues									0	0	0
Cost of sales									0	0	0
Research and development									0	0	0
Selling, general and administrative									59.8	24.9	109.4
Amortization of acquired intangible assets									0	0	0
Integration and acquisition costs									0	0	0
Reorganization costs									0	0	0
Gain on sale of product rights									0	0	0
Total operating expenses, net									59.8	24.9	109.4
Operating income from continuing operations									(59.8)	(24.9)	(109.4)
Interest (expense) / income, net									(100.6)	(63.6)	(42.8)
Other (expense)/income, net									0.9	0.9	0.3
Receipt of break fee											1,635.4
Total other (expense)/income, net									(99.7)	(62.7)	1,592.9
Income from continuing operations before income taxes and equity in (losses)/ earnings of equity method investees (in millions)									(159.5)	(87.6)	1,483.5
Income taxes									4.3	2.9	2.2
Equity in (losses)/ earnings of equity method investees, net of taxes									482.6	1,388.1	1,919.8
Income from continuing operations, net of taxes									327.4	1,303.4	3,405.5
(Loss)/gain from discontinued operations, net of taxes									0	0	0
Net income / (loss)									327.4	1,303.4	3,405.5
Comprehensive income / (loss)									(986.4)	1,151.1	3,263.8
SAIIDAC (SAIIDAC Notes Subsidiary Issuer)
Condensed Income Statements, Captions [Line Items]
Product sales									0	0	0
Royalties and other revenues									0	0	0
Total revenues									0	0	0
Cost of sales									0	0	0
Research and development									0	0	0
Selling, general and administrative									0	0	0
Amortization of acquired intangible assets									0	0	0
Integration and acquisition costs									0	0	0
Reorganization costs									0	0	0
Gain on sale of product rights									0	0	0
Total operating expenses, net									0	0	0
Operating income from continuing operations									0	0	0
Interest (expense) / income, net									36.5	(1.7)	0
Other (expense)/income, net									0	0	0
Receipt of break fee											0
Total other (expense)/income, net									36.5	(1.7)	0
Income from continuing operations before income taxes and equity in (losses)/ earnings of equity method investees (in millions)									36.5	(1.7)	0
Income taxes									(9.1)	0	0
Equity in (losses)/ earnings of equity method investees, net of taxes									0	0	0
Income from continuing operations, net of taxes									27.4	(1.7)	0
(Loss)/gain from discontinued operations, net of taxes									0	0	0
Net income / (loss)									27.4	(1.7)	0
Comprehensive income / (loss)									27.4	(1.7)	0
Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor)
Condensed Income Statements, Captions [Line Items]
Product sales									0	0	0
Royalties and other revenues									0	0	0
Total revenues									0	0	0
Cost of sales									0	0	0
Research and development									0.4	0	0
Selling, general and administrative									29.4	0	0
Amortization of acquired intangible assets									0	0	0
Integration and acquisition costs									302	0	0
Reorganization costs									0	0	0
Gain on sale of product rights									0	0	0
Total operating expenses, net									331.8	0	0
Operating income from continuing operations									(331.8)	0	0
Interest (expense) / income, net									(45.1)	0	0
Other (expense)/income, net									2.7	0	0
Receipt of break fee											0
Total other (expense)/income, net									(42.4)	0	0
Income from continuing operations before income taxes and equity in (losses)/ earnings of equity method investees (in millions)									(374.2)	0	0
Income taxes									88.9	0	0
Equity in (losses)/ earnings of equity method investees, net of taxes									(657.5)	0	0
Income from continuing operations, net of taxes									(942.8)	0	0
(Loss)/gain from discontinued operations, net of taxes									0	0	0
Net income / (loss)									(942.8)	0	0
Comprehensive income / (loss)									(2,148.9)	0	0
Non-Guarantor Non-Issuer Subsidiaries
Condensed Income Statements, Captions [Line Items]
Product sales									10,885.8	6,099.9	5,830.4
Royalties and other revenues									510.8	316.8	191.7
Total revenues									11,396.6	6,416.7	6,022.1
Cost of sales									3,816.5	969	979.3
Research and development									1,439.4	1,564	1,067.5
Selling, general and administrative									2,926	1,816.2	1,671.2
Amortization of acquired intangible assets									1,173.4	498.7	243.8
Integration and acquisition costs									581.9	39.8	158.8
Reorganization costs									121.4	97.9	180.9
Gain on sale of product rights									(16.5)	(14.7)	(88.2)
Total operating expenses, net									10,042.1	4,970.9	4,213.3
Operating income from continuing operations									1,354.5	1,445.8	1,808.8
Interest (expense) / income, net									(342)	27.9	36.7
Other (expense)/income, net									(29.2)	2.8	8.6
Receipt of break fee											0
Total other (expense)/income, net									(371.2)	30.7	45.3
Income from continuing operations before income taxes and equity in (losses)/ earnings of equity method investees (in millions)									983.3	1,476.5	1,854.1
Income taxes									42	(49)	(58.3)
Equity in (losses)/ earnings of equity method investees, net of taxes									(8.7)	(2.2)	2.7
Income from continuing operations, net of taxes									1,016.6	1,425.3	1,798.5
(Loss)/gain from discontinued operations, net of taxes									(276.1)	(34.1)	122.7
Net income / (loss)									740.5	1,391.2	1,921.2
Comprehensive income / (loss)									(572.9)	1,238.9	1,779.5
Non-Guarantor Subsidiaries of Baxalta Notes
Condensed Income Statements, Captions [Line Items]
Product sales									10,885.8	6,099.9	5,830.4
Royalties and other revenues									510.8	316.8	191.7
Total revenues									11,396.6	6,416.7	6,022.1
Cost of sales									3,816.5	969	979.3
Research and development									1,439.4	1,564	1,067.5
Selling, general and administrative									2,926	1,816.2	1,671.2
Amortization of acquired intangible assets									1,173.4	498.7	243.8
Integration and acquisition costs									581.9	39.8	158.8
Reorganization costs									121.4	97.9	180.9
Gain on sale of product rights									(16.5)	(14.7)	(88.2)
Total operating expenses, net									10,042.1	4,970.9	4,213.3
Operating income from continuing operations									1,354.5	1,445.8	1,808.8
Interest (expense) / income, net									(305.5)	26.2	36.7
Other (expense)/income, net									(29.2)	2.8	8.6
Receipt of break fee											0
Total other (expense)/income, net									(334.7)	29	45.3
Income from continuing operations before income taxes and equity in (losses)/ earnings of equity method investees (in millions)									1,019.8	1,474.8	1,854.1
Income taxes									32.9	(49)	(58.3)
Equity in (losses)/ earnings of equity method investees, net of taxes									(8.7)	(2.2)	2.7
Income from continuing operations, net of taxes									1,044	1,423.6	1,798.5
(Loss)/gain from discontinued operations, net of taxes									(276.1)	(34.1)	122.7
Net income / (loss)									767.9	1,389.5	1,921.2
Comprehensive income / (loss)									$ (545.5)	$ 1,237.2	$ 1,779.5

Guarantor Financial Informat149

Guarantor Financial Information (Condensed Consolidated Statement of Cash Flows) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net cash (used in) / provided by operating activities	$ 2,658.9	$ 2,337	$ 4,228.4
CASH FLOWS FROM INVESTING ACTIVITIES:
Transactions with subsidiaries	0	0	0
Movements in restricted cash	62.8	(32)	(32.6)
Purchases of subsidiary undertakings and businesses, net of cash acquired	(17,476.2)	(5,553.4)	(4,104.4)
Purchases of non-current investments and PP&E	(648.7)	(124.2)	(100.1)
Proceeds received on sale of product rights	10.9	17.5	127
Proceeds from short-term investments	0	67	57.8
Proceeds from disposal of non-current investments and PP&E	0.9	18.7	21.5
Other, net			(0.2)
Other, net	(41.9)	(13.5)	0.2
Net cash used in investing activities	(18,092.2)	(5,619.9)	(4,030.6)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long term and short term borrowings	32,443.4	3,760.8	2,310.8
Repayment of revolving line of credit, long term and short term borrowings	(16,404.3)	(3,110.9)	(1,461.8)
Repayment of debt acquired through business combinations	0	0	(551.5)
Proceeds from ViroPharma call options	0	0	346.7
Proceeds from intercompany borrowings	0	0	0
Payment of dividend	(171.3)	(134.4)	(121.2)
Debt issuance costs	(172.3)	(24.1)	(10.2)
Contingent consideration payments	(8)	(101.2)	(15.2)
Proceeds from exercise of options	129	16.6	17.4
Other, net	9.3	32.2	39.5
Net cash provided by financing activities	15,825.8	439	554.5
Effect of foreign exchange rate changes on cash and cash equivalents	0.8	(3)	(9.3)
Net increase/(decrease) in cash and cash equivalents	393.3	(2,846.9)	743
Cash and cash equivalents at beginning of period	135.5	2,982.4	2,239.4
Cash and cash equivalents at end of period	528.8	135.5	2,982.4
Eliminations
CASH FLOWS FROM OPERATING ACTIVITIES:
Net cash (used in) / provided by operating activities	0	0	0
CASH FLOWS FROM INVESTING ACTIVITIES:
Transactions with subsidiaries	26,306.8	6,618.2	1,441.7
Movements in restricted cash	0	0	0
Purchases of subsidiary undertakings and businesses, net of cash acquired	0	0	0
Purchases of non-current investments and PP&E	0	0	0
Proceeds received on sale of product rights	0	0	0
Proceeds from short-term investments		0	0
Proceeds from disposal of non-current investments and PP&E	0	0	0
Other, net			0
Other, net	0	0
Net cash used in investing activities	26,306.8	6,618.2	1,441.7
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long term and short term borrowings	0	0	0
Repayment of revolving line of credit, long term and short term borrowings	0	0	0
Repayment of debt acquired through business combinations			0
Proceeds from ViroPharma call options			0
Proceeds from intercompany borrowings	(26,306.8)	(6,618.2)	(1,441.7)
Payment of dividend	0	0	0
Debt issuance costs	0	0	0
Contingent consideration payments	0	0	0
Proceeds from exercise of options	0	0	0
Other, net	0	0	0
Net cash provided by financing activities	(26,306.8)	(6,618.2)	(1,441.7)
Effect of foreign exchange rate changes on cash and cash equivalents	0	0	0
Net increase/(decrease) in cash and cash equivalents	0	0	0
Cash and cash equivalents at beginning of period	0	0	0
Cash and cash equivalents at end of period	0	0	0
Parent Company
CASH FLOWS FROM OPERATING ACTIVITIES:
Net cash (used in) / provided by operating activities	(136.9)	(133.5)	1,512.6
CASH FLOWS FROM INVESTING ACTIVITIES:
Transactions with subsidiaries	(2,890)	(3,570)	(1,900)
Movements in restricted cash	0	0	0
Purchases of subsidiary undertakings and businesses, net of cash acquired	0	0	0
Purchases of non-current investments and PP&E	0	0	0
Proceeds received on sale of product rights	0	0	0
Proceeds from short-term investments		0	0
Proceeds from disposal of non-current investments and PP&E	0	0	0
Other, net			0
Other, net	0	0
Net cash used in investing activities	(2,890)	(3,570)	(1,900)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long term and short term borrowings	2,355	3,760	2,310
Repayment of revolving line of credit, long term and short term borrowings	(3,405)	(3,110)	(1,460)
Repayment of debt acquired through business combinations			0
Proceeds from ViroPharma call options			0
Proceeds from intercompany borrowings	4,077.8	3,048.2	(458.3)
Payment of dividend	(20.7)	(6.8)	(8.9)
Debt issuance costs	0	(4.5)	(10.6)
Contingent consideration payments	0	0	0
Proceeds from exercise of options	19.8	16.6	15.2
Other, net	0	0	0
Net cash provided by financing activities	3,026.9	3,703.5	387.4
Effect of foreign exchange rate changes on cash and cash equivalents	0	0	0
Net increase/(decrease) in cash and cash equivalents	0	0	0
Cash and cash equivalents at beginning of period	0	0	0
Cash and cash equivalents at end of period	0	0	0
SAIIDAC (SAIIDAC Notes Subsidiary Issuer)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net cash (used in) / provided by operating activities	232.8	0	0
CASH FLOWS FROM INVESTING ACTIVITIES:
Transactions with subsidiaries	(18,228.8)	0	0
Movements in restricted cash	0	0	0
Purchases of subsidiary undertakings and businesses, net of cash acquired	0	0	0
Purchases of non-current investments and PP&E	0	0	0
Proceeds received on sale of product rights	0	0	0
Proceeds from short-term investments		0	0
Proceeds from disposal of non-current investments and PP&E	0	0	0
Other, net			0
Other, net	0	0
Net cash used in investing activities	(18,228.8)	0	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long term and short term borrowings	30,079.9	0	0
Repayment of revolving line of credit, long term and short term borrowings	(13,009.2)	0	0
Repayment of debt acquired through business combinations			0
Proceeds from ViroPharma call options			0
Proceeds from intercompany borrowings	1,097.6	0	0
Payment of dividend	0	0	0
Debt issuance costs	(172.3)	0	0
Contingent consideration payments	0	0	0
Proceeds from exercise of options	0	0	0
Other, net	0	0	0
Net cash provided by financing activities	17,996	0	0
Effect of foreign exchange rate changes on cash and cash equivalents	0	0	0
Net increase/(decrease) in cash and cash equivalents	0	0	0
Cash and cash equivalents at beginning of period	0	0	0
Cash and cash equivalents at end of period	0	0	0
Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net cash (used in) / provided by operating activities	(51)	0	0
CASH FLOWS FROM INVESTING ACTIVITIES:
Transactions with subsidiaries	(480.7)	0	0
Movements in restricted cash	0	0	0
Purchases of subsidiary undertakings and businesses, net of cash acquired	0	0	0
Purchases of non-current investments and PP&E	(11.1)	0	0
Proceeds received on sale of product rights	0	0	0
Proceeds from short-term investments		0	0
Proceeds from disposal of non-current investments and PP&E	0	0	0
Other, net			0
Other, net	0	0
Net cash used in investing activities	(491.8)	0	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long term and short term borrowings	0	0	0
Repayment of revolving line of credit, long term and short term borrowings	0	0	0
Repayment of debt acquired through business combinations			0
Proceeds from ViroPharma call options			0
Proceeds from intercompany borrowings	521.9	0	0
Payment of dividend	0	0	0
Debt issuance costs	0	0	0
Contingent consideration payments	0	0	0
Proceeds from exercise of options	92.7	0	0
Other, net	(30.1)	0	0
Net cash provided by financing activities	584.5	0	0
Effect of foreign exchange rate changes on cash and cash equivalents	0	0	0
Net increase/(decrease) in cash and cash equivalents	41.7	0	0
Cash and cash equivalents at beginning of period	0	0	0
Cash and cash equivalents at end of period	41.7	0	0
Non-Guarantor Non-Issuer Subsidiaries
CASH FLOWS FROM OPERATING ACTIVITIES:
Net cash (used in) / provided by operating activities	2,614	2,470.5	2,715.8
CASH FLOWS FROM INVESTING ACTIVITIES:
Transactions with subsidiaries	(4,707.3)	(3,048.2)	458.3
Movements in restricted cash	62.8	(32)	(32.6)
Purchases of subsidiary undertakings and businesses, net of cash acquired	(17,476.2)	(5,553.4)	(4,104.4)
Purchases of non-current investments and PP&E	(637.6)	(124.2)	(100.1)
Proceeds received on sale of product rights	10.9	17.5	127
Proceeds from short-term investments		67	57.8
Proceeds from disposal of non-current investments and PP&E	0.9	18.7	21.5
Other, net			(0.2)
Other, net	(41.9)	(13.5)
Net cash used in investing activities	(22,788.4)	(8,668.1)	(3,572.3)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long term and short term borrowings	8.5	0.8	0.8
Repayment of revolving line of credit, long term and short term borrowings	9.9	(0.9)	(1.8)
Repayment of debt acquired through business combinations			(551.5)
Proceeds from ViroPharma call options			346.7
Proceeds from intercompany borrowings	20,609.5	3,570	1,900
Payment of dividend	(150.6)	(127.6)	(112.3)
Debt issuance costs	0	(19.6)	0.4
Contingent consideration payments	(8)	(101.2)	(15.2)
Proceeds from exercise of options	16.5	0	2.2
Other, net	39.4	32.2	39.5
Net cash provided by financing activities	20,525.2	3,353.7	1,608.8
Effect of foreign exchange rate changes on cash and cash equivalents	0.8	(3)	(9.3)
Net increase/(decrease) in cash and cash equivalents	351.6	(2,846.9)	743
Cash and cash equivalents at beginning of period	135.5	2,982.4	2,239.4
Cash and cash equivalents at end of period	487.1	135.5	2,982.4
Non-Guarantor Subsidiaries of Baxalta Notes
CASH FLOWS FROM OPERATING ACTIVITIES:
Net cash (used in) / provided by operating activities	2,846.8	2,470.5	2,715.8
CASH FLOWS FROM INVESTING ACTIVITIES:
Transactions with subsidiaries	(22,936.1)	(3,048.2)	458.3
Movements in restricted cash	62.8	(32)	(32.6)
Purchases of subsidiary undertakings and businesses, net of cash acquired	(17,476.2)	(5,553.4)	(4,104.4)
Purchases of non-current investments and PP&E	(637.6)	(124.2)	(100.1)
Proceeds received on sale of product rights	10.9	17.5	127
Proceeds from short-term investments		67	57.8
Proceeds from disposal of non-current investments and PP&E	0.9	18.7	21.5
Other, net			(0.2)
Other, net	(41.9)	(13.5)
Net cash used in investing activities	(41,017.2)	(8,668.1)	(3,572.3)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long term and short term borrowings	30,088.4	0.8	0.8
Repayment of revolving line of credit, long term and short term borrowings	(12,999.3)	(0.9)	(1.8)
Repayment of debt acquired through business combinations			(551.5)
Proceeds from ViroPharma call options			346.7
Proceeds from intercompany borrowings	21,707.1	3,570	1,900
Payment of dividend	(150.6)	(127.6)	(112.3)
Debt issuance costs	(172.3)	(19.6)	0.4
Contingent consideration payments	(8)	(101.2)	(15.2)
Proceeds from exercise of options	16.5	0	2.2
Other, net	39.4	32.2	39.5
Net cash provided by financing activities	38,521.2	3,353.7	1,608.8
Effect of foreign exchange rate changes on cash and cash equivalents	0.8	(3)	(9.3)
Net increase/(decrease) in cash and cash equivalents	351.6	(2,846.9)	743
Cash and cash equivalents at beginning of period	135.5	2,982.4	2,239.4
Cash and cash equivalents at end of period	$ 487.1	$ 135.5	$ 2,982.4

Quarterly Results of Operati150

Quarterly Results of Operations (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Total revenues	$ 3,806.1	$ 3,452.1	$ 2,429.1	$ 1,709.3	$ 1,715.7	$ 1,655	$ 1,557.6	$ 1,488.4	$ 11,396.6	$ 6,416.7	$ 6,022.1
Cost of sales	1,053.6	1,736.2	778.1	248.6	250.5	262.7	228	227.8	3,816.5	969	979.3
Income from continuing operations, net of taxes	475.9	(368.5)	86.6	409.5	283.4	477.1	164.1	412.9	603.5	1,337.5	3,282.8
(Loss)/ gain from discontinued operations	(18.6)	(18.3)	(248.7)	9.5	(2.8)	(24.3)	(4.5)	(2.5)	(276.1)	(34.1)	122.7
Net income / (loss)	$ 457.3	$ (386.8)	$ (162.1)	$ 419	$ 280.6	$ 452.8	$ 159.6	$ 410.4	$ 327.4	$ 1,303.4	$ 3,405.5
Earning per ordinary share - basic
Earnings from continuing operations (in USD per share)	$ 0.53	$ (0.41)	$ 0.12	$ 0.69	$ 0.48	$ 0.81	$ 0.28	$ 0.70	$ 0.780	$ 2.27	$ 5.596
(Loss)/gain from discontinued operations (in USD per share)	(0.02)	(0.02)	(0.36)	0.02	(0.01)	(0.04)	(0.01)	0	(0.350)	(0.058)	0.209
Earnings per ordinary share - basic (in USD per share)	0.51	(0.43)	(0.24)	0.71	0.47	0.77	0.27	0.70	0.43	2.21	5.81
Earnings per ordinary share - diluted
Earnings from continuing operations (in USD per share)	0.52	(0.41)	0.12	0.69	0.48	0.80	0.28	0.70	0.770	2.255	5.552
(Loss)/gain from discontinued operations (in USD per share)	(0.02)	(0.02)	(0.36)	0.02	(0.01)	(0.04)	(0.01)	0	(0.350)	(0.058)	0.208
Earnings per ordinary share - diluted (in USD per share)	$ 0.50	$ (0.43)	$ (0.24)	$ 0.71	$ 0.47	$ 0.76	$ 0.27	$ 0.70	$ 0.42	$ 2.20	$ 5.76

Schedule II - Valuation and 151

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance	$ 1,137.3	$ 1,033.9	$ 925.1
Provision charged to income	2,958.8	2,287.9	2,036.7
Additions through acquisitions	185.8	0	0
Costs incurred/ utilization	(2,660.9)	(2,184.5)	(1,927.9)
Ending balance	1,621	1,137.3	1,033.9
Accrued rebates - Medicaid and HMOs
Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance	982.4	882.1	806.5
Provision charged to income	2,702.4	2,128	1,877.7
Additions through acquisitions	185.8	0	0
Costs incurred/ utilization	(2,439.3)	(2,027.7)	(1,802.1)
Ending balance	1,431.3	982.4	882.1
Sales returns reserve
Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance	128.3	131.7	97.9
Provision charged to income	19.5	19.4	60.1
Additions through acquisitions	0	0	0
Costs incurred/ utilization	(29.4)	(22.8)	(26.3)
Ending balance	118.4	128.3	131.7
Accrued coupons
Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance	26.6	20.1	20.7
Provision charged to income	236.9	140.5	98.9
Additions through acquisitions	0	0	0
Costs incurred/ utilization	(192.2)	(134)	(99.5)
Ending balance	$ 71.3	$ 26.6	$ 20.1